Criteria 3: Research, Innovations and Extension



3.3.2 Number of books and chapters in edited volumes/books published and papers published in national/international conference proceedings per teacher during last five years

INDEX

| SR. NO. | PARAMETER | PAGE NO. |
|---------|---|----------|
| 1 | Total number of books and chapters in edited volumes/books published and papers in national/international conference proceedings year wise during last five years | 2 |
| 2 | List of chapter/book along with the links redirecting to the source website | 425 |





Total number of books and chapters in edited volumes/books published and papers in national/ international conference proceedings year wise during last five years

| Sr. No. | Parameter | Calendar Year | No. of Books and chapters in edited volumes /Books Published /Conference proceedings |
|---------|---|------------------|--|
| 1 | | 2022-2023 | 163 |
| 2 | Books and chapters in | <u>2021-2022</u> | 15 |
| 3 | edited volumes /Books Published /Conference | <u>2020-2021</u> | 13 |
| 4 | proceedings | <u>2019-2020</u> | 35 |
| 5 | | 2018-2019 | 43 |





ACADEMIC YEAR: 2022-2023

| Sr. No. | Title of Books and chapters in edited volumes / Books Published / Conference proceedings | Page No. |
|---------|--|----------|
| | BOOKS | |
| 1. | Quality control & standardization of herbals | 12 |
| 2. | Pharmaceutic Organic Chemistry -II | 20 |
| 3. | Dietary supplements & nutraceuticals | 27 |
| 4. | Principles of Drug Discovery | 32 |
| 5. | Pharmaceutical Organic Chemistry -III | 36 |
| 6. | Pharmaceutical Organic Chemistry -III | 36 |
| 7. | Regulatory Affairs | 41 |
| 8. | The Microbial World: Exploring the Diversity of Bacteria | 47 |
| 9. | The Microbial World: Exploring the Diversity of Bacteria | 47 |
| 10. | A Textbook of Organic Chemistry | 51 |
| 11. | Elements of Pharmacotherapeutics | 54 |
| 12. | Elements of Pharmacotherapeutics | 54 |
| | BOOK CHAPTERS | |
| 13. | Chapter 4 Quantitative analysis of ursolic acid in the leaves of species of genus tecoma and tabebuia of bignoniaceae family by high-performance thin-layer method | 60 |
| 14. | Chapter 2 Recent Advances in Microfluidics for Drug Screening and Its Applications | 64 |
| 15. | Chapter 9 Review article: ophthalmic niosomal in situ gel | 67 |
| 16. | Chapter-8 Prevotella histicola | 70 |
| 17. | Chapter-9 Prevotella denticola | 77 |
| 18. | Chapter-10 Prevotella micans | 79 |
| 19. | Chapter-11 Prevotella bryantii | 81 |







| 20. | Chapter-12 Prevotella fusca | 83 |
|-----|---|-----|
| 21. | Chapter-13 Prevotella albensis | 85 |
| 22. | Chapter-14 Prevotella saccharolytica | 87 |
| 23. | Chapter-15 Prevotella brevis | 89 |
| 24. | Chapter-16 Prevotella bivia | 96 |
| 25. | Chapter-17 Prevotella timonensis: Pathogenicity and Immune Response | 98 |
| 26. | Chapter-18 Prevotella loescheii | 100 |
| 27. | Chapter-19 Prevotella pallens | 102 |
| 28. | Chapter-20 Prevotella buccalis | 104 |
| 29. | Chapter-21 Prevotella amnii | 106 |
| | CONFERENCE PROCEEDINGS | |
| 30. | Burden of diseases in india and need for pharmaceutical care | 108 |
| 31. | Bioinformatic tools in clinical research | 109 |
| 32. | Bioinformatic tools in clinical research | 109 |
| 33. | Bioinformatic tools in clinical research | 109 |
| 34. | 3D printing in pharmaceutical and biomedical applications | 110 |
| 35. | 3D printing in pharmaceutical and biomedical applications | 110 |
| 36. | 3D printing in pharmaceutical and biomedical applications | 110 |
| 37. | Artificial intelligence in pharmaceutical science | 111 |
| 38. | Artificial intelligence in pharmaceutical science | 111 |
| 39. | Principle elements and plan for pharmaceutical care | 112 |
| 40. | Personalized medicine: new health care approach | 113 |
| 41. | Personalized medicine: new health care approach | 113 |
| 42. | Personalized medicine: new health care approach | 113 |







| 43. | Softwares used in medical coding. | 114 |
|-----|--|-----|
| 44. | Softwares used in medical coding. | 114 |
| 45. | Artificial intelligence in drug discovery | 115 |
| 46. | Artificial intelligence in drug discovery | 115 |
| 47. | Bioinformatics for healthcare applications | 116 |
| 48. | Artificial intelligence in healthcare | 117 |
| 49. | Artificial intelligence in healthcare | 117 |
| 50. | Monitor adverse drug reaction of theophylline in asthmatic patients | 118 |
| 51. | Monitor adverse drug reaction of theophylline in asthmatic patients | 118 |
| 52. | Pharmacist: a key to pharmaceutical care | 119 |
| 53. | Artificial intelligence in medicine | 120 |
| 54. | Introducing principle, elements and perceived barriers toward provision of pharmaceutical care | 121 |
| 55. | Digital Therapeutics and telemedicine | 122 |
| 56. | Therapeutic drug monitoring | 123 |
| 57. | Therapeutic drug monitoring | 123 |
| 58. | Pharmacoeconomics: an overview | 124 |
| 59. | Artificial intelligence in education | 125 |
| 60. | Digitalization in pharmaceutical care | 126 |
| 61. | Digitalization in pharmaceutical care | 126 |
| 62. | Digitalization in pharmaceutical care | 126 |
| 63. | Digital therapeutics in current era | 127 |
| 64. | Digital therapeutics in current era | 127 |
| 65. | Artificial intelligence in bioinformatics | 128 |
| 66. | Effect of digital therapeutics on health care industry | 129 |







| 67. | Pharmaceutical care | 130 |
|-----|---|-----|
| 68. | 3D printing in dosage form | 131 |
| 69. | 3D printing in dosage form | 131 |
| 70. | 3D printing in dosage form | 131 |
| 71. | Telemedicine an Evolving Health Practice with use of modern tools | 132 |
| 72. | Artificial intelligence in cloud computing in industrial sector | 133 |
| 73. | Artificial intelligence in marketing | 134 |
| 74. | The challenges, potential and future of digital therapeutics | 135 |
| 75. | The challenges, potential and future of digital therapeutics | 135 |
| 76. | The challenges, potential and future of digital therapeutics | 135 |
| 77. | Artificial intelligence & machine learning in robotics | 136 |
| 78. | Potential applications of human machine interface technology in different domains | 137 |
| 79. | Potential applications of human machine interface technology in different domains | 137 |
| 80. | Artificial intelligence in human resource management | 138 |
| 81. | Artificial intelligence in life style | 139 |
| 82. | Artificial intelligence in social media | 140 |
| 83. | Artificial intelligence in agriculture | 141 |







| 84. | Artificial intelligence in e-commerce | 142 |
|------|---|-----|
| 85. | Antidrug antibodies | 143 |
| 86. | Liquid roll-on formulation having foot deodorizing and antimicrobial activity | 144 |
| 87. | Liquid roll-on formulation having foot deodorizing and antimicrobial activity | 144 |
| 88. | Liquid roll-on formulation having foot deodorizing and antimicrobial activity | 144 |
| 89. | A case study report on anorectal fistula | 145 |
| 90. | A case study report on anorectal fistula | 145 |
| 91. | Mednme: a personalized e-health tool for patients and health care providers | 146 |
| 92. | Epidemiological study of anti- snake venom use in snake bite patients | 147 |
| 93. | Type d personality and its association with myocardial abstract code: mcop-20 infarction patients | 148 |
| 94. | Toxic pesticides drift- a study of 20 cases | 149 |
| 95. | Phytochemical evaluation, pharmacological activities and toxicological profile of impatiens balsamina | 150 |
| 96. | Phytochemical evaluation, pharmacological activities and toxicological profile of impatiens balsamina | 150 |
| 97. | Phytochemical evaluation, pharmacological activities and toxicological profile of impatiens balsamina | 150 |
| 98. | Phytochemical evaluation and pharmacological activities of neolamarckia cadamba | 151 |
| 99. | Medical health card | 152 |
| 100. | Medical health card | 152 |
| 101. | Medical health card | 152 |

Progressive Education Society's Modern College of Pharmacy, Nigdi, Pune 411044







| 102. | Effects of subacute administration of 4- hydroxyisoleucineon cognitive, suicidal, and sexual behavior in social isolation stress-induced olfactory bulbectomized rats | 153 |
|------|---|-----|
| 103. | Mass spectroscopy in bioanalytical method development | 154 |
| 104. | Tacrine derivatives as potential acetylcholine esterase inhibitors: pre- admet analysis and computational study | 155 |
| 105. | Green solvents: an eco-friendly approach in analytical chemistry | 156 |
| 106. | Green solvents: an eco-friendly approach in analytical chemistry | 156 |
| 107. | Development of terbinafine hydrochloride niosomal in situ gel for opthalmic drug delivery | 157 |
| 108. | Design and evaluation of an in-situ gel for ophthalmic drug delivery of gatifloxacine | 160 |
| 109. | Gsk-3 beta inhibitor: an emerging anti-alzheimer agent with its insilico scaffold and virtual screening | 161 |
| 110. | Gsk-3 beta inhibitor: an emerging anti-alzheimer agent with its insilico scaffold and virtual screening | 161 |
| 111. | Management of osteoarthritis and rheumatoid arthritis through diclofenac sodium along with herbal drugs | 162 |
| 112. | Development and characterization of niosomal insitu gel of ritonavir | 163 |
| 113. | Formulation and evaluation of polyherbal hair oil for the management of scalp dandruff | 164 |
| 114. | Formulation and evaluation of micronutrient transdermal patch as a potential supplement | 165 |
| 115. | QBD Driven method development and validation of Favipiravir and Siam by RP-HPLC | 166 |
| 116. | Herbal foot deodorizing spray with antimicrobial activity | 167 |
| 117. | Herbal foot deodorizing spray with antimicrobial activity | 167 |
| 118. | Synthesis and conjugation of aromatase inhibitors for targeted drug in treatment cancer | 168 |







| 119. | Synthesis and conjugation of aromatase inhibitors for targeted drug in treatment cancer | 168 |
|------|--|-----|
| 120. | Formulation development and characterization of melatonin based higher SPF herbal sunscreen formulation | 169 |
| 121. | Analysis of side effects observed due to cardiovascular drugs at a tertiary care hospital | 170 |
| 122. | Pharmacological studies on collagen induced arthritis in swiss albino mic | 171 |
| 123. | Recent advances in studies on guillain barre syndrome. | 172 |
| 124. | Synthesis, molecular docking of atenolol impurity: insights from spectroscopic and pharmacokinetic approaches | 173 |
| 125. | Molecular docking for antiviral compounds against sars-cov-2: a computational study | 174 |
| 126. | Molecular docking for antiviral compounds against sars-cov-2: a computational study | 174 |
| 127. | In silico study of Triazole linked Quinazolione derivatives for anti- diabetic as Dipeptidyl peptidase inhibitory activity. | 175 |
| 128. | In silico study of Triazole linked Quinazolione derivatives for anti- diabetic as Dipeptidyl peptidase inhibitory activity. | 175 |
| 129. | In silico study of quinazolinone-sulfonamide derivatives for Dipeptidyl peptidase-IV as anti- diabetic Activity | 177 |
| 130. | In silico study of quinazolinone-sulfonamide derivatives for Dipeptidyl peptidase-IV as anti- diabetic Activity | 177 |
| 131. | In sillico study of Novel Sulphonamide/Isothiocyanate Linked Quinazolinone Derivatives for DPP -IV inhibitory as antidiabetic activity | 178 |
| 132. | In sillico study of Novel Sulphonamide/Isothiocyanate Linked Quinazolinone Derivatives for DPP -IV inhibitory as antidiabetic activity | 178 |
| 133. | Targated delivery of 5-Fluorocil in breast cancer using hollow mesoporous alumina nanoparticles | 179 |
| 134. | Targated delivery of 5-Fluorocil in breast cancer using hollow mesoporous alumina nanoparticles | 179 |
| 135. | Influence of combination of phytoconstituents in ethanol withdrawal induced depression | 180 |







| 136. | Pursuit of natural compound as a potential NMDA Antagonist: An Insilico insight | 181 |
|------|---|-----|
| 137. | Pursuit of natural compound as a potential NMDA Antagonist: An Insilico insight | 181 |
| 138. | Virtual screening of phytochemical compounds as potential inhibitors against BACE 1 receptors | 182 |
| 139. | Virtual screening of phytochemical compounds as potential inhibitors against BACE 1 receptors | 182 |
| 140. | Anti-arthritic activity in experimental animals by using Freund's Complete Adjuvant(FCA) model. | 183 |
| 141. | Anti-atherosclerotic activity of Origanum majorana L. in experimental animals . | 184 |
| 142. | Anti-atherosclerotic activity of Origanum majorana L. in experimental animals. | 184 |
| 143. | Evaluating the Diabetic wound Healing Activity of Phytoconstituent Extracted from Ficus Racemosa LINN. Leaves Using Animal Model | 185 |
| 144. | GSK-3 Beta inhibitor: An emerging anti Alzheimer agent with its Insilico scaffold and virtual screening | 186 |
| 145. | GSK-3 Beta inhibitor: An emerging anti Alzheimer agent with its Insilico scaffold and virtual screening | 186 |
| 146. | In silico study of a natural compound as potential MAO-A inhibitor | 187 |
| 147. | In silico study of a natural compound as potential MAO-A inhibitor | 187 |
| 148. | Evalauation of antidiabetic and nephroprotective potential of cassia auriculata aerial parts in streptozotocin induced early diabetic nephropathy in rats | 188 |
| 149. | Protective effect of Hydroalcoholic extract of cassia auriculata leaves on High fructose Induced resistance in experimental animals | 189 |
| 150. | Protective effect of hydroalcoholic extract of Punica granatum leaves on high fructose induced insulin resistance in experimental animals | 190 |
| 151. | Antihistaminic effects of azadirachta indica leaves in laboratory animals | 191 |
| 152. | Antihistaminic effects of azadirachta indica leaves in laboratory animals | 191 |








| 153. | Evaluation of In-Vitro Anthelmintic Potential of Various Extracts of Emblica Officinalis | 192 |
|------|--|-----|
| 154. | Evaluation of in-vitro anthelmintic potential of various extracts of emblica officinalis | 193 |
| 155. | Effect of Standardized Extract of Commiphora Mukul Engl. (Burseraceae) on Bulbectomy Induced Sexual and Immune Dysfunction in Rats | 194 |
| 156. | Molecular Docking, Dynamics and Synthesis of some N-heteroaryl Flavon Hybrid Targeting Estrogen Receptor Alpha (ER-α) | 195 |
| 157. | Molecular Docking, Dynamics and Synthesis of some N-heteroaryl Flavon Hybrid Targeting Estrogen Receptor Alpha (ER-α) | 195 |
| 158. | Synthesis, characterization and in-silico study of two key impurities of propranolol. | 196 |
| 159. | Synthesis and Insilico study of six key impurities of Atenolol: β blocker | 197 |
| 160. | Computational approach, synthesis and characterization of two key impurities of metoprolol | 198 |
| 161. | Potential effect of venom from various Venomous animals in cardiovascular disease | 199 |
| 162. | A Validated Method Using HPTLC for Determination of Bilastine and Design New Drug Discovery of Antihistaminic Activity. | 200 |
| 163. | Evaluation of in-vitro anthelmintic potential of umbelliferone against pheretima posthuma | 201 |





Quality control & standardization of herbals














TABLE OF CONTENTS

Unit - I

| Chapter - 1 | Basic Tests, WHO Guidelines & Evaluation of Herbal Drugs | (1 - 1) to (1 - 140) |
|-------------|--|-------------------------|
| 1.1 Int | roduction | L. 6 Evaluation of Comm |
| | sic Tests for Drugs | |
| 1. | 2.1 Test Procedures for Pharmaceutical Substances | 30mp3wami4 0.0.1 |
| 1.3 Tes | t Procedures for Medicinal Plant Materials | IVV3 (G3IMBHT) E.O.A. |
| 1.4 Tes | t Procedures for Pharmaceutical Dosage Forms | 7 - 1/ |
| 1.5 WH | t Procedures for Pharmaceutical Dosage Forms | |
| 1. | O Guidelines for Quality Control of Herbal Drugs | 1 - 57 |
| | 5.1 Determination of Foreign Matter | |
| | 5.2 Macroscopic and Microscopic Examination 5.3 Visual Examination and Odour | |
| | 5.4 Histochemical Detection of Cell Walls and Content | |
| | 5.5 Measurement of Specimens | |
| | 5.6 Microsublimation | |
| | | |
| 1.5 | .8 Determination of Ash | 10 no zanilanio 1 S.S. |
| 1.5 | .9 Determination of Extractable Matter | OI Herbal Medic |
| 1.5 | .10 Determination of Water and Volatile Matter | 9T (stenes) A.S.S. |
| | .11 Loss on Drying (Gravimetric Determination) | |
| 1.5 | .12 Determination of Volatile Oils | 1 92 |
| 1.5 | .13 Determination of Bitterness Value | 1 - 85 |
| 1.5 | .14 Determination of Haemolytic Activity | 1 - 88 |
| 1.5 | 15 Determination of Tannins | 9.0minco <u>8.5.5</u> |
| 1.5. | 16 Determination of Swelling Index | 1 01 |
| 1.5. | 17 Determination of Foaming Index | 1 - 92 |
| | 18 Determination of Pesticide Residues | |
| 2.5. | 20 Determination of Pesticide Residues | 1 - 93 |

141





| | | nination of Particular Pesticide Residue | |
|-----------------|--|--|--|
| | | nination of Total Chlorine and Phosphorus | |
| | | nination of Desmetryn, Prometryn and Simazine | |
| | | nination of the Rate of Recovery | |
| | | nination by Gas Chromatography | |
| | | nination of Arsenic and Toxic Metals | |
| | | nination of Microorganisms : Total Viable Aerob | |
| 1.6 E | | Commercial Crude Drugs Intended for Use | |
| | | eptic Evaluation | |
| | | opic Evaluation | |
| | | al Evaluation | |
| | | Evaluation | |
| | 1.6.5 Biologica | al Evaluation | 1 - 13 |
| Mul | iple Choice Q | uestions with Answers | 1 - 13 |
| Que | stions | Unit - II lity Assurance in Herbal Drug Indust | ry |
| | stions | Unit - II lity Assurance in Herbal Drug Indust | ry (2 - 1) to (2 - 40 |
| Que | - 2 Qual | Unit - II | ry (2 - 1) to (2 - 40 |
| Que Chapter | - 2 Qual | Unit - II lity Assurance in Herbal Drug Indust | ry (2 - 1) to (2 - 40 |
| Que Chapter 2.1 | • 2 Qual Introduction | Unit - II lity Assurance in Herbal Drug Indust on Good Manufacturing Practices for the Ma | ry (2 - 1) to (2 - 40 2 - |
| Que Chapter 2.1 | - 2 Qual Introduction Guidelines of | Unit - II lity Assurance in Herbal Drug Indust on Good Manufacturing Practices for the Ma | ry (2 - 1) to (2 - 40 2 - anufacture |
| Que Chapter 2.1 | - 2 Qual Introduction Guidelines of Herbal Me 2.2.1 Gener | Unit - II lity Assurance in Herbal Drug Indust on Good Manufacturing Practices for the Ma | ry (2 - 1) to (2 - 40 |
| Que Chapter 2.1 | - 2 Qual Introduction Guidelines of of Herbal M 2.2.1 Gener 2.2.2 Sanita | Unit - II lity Assurance in Herbal Drug Indust on Good Manufacturing Practices for the Manufacturines al Terms | ry (2 - 1) to (2 - 40 |
| Que Chapter 2.1 | Property of the control of the contr | Unit - II lity Assurance in Herbal Drug Indust on Good Manufacturing Practices for the Ma edicines al Terms | ry (2 - 1) to (2 - 40 |
| Que Chapter 2.1 | Property of the property of th | Unit - II lity Assurance in Herbal Drug Indust on Good Manufacturing Practices for the Ma edicines al Terms | ry (2 - 1) to (2 - 40 inufacture 2 - 2 - 2 2 2 2 |
| Que Chapter 2.1 | Introduction Guidelines of of Herbal M 2.2.1 Gener 2.2.2 Sanita 2.2.3 Qualif 2.2.4 Compl 2.2.5 Produ | Unit - II lity Assurance in Herbal Drug Indust on Good Manufacturing Practices for the Ma edicines al Terms tion and Hygiene lication and Validation | ry (2 - 1) to (2 - 40 |
| Que Chapter 2.1 | Introduction Guidelines of Herbal M 2.2.1 Gener 2.2.2 Sanita 2.2.3 Qualif 2.2.4 Complex 2.2.5 Produ 2.2.6 Contra | Unit - II lity Assurance in Herbal Drug Indust on Good Manufacturing Practices for the Ma edicines al Terms tion and Hygiene ication and Validation laints | ry (2 - 1) to (2 - 40 anufacture 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 |
| Que Chapter 2.1 | Introduction Guidelines of of Herbal M 2.2.1 Gener 2.2.2 Sanita 2.2.3 Qualif 2.2.4 Compl 2.2.5 Produ 2.2.6 Contra 2.2.7 Person 2.2.8 Trainin | Unit - II lity Assurance in Herbal Drug Indust on Good Manufacturing Practices for the Manuf | ry (2 - 1) to (2 - 40 |
| Que Chapter 2.1 | Introduction Guidelines of of Herbal M 2.2.1 Gener 2.2.2 Sanita 2.2.3 Qualif 2.2.4 Compl 2.2.5 Produ 2.2.6 Contra 2.2.7 Person 2.2.8 Trainin | Unit - II lity Assurance in Herbal Drug Indust on Good Manufacturing Practices for the Ma edicines al Terms tion and Hygiene lication and Validation laints ct Recalls act Production and Analysis | ry (2 - 1) to (2 - 40 |







| | 2.2.11 | L Storage Areas | 2 - 9 |
|---------|----------|--|---------------|
| | 2.2.12 | 2 Production Areas | 2 - 10 |
| | 2.2.13 | B Equipment | 2 - 10 |
| | 2.2.14 | Materials | 2 - 11 |
| 2.3 | Docu | mentation | 2 - 11 |
| | 2.3.1 | Specifications | 2 - 11 |
| | 2.3.2 | Herbal Materials | 2 - 12 |
| | 2.3.3 | Finished Herbal Products | 2 - 13 |
| 2.4 | Good | Agricultural Practices for Medicinal Plants | 2 - 21 |
| | 2.4.1 | Identification/Authentication of Cultivated Medicinal Plants | 2 - 21 |
| 2.5 | Good | Collection Practices for Medicinal Plants | 2 - 27 |
| | 2.5.1 | Permission to Collect | 2 - 27 |
| | 2.5.2 | Technical Planning | 2 - 28 |
| | 2.5.3 | Selection of Medicinal Plants for Collection | 2 - 28 |
| | 2.5.4 | Collection | 2 - 29 |
| | 2.5.5 | Personnel | 2 - 30 |
| Mul | tiple Cl | hoice Questions with Answers | 2 - 31 |
| Que | stions | Cinica (Feb Exotorol Devolence), elementum Exotorol (Elementum Exotorol Devolence) | 2 - 39 |
| | | Unit - III | |
| Chapter | - 3 | memorating programs appears likely of and to estillidize (3 - 1 |) to (3 - 28) |
| 3.1 | | duction | |
| 3.2 | Scope | 2 | 3 - 3 |
| 3.3 | Quali | tative and Quantitative Particulars of the Active Substance | (s) of |
| | | bal Medicinal Product | |
| | 3.3.1 | Herbal Substances and Herbal Preparations Consisting of Composition Powdered Herbal Substances | |
| | 3.3.2 | Herbal Preparations Produced by Steps Which Exceed Commin | ution3 - 5 |
| 3.4 | | ription of the Method of Preparation of the Herbal cinal Product | |
| | | | |

(vii)







| 3.5 | Control of Starting Materials |
|-----|--|
| 3.3 | 3 5 1 Control of Herbal Substances |
| | 3.5.2 Control of Herbal Preparations |
| 26 | Central Tasts Carried Out at an Intermediate Stage of the Manufacturing |
| 5.0 | Process of the Herbal Medicinal Product |
| | 3.6.1 Control Tests on the Herbal Medicinal Product |
| 3.7 | Stability Tests 3 - 9 |
| 3.8 | Bases Cuidelines for Evaluating the Safety |
| 3.0 | and Efficacy of Herbal Medicines |
| | 3.8.1 General Considerations in Herbal Medicine Research |
| | 3.8.2 Research Approaches3 - 13 |
| 3.9 | Research Studies |
| 3.3 | 3 9 1 Literature Background3 - 14 |
| | 3.9.2 Protocol Preparation |
| | 3.9.3 Quality Specifications of Plant Materials and Preparation |
| | 3.9.4 Methods in the Conduct of Non-clinical Research on Herbal Medicines 3 - 15 |
| | 3 9 5 Clinical Trials using Herbal Medicines |
| | 3 9 6 Clinical Trial Protocol Development3 - 16 |
| | 3 9 7 Phases of a Clinical Trial |
| | 3 9 8 Fthics Review Board3 - 18 |
| | 3.9.9 Responsibilities of the Investigators |
| | 3.9.10 Responsibilities of the Sponsor |
| | 3 9 11 Data Management |
| | 3 - 20 |
| | 3.9.13 Reporting3 - 20 |
| | 3.9.14 Evaluation of Herbal Medicine Research3 - 20 |
| 3 | 10 Technology Transfer and Education |
| | 3 10 1 Information for Fresh, Dried and Processed Plant Materials 3 - 2 |
| | 3.10.2 Quality Specifications |
| | 3.10.3 Information for Medicinal Preparations of Plant Materials |
| N | Multiple Choice Questions with Answers |
| C | uestions |






Init - IV

| Chapter | -4 | Stability Testing & GMP Requirements of Herbal Medicine (4 - 1) to (4 - 44) |
|---------|------------------------|--|
| 4.1 | Stab | ility Testing of Herbal Medicine |
| | | Shelf-Life |
| | | Challenges in Stability Testing of Herbal Medicinal Product |
| | 4.1.3 | |
| 4.2 | Appl | ication of Various Chromatographic Techniques in Standardization of |
| | | al Products |
| | | Column Chromatography 4 - 7 |
| | | 4.2.1.1 Packing of the Column |
| | | 4.2.1.2 Sample Introduction |
| | 4.2.2 | |
| | 4.2.3 | Thin Layer Chromatography4 - 11 |
| | 4.2.4 | High Pressure Liquid Chromatography (HPLC)4 - 13 |
| | 4.2.5 | Gas Chromatography4 - 16 |
| | 4.2.6 | High Performance Thin Layer Chromatography (HPTLC)4 - 18 |
| 4.3 | Prepa | aration of Documents for New Drug Application |
| | and E | xport Registration 4 - 20 |
| | 4.3.1 | |
| | 4.3.2 | Intellectual Property Rights (IPRs) |
| | 4.3.3 | Farmer's Rights |
| | 4.3.4 | Plant Breeder's Rights (PBR) |
| | | Traditional Knowledge (TK)4 - 24 |
| | 4.3.6 | Case Study of Neem4 - 25 |
| | 4.3.7 | Case Study of Turmeric |
| 4.4 | | atory Issues in India Herbal Drug Regulation in India 4 - 27 |
| 4.5 | and Cosmetics Act 1940 | |
| | 4.5.1 | The Drugs Technical Advisory Board (DTAB) |
| | 4.5.2 | The Central Drugs Laboratory (CDL) |













Pharmaceutic Organic Chemistry -II




















| 1.13 Sacc | harin (Benzoic Sulfimide)1 - 40 |
|-------------|--|
| 1.14 Benz | zene Hexachloride (BHC) |
| 1.15 Chlo | ramine |
| Multiple | Choice Questions with Answers |
| Short Ans | wer Questions |
| Long Ans | wer Questions 1 - 47 |
| 9 75 | Unit - II |
| Chapter - 2 | Phenols, Aromatic Amines and Aromatic Acids (2 - 1) to (2 - 52) |
| 2.1 Introd | luction |
| | fication of Phenol |
| | ration of Phenol |
| | ical Reaction of Phenol |
| 2.5 Acidit | y of Phenols |
| 2.6 Effect | of Substituents on Acidity of Phenols 2 - 13 |
| | ative Tests for Phenols |
| 2.8 Struct | ture and Uses of Phenol |
| 2.9 Struct | ture and Uses of Cresols Structure 2 - 17 |
| 2.10 Strue | cture and Uses of Resorcinol |
| 2.11 Struc | cture and Uses of Naphthol Structure 2 - 19 |
| | Aromatic Amines |
| 2.12 Intro | oduction |
| 2.13 Prep | aration of Amines 2 - 24 |
| 2.14 Cher | nical Reaction of Amines |
| 2.15 Basic | city of Amines |
| | cts of Substituents on Basicity |
| 2.17 Synt | hetic Uses of Aryl Diazonium Salts |
| | Aromatic Acid |
| 2 18 Intro | oduction |





| 4.3.2.3 Synthesis of Naphthalene from 4-Phenyl-3-Butenoic Acid4 - 7 |
|---|
| 4.3.2.4 Haworth Synthesis of Naphthalene |
| 4.3.3 Physical Properties of Naphthalene |
| 4.3.4 Chemical Reactions of Naphthalene |
| 4.3.4.1 Nitration4 - 9 |
| 4.3.4.2 Friedal-Craft Acylation |
| 4.3.4.3 Friedal-Craft Alkylation |
| 4.3.4.4 Reduction |
| 4.3.4.5 Oxidation |
| 4.3.5 Medicinal Uses of Naphthalene |
| 4.3.6 Derivatives |
| 4.4 Phenanthrene |
| 4.4.1 Resonance of Phenanthrene |
| 4.4.2 Physical Properties of Phenanthrene |
| 4.4.3 Synthesis of Phenanthrene |
| 4.4.3.1 Synthesis of Phenanthrene by Haworth Synthesis |
| 4.4.3.2 Synthesis of Phenanthrene from Dibenzyl |
| 4.4.4 Reactions of Phenanthrene |
| 4.4.4.1 Friedal-Craft Acylation |
| 4.4.4.2 Nitration |
| 4.4.4.3 Reduction |
| 4.4.4.4 Oxidation4 - 15 |
| 4.4.5 Uses of Phenanthrene |
| 4.5 Anthracene |
| 4.5.1 Resonance of Anthracene |
| 4.5.2 Synthesis of Anthracene |
| 4.5.2.1 By Friedal Craft Reaction |
| 4.5.2.2 By Haworth Synthesis |
| 4.5.2.3 By Elbs Reaction |
| 4.5.2.4 By Diels-Alder Reaction |





| | 4.5.3 Physical Properties of Anthracene | 4 - 1 |
|---|---|----------------|
| | 4.5.4 Reactions of Anthracene | |
| | 4.5.4.1 Nitration | 4 - 1 |
| | 4.5.4.2 Friedal-Craft Acylation | 4 - 1 |
| | 4.5.4.3 Reduction | 4 - 1 |
| | 4.5.4.4 Oxidation | 4 - 2 |
| | 4.5.4.5 Diels-Alder Reaction | 4 - 2 |
| | 4.5.5 Uses of Anthracene | 4 - 2 |
| | 4.5.6 Derivatives of Anthracene | 4 - 2 |
| 4 | .6 Diphenyl Methane | 4 - 2 |
| | 4.6.1 Physical Properties of Diphenyl Methane | 4 - 2 |
| | 4.6.2 Synthesis of Diphenyl Methane | 4 - 2 |
| | 4.6.2.1 Friedal-Craft Reaction | 4 - 2 |
| | 4.6.2.2 From Benzene | 4 - 2 |
| | 4.6.2.3 From Benzophenone | 4 - 2 |
| | 4.6.2.4 From Grignard Reagent | 4 - 2 |
| | 4.6.3 Reactions of Diphenyl Methane | |
| | 4.6.3.1 Nitration | 4 - 2 |
| | 4.6.3.2 Halogenation | 4 - 2 |
| | 4.6.3.3 Oxidation | 4 - : |
| | 4.6.3.4 Cyclization | 4 - 2 |
| | 4.6.4 Uses of Diphenyl Methane | 4 - 2 |
| | 4.6.5 Derivatives of Diphenyl Methane | 4 - 2 |
| 4 | .7 Triphenyl Methane | |
| | 4.7.1 Synthesis of Triphenyl Methane | Increase 1.2.A |
| | 4.7.1.1 Friedal-Craft Reaction | adime 5.8.5 |
| | 4.7.1.2 Condensation with Chloroform | 4 - : |
| | 4.7.1.3 Condensation with Benzaldehyde | 4 - 1 |
| | 4.7.2 Reactions of Triphenyl Methane | 4 - 2 |
| | 4.7.3 Uses of Triphenyl Methane | |








| 4.7.4 Derivatives of Triphenyl Methane | 4 - 26 |
|--|---------------------|
| Multiple Choice Questions with Answers | |
| Short Answer Questions | |
| Long Answer Questions | |
| Unit - V | |
| Chapter - 5 Cycloalkanes | (5 - 1) to (5 - 18) |
| 5.1 Introduction | 5 - 2 |
| 5.1.1 Nomenclature | 5 - 2 |
| 5.1.2 Structure | 5 - 3 |
| 5.1.3 Physical Properties | 5 - 5 |
| 5.2 Cycloalkanes Preparation | 5 - 5 |
| 5.3 Reactions of Cycloalkanes | 5 - 7 |
| 5.4 Stability | 5 - 8 |
| 5.5 Baeyer Strain Theory | |
| 5.6 Limitations of Baeyer Strain Theory | 5 - 11 |
| 5.7 Coulson and Moffitt's Modification | 5 - 12 |
| 5.8 Sachse's S-Mohr's Theory (Theory of Strainless Ring) | 5 - 14 |
| 5.9 Reactions of Cyclopropane and Cyclobutane | |
| Multiple Choice Questions with Answers | |
| Short Answer Questions | |
| Long Answer Questions | |
| to 1115) where exidence of benzing an amount | |






Dietary supplements & nutraceuticals











| TABLE OF CONTENTS | 2.5 Occurrence and Characteristic Features of Flavonoids 2 - 13 |
|---|--|
| | 2.6 Occurrence and Characteristic Features |
| UNIT - I | of Prebiotics / Probiotics |
| | 2.7 Occurrence and Characteristic Features of Phytoestrogens . 2 - 35 |
| hapter 1 Nutraceuticals (1 - 1) to (1 - 40) | 2.8 Occurrence and Characteristic Features of Tocopherols 2 - 39 |
| 1 Definitions | 2.9 Occurrence and Characteristic Features of Proteins, Vitamins, |
| | Minerals, Cereal, Vegetables and Beverages as |
| 2 Classification of Nutraceuticals | Functional Foods2 - 41 |
| Health Problems and Diseases that can be Prevented or Cured by Nutraceuticals | UNIT - III |
| 4 Public Health Nutrition, Maternal and Child Nutrition, | C |
| Nutrition and Ageing, Nutrition Education in Community 1 - 13 | Chapter 3 Free Radicals, Dietary Fibers and Complex Carbohydrates (3 - 1) to (3 - 33 |
| 5 Source, Name of Marker Compounds and their Chemical Nature, | |
| Medicinal Uses and Health Benefits Used as | 3.1 Introduction to Free Radicals |
| Nutraceuticals/Functional Foods1 - 30 | 3.2 Dietary Fibres and Complex Carbohydrates as Functional |
| 77377W 77 | Food Ingredients |
| UNIT - II | UNIT - IV |
| hapter 2 Phytochemicals as Nutraceuticals | |
| (2 - 1) to (2 - 60) | Chapter 4 Role of Free Radicals in Diseases, |
| 1 Introduction | Anti-oxidants and Functional Food for Chronic Diseases (4 - 1) to (4 - 50 |
| Occurrence and Characteristic Features of Carotenoids 2 - 2 | 4.1 Free Radicals in Diseases |
| Occurrence and Characteristic Features of Sulfides2 - 9 | 4.2 Introduction to Anti-oxidants |
| 4 Occurrence and Characteristic Features of Polyphenolics 2 - 11 | 4.3 Functional Foods for Chronic Disease Prevention |
| | |






| | | UNIT | - V | | |
|-----|------------------|---|--------------|------------------------------------|---|
| Cha | and of D | ency, Regulato Pharmacopoe ietary Supplen aceuticals | ial Specific | s cations (5 - 1) to (5 - 48 |) |
| 5.1 | Various Environ | | the Potentia | ıl 5 - 1 | |
| 5.2 | Pharmacopoeial | Specifications for | Dietary Supp | | |
| | and Nutraceutica | ils | | 5 - 45 | |












Principles of Drug Discovery







Principles of Drug Discovery

As per PCI Regulations For M.Pharm : Semester-II

FIRST EDITION

Dr. Padmaja Santosh Kore

M.Pharm, Ph.D.(Pharmacology)
Assistant Professor, Department of Pharmacology
Progressive Education Society's Modern College of Pharmacy,
Yamunanagar, Nigdi, Pune- 411 044

Dr. Subhash Laxmanrao Bodhankar

M.Sc, Ph.D.(Pharmacology)
Professor, Department of Pharmacology
Bharati Vidyapeeth, Deemed to be University, Poona College of Pharmacy,
Paud Road, Erandwane, Pune- 411 038







Principles of Drug Discovery

First Edition: October - 2022

ISBN: 978-93-92867-15-6

© All rights reserved. No part of this book may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior written permission of the publishers.

Published by:

Career and Pharma Publications Reg. Off.: 432/B, Deshmukh Bungalow, Vakil Wadi, Nashik - 422 001. Maharashtra, India.

Communication Address:

Second Floor, Kaveri Smruti, Vakil Wadi, Ashok Stambh, Nashik - 422 001 Maharashtra, India. Ph.: (0253) 2311422, 2576175

E-mail:stores@careerandyou.com www.pharmacareerbooks.com

Typesetting:

Renuka Chandwadkar

Cover Design:

Satish More

Editor:

Sudhanva Tipare

Printer:

Trinity Academy for Corporate Training Ltd.





About the Book

Salient features of the book:

- ✓ The book covers the basic principles of the drug discovery.
- ✓ The concepts are made simpler for the postgraduate students.
- ✓ The book covers the contents as per the PCI syllabus.

About the Authors



Dr. Padmaja Santosh Kore is Assistant Professor (Pharmacology) at Progressive Education Society's Modern College of Pharmacy, Pune. She has teaching experience of 12 years and has guided 3 M.Pharm students for their project. She has published various review and research papers in peer reviewed, national and

international journals and presented various oral research papers. She has reviewed 4 research papers and has published several book chapters in national books and has 5 upcoming book chapters in international books.



Dr. Subhash Laxmanrao Bodhankar is working as Professor of Pharmacy Practice at Poona College of Pharmacy, Pune. He has started his career as Lecturer in Pharmacology at Lady Hardinge Medical College, New Delhi and Holkar Science College, Indore. He has worked for ten years as faculty at Ahmadu Bello University,


Zaria, Nigeria. He has guided 27 Ph.D. and more than 150 M.Pharm. students. He has also completed about 150 industrial projects. He has published 404 research papers and has H index-59 and citations 10248 and I10 index 225. He has written a text book and co-authored many book chapters. His name has been included by Stanford University USA in the list of top two percent scientists in the world.







Pharmaceutical Organic Chemistry -III














TABLE OF CONTENTS

| 1977 | Unit - I | |
|--------------------|-------------------------------------|---------------------|
| Chapter - 1 Stereo | Isomerism | (1 - 1) to (1 - 58) |
| 1.1 Introduction | of Stereo Isomerism | 1 - 2 |
| 1.2 Optical Isome | erism | 1 - 4 |
| | Activity | |
| 1.2.2 Enantic | omerism | 1 - 6 |
| 1.2.3 Diaster | eomerism | 1 - 7 |
| 1.2.4 Meso 0 | Compounds | 1 - 9 |
| 1.3 Elements of S | Symmetry | 1 - 9 |
| 1.4 Chiral and Ac | hiral Molecules | 1 - 12 |
| 1.5 D, L System o | of Nomenclature | 1 - 13 |
| 1.6 RS System of | Nomenclature | 1 - 15 |
| 1.6.1 Sequer | nce Rules | 1 - 15 |
| 1.7 Reactions of | Chiral Molecules | 1 - 21 |
| 1.8 Racemic Mod | dification and Resolution of Racemi | c Mixtures 1 - 25 |
| 1.9 Asymmetric | Synthesis | 1 - 31 |
| Multiple Choice | Questions with Answers | 1 - 37 |
| Short Answer Qu | estions | 1 - 56 |
| Long Answer Qu | estions | 1 - 57 |
| | Unit - II | |
| Chapter - 2 Geo | metrical Isomerism | (2 - 1) to (2 - 50) |
| 2.1 Introduction | of Geometrical Isomerism | 2 - 2 |
| 2.1.1 Isomer | 5 | 2 - 2 |
| 2.1.2 Geome | etric (Cis / Trans) Isomerism | 2 - 2 |
| 2.1.3 The Im | portance of Drawing Geometric Isome | ers2 - 4 |
| 2.1.4 Identifi | cation of Geometric Isomers | 2 - 4 |
| | (ix) | |





| 2.2 Conformational Isomerism | |
|--|-------------------------|
| 2.2.1 Introduction of Conformational Isomers | |
| 2.2.2 Conformation of Ethane | |
| 2.2.3 Conformational Isomerism of n-butane | |
| 2.2.4 Conformations of Cyclohexane | |
| 2.3 Stereoisomerism in Biphenyl Compound (Atropisomer | rism) and |
| Condition for Optical Activity | |
| 2.3.1 Stereoisomerism | |
| 2.3.2 Conformers | |
| 2.3.3 Anomers | |
| 2.3.4 Atropisomers | |
| 2.3.5 Stereoisomerism in Biphenyls Compounds | |
| 2.4 Stereospecific and Stereo Selective Reactions | |
| Multiple Choice Questions with Answers | |
| Short Answer Questions | |
| Long Answer Questions | |
| Unit - III | (3 - 1) to (3 |
| Unit - III Chapter - 3 Heterocyclic Compounds - I | (3 - 1) to (3 |
| Unit - III Chapter - 3 Heterocyclic Compounds - I 3.1 Nomenclature and Classification of Heterocyclic Com | (3 - 1) to (3 |
| Unit - III Chapter - 3 Heterocyclic Compounds - I 3.1 Nomenclature and Classification of Heterocyclic Compounds into Classes | (3 - 1) to (3 |
| Unit - III Chapter - 3 Heterocyclic Compounds - I 3.1 Nomenclature and Classification of Heterocyclic Com | (3 - 1) to (3 pounds |
| Unit - III Chapter - 3 Heterocyclic Compounds - I 3.1 Nomenclature and Classification of Heterocyclic Compounds into Classes | (3 - 1) to (3 |
| Unit - III Chapter - 3 Heterocyclic Compounds - I 3.1 Nomenclature and Classification of Heterocyclic Compounds | (3 - 1) to (3 |
| Unit - III Chapter - 3 Heterocyclic Compounds - I 3.1 Nomenclature and Classification of Heterocyclic Compounds into Classes | (3 - 1) to (3 |
| Unit - III Chapter - 3 Heterocyclic Compounds - I 3.1 Nomenclature and Classification of Heterocyclic Compounds into Classes | (3 - 1) to (3 |
| Unit - III 3.1 Nomenclature and Classification of Heterocyclic Compinto Classes | (3 - 1) to (3 |
| Unit - III 3.1 Nomenclature and Classification of Heterocyclic Compinto Classes | (3 - 1) to (3 |
| Unit - III 3.1 Nomenclature and Classification of Heterocyclic Compinto Classes | (3 - 1) to (3 |






| 3.4 Thiophene | 3 - 2 |
|--|--|
| 3.4.1 Synthesis of Thiophene | 3 - 2 |
| 3.4.2 Reactions of Thiophene | 3 - 2 |
| 3.4.3 Medicinal Uses Thiophene | 3 - 3 |
| 3.5 Molecular Orbital Picture of Heterocyclic Compounds | 3 - 3 |
| 3.6 Relative Aromaticity and Reactivity of Pyrrole | 3 - 3 |
| 3.7 Relative Aromaticity and Reactivity of Furan | 3 - 3 |
| 3.8 Relative Aromaticity and Reactivity of Thiophene | 3 - 3 |
| Multiple Choice Questions with Answers | 3 - 4 |
| Short Answer Questions | 3 - 5. |
| Long Answer Questions | 3 - 5. |
| Unit - IV | MARK DELLAS |
| 4.3 Indidentia | |
| 4.2 Imidazole | |
| | 4 - 9 |
| 4.3 Oxazole | 4 - 1 |
| 4.3 Oxazole | 4 - 1: 4 - 1: |
| 4.3 Oxazole | |
| 4.3 Oxazole | |
| 4.3 Oxazole | 4 - 15 |
| 4.3 Oxazole | 4 - 19 4 - 19 4 - 18 4 - 22 4 - 32 4 - 38 4 - 38 |
| 4.3 Oxazole 4.4 Thiazole 4.5 Pyridine 4.6 Quinoline 4.7 Isoquinoline 4.8 Acridine 4.9 Indole | 4 - 15 |
| 4.3 Oxazole | 4 - 1 4 - 1 4 - 1 4 - 2 4 - 3 4 - 3 4 - 3 4 - 4 4 - 4 |
| 4.3 Oxazole | 4 - 10 4 - 11 4 - 12 4 - 13 4 - 22 4 - 33 4 - 34 4 - 45 4 - 45 4 - 56 4 - 56 |
| 4.3 Oxazole | 4 - 1 4 - 1 4 - 1 4 - 2 4 - 3 4 - 3 4 - 3 4 - 4 4 - 4 4 - 5 4 - 5 4 - 5 |
| 4.2 Imidazole | 4 - 10 |





Regulatory Affairs







REGULATORY AFFAIRS (MPH 104T)

Dr. Vivek S. Tarate

Asst. Professor, Navsahyadri Institute of Pharmacy, Nasarapur, Pune.

Dr. Upendra C. Galgatte

Associate Professor,
Department of Pharmaceutics,
Modern College of Pharmacy,
Nigdi, Pune.

Dr. Sachinkumar D. Gunjal

Assistant Professor, Amrutvahini College of Pharmacy, Sangamner.

Dr. Shilpa S. Kolhe

Assistant Professor,

Vishal Institute of Pharmaceutical Education and Research Ale,


Pune.



Kripa-Drishti Publications, Pune.











INDEX

| | Unit 1- A | 1 |
|---|---|------|
| | 1.1 Documentation in Pharmaceutical Industry: | 1 |
| | 1.1.1 General Requirement: | 7 |
| | 1.1.2 Importance of Documentation in Pharmaceutical Industry: | 3 |
| | 1.1.3 Master Formula Record: | 5 |
| | 1.2 Manufacturing: | 9 |
| | 1.2.1 Packaging: | 9 |
| | 1.2.2 Drug Master File (DMF): | 10 |
| | 1.2.3 DMF Format and Delivery: | 14 |
| | 1.3 Generic Drugs Product Development Introduction: | 16 |
| | 1.3.1 Generic Drug: | 16 |
| | 1.4 Hatch- Waxman Act and Amendments: | 20 |
| | 1.5 CFR (Code of Federal Regulation): | 22 |
| | 1.5.1 CFR Organization: | 22 |
| | 1.6 ANDA Regulatory Approval Process: | 25 |
| | 1.6.1 ANDA Requirement: | 27 |
| | 1.6.2 NDA Approval Process: | 30 |
| | 1.6.3 BE and Drug Product Assessment: | 31 |
| | 1.7 SUPAC - Scale-Up and Post-Approval Changes: | 22 |
| | 1.7.1 SUPAC guidelines: | 34 |
| | 1.7.2 The Systematic Aspect of SUPAC: | 35 |
| | 1.7.3 Post-Marketing Surveillance: | 36 |
| | 1.8 Outsourcing BA and BE to CRO: | 30 |
| | 1.8.1 Selection of CRO: | . 40 |
| | Unit 1- B | |
| | 1.2 Active Pharmaceutical Ingredient (API): | 43 |
| | 1.2.1 Classification of Active Pharmaceutical Ingredient (API): | 44 |
| | 1.3 Selection of Reference Biologic: | 47 |
| | 1.4 Novel: | 48 |
| | 1.4.1 Novel Drug Delivery Approaches: | 48 |
| | 1.5 Therapies Obtaining NDA: | 50 |
| | 1.5.1 Abbreviated New Drug Application (ANDA): | 51 |
| | Unit 2. | |
| | 2.1 CMC: | 53 |
| | - 2.1.1 Applications: | 54 |
| | 2.1.2 Description: | 55 |
| 1 | * | |
| ١ | | |





| | 2.1.3 Chemical Structure & Identifiers: | |
|---|---|------|
| 2. | 2 Correct Steps for Dispersing Carboxymethylcellulose Sodium. | |
| | 2.2.1 Post Approval Regulatory Affairs | |
| | 2.2.2 Regulation for Combination Products and Medical Devices | |
| | 2.2.3 Combination Products: | |
| 2.3 | C1D (Common Technical Document): | |
| | 2.3.1 CTD Structure: | |
| | 2.3.2 Silent Benefits of the CTD: | **** |
| | 2.3.3 Limitations of CTD: | **** |
| | 2.3.4 The CTD dossier is divided into five main modules: | |
| | 2.3.5 Benefits of eCTD: | •••• |
| | 2.3.6 COMPARISON ASCED A COTO | |
| 2.4 | 2.3.6 COMPARISON of CTD and eCTD: | |
| 2,4 | M. Regulatory Requirements of Eu, Tga, Mhra and Row Countries | |
| 2.0 | 2.4.1 EU: | |
| 2.3 | Guidelines and Scientific Advice: | |
| | 2.5.1 Authorisation and Supervision of Manufacturers | |
| 2.6 | TGA: | |
| | 2.6.1 Role of TGA: | |
| | 2.6.2 Structure of TGA: | |
| 2.7 | MHRA: | |
| | 2.7.1 Objectives of MHRA: | |
| 100 | 2.7.2 MHRA's Activities: | " |
| | 2.7.3 Role of MHRA: | •••• |
| | | |
| | it 3 | |
| | Non Clinical Drug Development: | |
| 3.1 | Non Clinical Drug Development: 3.1.1 Types of Non-Clinical Study | |
| 3.1 | Non Clinical Drug Development: 3.1.1 Types of Non-Clinical Study First Dose Estimation in Humans: | |
| 3.1 | Non Clinical Drug Development: 3.1.1 Types of Non-Clinical Study First Dose Estimation in Humans: Global Submission of IND: | |
| 3.1 | Non Clinical Drug Development: 3.1.1 Types of Non-Clinical Study First Dose Estimation in Humans: Global Submission of IND: 3.2.1 There are Three IND Types: | |
| 3.1 | Non Clinical Drug Development: 3.1.1 Types of Non-Clinical Study First Dose Estimation in Humans: Global Submission of IND: 3.2.1 There are Three IND Types: 3.2.2 Global Submission of NDA: | |
| 3.1 | Non Clinical Drug Development: 3.1.1 Types of Non-Clinical Study First Dose Estimation in Humans: Global Submission of IND: 3.2.1 There are Three IND Types: 3.2.2 Global Submission of NDA: 3.2.3 Guidance Documents for NDAs: | |
| 3.1 | Non Clinical Drug Development: 3.1.1 Types of Non-Clinical Study First Dose Estimation in Humans: Global Submission of IND: 3.2.1 There are Three IND Types: 3.2.2 Global Submission of NDA: 3.2.3 Guidance Documents for NDAs: | |
| 3.1 3.2 3.3 | Non Clinical Drug Development: 3.1.1 Types of Non-Clinical Study First Dose Estimation in Humans: Global Submission of IND: 3.2.1 There are Three IND Types: 3.2.2 Global Submission of NDA: 3.2.3 Guidance Documents for NDAs: 3.2.4 Global Submission of ANDA: Format of an IMPD: | |
| 3.1 3.2 3.3 | Non Clinical Drug Development: 3.1.1 Types of Non-Clinical Study First Dose Estimation in Humans: Global Submission of IND: 3.2.1 There are Three IND Types: 3.2.2 Global Submission of NDA: 3.2.3 Guidance Documents for NDAs: 3.2.4 Global Submission of ANDA: Format of an IMPD: | |
| 3.1 3.2 3.3 3.3 3.4 | Non Clinical Drug Development: 3.1.1 Types of Non-Clinical Study First Dose Estimation in Humans: Global Submission of IND: 3.2.1 There are Three IND Types: 3.2.2 Global Submission of NDA: 3.2.3 Guidance Documents for NDAs: 3.2.4 Global Submission of ANDA: | |
| 3.1 3.2 3.3 3.4 Uni | Non Clinical Drug Development: 3.1.1 Types of Non-Clinical Study First Dose Estimation in Humans: Global Submission of IND: 3.2.1 There are Three IND Types: 3.2.2 Global Submission of NDA: 3.2.3 Guidance Documents for NDAs: 3.2.4 Global Submission of ANDA: Format of an IMPD: Investigator Brochure (IB): | |
| 3.1 3.2 3.3 3.4 Uni | Non Clinical Drug Development: 3.1.1 Types of Non-Clinical Study First Dose Estimation in Humans: Global Submission of IND: 3.2.1 There are Three IND Types: 3.2.2 Global Submission of NDA: 3.2.3 Guidance Documents for NDAs: 3.2.4 Global Submission of ANDA: Format of an IMPD: Investigator Brochure (IB): | |
| 3.1 3.2 3.3 3.4 Uni 4.1 4.2 | Non Clinical Drug Development: 3.1.1 Types of Non-Clinical Study First Dose Estimation in Humans: Global Submission of IND: 3.2.1 There are Three IND Types: 3.2.2 Global Submission of NDA: 3.2.3 Guidance Documents for NDAs: 3.2.4 Global Submission of ANDA: Format of an IMPD: Investigator Brochure (IB): t 4 Clinical Trials: Clinical Trial Protocol Development: | |
| 3.1 3.2 3.3 3.4 Uni 4.1 4.2 | Non Clinical Drug Development: 3.1.1 Types of Non-Clinical Study First Dose Estimation in Humans: Global Submission of IND: 3.2.1 There are Three IND Types: 3.2.2 Global Submission of NDA: 3.2.3 Guidance Documents for NDAs: 3.2.4 Global Submission of ANDA: Format of an IMPD: Investigator Brochure (IB): t 4 Clinical Trials: Clinical Trial Protocol Development: HIPAA – New, Requirement to Clinical Study Process: | |
| 3.1 3.2 3.3 3.4 Uni 4.1 4.2 | Non Clinical Drug Development: 3.1.1 Types of Non-Clinical Study First Dose Estimation in Humans: Global Submission of IND: 3.2.1 There are Three IND Types: 3.2.2 Global Submission of NDA: 3.2.3 Guidance Documents for NDAs: 3.2.4 Global Submission of ANDA: Format of an IMPD: Investigator Brochure (IB): t 4 Clinical Trials: Clinical Trial Protocol Development: HIPAA – New, Requirement to Clinical Study Process: 4.4.1 HIPAA Privacy Rule: | |
| 3.1 3.2 3.3 3.4 Uni 4.1 4.2 | Non Clinical Drug Development: 3.1.1 Types of Non-Clinical Study First Dose Estimation in Humans: Global Submission of IND: 3.2.1 There are Three IND Types: 3.2.2 Global Submission of NDA: 3.2.3 Guidance Documents for NDAs: 3.2.4 Global Submission of ANDA: Format of an IMPD: Investigator Brochure (IB): t 4 Clinical Trials: Clinical Trial Protocol Development: HIPAA – New, Requirement to Clinical Study Process: 4.4.1 HIPAA Privacy Rule: 4.4.2 Pre-Research Review of Medical Records | |
| 3.1 3.2 3.3 3.4 Uni 4.1 4.2 | Non Clinical Drug Development: 3.1.1 Types of Non-Clinical Study First Dose Estimation in Humans: Global Submission of IND: 3.2.1 There are Three IND Types: 3.2.2 Global Submission of NDA: 3.2.3 Guidance Documents for NDAs: 3.2.4 Global Submission of ANDA: Format of an IMPD: Investigator Brochure (IB): t 4 Clinical Trials: Clinical Trial Protocol Development: HIPAA – New, Requirement to Clinical Study Process: 4.4.1 HIPAA Privacy Rule: | |





ABOUT THE AUTHORS



ntly working as Asst. Professor at Navsahyadri Institute of Pharmacy, Nasarapur, Pune. He has

He is presently working as Asst. Professor at Navsahyadri Institute of Pharmacy, Nasarapur, Pune. He has completed M-Pharm in Pharmaceutics from Savitribai Phule Pune University, Pune. He has completed PhD in Naturopathy (Diabetes Reversal) & another PhD (HC) in subject healthcare from Commonwealth University, kingdom of Tonga for his contribution to healthcare sector. He also Completed Certificate and Diploma courses in Naturopathy, Medical Astrology (International Medical Astrologer), Cupping Therapy (TCM - China), Code Blue Trainer (Lincoln University, Malaysia), Nutrition & Diet Planning (FAB Acomy, USA) and Regulatory Africa (LIDL, UK approved) from various national & International Universities. He received 1 Indian Patent Grant (Designs) & 4 International Germany utility patent grants. His research works under patent grant process in India and South Africa country. His research interest includes GRDDS, Manoparticles, Herbal formulations, Type 1 & 2 diabetes reversal. He received 2 copyrights for his value added courses designs. He published review as well as research papers in various UGC Care, Scopus journals. He is a founder of Intellect institute of Education and Research, Pune. He is also founder of Savityava Natural Cure, Satara. He is also working as consultant for Hospitals and Pharma giants. In 2021 he is appointed and upgraded as ILI Paramedic at Hospital & Institute of Integrated Medical Sciences, Chandigarh. He is a fellow member of Screenwriters Association, Mumbal. He is a certified Psychological Counselor. He is also member of Indo-Vietnam medical board and appointed as Network of Influenza Care Expert.



He is presently working as Associate Professor in Department of Pharmaceutics at Modern College of Pharmacy, Nigdi, Pune. He has completed post-graduation in Pharmaceutics from Rashtrasant Tukdoji Maharaj Nagpur University and doctorate in Pharmaceutical Sciences from Jawaharial Mehru Technological University, Hyderabad. He has 20 years of experience in academics teaching to undergraduate and postgraduate levels. His research interest includes development of in-situ gels, nasal drug delivery, quantum enters, self-emulsifying drug delivery systems, colloidal drug delivery, fast disintagrating/dissolving oral films, gastro retentive delivery systems, polymer forming matrix delivery. He has been awarded 'Best Teacher Award' by Progressive Education Society, Pune. He is the life-member of different professional bodies vix Indian Pharmaceutical Association, Indian Society for Technical Education, Association of Pharmaceutical Teachers of India, InPharm Association and All India Council for Technical Skill Development. He has more than twenty-seven publications in the technical journals of national and international repute He has successfully completed sponsored projects of University Grants Commissions and Sovitrial Phale Pune University. He is approved post graduate teacher in Pharmaceutics at Sovitrial Phule Pune University and he has guided more than 45 students for M. Pharm. Dissertation. He is current working as an Editorial Board member of Open Access Journal of Pharmaceutical Research and has reviewed several manuscripts of various national and international journals. He has been resource person for seminars, workshops and conferences. His 2 Indian Patents published and under grant process.



He is presently working as Assistant Professor at Amrutvahini College of Pharmacy, Sangamner. He has completed B. Pharm. from Bharati Vidyapeeth's Poona College of Pharmacy, Erandwane, Pune (Savitribai Phule Pune University) and M. Pharm from Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune (Savitribai Phule Pune University). He has completed M.B.A. From P.L.R.E.N. Sinstitute of Business Management and Administration, Loni (Savitribai Phule Pune University). He has completed his PhD, in Pharmaceutics Subject form Savitribai Phule Pune University under guidance of Dr. S. V. Shirolkar sir at Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune. His research works is published in many National and International Journals. He has worked as Assistant Professor at M.A.E.E.R'S Maharashtra Institute of Pharmacy, Pune from December, 2005 to November, 2015. He is a member of Indian Pharmaceutical Association (IPA) and Association of Pharmaceutical Teachers of India (APTI).



She is presently working as Assistant Professor at Vishal Institute of Pharmaceutical Education and Research Ale, Pune. She has completed B. Pharm from Savitribai Phule Pune University Pune and M.Pharm in Pharmacognosy from Solapur University. She has completed PhD from Bhagwant University, Ajmer. She published 1 Indian Patent. Her research interest includes phytopharmacy, Nanoparticles, Herbal formulations. She published 3 review as well as 6 research papers in various UGC Care, Scopus journals. She participated in 15 International, national and state level conference and workshop. She also work as evaluator for state level poster presentation competition.



Kripa-Drishti Publications A-503 Poorva Heights, Pashan-Sus Road, Near Sai Chowk, Pune - 411021, Maharashtra, India. Mob: +91 8007068686

Email: editor@kdpublications.in Web: https://www.kdpublications.in




Price: ₹399

Progressive Education Society's Modern College of Pharmacy, Nigdi, Pune 411044






The Microbial World: Exploring the Diversity of Bacteria













Published By: Rubicon Publications

4/4A Bloomsbury Square,
Bloomsbury Square,
London, WC1A 2RP, England
Email: info@rubiconpublications.com

Authors: Dr. Smeeta Sadar, Dr. Padmaja Kore and Dr. Anuradha More

The editors/publisher has attempted to trace and acknowledge the materials reproduced in this publication and apologize if permission and acknowledgements to publish in this form have not been given. If any material has not been acknowledged please write and let us know so that we may rectify it.

© Rubicon Publications

Edition: 1st

Publication Year: 2023 ISBN: 978-1-80433-971-8

Pages: 227
Price: £ 21








| ei " | | | |
|------|-----|---|---------|
| | 14. | Prevotella saccharolytica (Payal Patel and Dr. Padmaja Kore) | 145-154 |
| | 15. | Prevotella brevis | 155-162 |
| | 16. | (Payal Patel and Dr. Anuradha More) Prevotella bivia (Aditya Prakash Sarode and Dr. Anuradha More) | 163-182 |
| | 17. | Prevotella timonensis: Pathogenicity and Immune Response | 183-191 |
| | 18. | (Aditya Prakash Sarode and Dr. Anuradha More) Prevotella loescheii | 193-200 |
| | 19. | (Tanaya Deshpande and Dr. Anuradha More) Prevotella pallens (Ishika Shukla and Dr. Anuradha More) | 201-210 |
| | 20. | Prevotella buccalis (Ishika Shukla and Dr. Anuradha More) | 211-217 |
| | 21. | Prevotella amnii (Vaibhavi Kulkarni and Dr. Anuradha More) | 219-227 |
| | | Coilege of San August Pump Art 1 | |
| | | | |
| | | | |
| | | | |
| | | NI DEA DESTRUCTION PAR EL | |





A Textbook of Organic Chemistry









Title of the Book: A Textbook of Organic Chemistry

Edition: First - 2023 Copyright © Authors

No part of this text book may be reproduced or transmitted in any form by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the copyright owners.

Disclaimer

The authors are solely responsible for the contents published in this text book. The publishers or editors do not take any responsibility for the same in any manner. Errors, if any, are purely unintentional and readers are requested to communicate such errors to the editors or publishers to avoid discrepancies in future.

ISBN: 978-93-5757-313-9

MRP: Rs 600 /-

PUBLISHER & PRINTER: Scientific International Publishing House

Website: www.sipinternationalpublishers.com






CONTENTS

| CHAPTER | TITLE | PAGE.NO |
|---------|--|---------|
| I | Derivatives of Hydrocarbons: Aldehydes | 1-42 |
| п | Derivatives of Hydrocarbons: Ketons | 43-76 |
| Ш | Derivatives of Hydrocarbons: Carboxylic Acids | 77-118 |
| IV | Functional Derivatives of Monocarboxylic Acids | 119-146 |
| v | Organic Compounds Containing Nitrogen | 147-168 |
| VI | Amino Compounds | 169-200 |
| | References | 201-202 |






Elements of Pharmacotherapeutics



























| No. | CONTENTS | D |
|--------|---|--------|
| | Chapter | Page n |
| 0 | Medical terminologies and first aid | 1 |
| 1. | Pharmacotherapeutics - introduction | 5 |
| 2. | Cardiovascular system | 13 |
| 2.1 | Hypertension | 19 |
| 2.2 | Angina and myocardial infarction | 29 |
| 2.3 | Hyperlipidaemia | 42 |
| 2.4 | Congestive heart failure | 48 |
| 3. | Respiratory system | 63 |
| 107/21 | | 1.5000 |
| 3.1 | Bronchial asthma | 64 |
| 3.2 | COPD | 71 |
| 4. | Endocrine system | 76 |
| 4.1 | Diabetes | 77 |
| 4.2 | Thyroid disorders | 90 |
| 5. | Central nervous system | 97 |
| 5.1 | Epilepsy | 98 |
| 5.2 | Parkinson's disease | 102 |
| 5.3 | Alzheimer's disease | 107 |
| 5.4 | Stroke | 109 |
| 5.5 | Migraine | 112 |
| 6. | Gastro intestinal disorders | 120 |
| 6.1 | GERD (Gastro Esophageal Reflux Disease) | 121 |
| 6.2 | Peptic ulcer disease | 125 |
| 6.3 | Alcoholic liver disease | 132 |
| 6.4 | Inflammatory bowel diseases | 136 |
| 7. | Haematological disorders | 140 |
| 7.1 | Iron deficiency anaemia | 142 |
| 7.2 | Megaloblastic anaemia | 146 |
| 8. | Infectious diseases | 149 |
| 8.1 | Tuberculosis | 150 |
| 8.2 | Pneumonia | 154 |
| 8.3 | Urinary tract infections | 156 |
| 8.4 | Hepatitis | 158 |








| No. | Chapter | Page no |
|------|----------------------------------|---------|
| 8.5 | Gonorrhoea and Syphilis | 163 |
| 8.6 | Malaria | 166 |
| 8.7 | HIV and Opportunistic infections | 171 |
| 8.8 | Viral infections | 174 |
| 9. | Musculoskeletal disorders | 189 |
| 9.1 | Rheumatoid arthritis | 191 |
| 9.2 | Osteoarthritis | 195 |
| 10. | Dermatology | 199 |
| 10.1 | Psoriasis | 200 |
| 10.2 | Scabies | 204 |
| 10.3 | Eczema | 205 |
| 11. | Psychiatric disorders | 209 |
| 11.1 | Depression | 210 |
| 11.2 | Anxiety | 213 |
| 11.3 | Psychoses | 216 |
| 12. | Ophthalmology | 220 |
| 12.1 | Conjunctivitis | 221 |
| 12.2 | Glaucoma | 224 |
| 13. | Anti-microbial resistance | 230 |
| 14. | Women's health | 235 |
| 14.1 | Polycystic ovary syndrome | 236 |
| 14.2 | Dysmenorrhea | 239 |
| 14.3 | Premenstrual syndrome | 240 |
| | Bibliography | |
| | Index | 244 |
| | | (i)-(ii |





Chapter 4 Quantitative analysis of ursolic acid in the leaves of species of genus tecoma and tabebuia of bignoniaceae family by high- performance thin-layer method





Edited Book: Recent Advances in Pharmaceutical Sciences (Volume 7) Pharmaceutical sciences includsubject seeking to foster the in-Publication Year: May. 2022 locus on all facet of drug and ranges from identification and MRP: INR 500 design of drug, formulation, clinand audit of drugs, manufacture © Innovare Academic Sciences Pvt Ltd total sciences, public, to enviro quality of human life. ISBN: 978-81-952065-9-9 The Chapter of the compiler knowledge and the updated resea It touched on addressing the rewarness through the different betterment of society and heal Publisher and address: multidisciplinary nature in pl Innovare Academic Sciences Pvt Ltd valuably to other research areas I T-8, Mahaveer Apartment, Near SIRT College, Ayodhya Bypass, Bhopal 462041, MP, India. Phone: +91 9425108574 The edited book aims to bring Email: info@innovareacademics.in | https://innovareacademics.in/ different subjects of Pharmace knowledge for further research. Printer: Innovare Academic Sciences Pvt Ltd We hope that this book may upgrading and acquiring the late the study. he continuous volume will con information and knowledge on rec-





| | Index | | | Chapter No | Title | Author(s) | Page No. |
|----------------|---|--|-------------|---------------|--|---|-------------|
| Chapter No. | Title | Author(s) | Page No. | " | ANTIVIRALS SHORTAGES AMIDST COVID-19 IN AFRICA: HOW AFRICA IS STRUGGLING | Sudhan Rackimuthu, Zohra Kazmi, Osman Kamal Osman Elmahi, Roem Hunain, Behram | 220-228 |
| L | BISPHOSPHONATE DRUG IBANDRONATE LOADED CHITOSAN NANOPARTICLES FOR EFFECTIVE MANAGEMENT OF OSTEOIVOROSIS DEVELOPMENT TO RELESE KINETIC STUDY | Sandhya Pathak, Archna Pandey | 1-14 | | | Khan Ghazi, Syed Zain Ali, Ana Carla dos Santos Costa, Shoaib Ahmad, Mohammad Yasir Essar | |
| 2 | OLEANOLIC ACID, A PROSPECTIVE PROTECTIVE AGENT AGAINST BRAIN ENERGY METABOLISM AND OXIDATIVE DYSFINCTIONS FOLLOWING HEXAVALENT | Sudipta Pal | 15-44 | " | FORMULATION AND CHARACTERIZATION OI SAQUINAVIR NANOPARTICLES PREPARED BY NANOPRECIPITATION METHOD HERBAL REMEDIES FOR DIABETES | S.Sivaprasad, CH. Sadakvali. Rajesh A. Maheshwari. | 229-242 |
| 3. | CHROMIUM EXPOSURE IN MICE OBSTETRIC OUTCOME AFTER EMERGENCY CERVICAL CERCLAGE: A PROSPECTIVE OBSERVATIONAL STUDY PERFORMED IN CSI KALYANI HOSPITAL, CHENNAI | Shalini, Umachander Meena, R Malari | 45-51 | | NEPHROPATHY | Kinjal P. Patel, Ashim Kumar Sen, Ramachandran Bolaraman, Dhanya B. | 243-253 |
| 4. | QUANTITATIVE ANALYSIS OF URSOLIC ACID IN THE LEAVES OF SPECIES OF GENUS TECOMA AND TABEBUIA OF BIGNONIACEAE FAMILY BY HIGH-PEIFORMANCE THIN-LAYER | Kalyani A. Kedar | 52-63 | | ANTIBACTERIAL AND HAEMOLYTIC ACTIVITY OF PHYTOCHEMICALS FROM FRESHWATER MICRO ALGA, EUGLENA VIRIDIS (EHREN) | Sen Jyotirmayee Pradhan, Basanta Kumar Das | 254-269 |
| 5. | CHROMATOGRAPHIC METHOD UTILITY OF PRAMANA IN AYURVEDA – A REVIEW | K. Manjula, V. Asokan | 64-71 | 17 | FORMULATION AND EVALUATION OF PULSATILE DRUG DELIVERY SYSTEM FOR ANTI ASTHMATIC DRUG SALBUTAMOL | Vigneshwar M, Senthilnathan B, Muniyappan S, Masilamani K | 270-279 |
| 6. | MANAGEMENT OF COMPUTER VISION SYNDROME WITH SAINDHAVA JALA SEKA AND TRUPHALA GHRITAPANA – A CASE STUDY | Dr. Borkar Manasi II. Dr. Kotangale Sumedha Y., Dr. Kotangale Yogesh T. | 72 78 | ** | HERBAL DRUGS FOR DIABETES MELLITUS | Dhanya B. Sen, Ashim Kumar Sen, Aarti S. Zanwar, Kinjal P. Patel, Rajesh A. Maheshwari | 280-292 |
| 7. | ETHNOMEDICINAL VALUE OF ANTIDIABETIC PLANTS | Sunand Katta, Narender Boggula, Himabindu Peddapalli, Swetha Naramreddy | 79-96 | - | THE MOST BENEFICIAL ADIPOKINE - AMPONECTIN | Kinjal P. Patel, Ashim Kumar Sen, Ramachandran Balaraman, Dhanya B. | 293-308 |
| 8. | IMPORTANCE OF NANOCARRIERS AND PROBIOTICS IN THE TREATMENT OF ULCERATIVE COLITIS | Vandana Thukurt, Bhupendra Singht, Ankita Sharmat, Nisha | 97-123 | - | NIMULTANEOUS ASSESSMENT OF | Sen, Rajesh A. Maheshwari | |
| | | Kumarit, Inder Kumar, Kritika Verma, Arvind Kumar, Sushmita Rana | | - | ALOGLIPTIN BENZOATE AND PIOGLITAZONE HYDROCHLORIDE IN TABLET DOSAGE FORM BY SIMULTANEOUS | Ashim Kumar Sen, Dhanya B. Sen, Aarti S. Zanwar, Ramachandran Balaraman, Kinjal P. | 309-322 |
| 9. | AN ASSESSMENT ON FABRICATION AND PORTRAYAL OF NANOPARTICLES FOR PARENTERAL AND OPHTHALMIC | Om M. Bagade, Priyanka E. Doke | 124-152 | - | EQUATION AND ABSORBANCE RATIO METHODS TOXIC PLANTS: ALARM FOR HUMANS AND | Patel, Rajesh A. Maheshwari Faruk Alam, | 323-359 |
| 10. | ADMINISTRATION CONCEPT OF IONTOPHORESIS IN MIDDLE OF CONTROLLED DRUG DELIVERY AND ITS DEVELOPMENT | Om M. Bagade, Priyanka E. Doke | 153-181 | | ANIMALS | Durgaprasad Kemisetti, Ashim Kumar Sen, Jithendar Reddy Mandhadi, Chandrashekar Talluri, | |
| IL. | LINUM USITATISSIMUM AN INSIGHT INTO CURRENT RESEARCH ON THERAPEUTIC APPLICATION | Kinjal P. Patel, Ashim Kumar Sen, Dhanya B. Sen, Rajesh A. | 182-208 | | ADIPOCYTOKINES: A MIXED BAG IN THE DEVELOPMENT OF METABOLIC SYNDROME | Biplab Kumar Dey, Partha Pratim Dutta' Rajesh A. Maheshwari, Ramachandran | 360-378 |
| 12. | A REVIEW ON SMART DRUG DELIVERY SYSTEM | Maheshwari Alankar Shrivastava | 209-219 | | THE THE PROPERTY OF THE PROPER | Balaraman, Sarthak Mehta, Ashim Kumar Sen, Dhanya B. Sen | |





Innovare Academic Sciences Pvt Ltd

Recent Advances in Pharmaceutical Sciences [Volume 7] Aut we Academic Sciences Pvt Ltd

Recent Advances in Pharmaceutical Sciences [Volume 7]

Chapter-04

QUANTITATIVE ANALYSIS OF URSOLIC ACID IN THE LEAVES OF SPECIES OF GENUS TECOMA AND TABEBUIA OF BIGNONIACEAE FAMILY BY HIGH-PERFORMANCE THIN-LAYER CHROMATOGRAPHIC METHOD

Kalyani A. Kedar

Department of Pharmacognosy, P. E. Society's Modern College of Pharmacy, Nigdi, Pune Maharashtra, India.

ABSTRACT: A simple and sensitive high-performance thin-layer chromatographic (HPTLC) method was developed for the quantification of ursolic acid in the leaves of three species of genus Tecoma (Tecoma gaudichaudi DC, Tecoma capensis (Thunb.) Lindl, Tecoma stans (L.) Juss. ex Kunth) and genus Tabebuia (Tabebuia rosea Bertol) belong to family Bignoniaceae. Chromatography was performed on Silica gel 60 F254 precoated HPTLC Plates with optimized mobile phase pet ether: ethyl acetate: formic acid (7:3:0.5, v/v/v). The method was validated using International Council for Harmonization (ICH) guidelines, including linearity, precision, accuracy, and robustness. Ursolic acid was found to be present in four species, i.e., Tecoma gaudichaudi DC (1.48%w/w), Tecoma capensis (Thunb.) Lindl. (0.79%w/w), Tecoma stans (L.) Juss.Ex Kunth (1.11%w/w), Tabebuia rosea (Bertol.) (1.13%w/w). A good linearity relationship was found to be (200-1400ng band-1) with correlation coefficient (r2) value of 0.9946 with ursolic acid. The proposed method for the quantitation of ursolic acid was found to be reproducible and simple.

INTRODUCTION

Bignonia Linn (Bignoniaceae) is a monotypic genus of woody climbers, native to North America and mostly grown for ornament in the tropics of the old world [1]. Bignoniaceae family was having 100 genera and more than 750 plant species observed in various tropical regions of India. Known numbers of this family are *Bignonia*, *Tecoma*, *Catalpa*,

times reduced to a rhizome or tuber. Numerous species of this family observed as poisonous to leeches [2]. In Charak, Sushruta, the root, stem and leaf of some species of Bignoniaceae family is useful for bite, the stem and wood for scorpion sting. In Bangladesh whole plant of some species of a remedy for diabetes and infertility problems [3].

all secondary metabolite's pentacyclic triterpenes, are an important out of it considered as lupenyl, ursanyl, betulenyl or oleanyl. They are sented in plant species as the form of aglycone's saponin triterpenoids [4-5] Previous reports state that species of Bignoniaceae family show presence promising active constituents such as tannins, flavonoids, triterpenes, aloids, carbohydrates, etc. [6].Ursolic acid was pentacyclic triterpene sported in several plant species such as Alstonia scholars R. Br., Diospyros lanoxlon, Holoptelea integrifolia [7-9]. Ursolic acid was reported to for various biological activities such as anti-inflamatory, antidiabetic and an target several steps of cancer development. Thus, being a promising ool for the treatment and chemoprevention of cancer [10-12].

The phytochemical analysis of various species of Bignoniaceae family was not studied so far hence; the following research deals with to carry an out analysis of ursolic acid by high-performance thin layer chromatography in our species of Bignoniaceae family (Tecoma gaudichaudi DC, Tecoma capensis (Thunb.) Lindl, Tecoma stans (L.) Juss.Ex Kunth, Tabebuia rosea (Bertol.) Besto).

MATERIALS AND METHODS

Plant Materials

All four species of Bignoniaceae family, i.e. Tecoma gaudichaudi DC (Sample 1), Tecoma capensis (Thunb.) Lindl. (Sample 2), Tecoma stans (L.) Juss.Ex Kunth (Sample 3), Tabebuia rosea (Bertol.) (Sample 4) were collected from different area of Pupe district (Maharashtra), and the plants were authenticated at Botanical Survey of India, Pune with reference no. BSI/WRC/Iden./2015/576 on dated 18-12-2015. The specimen voucher number is KALKTEG1, KKA-2, KKA-3, KKA-1 specimens of plants were deposited at the Botanical Survey of India, Pune and department of Pharmacogosy, Modern College of Pharmacy, Nigdi, Pune.

Chemicals and reagents

Ursolic acid was purchased from Sigma-Adrich (USA), analytical grade solvents, reagents, silica gel 60 F254 precoated HPTLC Plates (20×20cm) were purchased from Merck (Germany).


HPTLC instrumentation and experimental conditions

Chromatographic analysis was done on $20\times10\mathrm{cm}$ HPTLC Silica gel F254 plates (Merck, Germany). Samples of extracts and standards were applied as





Chapter 2 Recent Advances in Microfluidics for Drug Screening and Its Application








| Published By: AkiNik Publications AkiNik Publications 169, C-11, Sector - 3, | Contents | |
|--|---|----------|
| Rohini, Delhi-110085, India | Chapters | Page No. |
| Toll Free (India) – 18001234070 Phone No. – 9711224068, 9911215212 Email – akinikbooks@gmail.com | Antihyperglycemic and antioxidant effect of Pimpinella tirupatiensis in STZ Induced Diabetes Mellitus (Dr. D. Veera Nagendra Kumar) | 01-21 |
| Chief Editor: Dr. Chhavi Singla | Recent Advances in Microfluidics for Drug Screening and its Applications (Dr. Kalyani Shrinivas Kakad and Badke Sarang Vilas) | 23-42 |
| The author/publisher has attempted to trace and acknowledge the materials reproduced in this publication and apologize if permission and acknowledgements to publish in this form have not been given. If any material has not been acknowledged please write and let us know so that we may rectify it. | Application of Computer Aided Drug Design in Drug Discovery (Ramen Kalia, Amir Ali, Madhusmita Kumari, Kunal Bhattacharya, Satyendra Deka and Satyasish Sandilya) | 43-53 |
| © AkiNik Publications | 4. Insights of Hospital and Hospital Pharmacy | 55-80 |
| Publication Year: 2022 | (Sohail Yakub Sayyed, Iramnaaz Pathan, Ravindra Karande and Shanvi Gawli) | |
| Pages: 129 ISBN: 978-93-5570-434-4 Book DOI: https://doi.org/10.22271/ed.book.1925 | Analytical Method Development and Validation for the Simultaneous Estimation of Gemeitabine and Carboplatin in Bulk and Dosage Forms Using RP-HPLC Method | 81-94 |
| Price: ₹ 795/- | (Dr. PV Murali Krishna) 6. Pharmaceutical Granulation Technology (Neetu Khatri and Shilpa Chaudhari) | 95-129 |
| | | |
| Tollege or | | |
| D. J. C. | | |
| Auna Att of | | |











Chapter 9 Review article: ophthalmic niosomal in situ gel

Edited Book

Recent Advances In Pharmaceutical Sciences

(Volume 9)

Dr. M S Sudeesh and Dr. Yuvraj Singh Dangi



Publisher



Innovare Academic Sciences Pvt Ltd

T-8, Mahaveer Apartment, Near SIRT College, Ayodhya Bypass, Bhopal 462041, MP, India. Phone: +91 9425108574
Email: info@innovareacademics.in | https://innovareacademics.in/





Edited Book: Recent Advances in Pharmaceutical Sciences (Volume 9)

Publication Year: October, 2022

MRP: INR 800

© Innovare Academic Sciences Pvt Ltd

ISBN: 978-81-952065-5-1

Publisher and address:

Innovare Academic Sciences Pvt Ltd
T-8, Mahaveer Apartment, Near SIRT College, Ayodhya Bypass,
Bhopal 462041, MP, India. Phone: +91 9425108574
Email: info@innovareacademics.in | https://innovareacademics.in/

Printer: Innovare Academic Sciences Pvt Ltd



About the Book

Pharmaceutical sciences include broad range of multidisciplinary subject seeking to foster the integration of areas of knowledge that focus on all facet of drug and therapies. Pharmaceutical sciences ranges from identification and control of organism causing disease, design of drug, formulation, clinical trial, metabolism, quality control and audit of drugs, manufacturing, plant-based source of medicines, food sciences, public, to environmental health for improving the quality of human life.

The Chapter of the compiled edited book contains advanced knowledge and the updated research outcomes to update the readers. It touched on addressing the recent advancement of pharmaceutical sciences through the different approaches with the aim for the betterment of society and health of wellbeing. Additionally, its multidisciplinary nature in pharmaceutical sciences contributes valuably to other research areas like medical, biological, and chemical sciences. The edited book aims to bring authors to one platform with the different subjects of Pharmaceutical sciences and share their knowledge for further research.

We hope that this book may interest a broad readership for upgrading and acquiring the latest information for the extension of the study.

Its continuous volume will come one by one to share more information and knowledge on recent advancements in pharmaceutical science.





Innovare Academic Sciences Pvt Ltd

Recent Advances in Pharmaceutical Sciences [Volume 9] Innovare Academic Sciences Pvt Utd

Recent Advances in Pharmaceutical Sciences [Volume 9]

Chapter-09

REVIEW ARTICLE: OPHTHALMIC NIOSOMAL IN SITU GEL

Dr. Ujwala Desai¹, Dr. Punam Kela², Esha Patel³

Assistant Professor, Department of Pharmaceutics, PES

Modern College of Pharmacy, sector no. 21, yamunanagar,
Nigdi, Pune, Maharashtra, India, ²Assistant professor,
Department of Pharmacy practice, PES Modern College of
Pharmacy, sector no. 21, yamunanagar, Nigdi, Pune,
Maharashtra, India, ³Pharm D Student, PES Modern
College of Pharmacy, sector no. 21, yamunanagar, Nigdi,
Pune, Maharashtra, India

ABSTRACT: The main aim of a pharmaceutical formulation is the achievement of minimum therapeutic drug concentration at the location of action a sufficient time period to elicit a response. The bioavailability of drugs of ocular desage form are reduced due to tear production, nunproductive absorption, transient residence time, impermeability of corneal epithelium and metabolism of drug by lysosomal enzymes present in lachrymal fluids. Though the topical application is still the best way to achieve desired drug concentration in treatment of ocular disorder. Other ophthalmic solutions, suspensions and various other dosage form are still not able to treat ocular disorders. The article affirms the significance of using niosomes as a likely ocular drug delivery system and emphasizes the requirement for its successful formulation to fulfill the future tasks and thereby deliver the dosage form for ocular therapy more effectively. The solitary physicochemical characteristics can be exploited by different polymers in combination with niosomes. This strategy has thus brings out upgraded outcomes compared with conventional systems. We have discussed here, the latest in use of biocompatible and biodegradable polymers in colloidal shipper systems foremost competent plan giving outcomes in the exponential expand of the bioavailability of the ophthalmic drugs.

INTRODUCTION

Ocular diseases were widely noticed since the beginning of human race and animals. There have been references to ailments of the eve in dogs and cattle in 4000 year old papyri of Ancient Egypt Between 450 and 510 AD, eight chapters devoted to the eye ailments of the horse and associated remedies were translated from Greek by Publius Vepetius Renatus in Artis Veterinariaesive Mulomedicinae [1,2]. Drug delivery in ocular healing is a challenging problem for scientists working untre multi-disciplinary areas regarding the eye, incorporating chemical, boochemical, pharmaceutical, medical, clinical, and toxicological sources. Recently, increased attention has been targeted on two main objectives: (A) To find or make newer efficacious, secure drug modecutes for diversified acular disorders and diseases (B) To enhance prevailing ocular dosage form and exploit the recent delivery systems for opgrading the ocular bioavailability of abiding molecule [3]. Newer up to dates in ocular therapeutics aim at replacing the prevailing dosage forms with novel drug delivery systems that bid improved lamptarmaceutical properties with the capacity to give our therapeutic opens more exactly to aimed receptors in the eye in aliable manner [4,5].

Poor bioavailability of drugs from ocular dosage form is chiefly due to the precorneal deprive elements which include tear dynamics (blinking orders and tear turnover), non-fruitful absorption, fleeting residence time in the cul-de-sae, relative impermeability through corneal epithelial membrane, quick precorneal, drainage by gravity, recurring infusion increatacrimal drainage, and the non attendance of steer liberation [6, 7, 8, 9, 10, 11, 12, 13, 14]. Due to anatomical and physiological constraints, a small part of the administered drug (approx. 1% or even less) of the introd dose is accessible or ocular absorption [15, 16]. Recurred dosing of drugs thus becomes requisite to achieve the healing concentration at the anneal side. This often results in corresponding increase in systemic and local side effects. The highdose and dosing frequency causes incomplishe side effects like GI disturbances and stomach upset [17]. The extensic route can overpower this but due to the proximity of blood-tettual barrier and blood-aqueous barrier, it finally leads to lefty versishedming of dose at the aimed site. In order to beat the dilemma of reuncontional ocular therapy, such as, drug drainage, short domicile time and recurred infusion; latest delivery systems are being surveyed, in general, to uplift the ocular bioavailability of the drug. Various, advances like particulate drug delivery, use of mucoadhesive, viscosity improvement, vesicle drug delivery, prodrugs, and other controlled







Chapter-8 Prevotella histicola







The Microbial World: Exploring the Diversity of Bacteria

Authors

Dr. Smeeta Sadar Dr. Padmaja Kore Dr. Anuradha More







Published By: Rubicon Publications

4/4A Bloomsbury Square,
Bloomsbury Square,
London, WC1A 2RP, England
Email: info@rubiconpublications.com

Authors: Dr. Smeeta Sadar, Dr. Padmaja Kore and Dr. Anuradha More

The editors/publisher has attempted to trace and acknowledge the materials reproduced in this publication and apologize if permission and acknowledgements to publish in this form have not been given. If any material has not been acknowledged please write and let us know so that we may rectify it.

© Rubicon Publications

Edition: 1st

Publication Year: 2023

ISBN: 978-1-80433-971-8

Pages: 227
Price: £ 21







| | <u>Contents</u> | |
|--------|---|----------|
| S. No. | Chapters | Page No. |
| 1. | Prevotella intermedia | 01-09 |
| | (Vaishnavi Tanwade and Dr. Smeeta Sadar) | |
| 2. | Prevotella marshii | 11-20 |
| | (Vaishnavi Tanwade and Dr. Smeeta Sadar) | |
| 3. | Prevotella maculosa | 21-28 |
| | (Bhavik Gala and Dr. Smeeta Sadar) | |
| 4. | Prevotella melaninogenica | 29-43 |
| | (Bhavik Gala and Dr. Smeeta Sadar) | |
| 5. | Prevotella copri: Beneficial Role and its Cultivation | 45-63 |
| | (Aishwarya Reddy and Dr. Smeeta Sadar) | |
| 6. | Prevotella nigrescens: Identification and | 65-74 |
| | Pathogenicity | |
| | (Aishwarya Reddy and Dr. Smeeta Sadar) | |
| 7. | Prevotella oris: Pathogenicity and Immune Response | 75-89 |
| | (Mahesh Ravindra Bhadane and Dr. Smeeta Sadar) | |
| 8. | Prevotella histicola | 91-99 |
| | (Falak Ameesh Patel and Dr. Padmaja Kore) | |
| 9. | Prevotella denticola | 101-109 |
| | (Falak Ameesh Patel and Dr. Padmaja Kore) | |
| 10. | Prevotella micans | 111-118 |
| | (Shreya Mishra and Dr. Padmaja Kore) | |
| 11. | Prevotella bryantii | 119-124 |
| | (Shreya Mishra and Dr. Padmaja Kore) | |
| 12. | Prevotella fusca | 125-132 |
| | (Shreya Koche and Dr. Padmaja Kore) | |
| 13. | Prevotella albensis | 133-143 |
| | (Shreya Koche and Dr. Padmaja Kore) | |
| | College of College | |








| 6 | | |
|-----|---|---------|
| 14. | Prevotella saccharolytica (Payal Patel and Dr. Padmaja Kore) | 145-154 |
| 15. | Prevotella brevis (Payal Patel and Dr. Anuradha More) | 155-162 |
| 16. | Prevotella bivia (Aditya Prakash Sarode and Dr. Anuradha More) | 163-182 |
| 17. | Prevotella timonensis: Pathogenicity and Immune Response | 183-191 |
| 18. | (Aditya Prakash Sarode and Dr. Anuradha More) Prevotella loescheii (Tanaya Deshpande and Dr. Anuradha More) | 193-200 |
| 19. | Prevotella pallens (Ishika Shukla and Dr. Anuradha More) | 201-210 |
| 20. | Prevotella buccalis (Ishika Shukla and Dr. Anuradha More) | 211-217 |
| 21. | Prevotella amnii (Vaibhavi Kulkarni and Dr. Anuradha More) | 219-227 |
| | College or | |
| | | |
| | | |







Prevotella histicola

Falak Ameesh Patel and Dr. Padmaja Kore

Abstract

Prevotella histicola is a gram-negative, anaerobic bacteria that was first identified in the oral cavity of humans. It is part of the normal oral microbiome and is often found in dental plaque, which is a sticky biofilm that forms on the teeth. P. histicola has been studied in relation to its role in dental health and disease. In healthy individuals, it has been shown to help maintain the balance of the oral microbiome and prevent the growth of pathogenic bacteria. However, in individuals with periodontal disease, an infection of the gums and surrounding tissue, P. histicola has been found to be overrepresented in the oral microbiome and has been associated with the progression of the disease. In addition to its role in oral health, P. histicola has also been studied in the context of other infections and diseases. It has been found in the lower respiratory tract of patients with pneumonia and has been associated with the development of the infection.


It has also been isolated from infected wounds and has been shown to be involved in the development of wound infections. *P. histicola* is resistant to many common antibiotics, including penicillin and amoxicillin, making it difficult to treat infections caused by this bacteria. However, it is sensitive to other antibiotics, such as clindamycin and metronidazole, which can be used as alternative treatments. In conclusion, *P. histicola* is a gram-negative anaerobic bacteria that is commonly found in the oral cavity. It plays a role in maintaining the balance of the oral microbiome, but can also contribute to the progression of periodontal disease and other infections. It is resistant to some antibiotics but can be treated with alternative options. Further research is needed to fully understand the role of *P. histicola* in human health and disease.

Discovered by: Prevotella is a genus named by French microbiologist A. R. Prevol [1,5].





Chapter-9 Prevotella denticola



77



Prevotella denticola

Falak Ameesh Patel and Dr. Padmaja Kore

Abstract

Prevotella denticola is a gram-negative, anaerobic bacteria that was first identified in the oral cavity of humans. It is part of the normal oral microbiome and is often found in dental plaque, which is a sticky biofilm that forms on the teeth. P. denticola has been studied in relation to its role in dental health and disease. In healthy individuals, it has been shown to help maintain the balance of the oral microbiome and prevent the growth of pathogenic bacteria. However, in individuals with periodontal disease, an infection of the gums and surrounding tissue, P. denticola has been found to be overrepresented in the oral microbiome and has been associated with the progression of the disease. In addition to its role in oral health, P. denticola has also been studied in the context of other infections and diseases. It has been found in the lower respiratory tract of patients with pneumonia and has been associated with the development of the infection. It has also been isolated from infected wounds and has been shown to be involved in the development of wound infections. P. denticola is resistant to many common antibiotics, including penicillin and amoxicillin, making it difficult to treat infections caused by this bacteria. However, it is sensitive to other antibiotics, such as clindamycin and metronidazole, which can be used as alternative treatments. In conclusion, P. denticola is a gram-negative anaerobic bacteria that is commonly found in the oral cavity. It plays a role in maintaining the balance of the oral microbiome, but can also contribute to the progression of periodontal disease and other infections. It is resistant to some antibiotics but can be treated with alternative options. Further research is needed to fully understand the role of P. denticola in human health and disease.

Prevotella is a genus named by French microbiologist A. R. Prevol.

Gram classification: It is a gram negative bacteria (50%)


Shape: BacilliSize: 2.93759Mb







Chapter-10 Prevotella micans







Prevotella micans

Shreya Mishra and Dr. Padmaja Kore

Abstract

Four strains of anaerobic Gram-negative bacilli isolated from the human mouth were characterized using a variety of phenotypic and genotypic tests. The strains were found to comprise a homogeneous group and 16S rRNA gene sequence analysis revealed them to be distinct from but related to a loose cluster of *Prevotella* species including *Prevotella buccalis*, *Prevotella nanceiensis* and *Prevotella marshii*. A novel species, *Prevotella micans* sp. nov., is proposed to accommodate these strains. *Prevotella micans* is saccharolytic and produces acetic, isovaleric and succinic acids and minor amounts of isobutyric acid as end products of fermentation. The G+C content of the DNA of the type strain is 46 mol%. The type strain of *Prevotella micans* is E7.56^T (=DSM 21469^T=CCUG 56105^T).

Introduction


Strain E7.56T was recovered from necrotic pulp, strain 4D22 from subgingival plaque in a deep periodontal pocket and strains AHN 8723 and AHN 8376 from the gingival crevices of two children. Under anaerobic conditions (80% N₂, 10% H₂, 10% CO₂), strains were cultivated at 37 °C on meticulous anaerobe agar supplemented with 5% horse blood. After being incubated for five days, colony morphologies were observed under a dissecting microscope and documented. After Gram staining of smears made from 2-day FAA plate cultures, cellular morphology was noted. Using phase-contrast imaging, the cellular motility of 18-hour cultures of peptone-yeast extract-glucose (PYG) broth was investigated. The cell-wall ultra structure was examined using transmission electron microscopy (1).







Chapter-11 Prevotella bryantii







Prevotella bryantii


Shreya Mishra and Dr. Padmaja Kore

- Discovered by: Avgustin et al. (1997)
- Gram's classification: Gram negative bacteria
- · Shape: Rod shape
- Size: 3.59Mb
- · Motility: No
- Capsule: lipopolysaccharide capsule
- Endospores: Do not form spores.
- Scientific classification
 - Domain: Bacteria
 - > Phylum: Bacteroidetes
 - Class: Bacteroidetes
 - > Order: Bacteroidales
 - > Family: Bacteroidaceae
 - Genus: Prevotella
 - > Species: Bryantii
- Respiration: Anaerobic
- Optimum Temperature: 30-37 °C
- Optimum pH: 5.5
- Colony morphology in nutrient agar: Deep colonies are lenticular,
 2-3mm in diameter, smooth convex and opaque, light buff in colour.
- · Colony morphology in MacConkey agar: Not found
- Hemolysisin blood agar: They are anaerobically cultured in blood agar (5-10% blood), shows pink colonies
- · Colony morphology in Selective medium: Not found





Chapter-12 Prevotella fusca





Prevotella fusca

Shreya Koche and Dr. Padmaja Kore

Abstract

The human oral Microbiome is the most studied human microflora, due to the fact that it is easily sampled and is strongly associated with important oral infectious diseases such as tooth decay and gum disease [2]. Within the oral microbiome the microbes are characterized from the 16S rRNA gene sequence as they are used during a cloning process in hope of a clear understanding of the roles that microbes provide [3]. There are many different species of bacteria that are living in the oral cavity, *Prevotella fusca* are among one of the species. *Prevotella fusca* originates from the subgingival plaque that is located within the oral cavity [4]. The DNA G+C content of the type strain is 43 mol % [4].

Introduction

Prevotella fusca exists with the following characteristics


Table 1: Characteristics of Prevotella fusca

| Character | Description | | |
|--|---|--|--|
| Gram's Classification | Gram-negative | | |
| erial months to make | Kingdom-Bacteria | | |
| Mar application on the | Phylum-Bacteroidetes | | |
| Market Street, | Class-Bacteroidetes | | |
| Scientific classification | Order-Bacteroidales | | |
| | Family-Prevotellacea | | |
| | Genus-Prevotella | | |
| | Species- P. fusca | | |
| Isolation | Subgingival plaque within the oral cavity | | |
| Motility | Non- Motile | | |
| Genome Size | 0.8 μm wide by 1.2-6.0 μm long. | | |
| Appearance | Off-white rough surface appearance | | |
| Shape | Bacili or circular shaped | | |





Chapter-13 Prevotella albensis





Prevotella albensis

Shreya Koche and Dr. Padmaja Kore

Abstract

Prevotella albensis was previously known as Bacteroides ruminicola subsp. ruminicola, is a species of bacterium. Prevotella species are mainly found in human oral and vaginal flora. They play a vital role in the pathogenesis of periodontal disease, gingivitis, extraoral and some odontogenic infections. The strains are usually carried in families and hence are also as called intrafamilial carriage. They are also associated with carotid atherosclerosis.




Fig 1: Prevotella albensis


Introduction

Prevotella albensis is a gram-negative, rod-shaped bacteria. Prevotellais a genus named by French microbiologist A. R. Prevol. It is an anaerobic organism which is isolated from the rumen of cattles [1]. Temperature range of these microorganisms is Mesophilic. The strains grew at pH 4.7 to 7.6 with optimum growth at pH 5.7 to 6.7 a rather wide pH range for optimum growth.





Chapter-14 Prevotella saccharolytica





Prevotella saccharolytica

Payal Patel and Dr. Padmaja Kore

Abstract

A wide range of phenotypic and genotypic tests was performed on two strains of anaerobic, Gram-negative bacilli that were discovered to be unique from any previously identified species (D033B-12-2T and D080A-01). These strains were found to be present in the human oral cavity. The strains had 93.5 percent of their sequence identity with the *Prevotella marshii* type strain, according to the examination of the 16S rRNA gene. C16:0, iso-C14:0, C14:0, anteiso-C15:0, iso-C16:0, and C16:0 3-OH were the main long-chain fatty acids found in cells.

The DNA of strain D033B-12-2T included 44 mol% G+C. The name *Prevotella saccharolytica* sp. nov. is proposed for the strains D033B-12-2T and D080A-01, which are thought to represent a single unique species of the genus *Prevotella*. The strain is designated as D033B-12-2T (also known as DSM 22473T or CCUG 57944T).

Keywords: PRAS, juvenile periodontitis, supragingival plaque, acetic acid.

Introduction


Prevotella species are commonly isolated from human oral tissues in both health and oral and dental illnesses. Bacteroides group D33 was assigned to the strains D033B-12-2T and D080A-01, which were part of W. E. C. Moore and L. V. Holdeman Moore's collection and formerly of the Virginia Polytechnic Institute [1]. The novel strains were saccharolytic and produced acetic acid and succinic acid as end products of fermentation (fig.4). Although the strains were different from identified species, preliminary screening based on incomplete 16S rRNA gene sequence analysis revealed that they belonged to the same taxon of the genus Prevotella. A person with juvenile periodontitis had the strain D033B-12-2T isolated from a 9-mm-deep periodontal pocket, and a healthy participant had the strain D080A-01 isolated from supragingival plaque [2].

The two bacteria had a 99.4% similarity in 16S rRNA gene sequence over 1452 clearly matched bases and were most closely linked to the





Chapter-15 Prevotella brevis







The Microbial World: Exploring the Diversity of Bacteria

Authors

Dr. Smeeta Sadar Dr. Padmaja Kore Dr. Anuradha More







Criteria 3: Research, Innovations and Extension



Published By: Rubicon Publications

4/4A Bloomsbury Square,
Bloomsbury Square,
London, WC1A 2RP, England
Email: info@rubiconpublications.com

Authors: Dr. Smeeta Sadar, Dr. Padmaja Kore and Dr. Anuradha More

The editors/publisher has attempted to trace and acknowledge the materials reproduced in this publication and apologize if permission and acknowledgements to publish in this form have not been given. If any material has not been acknowledged please write and let us know so that we may rectify it.

© Rubicon Publications

Edition: 1st

Publication Year: 2023 ISBN: 978-1-80433-971-8

Pages: 227
Price: £ 21







| | <u>Contents</u> | |
|--------|---|----------|
| S. No. | Chapters | Page No. |
| 1. | Prevotella intermedia | 01-09 |
| 1. | (Vaishnavi Tanwade and Dr. Smeeta Sadar) | 01-09 |
| 2. | Prevotella marshii | 11-20 |
| | (Vaishnavi Tanwade and Dr. Smeeta Sadar) | 11-20 |
| 3. | Prevotella maculosa | 21-28 |
| | (Bhavik Gala and Dr. Smeeta Sadar) | |
| 4. | Prevotella melaninogenica | 29-43 |
| | (Bhavik Gala and Dr. Smeeta Sadar) | |
| 5. | Prevotella copri: Beneficial Role and its Cultivation | 45-63 |
| | (Aishwarya Reddy and Dr. Smeeta Sadar) | |
| 6. | Prevotella nigrescens: Identification and | 65-74 |
| | Pathogenicity (Aishwarya Reddy and Dr. Smeeta Sadar) | |
| - | | 75.00 |
| 7. | Prevotella oris: Pathogenicity and Immune Response (Mahesh Ravindra Bhadane and Dr. Smeeta Sadar) | 75-89 |
| 8. | Prevotella histicola | 91-99 |
| | (Falak Ameesh Patel and Dr. Padmaja Kore) | |
| 9. | Prevotella denticola | 101-109 |
| | (Falak Ameesh Patel and Dr. Padmaja Kore) | |
| 10. | Prevotella micans | 111-118 |
| | (Shreya Mishra and Dr. Padmaja Kore) | |
| 11. | Prevotella bryantii | 119-124 |
| | (Shreya Mishra and Dr. Padmaja Kore) | |
| 12. | Prevotella fusca | 125-132 |
| | (Shreya Koche and Dr. Padmaja Kore) | |
| 13. | Prevotella albensis | 133-143 |
| | (Shreya Koche and Dr. Padmaja Kore) | |
| | College | |






| e 1 6 | | | |
|-------|-----|--|---------|
| | 14. | Prevotella saccharolytica (Payal Patel and Dr. Padmaja Kore) | 145-154 |
| | 15. | Prevotella brevis (Paval Patel and Dr. Anuradha More) | 155-162 |
| | 16. | Prevotella bivia (Aditya Prakash Sarode and Dr. Anuradha More) | 163-182 |
| | 17. | Prevotella timonensis: Pathogenicity and Immune Response (Aditya Prakash Sarode and Dr. Anuradha More) | 183-191 |
| | 18. | Prevotella loescheii (Tanaya Deshpande and Dr. Anuradha More) | 193-200 |
| | 19. | Prevotella pallens (Ishika Shukla and Dr. Anuradha More) | 201-210 |
| | 20. | Prevotella buccalis (Ishika Shukla and Dr. Anuradha More) | 211-217 |
| | 21. | Prevotella amnii (Vaibhavi Kulkarni and <mark>Dr. Anuradha More)</mark> | 219-227 |
| | | College of the state of the sta | |
| | | | |
| | | | |

93











Prevotella brevis

Payal Patel and Dr. Anuradha More

Abstract

Prevotella brevis (bre'vis, adj. brevis, short) is a bacterium. Gramnegative bacilli that were discovered by Holdeman et al. introduced the biovars 1 and 2 of brevis (formerly Bacteroides ruminicola subs P. brevis), which include type strain GA33 [= ATCC 19188]. These strains were found to be present in the rumen and human oral cavities.

Those strains that have DNA G+C levels between 45 and 52 mol% and resemble strain GA33T are the only ones that fall under this new species. The extracellular DNase activity produced by *P. brevis* strains was relatively high. It frequently failed to develop dipeptidyl peptidase activity and carboxymethyl cellulase (CMCase) activity that plate assays could detect. Nacetylglucosamine is fermented by *Prevotella brevis* but not xylose. In a medium without rumen fluid but with trypticase and yeast extract added, certain bacteria thrive. Gum arabic can be used as an energy source for strains to grow. Cell morphology in *P. brevis* strains can range from coccoid to oval.

Introduction


Holdeman et al. provided Prevotella brevis, gram-negative bacilli, including the type strain GA33 (ATCC 19188). Only strains with DNA G+C levels between 45 and 52 mol% that resemble strain GA33T are included in this new species. Lack CMCase activity in plate assays and ferment N-acetylglucosamine but not xylose, salicin, arbutin, or rhamnose. Gum arabic can be used by strains as a source of energy. Coccoid to oval cell shape is common in P. brevis strains. Prevotella P. brevis strains displayed dipeptidyl peptidase activity and extracellular DNase activity in large quantities and with the highest mean activity [1, 2]. It also produces succinic acid [3].

Rumen fluid is necessary for the growth of this bacterium. Additionally, oxygen sensitivity is high. It is required to thoroughly minimize all media. The culture will die if it is exposed to oxygen in any way [3]. All strains





Chapter-16 Prevotella bivia



96





Prevotella bivia

Aditya Prakash Sarode and Dr. Anuradha More


Abstract

Prevotella bivia is a gram-negative anaerobic bacterium that is commonly found in the female genital tract. This microorganism is a member of the Prevotella genus, which is known to be associated with various human diseases, including bacterial vaginosis, periodontitis, and infections of the respiratory, gastrointestinal, and urinary tracts. P. bivia is also considered to be a potential opportunistic pathogen that can cause serious infections in immunocompromised individuals. This article aims to provide an overview of the current knowledge on P. bivia, including its taxonomy, morphology, and pathogenesis. The article also discusses the clinical significance of this microorganism, its epidemiology, and its role in various diseases. One of the main topics covered in this article is the association between P. bivia and bacterial vaginosis. Bacterial vaginosis is a common vaginal infection that is characterized by an imbalance of the vaginal microbiota. P. bivia has been identified as one of the key bacterial species involved in the pathogenesis of this condition. The article discusses the potential mechanisms by which P. bivia contributes to bacterial vaginosis, including its ability to produce biofilms and to induce inflammation in the vaginal mucosa. The article also discusses the role of P. bivia in other human diseases, such as periodontitis and respiratory infections. P. bivia has been implicated in the pathogenesis of periodontitis, a chronic inflammatory disease that affects the supporting tissues of the teeth. The article reviews the evidence linking P. bivia to periodontitis and discusses the potential mechanisms by which this microorganism contributes to the disease. Finally, the article reviews the current diagnostic methods for P. bivia infections and the available treatment options. The article also highlights the importance of further research on P. bivia and its role in human health. In conclusion, P. bivia is a microorganism that has important clinical implications and has been associated with several human diseases. Further research is needed to fully understand the pathogenesis of P. bivia infections and to develop effective diagnostic and therapeutic strategies.





Chapter-17 Prevotella timonensis: Pathogenicity and Immune Response





Prevotella timonensis: Pathogenicity and Immune Response

Aditya Prakash Sarode and Dr. Anuradha More

Abstract

The gram-negative obligate anaerobe *Prevotella* species is widely connected with human infections such as dental caries and periodontitis, as well as other disorders such as chronic osteomyelitis, bite-related infections, rheumatoid arthritis, and intestinal diseases such as ulcerative colitis. This often-benign commensal contains virulence elements such adhesins, hemolysins, secretion systems exopolysaccharide, LPS, proteases, quorum sensing molecules, and antibiotic resistance to develop into a well-adapted pathogen capable of infecting and multiplying well in the host tissue. This review discusses a few of these virulence factors and how *Prevotella* species might benefit from them to spread inflammatory disorders like periodontitis. Additionally, we looked at other possible virulence factors utilizing genome analysis of *Prevotella* reference strains, which may offer insights as biomarkers and serve as the targets for efficient therapies in *Prevotella*-related disorders including periodontitis.

Introduction:


Prevotella spp. are obligate anaerobes that are mostly found at mucosal surfaces and are part of the normal human microbiota in the oral cavity, gastrointestinal system, and urogenital tract in healthy people [1]. Other taxonomic investigations, such as 16S rDNA, PCR-RFLP, and DNA-DNA hybridization, have revealed the presence of Prevotella spp. in the rumen of various animals, demonstrating that it is not limited to humans [12]. Previously, microflora studies relied on culture-based methods; however, recent studies have enumerated the use of high throughput sequencing, which has outperformed these methods and improved detection of new non-cultivable Prevotella spp [13, 14].

Their heightened prevalence in the gut has been associated with diets high in carbs and fibre, as demonstrated by several authors, supporting it as a beneficial bacteria of the gu [15-16]. Prevotella spp., despite being a





Chapter-18 Prevotella loescheii





Prevotella loescheii

Tanaya Deshpande and Dr. Anuradha More

Abstract

Prevotella loescheii is a gram-negative bacterium which is rod shaped and is often found in the human mouth. It is also nonmotile, an obligate anaerobe, and is a non-spore forming bacterium. It was given after Walter J. Loesche's name, an American dental microbiologist. The growth was first observed on blood agar, the colonies formed were round, convex and smooth. Cells are usually single, in pairs or they can be in short chains when viewed under a microscope. Prevotella loescheii produces a light brown pigment when cultured for more than 48 hours. This type of species is often observed in people suffering with oral diseases, that include gingivitis and periodontitis. It has been demonstrated to occasionally be resistant to the antibiotic metronidazole. The C+G of Prevotella loescheii is 49 to 51 mol%



Fig 1: Growth of P. loescheii in the presence of S. aureus [2]


Introduction

Earlier, Prevotella loescheii was placed in the genus Bacteroides. Soon after that similar species such as P. melaninogenicus and P. oralis were reexamined, and it led to an observation that they were different enough from other Bacteroides species therefore they were classified in a new genus,





Chapter-19 Prevotella pallens



102



Prevotella pallens

Ishika Shukla and Dr. Anuradha More

Abstract

Prevotella pallens strain NCTC 13042 is a bacterial type strain isolated from the saliva of a human child. This strain is grown anaerobically on modified chopped meat medium and trypticase soy medium. It is a species of small flowering plant that belongs to the Asteraceae family. It is found in arid to semi-arid regions of the southwestern United States and Mexico. Prevotella pallens serves as an important food source for pollinators and a host plant for herbivores, and has traditional medicinal uses. This species warrants further research to better understand its taxonomy, distribution, ecological significance, and conservation status.

Introduction

Prevotella pallens is a Gram-negative anaerobic bacterium that belongs to the Asteraceae family and is commonly found in the human gut microbiota. This bacterial species has garnered significant attention due to its unique characteristics and potential impact on human health.

In recent years, research on *Prevotella pallens* has revealed its involvement in various physiological and pathological processes in the human body. Studies have shown that *Prevotella pallens* is associated with conditions such as periodontal disease, inflammatory bowel disease (IBD), and obesity. Furthermore, *Prevotella pallens* has been found to possess distinctive metabolic capabilities, including the ability to degrade complex carbohydrates, produce short-chain fatty acids (SCFAs), and modulate immune responses.

Table 1: Characteristics of Prevotella pallens

Scientific classification

Scientific classification

Scientific classification

Scientific classification

Scientific classification


Class-Bacteroidia

Order-Bacteroidales
Family-Prevotellaceae





Chapter-20 Prevotella buccalis





Prevotella buccalis

Ishika Shukla and Dr. Anuradha More

Abstract

Prevotella buccalis is a gram-negative anaerobic bacteria found in the oral cavity. It is a member of the Prevotella genus and is commonly associated with periodontal diseases. P. buccalis has been shown to produce a variety of virulence factors, including proteases and lipases, which can contribute to tissue destruction in the oral cavity. The bacterium has also been linked to systemic diseases such as cardiovascular disease, diabetes, and respiratory infections. The prevalence of P. buccalis in the oral microbiome is influenced by a variety of factors, including diet, oral hygiene practices, and host immune response. Understanding the role of P. buccalis in oral and systemic health is an area of active research, with potential implications for the development of new diagnostic and therapeutic approaches for periodontal diseases and related conditions.

Introduction

Prevotella buccalis is a gram-negative anaerobic bacteria that is commonly found in the human oral cavity. It is a member of the Prevotella genus and is known to be a key contributor to the development and progression of periodontal disease. The bacterium has also been implicated in the pathogenesis of several systemic diseases, such as cardiovascular disease, diabetes, and respiratory infections.


P. buccalis is a versatile pathogen that produces a wide range of virulence factors, including proteases, lipases, and other enzymes, which can contribute to tissue destruction and inflammation in the oral cavity. These virulence factors can also activate host immune responses and facilitate the dissemination of the bacterium to other parts of the body.

The prevalence of *P. buccalis* in the oral microbiome is influenced by a variety of factors, including diet, oral hygiene practices, and host immune response. Studies have also shown that the presence of *P. buccalis* in the oral cavity is associated with a higher risk of developing periodontal disease and systemic diseases.





Chapter-21 Prevotella amnii





Prevotella amnii

Vaibhavi Kulkarni and Dr. Anuradha More

Abstract

By influencing immunological development, immune responses, metabolism, and defence against invasive pathogens, the microbiota plays a crucial role in human health and disease. The search for microorganisms that modulate disease has been prompted by technological developments that enable thorough genetic sequencing characterisation of microbial communities. Recent investigations in humans have connected localised and systemic disease, such as periodontitis, bacterial vaginosis, rheumatoid arthritis, metabolic abnormalities, and low-grade systemic inflammation, to the increased prevalence of Prevotella species at mucosal locations [1]. From human amniotic fluid, two rod-shaped, Gram-negative, anaerobic, nonspore-forming organisms were identified. The strains were tentatively classified as Bacteroidaceae based on morphological and biochemical criteria, although they did not seem to belong to any recognised species of this family. Sequencing analyses of the 16S rRNA gene revealed that the strains were closely related to one another and established that they belonged to the genus Prevotella, however sequence divergence values of >4% with reference to the organisms from human clinical sources are a novel species, as shown by Prevotella species. The unique organism was shown to be most closely related to Prevotella bivia, an organism typically linked to pelvic inflammatory disorders, according to phylogenetic analysis. It is suggested that the unidentified isolates from human amniotic fluid be classified as Prevotella amnii sp. nov., which is a new species of the genus Prevotella, based on biochemical standards and phylogenetic considerations. Prevotella amnii strain CCUG 53648 T (=JCM 14753T) is the type [2].

Introduction

Prevotella amnii exists with the following characteristics-



Criteria 3: Research, Innovations and Extension



Burden of diseases in India and need for pharmaceutical care

BURDEN OF DISEASES IN INDIA AND NEED FOR PHARMACEUTICAL CARE

DR. SUNITA PAWAR

PES MODERN COLLEGE OF PHARMACY, NIGDI, PUNE

Non communicable diseases (NCDs) are one of the major challenges for public health in the 21st century, not only in terms of human suffering they cause but also the harm they inflict on the socio-economic development of the country. NCDs kill approximately 41 million people (71% of global deaths) worldwide each year, including 14 million people who die too young between the ages of 30 and 70. The majority of premature NCD deaths are preventable.

In India, nearly 5.8 million people (WHO report, 2015) die from NCDs (heart and lung diseases, stroke, cancer, and diabetes) every year or in other words, 1 in 4 Indians has a risk of dying from an NCD before they reach the age of 70.

In a report "India: Health of the Nation's States" by the Ministry of Health and Family Welfare (MOHFW), Government of India (GOI), it is found that there is an increase in the contribution of NCDs from 30% of the total disease burden- 'disability-adjusted life years (DALYs) in 1990 to 55% in 2016 and also an increase in the proportion of deaths due to NCDs (among all deaths) from 37% in 1990 to 61% in 2016. This shows a rapid epidemiological transition with a shift in disease burden to NCDs.

The major NCDs are cardiovascular diseases, cancers, chronic respiratory diseases, and diabetes. Physical inactivity, unhealthy diets (diets low in fruit, vegetables, and whole grains, but high in salt and fat), tobacco use (smoking, secondhand smoke, and smokeless tobacco), and the harmful use of alcohol are the main behavioral risk factors for NCDs.

Actions to beat non-communicable diseases

The sweeping increase of the burden due to this combination of risks in every part of the country indicates emphatically that major efforts need to be put in place to control their impact in every state before the situation gets totally out of control. The epidemic of NCDs cannot be halted simply by treating the sick, healthy persons have to be protected by addressing the root causes. Reducing the major risk factors for NCDs is the key focus currently to prevent deaths from NCDs. Tackling the risk factors will therefore not only save lives; it will also provide a huge boost for preventing NCDs and the economic development of the country.

The diabetes-pandemic is spreading like wildfire, especially among developing countries. The IDF Diabetes Atlas 9th edition 2019 shows that 463 million adults are currently living with diabetes worldwide, 77 million in India (second-largest nation housing this disease), and the estimated 578 million adults with diabetes are expected by 2030. Indians ranking highest (population) followed by China and the USA. India is one of the 7 countries of the IDF SEA region.

7





Bioinformatics tools in clinical research

BIOINFORMATIC TOOLS IN CLINICAL RESEARCH

UJWALA DESAI, PADMAJA KORE, PRAVEEN CHAUDHARI

PES MODERN COLLEGE OF PHARMACY, NIGDI, PUNE

Introduction

Clinical research is putting in great effort to improve peoples' health and well-being. Diseases including cancer, hepatitis, HIV, and others are spreading quickly and becoming more severe, leading to significant morbidity and mortality. Clinical trials are carried out to determine the safety and effectiveness of pharmaceuticals, whereas clinical research involves the discovery and development of drugs. The identification, validation, and lead optimization of targets are the first steps in the lengthy process of drug discovery. Preclinical trials, extensive clinical trials, and finally post-marketing vigilance for drug safety come after this. Clinical and preclinical research is frequently a time-consuming, expensive, and dangerous process. As a result, predicting the efficacy of a drug is necessary in order to ensure the success of the drug development process. Bioinformatics is the applications of computer science in biology thatcan improve drug discovery with efficient statistical algorithms, rationale approaches for target identification, validation, and optimization. Computers and softwaretools greatly help creating databases, predict the function proteins, model the structure of proteins, determinethe coding regions of nucleic acid sequences, find suitabledrug compounds from a large pool, perform data mining, analyzing, and interpret data faster thereby reducing time of drug discovery and eventually the cost involved in it.

Clinical research is a branch of science that ensures thesafety and effectiveness of medications, devices, diagnostic products, and treatment regimens for human use. Various software can predict the possible interactions, toxicities, and indications thereby, accurately defining the successof a novel compound or the repositioning for new uses.

Software and bioinformatics tools in Pharmacovigilance

ARISG

It is the top platform for both the clinical safety system and pharmacovigilance. This programme offers a practical and all-inclusive solution for handling adverse event reporting in accordance with legal standards. ARISg offers a combined system for Pharmacovigilance and risk management, so enabling pharmaceutical businesses to monitor and analyze their products for safety risk.

Argus

Oracle Software called Argus enables pharmaceutical businesses to maximize worldwide compliance, make quick and better safety choices, and integrate risk management systems. With automated case processing, regular reporting, in-depth analytics, and safety operations all integrated into a single system, Argus offers configurable end-to-end safety processes.

Software used in clinical trials:

Promiscuous



3D printing in pharmaceutical and biomedical applications

3D PRINTING IN PHARMACEUTICAL AND BIOMEDICAL APPLICATIONS

ANURADHA MORE, SUVARNA VADJE, VITTHAL CHOPDE
PES MODERN COLLEGE OF PHARMACY, NIGDI, PUNE.

Introduction

Three-dimensional (3D) printing technology is a new rapid prototyping technique in which solid objects are constructed by depositing material in layers. The 3D printing offers more advantages over the conventional process of manufacturing like pulverization, blending, granulation and compaction to overcome some challenges of pharmaceutical field.3D printing also very beneficial in designing of several dosage forms which contains several active ingredients, which can be formulated as single or multi-layer printed tablet with better release profile.3D printing technology achieves extraordinary success in the design and manufacturing of dosage forms, which can be used in personalized and customized medication.

Advantages of 3D printing in the pharmaceuticals

High efficiency: It works much faster than conventional methods of manufacturing especially when it comes to manufacturing objectives like artificial organs and implantable devices

Customization and personalization: It provide a great benefit for the pharmaceutical and medical sectors

Increased cost-effectiveness: This technique is very useful for small scale manufacturing unit that produces highly complicated products and used inexpensive materials. A controlled particle size can be achieved in dosage form and maintain better drug release profiles, improve efficacy of dosage, and minimizes multi-dosing.

3D Printing Vs Traditional Printing

3D printing technology is a computer-driven manufacturing technology used for manufacturing the product from a digital model.

Table No. 1: 3D Printing Vs Traditional Printing

| Traditional Printing | 3D Printing |
|-------------------------|--|
| High Manufacturing Cost | Low Manufacturing cost |
| Less innovative | Easy and inexpensive innovation |
| More time required | Lesser time taken due to compressed design cycle |
| Creates more waste | Lighter and smaller amount of waste |

2. 3D printing procedure

Various digital CAD (computer-aided design) software's like onshape, solid works, creo parametric, auto CAD, autodesk etc. are used for designing 3D models.

Process:





Artificial intelligence in pharmaceutical science

ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL SCIENCE

PADMAJA KORE, GANESH PORE, UJWALA DESAI
PESS MODERN COLLEGE OF PHARMACY, NIGDI, PUNE

Introduction

Artificial intelligence (AI) is the simulation of human behaviour in terms of intelligence processes used in problem solving. Human cognitive science reading, observation, preparation, interpretation, reasoning, correction, speech recognition, linguistics, and other sources are examples of such mechanisms. Artificial intelligence is defined as the study and application of algorithms for data analysis, learning, and interpretation. Artificial intelligence and machine learning, in particular, provide the pharmaceutical industry with a real opportunity to do R&D differently, allowing it to operate more efficiently and significantly improve the early stages of drug development success. Artificial intelligence (AI) is concerned with understanding data and analysing how algorithms are used. Artificial intelligence (AI) uses sophisticated computer algorithms to carry out human-like functions including decision-making and data interpretation. AI makes activities easier by teaching machines from past experiences, connecting actions and effort to outcomes, seeing faults and fixing them, adapting to novel and random input values, and doing human-like tasks with ease through extensive scenario analysis. To do this, AI employs Natural Language Processing (NLP) to transform human speech into a language that robots can understand. AI is essential for validating novel drug targets and creating better therapeutic compounds. Repurposing the medications for current drug candidates to uncover novel indications helps speed up clinical studies like drug performance prediction, in vitro testing, and toxicity computation prior to clinical trial findings, computer-based synthesis, synthesis and designing of organic compounds, synthetic complex scoring, molecular design automation, predicting organic reaction outcomes, and medicine. In order to solve issues and challenges in the drug design process, artificial intelligence (AI), particularly deep learning (DL) and machine learning (ML) algorithms, has emerged as a potential solution. AI is a rapidly developing technology with several uses in both business and daily life. The pharmaceutical industry has recently found new and inventive methods to leverage this potent technology to assist address some of the most pressing issues confronting pharma at the moment. AI is implemented into machines to analyse and forecast the outcomes of treatment regimens for various illnesses and conditions.

Applications of Artificial intelligence in pharmaceutical science

AI is essential for developing new medication candidates and creating better therapeutic compounds. Repurposing the medications for current drug candidates to uncover novel indications helps speed up clinical studies like drug performance prediction, in vitro testing, and toxicity computation prior to clinical trial findings, computer-based synthesis, synthesis and designing of organic compounds, synthetic complex scoring, molecular design automation, predicting organic reaction outcomes, and medicine.

1. Drug discovery



Principle elements and plan for pharmaceutical care

PRINCIPLE ELEMENTS AND PLAN FOR PHARMACEUTICAL CARE

ANURADHA MORE, RENUKA ZAREKAR, NEHA SHEGOKAR

PES MODERN COLLEGE OF PHARMACY, NIGDI, PUNE.

Pharmaceutical care is the pharmacist's primary responsibility. A patient's quality of life can be improved through pharmaceutical care, which is the direct and responsible administration of medication-related care.

Principal Elements of Pharmaceutical care

The main characteristics of pharmaceutical care are that it is medication-related, that it directly affects the patient that it is given to produce definite results, that these results are intended to improve the patient's quality of life, and that the provider accepts personal responsibility for the results. Some important principle elements are mention are-

- Medication Related: Pharmaceutical care includes both decisions about medication use for specific patients as well as pharmaceutical therapy (the administration of medications). This can involve deciding not to utilize medication therapy, as well as making decisions about medication selection, dosages, routes of administration, monitoring medication therapy, and giving specific patients counselling and information on medications as needed.
- 2. Pharmaceutical Care: Caring, or a genuine concern for another person's well, lies at the heart of the concept of care. Medical, nursing, and pharmaceutical care is only a few of the integrated care areas that make up overall patient care. Each of these specialties in medicine has its own set of specialists who must work together for the patient's complete recovery. In the creation, implementation, and monitoring of a therapeutic plan intended to provide specific therapeutic outcomes that enhance the patient's quality of life, the pharmacist collaborates directly with other experts and the patient.
- 3. Outcomes: Pharmaceutical care aims to enhance the quality of life of each patient by achieving specific (predefined), medication-related therapeutic objectives. The desired results are:
 - ✓ The sickness of a patient is cured.
 - ✓ Reduction or elimination of a patient's symptoms
 - ✓ Slowing or stopping the progression of an illness
 - ✓ Controlling a disease or its symptoms.

The following are some categories of medication-related issues-

- ✓ Indications that have not been treated
- ✓ Incorrect drag selection
- ✓ Inadequate dose
- ✓ Inability to take medication
- ✓ Overdose
- ✓ Adverse drug reactions



Personalized medicine: new health care approach

PERSONALIZED MEDICINE: NEW HEALTH CARE APPROACH

SHEETAL CHAUDHARI, VASUDHA BAVADEKAR, RUPALI JINTURKAR

PES MODERN COLLEGE OF PHARMACY, NIGDI, PUNE.

Personalized medicine

Personalized medicine is frequently regarded as the direction of medicine in the future. With a few notable exceptions, cancer research has not advanced as anticipated because of the difficulties presented by tumour heterogeneity and clonal evolution. Diseases brought on by solitary genetic changes are more susceptible to precision medicine techniques in both benign and malignant disease. Personalized medicine is much more difficult because the majority of common diseases are brought on by a complicated interplay of numerous genetic and environmental factors. Clinical consultations, resource allocation, and research funding prioritisation are being distorted by the current euphoria around personalised medicine. A clinical researcher must operate as both a change and development agent and a communicator of reality. As a result, personalised medicine that emphasises the individual as a person and not just as a genome, along with continuous attention to the individual as a person, will lead to further advancements in health and healthcare.




Figure 1: Personalized medicine

An emerging area of medicine is personalised medicine, which analyses a person's genetic profile to inform decisions about illness prevention, diagnosis, and treatment. Doctors can choose the best treatment and deliver it with the right dosage or regimen by having knowledge about a patient's genetic profile. Human Genome Project data is being used to enhance personalised treatment.

People have high expectations for "personalised medicine" as a type of treatment that is more suited to the requirements of individuals. The goal is for healthcare to move away from a "one size fits all" philosophy and towards more specialised illness prediction, prevention, and treatment 1, 2, 3, 4, 5. One of the



Softwares used in medical coding.

SOFTWARES USED IN MEDICAL CODING.

GANESH KUDKE, PAVAN MARE, PADMAJA SANTOSH KORE, UJWALA DESAI

PES MODERN COLLEGE OF PHARMACY, NIGDI, PUNE.

Introduction:

Medical coding is the process of assigning specific codes to medical diagnoses and procedures. These codes are used for a variety of purposes, such as billing insurance companies, tracking healthcare data, and analyzing the effectiveness of treatments. There are several different systems of medical coding, including the International Classification of Diseases (ICD) and the Current Procedural Terminology (CPT). Medical coders are responsible for accurately assigning the appropriate codes to medical records, using coding manuals and guidelines. It is a growing field, with many opportunities for employment in hospitals, clinics, and insurance companies. Some medical coders work as freelancers, offering their services to healthcare providers on a contract basis.

Importance of medical coding:

Medical coding is the process of assigning standardized codes to medical diagnoses, procedures, and treatments. These codes are used for a variety of purposes, including reimbursement, research, quality assurance, and public health reporting. The importance of medical coding can be summarized as follows:

Accurate billing and reimbursement:

 Medical coding ensures that healthcare providers are accurately reimbursed for the services they provide. Insurance companies and government programs such as Medicare and Medicaid rely on medical codes to determine payment for services. Accurate coding helps to prevent errors and fraud.

Improved patient care:

 Medical coding provides a standardized way to track patient care and outcomes. This information can be used to improve patient care by identifying patterns and trends, tracking the effectiveness of treatments, and identifying areas for improvement.

Compliance with regulations

 Healthcare providers must comply with numerous regulations, including those related to billing and reimbursement. Medical coding helps providers ensure that they are following regulations and avoiding penalties.

Research and public health:

 Medical codes provide a way to track health trends and identify areas for public health interventions. Researchers can use medical codes to study disease patterns, treatment outcomes, and health disparities.

There are several different types of medical coding, including ICD-10 (International Classification of Diseases, 10th revision) coding, CPT (Current Procedural Terminology) coding, and HCPCS (Healthcare Common Procedure Coding System) coding. Each of these coding systems has its own set of codes and guidelines that must be followed to ensure accuracy and compliance with regulatory requirements.



Artificial intelligence in drug discovery


ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY

PADMAJAKORE, UJWALA DESAI, PRAJAKTATAMBE

PES MODERN COLLEGE OF PHARMACY, NIGDI, PUNE- 411044

Introduction

The advancement of computational science has accelerated the research and discovery of new drugs. Artificial intelligence is widely used in both the business and academic worlds (AI). Machine learning (ML), a key component of AI, has been used in many different areas, including data generation and analytics. ML is an example of an algorithm-based technique that has a solid mathematical and computational theory background.



1. AI in drug screening

A drug's discovery and development can take over ten years and cost an average of US\$2.8 billion. Even then, nine out of 10 medicinal compounds fall short of passing regulatory approval and Phase II clinical trials. Based on the practicality of the synthesis, algorithms are like deep neural networks (DNNs), extreme learning machines (ELMs), and nearest-neighbour classifiers (RF). These algorithms can also predict in vivo activity and toxicity. Many biopharmaceutical firms, including Bayer, Roche, and Pfizer, have partnered with IT businesses to create a platform for the identification of treatments for conditions like immuno-oncology and cardiovascular illnesses.

2. AI in designing drug compounds

Predicting the structure of the target protein, assigning the right target during drug molecule development is crucial for effective treatment. The development of the disease involves many proteins, some of which are over expressed. So, it is essential to predict the structure of the target protein while designing the therapeutic molecule in order to selectively target disease. Because the design is in line with the chemical environment of the target protein site, AI can help in structure-based drug discovery by anticipating the 3D protein structure. This aids in anticipating the effect of a compound on the target along with safety considerations before their synthesis or production.

3. Prediction of the physicochemical properties



Bioinformatics for healthcare applications

BIOINFORMATICS FOR HEALTHCARE APPLICATIONS

PAVAN MARE, GANESH KUDKE, PADMAJA KORE

PES MODERN COLLEGE OF PHARMACY, NIGDI, PUNE

Bioinformatics is an integrative field in life sciences that combines biology and information technology. Its application includes the study of molecular sequences and genomics data. Being a combination of different branches of life sciences, the objective of bioinformatics is to develop methodologies and tools to study large volumes of biological data in order to organize, store, systematize, visualize, annotate, query, understand and interpret those data.

Bioinformatics includes


- · Cloud computing
- Statistic
- Mathematics
- · Pattern recognition
- Machine learning
- · Molecular modeling

In simpler terms, bioinformatics is the computer technology to manage large amount of biological information.

Objectives:

The main objective of bioinformatics is to collect, store, analyze and disseminate biological data and information, such as DNA and amino acid sequences or annotations about those sequences.

Applications of bioinformatics:



The various applications of the bioinformatics are as follows:

A. Sequence Analysis :

The genetic basis of organism is depending on all genes of its genome. Sequence analysis is a method used to understand its structure, function, features. There are various powerful tools are available in the computer science and each tool has its own merits and demerits. These tools are used to identify the sequences which are related to DNA mutations of an organism. Shotgun sequence technique is used for sequence analysis of various fragments of DNA.

B. Prediction of Protein Structure :



Artificial intelligence in healthcare

ARTIFICIAL INTELLIGENCE IN HEALTHCARE

PADMAJA KORE, DHANASHRI KATKAR, UJWALA DESAI PES MODERN COLLEGE OF PHARMACY, NIGDI, PUNE

Introduction

Artificial intelligence (AI) is defined as machine intelligence as opposed to human or other living species intelligence. AI can also be defined as the study of "intelligent agents," which are any agents or devices that can perceive and understand their surroundings and take appropriate action to maximise their chances of achieving their goals. Big data and machine learning are influencing almost every aspect of modern life, including entertainment, commerce, and healthcare.

Al's ability to deliver better and faster results in healthcare is reshaping the way healthcare providers deliver care, allowing them to devote more time and resources to their patients. With artificial intelligence Al in healthcare leading the charge in improving patient care, medical professionals can be confident in their ability to focus on providing quality care while saving time and money with Al-powered administrative tasks. Finally, artificial intelligence in healthcare enables healthcare providers to provide better and faster patient care. Artificial intelligence can help medical professionals save time and money by automating mundane administrative tasks, while also giving them more control over their workflow process.

The healthcare ecosystem is beginning to recognise the significance of AI-powered tools in nextgeneration healthcare technology. AI is thought to be capable of improving any process in the healthcare industry delivery. The cost savings that AI can bring to the healthcare system, for example, is a major motivator for the implementation of AI applications. A significant portion of these cost savings result from shifting the healthcare model from a reactive to a proactive approach, with a focus on health management rather than disease treatment.

Artificial intelligence applications in healthcare

There are various viewpoints on the most beneficial applications of AI in healthcare. According to Forbes, the most important areas in 2018 will be administrative workflows, image analysis, robotic surgery, virtual assistants, and clinical decision support. Accenture's 2018 report mentioned the same topics, as well as connected machines, dosage error reduction, and cyber security. AI allows for the review and translation of mammograms to be completed 30 times faster and with 99% accuracy, reducing unnecessary biopsies.

1. Managing Medical Records and Other Data

Data management is the most widely used application of artificial intelligence and digital automation because the first step in health care is compiling and analyzing information (such as medical records and another past history). To provide faster, more consistent access, robots collect, store, re-format, and trace data.

2. Accurate Cancer Diagnosis & Early Diagnosis of Fatal Blood Diseases



Monitor adverse drug reaction of theophylline in asthmatic patients

MONITOR ADVERSE DRUG REACTION OF THEOPHYLLINE IN ASTHMATIC PATIENTS

ANURADHA MORE, SWAPNIL TARATE, ADIL PATHAN, AMIT TAPKIR
PES MODERN COLLEGE OF PHARMACY NIGDI, PUNE

Pharmacovigilance (PV) was officially introduced in December 1961 with the publication in the peerreviewed medical journal. The Lancet' by William McBride's by the Australian doctor who first
suspected a causal link between serious fatal deformities and thalidomide drug used during pregnancy.

Thalidomide is used as an anti-emetics and sedative agent in pregnant women. In 1968, the world health
organization (WHO) proposed the program for International drug monitoring of pilot project to centralize
world data on adverse drug reactions. The main aim of the WHO program was to identifying the earliest
possible PV signals. PV is the science and activities related to the detected assessment, understanding,
and prevention of adverse effects, particularly long-term and short-term adverse effects of medicines.

Pharmacovigilance (PV) is a continuous process accepted for safety evaluation accompanied by steps to

Pharmacovigilance (PV) is a continuous process accepted for safety evaluation accompanied by steps to improve safe usage of medicines. Fig.1 represents the scope of the Pharmacovigilance in pharmaceutical field.

Scope of Pharmacovigilance




Fig. 1. Scope of Pharmacovigilance

Pharmacovigilance cycle

The WHO Pharmacovigilance ensures the safe use of medicines and vaccines throughout the life cycle of the products.







Pharmacist: a key to pharmaceutical care

PHARMACIST: A KEY TO PHARMACEUTICAL CARE

PRIYANKA BAGADE

PES MODERN COLLEGE OF PHARMACY, NIGDI, PUNE.

Pharmaceutical science, defined by the AACP (American Association of College of Pharmacy) Research and Graduates Affairs committee, encompasses a broad range of interdisciplinary fields related to drug discovery, optimization, delivery, optimal dosing as well as health outcome and policy. Although many pharmaceuticals helping to directly cure diseased conditions, they can also be used to manage pain, symptoms and side effects of other treatments, helping to relieves discomfort so pharmaceutical care is a boon for society.

Pharmaceutical care gives a valuable contribution from being drug product oriented to one that is patient oriented to achieve definite results that improves patient's quality of life. In order to get pharmaceutical care, Pharmacists have to accept for a shift of a practice in pharmacy the role of a pharmacist, communicator, decision maker, teacher, researcher, lifelong learner, leader, and manager, which will help them to provide personalized care. As a patient's visit community pharmacists usually, they are playing a major role in providing respective care to the patients, especially in the treatment of chronic, acute and non-communicable diseases.

Many studies have been organized; it shows that the allocation of pharmaceutical care has its valuable contribution in common disorders such as high sugar level, high blood pressure, asthma, hyperlipidemia, body pain, rheumatic disease, cancer, tuberculosis, nervous disorders as well as in-communicable diseases. Abundant data is currently being published in many scientific journals, in an account to establish the clinical, economic and humanistic viability of pharmaceutical care. In pharmaceutical care, the major role is of pharmacists because pharmacists are improving the quality of dosage forms and drug therapy by modifying the structure through which drug therapy is provided. The other important side of pharmaceutical care is medication of drugs which have an adorable value to treating disease conditions. So, the heart of pharmaceutical care is pharmacists and medicine that directly provides special care to raise patient's quality of life and accepts personal responsibility for their betterment. Thus, the focus of this review is to study the importance of various aspects in pharmaceutical care which have to be carried out by pharmacists.





Artificial intelligence in medicine

ARTIFICIAL INTELLIGENCE IN MEDICINE

PADMAJA KORE, PRANALI BHANDARE

PES MODERN COLLEGE OF PHARMACY, NIGDI, PUNE.

Introduction

Artificial intelligence (AI) refers to the use of technology and computers to simulate intelligent behaviour and critical thinking that is comparable to that of a human being. In 1956, John McCarthy used the term "AI" for the first time to refer to the engineering and science of creating intelligent machines. The two categories of artificial intelligence (AI) in medicine are virtual and physical. Applications like electronic health record systems and neural network-based treatment decision guidance are examples of the virtual part. The physical section focuses on geriatric care, robotic surgery assistants, and intelligent prosthetics for the disabled. The difficulty for modern medicine is to gather, examine, and use the vast amount of knowledge required to address challenging clinical issues. The creation of AI systems aimed at assisting the clinician in the formulation of a diagnosis, the making of therapeutic decisions, and the prediction of outcome has been linked to the development of medical AI. They are made to help healthcare professionals perform daily tasks that require the manipulation of data and knowledge. The creation of AI systems aimed at assisting the clinician in the formulation of a diagnosis, the making of therapeutic decisions, and the prediction of outcome has been linked to the development of medical AI. The term "Medical Technology" is frequently used to refer to a variety of instruments that can help medical practitioners diagnose patients earlier, prevent problems, optimise therapy and/or offer less intrusive options, and shorten hospitalisation for patients and society as a whole. The general public has embraced intelligent medical technologies (i.e., AI-powered ones) in part because they enable the 4P model of medicine (Predictive, Preventative, Personalized, and Participatory) and, consequently, patient autonomy.

Current Applications of Artificial Intelligence in medicine

1. Pulmonary Medicine

According to reports, the interpretation of pulmonary function tests represents a viable area for the creation of AI applications in the field of pulmonary medicine. According to a new study, when it comes to analysing the results of pulmonary function tests, AI-based software offers more accurate interpretation and acts as a decision support tool. The study was subject to a number of criticisms, one of which was how the study's pulmonologists had significantly lower rates of accurate diagnosis than the national average.

2. Nephrology

Clinical nephrology has used artificial intelligence in a number of settings. It has been shown to be helpful, for instance, in predicting the decline in glomerular filtration rate in individuals with polycystic kidney disease and determining the risk for progressive IgA nephropathy. Yet, a recent analysis shows how the sample size required for inference currently limits research.

3. Neurology



Introducing principle, elements and perceived barriers toward provision of pharmaceutical care

INTRODUCING PRINCIPLE, ELEMENTS AND PERCEIVED BARRIERS TOWARD PROVISION OF PHARMACEUTICAL CARE

RAJANI MALI, SUMEDHA SAVANE

PES MODERN COLLEGE OF PHARMACY, NIGDI, PUNE.

Pharmaceutical care: The conception of pharmaceutical care in its modern sense was introduced in 1980: "Pharmaceutical care includes the determination of the medicine needs for a given specific and the provision not only of the medicine required but also the necessary services to assure optimally safe and effective treatment.

"Responsibility exception of medical treatment for the purpose of achieving definite outcomes that enhance a patient's quality of life."

* Principles of Pharmaceutical Care:

1. Subjects need timely & precise responses to signs and symptoms. First, patients need timely and accurate responses to their essential medical problems by the initiator (physician, nurse practitioner, etc.). The "drug of choice" for the wrong evidence will not improve a patient's clinical condition or quality of life. Others involved in drug therapy often should delay to the physician's diagnostic expertise. For pharmacists and other cotherapists, this concept would most frequently refer to determining and resolving drug therapy problems

2. Subjects need access to safe & cost-effective medications:

There are at least six situations at which access to medications can be constricted: national drug license laws; finances, including insurance provisions and formulary inclusions; prescribing; inventory availability; dispensing; and use by the patient (including bioavailability).

- National drug licensing decisions (marketing controls) are part of the environment of medications
 use system. These are behind a professional's control in the treatment of a particular patient. I'm
 including them here for completeness. Nonetheless, sometimes a so-called orphan drug.
- Some patients cannot afford to pay for the medications they need. A formulary may behind a
 patient's getting the medicine that the doctor would prefer, or even deny any prescription beyond
 coverage limits.
- 3. Patients Need Planned, Professional, Follow-up: This statement is closely related to statement 1 (responsiveness). It emphasizes the need for planned, continual, detecting throughout therapy. Systematic analysis and result to drug therapy issues may be the most important area of possible development in medications use. Two levels of monitoring are necessary: facilitator (patient) and cotherapist (professional).

4. Patients Need Cooperation with and Among Health Professionals

As with monitoring, two 4 levels of cooperation can be discerned.

Patient participation in care: Outcomes of drug therapy may be unrecognizable, and in some
cases may depend on patients' faith, at least faith influence a patient's medication-taking



Digital therapeutics and telemedicine

DIGITAL THERAPEUTICS AND TELEMEDICINE

ANURADHA MORE, AISHWARYA MAHANGADE, AMRUT GODBHARLE

PES MODERN COLLEGE OF PHARMACY, NIGDI, PUNE-411044

Digital therapeutics

Digital therapeutics, a subset of digital health, is a care discipline and treatment option that treats a medical or psychological condition using digital and often online health technologies. All technologies that interact with patients for health-related purposes are referred to as digital health. It includes a diverse range of products used in the wellness and healthcare industries. Digital therapeutics can be identified from the other digital health categories by its primary function of core target software-generated therapeutic strategies to patients in order to prevent, operate, or treat medical disorders or diseases.

A Digital Therapeutic, like a drug, is composed of digital active ingredients and excipients that comprise the patient's application of use (patient-facing). This distinction may be important in clinical development, particularly in confirmatory clinical trials, where it is not possible to modify the digital active ingredient during development but is possible to update the excipients within certain limits.

In addition to the patient-facing components, Digital Therapeutics includes a dashboard for the physician and a delivery platform from which the application can be downloaded.




Fig.1. Composition of Digital Therapeutics

Telemedicine

Telemedicine is a general concept for any medical activity that involves a distance element. It dates back at least to the use of ship-to-shore radio for giving medical advice to sea captains in its commonly understood sense, in which a doctor-patient interaction involves telecommunication. A few years ago, the term telemedicine was supplanted by the term telehealth, which was thought to be more "politically correct," but in the last year or so, it has been supplanted by even more fashionable terms such as online health and e-health.

Benefits of telemedicine

Through virtual mode, it is quite beneficial to use telemedicine as it avoids the cross-contamination of contagious diseases. Telemedicine offers extended patient care through self-care management and risk assessment. It provides better convenience and comfort to the patient especially in chronic disorders by





Therapeutic drug monitoring

THERAPEUTIC DRUG MONITORING

AMIT TAPKIR, ANURADHA MORE

PES MODERN COLLEGE OF PHARMACY, NIGDI, PUNE

Therapeutic drug monitoring (TDM) is a branch of pharmacology that specializes in the measurement of medication levels in blood. Its main focus is on drugs with a narrow therapeutic range, means the drugs that can easily be under or overdosed.

The incorporation of TDM in clinical practice can enable healthcare professionals to optimize drug treatment. Conventional TDM was started way back in the 1960s. Over the past several decades, TDM has made a substantial contribution to personalize pharmaco-therapy. In the current times, the scope of TDM has extended to be applied in various medical conditions.

Most drugs can be dosed correctly without special testing or monitoring. But for certain types of drugs, it can be hard to figure out a dose that provides enough medicine to treat patient's condition without causing dangerous side effects. TDM helps your provider find out if you are taking the right dose of medicine.

TDM is the measurement of drug concentration in biological fluids to determine the drug dose achieving a pre-defined target level for a patient. This technique requires that a relationship between concentration (i.e., exposure) and effect (i.e., pharmacodynamic response) to be demonstrated. Measures of exposure include the area under the plasma concentration-time curve (AUC), time above a threshold concentration, maximum concentration (Cmax), and trough concentration. TDM can correct for most of PK variability, consequently reducing the variability in response.

Indications for requesting plasma drug concentrations

- Monitoring compliance
- Individualizing therapy during early therapy and during dosage changes
- Diagnosing under treatment
- Avoiding toxicity
- Monitoring and detecting drug interactions
- · Guiding withdrawal of therapy

Following information is required for Therapeutic Drug Monitoring

- Patient's clinical history concerning past therapeutic responses
- Patient's clinical condition
- Pharmacokinetics of the drug
- Dosage regimen
- Sampling time
- Purpose of therapeutic drug monitoring.
- Patient's clinical responses

The process of TDM





Pharmacoeconomics: an overview

PHARMACOECONOMICS: AN OVERVIEW

RAJANI MALI, JAGRUTI YENPURE

PES MODERN COLLEGE OF PHARMACY, NIGDI, PUNE.

Introduction:

The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) defines pharmacoeconomics as "the field of study that evaluates the behaviour of individuals, firms, and markets relevant to the use of pharmaceutical products, services, and programs, and which frequently focuses on the costs (inputs) and consequences (outcomes) of that use". The demand for and the cost of pharmaceutical care are rising in all countries as the digitalization in and improvement of health technologies. The pharmacoeconomic assessment is essential to find the rational therapy at the lowest price.

Pharmacoeconomics can be defined as the branch of economics that utilizes cost-benefit, costeffectiveness, cost minimization, cost-of-illness and cost-utility analyses to compare pharmaceutical items
and treatment management. It is the part of health economics that focuses on the economic evaluation of
pharmaceutical Products, health Economics and outcomes research, and patient-reported outcomes (PRO)
in Individual, aim at determining patient worth in terms of impact of disease and its treatment on physical
working skills and psychological and social wellbeing, known also as "health-related quality of life"
(HRQL).

Importance of Pharmacoeconomics:

Pharmacoeconomics has become most important over the past 20 years, due to an increased need of Economic drug therapies for the diseases

- Increasing health Value has led to the necessity to find the optimum therapy at the minimum price.
- Pharmaceutical consumption which comprises a large part of healthcare expenditures, have been rising much faster than total healthcare expenditures.
- Several drug alternatives and authorized consumers also fuel the demand for economic analyses of pharmaceutical products.
- 4) The increasing cost of healthcare products and services has become a wide concern for consumers, healthcare professionals, patient and the common public.
- 5) This rising concern has brought about demand for the utilization of economic estimation of alternative healthcare outcomes. This expansion in healthcare spending is due to increased life expectancy, expanded technology, increased assurance, raised in standards of living and increasing need in healthcare quality and services.
- 6) Healthcare resources are not easily reachable and affordable to many patients; hence Pharmacoeconomic evaluations play a key role in the issuing of these resources.



Artificial intelligence in education

ARTIFICIAL INTELLIGENCE IN EDUCATION

PADMAJAKORE, PRADNYA KHELBUDE

PES MODERN COLLEGE OF PHARMACY, NIGDI, PUNE-411044.

Introduction

Artificial intelligence (AI), generally expressed by the general public as the ability of machines or computers to think and act as humans do, represents the efforts towards computerized systems to imitate the human mind and actions. With the advancement of worldwide science and technology, AI technology has advanced by leaps and bounds. AI technology is frequently utilized and updated across many industries. It is evident that AI has significantly affected the learning environment and teaching approaches in schools. More and more people are becoming aware of the value of this technology in the field of education as it grows. AI has been implemented extensively in the field of education and has showed great application benefits, which have a significant impact on the teaching process and classroom management. At the current, many nations throughout the world are worried about the implementation of artificial intelligence in education, specifically how to make it valuable to all people. The use of AI in education has resulted in the complete implementation of teaching and learning, as well as the possibility for teaching and learning reform. This article examines and assesses the application of AI in education in detail.




Fig-1 AI in Education

Applications of AI in Education-

Applications for artificial intelligence in education typically involve intelligent tutor-assisted personalized teaching and learning, intelligent assistants like educational robots, children's partners at home, intelligent assessment, mining and intelligent analysis of educational data, learning analysis and learning, digital portraits, etc. Literature studies show that artificial intelligence technology in education has been used in the following aspects:

(i) The Automatic Grading System: The automatic grading system is an expert computer programme with artificial intelligence that replicates the actions of a teacher to grade student work in a classroom. It





Digitalization in pharmaceutical care

DIGITALIZATION IN PHARMACEUTICAL CARE

RUPALI JINTURKAR, SHEETAL CHAUDHARI, VASUDHA BAVADEKAR

PES MODERN COLLEGE OF PHARMACY, NIGDI, PUNE

Pharmaceutical care is an approach to patient care that emphasizes the responsible provision of medication therapy to achieve definite outcomes that improve patients' quality of life. In recent years, there have been several significant developments in pharmaceutical care. To optimize the health of all members of society the promotion of safe, effective and rational medicine use, through pharmaceutical care has become the need of the hour. This article focuses on emerging trends in pharmaceutical care, Digitalization in pharmaceutical care, Digital therapeutics, Health related quality of life and antimicrobial resistance. Overall, the pharmaceutical care industry is rapidly evolving, with new technologies, treatment approaches, and care models emerging. As these trends continue to develop, pharmacists and other healthcare providers will need to adapt and evolve to provide the best possible care to patients.

Pharmaceutical care is increasingly moving from a product-oriented model, where medications are the focus of treatment, to a patient-oriented model that emphasizes the delivery of comprehensive services to patients. In this model, pharmacists and other healthcare providers work collaboratively with patients to manage their health and improve outcomes. There are several ways that pharmaceutical care is becoming



Digital therapeutics in current era

DIGITAL THERAPEUTICS IN CURRENT ERA

ROHINI CHAVAN, SANGITA KALE

PES MODERN COLLEGE OF PHARMACY, NIGDI, PUNE

A digital therapeutic is a software-based intervention designed to treat or manage a medical or mental health condition. It is a type of digital health technology that uses evidence-based therapeutic interventions to support patient care and outcomes. Digital therapeutics can be delivered through various digital platforms such as mobile applications, websites, wearable devices, and virtual reality. They often use cognitive behavioral therapy (CBT), mindfulness-based interventions, or other behavioral interventions to help patients manage their symptoms, improve their health, and achieve better health outcomes. Digital therapeutics are often used as an adjunct to traditional therapy or medication, but they can also be used as a standalone treatment option. They are typically backed by clinical studies and regulatory approvals, which help to ensure their safety and efficacy.DTx is becoming increasingly popular in the new era due to its ability to offer personalized and cost-effective treatment options.

Digital Therapeutic Core Principles:

Digital therapeutics (DTx) is evidence-based therapeutic interventions that use digital technology to treat, manage, or prevent medical conditions. Evidence-based: Digital therapeutics are grounded in scientific research and clinical evidence. They are designed to deliver measurable outcomes, such as improvements in symptoms, functional ability, or quality of life. User-centered: Digital therapeutics should be designed with the end-user in mind. They should be easy to use, engaging, and accessible to patients, caregivers, and healthcare providers. Scalable: Digital therapeutics should be scalable and have the potential to reach large numbers of patients. They should be designed to integrate into existing healthcare systems, and support the needs of healthcare providers and payers. Secure and private: Digital therapeutics should adhere to strict data security and privacy standards. Patient data should be encrypted, and the platform should comply with applicable regulatory standards, such as HIPAA and GDPR. Continuous engagement: Digital therapeutics should offer continuous engagement and monitoring to support patients in achieving their health goals. The platform should offer ongoing support, feedback, and personalized recommendations. Interoperability: Digital therapeutics should be interoperable and integrate with other healthcare systems, such as electronic health records, to ensure continuity of care. Regular updates and improvements: Digital therapeutics should be regularly updated to reflect the latest evidence-based practices and technologies. The platform should be designed to support ongoing research and development, and incorporate user feedback and insights.

Here are some ways that digital therapeutics is being used in the new era:

 Mental health treatment: DTx can provide mental health treatment for conditions such as anxiety, depression, and addiction. Patients can use apps and online programs to receive cognitive behavioral therapy, mindfulness exercises, and other types of therapy.



Artificial intelligence in bioinformatics

ARTIFICIAL INTELLIGENCE IN BIOINFORMATICS

PADMAJA KORE, MOHSIN MANSOORI

PES MODERN COLLEGE OF PHARMACY, NIGDI, PUNE.

Introduction

The advancement of Artificial Intelligence (AI) extends the frontiers of new computer concepts, making much science and engineering difficulties a reality. When we can't use a computational tool to produce value or solve issues, its sensitivity and flexibility are meaningless. Machine learning, a popular branch of AI technology, is concerned with gathering and recognizing useful and relevant information from large and complicated databases using various kinds of neural networks. Machine learning algorithms, which are by definition data-hungry, typically excel in real sectors that create and contain a large amount of data. The major applications in which we are most interested include bioinformatics and other fields that generate a great amount of data.

Bioinformatics

Bioinformatics is the investigation of biological data. Basic applications in this discipline include genetic sequence and molecular structure analysis, while advanced applications include biological system modeling. AI in Bioinformatics provide both fundamental and clinical research using biological data matching, protein binding, and function-structure analysis. This analysis aids in the development of medications as well as complicated systems.

Applications of AI in bioinformatics

Advances in fields of immunology and vaccinology depend on innovations in biotechnology, particularly genomics, proteomics, signature tagged mutagenesis, immune modulation, complex system analysis, and computational simulations.











Applications of AI in Bioinformatics

a) Applications of AI in Immunology

82

Effect of digital therapeutics on health care industry





EFFECT OF DIGITAL THERAPEUTICSS ON HEALTH CARE INDUSTRY

ANURADHA MORE, OMKAR LOKHANDE

PES MODERN COLLEGE OF PHARMACY, NIGDI, PUNE.

The digital revolution has radically changed all sectors of society, and recently it began to affect the health industry in particular, mainly due to the increase in the amount of health information produced by each individual patient. The COVID-19 pandemic has significantly accelerated the digital transformation of health care, and many digital health solutions have become key components of the functioning of the post-Covid-19 system. Physicians are increasingly using consumer digital tools for routine monitoring and diagnosis of a number of diseases. According to IQVIA's (Institute for Human Data Science Reports) July 2021 investment in digital health will grow to a record \$2.00. Billion in 2020 have driven primarily by continued acceleration in mergers and acquisitions activity and the growing influence of venture capitalists.

What is digital therapeutics (DTx)?

Digital therapeutics (DTx) are evidence-based, outcome-enhancing health interventions delivered directly to patients through software applications to prevent, manage, alleviate or treat a range of physical and mental illnesses. Some of his (DTx) interventions combine software with hardware such as external sensors and virtual reality (VR) glasses. (DTx) combines a set of mature software technologies guided by clinical insights. (DTx) is not about technology, but how these digital interventions are developed and used. (DTx) is a subdivision of digital health that represents a collection of technologies, products and services in the health and wellness sector.

The term "digital therapies defined as evidence-based behavioural therapies delivered online that can increase the accessibility and effectiveness of health care. The digital therapeutics Alliance (DTA) defines as "the delivery of evidence-based therapeutic interventions to patients, guided by software, to prevent, manage or treat a medical disease or illness.DTA also envisions that all stakeholders, including patients, health care providers and payers, adopt smart and accessible tools to approach various diseases with high quality, safe and effective data measures.

Relationship between digital Health, digital Medicine, and digital therapeutics

The relationship between digital health, digital medicine and digital therapeutics is necessary to avoid confusion between digital health stakeholders and the manufacturers and developers of these products to better position and use these products in the market. Digital Health acts as an umbrella entity covering digital medicine, which also includes DTx. Products classified in each of these categories present different levels of requirements and risks. In addition, their requirements for clinical evidence and formal monitoring differ. Digital health is a broad category of technologies, platforms, and systems that engage consumers in achieving lifestyle, wellness, and health-related goals. Examples of digital health systems include health information technologies, telehealth systems, systems that use consumer health information, and clinical care management tools.



Pharmaceutical care

PHARMACEUTICAL CARE

ANURADHA MORE, PATHAN ADIL, TARATE SWAPNIL, BHAND NITIN

PES MODERN COLLEGE OF PHARMACY, NIGDI, PUNE.

Introduction

Pharmaceutical care refers to the process in which a pharmacist works in collaboration with a patient and other professional to develop, carry out, and track a therapeutic plan that will result in a particular therapeutic outcome for the patient. Pharmaceutical care refers to a change in pharmacy practice from one that is patient-oriented to one that is drug product-oriented in order to achieve specific results that enhance patients' quality of life. Pharmacists must take on the roles of caretaker, communicator, decision-maker, teacher, researcher, good leader, leadership, and management in order to deliver pharmaceutical care, which will assist them to provide tailored treatment. Community pharmacists can play a significant role in providing individualized care to patients as a result of the increased frequency of patient visits, particularly in the management of chronic non- communicable diseases (NCDs).

Definition

It is defined as "the responsible provision of drug therapy for the purpose of achieving definite therapeutic outcomes that improve the patient's quality of life".

Process of pharmaceutical

> Develop patient-pharmacist relationships

Gather data Analyze data Determine the issues associated to drugs

Assess the severity of drug-related issues.

Define intended results (clinical or therapeutic), create a treatment plan, and create a monitoring strategy. Execute the pharmacological care plan and monitor it.

Major functions of pharmaceutical care

- Identifying potential and actual drug related problems.
- > Resolving actual drug related problems
- > Preventing potential drug related problems

The pharmaceutical care cycles





3D printing in dosage form

3D PRINTING IN DOSAGE FORM

VASUDHA BAVADEKAR, RUPALI JINTURKAR, SHEETAL CHAUDHARI

PES MODERN COLLEGE OF PHARMACY, NIGDI, PUNE

Years of medication therapy saw patients suited to the manufacturer's dosage recommendations rather than the dose being fitted to the patient's needs. As a result of the incorrect dose, there was a high prevalence of side effects. Nonetheless, there has been a shift in recent years towards customised dosing. Whether patients are being treated with thyroid hormones or insulin, it has been shown that the idea of customised dose benefits the patients. Thyroid hormone therapy is a unique instance of customised therapy. Here, each person's dose adjustment is managed individually by measuring blood levels at predetermined intervals. The therapy can be tailored to the unique patient's age, weight, and medical history by changing the dose.

3d printing technologies

1. Drop-on-solid Printing (DoS)

The Massachusetts Institute of Technology introduced DoS printing, also known as binder jetting or the drop-on-powder technique, for the first time in 1993. DoS printing are used in a variety of industries, including the manufacturing of automobiles, medical devices, and pharmaceuticals, due to the vast range of materials that are suited for it. With DoS, the first FDA-approved drug is printed. As a result, this method attracted a lot of interest in the industrial industry.

2. Pressure-assisted Microsyringes (PAM)

The PAM method is an alternate printing approach for tissue engineering that was created by Vozzi et al. in 2002. A glass syringe, an electronic pressure regulator, and a computer to regulate the printing settings were all included in the developed printer prototype. This prototype has been improved throughout the years, and PAM is now well-known in the tissue engineering research community.

3. Fused Filament Fabrication

S. Scott Crump created the technique in 1988 under the name Fused Deposition Modeling (FDMTM), which Stratasys eventually patented and commercialised. FFF is currently a growing technology used in many different applications. Because of its low-cost equipment and ability to tailor solid dosage forms to the demands of the patient, it has already been used in the medical area and is the most extensively researched 3DP technology for pharmaceutical applications. This approach has been the focus of many pharmaceutical research groups, especially over the last four years. Because of the wide range of applications, there is a wide variety of literature available, particularly on the examination of oral DDS.

4. Selective Laser Sintering (SLS)

The United States' University of Texas at Austin's Deckard and Beaman introduced and patented selective laser sintering (SLS) in 1990. SLS has a wide range of uses, especially in the disciplines of tissue engineering and aerospace, where it is routinely employed to create bone scaffolds.

5. Stereolithography (SLA)





Telemedicine an Evolving Health Practice with use of modern tools

TELEMEDICINE AN EVOLVING HEALTH PRACTICE WITH USE OF MODERN TOOLS

SWATI MUTHA¹, ANURADHA MORE²

¹SCHOOL OF PHARMACY, VISHWAKARMA UNIVERSITY, PUNE

²PES MODERN COLLEGE OF PHARMACY, NIGDI

Telemedicine concept is gamechanger in modern healthcaresystem and it offers access to the patient to healthcare services, irrespective of their location or mobility, and to reduce the barriers of distance, time, and cost to access the healthcare services. The COVID-19 pandemic has enhanced telemedicine adoption in India, as many patients turning to virtual consultations to avoid exposure to the virus. Telemedicine can also enable the delivery of healthcare services during public health emergencies or natural disasters, when in-person healthcare services may not be feasible or safe.

Telemedicine refers to the delivery of healthcare services, such as consultations, diagnosis, treatment, and monitoring, using telecommunication technologies such as video conferencing, phone calls, text messages, email, and other digital communication channels. In this review we explore the latest tools used in telemedicine as follows

Telehealth platforms: Telehealth app platforms, such as 'Teladoc' (United State and Canada), 'Amwell' (United State), and Doctor on Demand, provide patients with access to virtual consultations with healthcare providers. These platforms often offer a range of services, including primary care, mental health care, skin care and specialty care. Some examples of telehealth apps that popular in India are Practo, Medlife, Apollo 24/7, Portea. Mfine is an AI-powered telehealth app that offers virtual consultations with doctors and specialists. The app uses AI to provide personalized treatment recommendations based on patient data. The key advances in telehealth platforms:

Mobile apps: Many telehealth platforms now offer mobile apps that allow patients to access
virtual consultations and other services from their smartphones and tablets. Mobile apps make it



Artificial intelligence in cloud computing in industrial sector

ARTIFICIAL INTELLIGENCE IN CLOUD COMPUTING IN INDUSTRIAL SECTOR

PADMAJA KORE, AKANKSHA AMRITKAR

PES MODERN COLLEGE OF PHARMACY, NIGDI, PUNE.

Introduction

The term "cloud" in cloud computing refers to a collection of networks; similar to how real clouds are made up of water molecules. The user has unrestricted access to cloud computing modalities at any time. Users often prefer a middleman provider for internet service in cloud computing rather than building up their own physical infrastructure. Users must only pay for the services they have utilized. In cloud computing, the workload may be transferred to lessen the workload.

To use cloud computing, all we need is a web browser like Chrome. The following are the main characteristics of cloud computing:

- 1. Elasticity and Resource Pooling
- 2. On-Demand and Self-Service Services
- 3. Costing
- 4. Service Quality

Software as a Service (SaaS), Platform as a Service (PaaS), and Infrastructure as a Service (IaaS) are the three types of cloud computing services. Facebook, YouTube, Dropbox, and Gmail are just after instances of cloud computing that people use on a regular basis. It provides scalability, flexibility, agility, and simplicity, which is why its use in businesses is quickly expanding.




Fig1-CloudServiceModel

Applications of cloudcomputing

1. Ecommerce and Business Applications

Ecommerce is the internet-based sales and services setup that got attention in the 20th century. The recent trends of mobile computing encourage vendors and service providers to take additional benefits from the internet revolution in terms of business. The dawn of mobile apps and ecommerce websites helps entrepreneurs to take risks into new ventures. The e-commerce increased revenues of companies at very minimum investment. The architecture of today's ecommerce relies on the availability of the website's





Artificial intelligence in marketing

ARTIFICIAL INTELLIGENCE IN MARKETING

PADMAJA KORE, VINOD GAIKWAD

PES MODERN COLLEGE OF PHARMACY, NIGDI, PUNE

Introduction

World trends are influenced by technological disruption, where Artificial Intelligence (AI) plays a significant part in the development of machines that can mimic human intelligence through the use of computer and information technology. In digital marketing campaigns where speed is crucial, AI is frequently deployed. To ensure optimal efficiency, AI marketing solutions analyse data and customer profiles to learn how to best engage with clients. They then give them personalised messages at the appropriate moment without help from marketing team employees. Today's digital marketers frequently employ AI to support marketing teams or carry out more tactical jobs that don't require as much human finesse.

To the best of our knowledge, there is no study that covers completely and holistically the body of knowledge produced on AI in the closely related fields of marketing, consumer research, and psychology, despite the fact that the adoption of AI by marketing managers and consumers is growing exponentially. Engineers, IT specialists, and analysts have been drawn to AI up to this point, but it is now expanding beyond of its usual spheres of application and making a bigger impact in the management and marketing sectors.

AI is increasingly widely used in the field of digital marketing as well, working behind the scenes to improve pay-per-click advertising, personalize websites, provide content, forecast behaviour, and more. According to Forbes, 84 percent of marketing businesses are introducing or increasing their use of AI and machine learning in 2018 as marketers swiftly recognize the advantages of the technology. The way businesses are run has been changed by artificial intelligence (AI), and digital marketing is no exception. Businesses are using AI to automate their marketing processes and gain a competitive edge in the market as a result of technological advancements.

The gap between data science and implementation can be closed with the help of artificial intelligence marketing solutions. It used to be impossible to go through and analyze massive amounts of data, but today it's not only possible but also simple. Marketing strategies based on artificial intelligence actually comprehend the world in the same manner that a human would. This implies that the platforms can quickly find meaningful concepts and themes among massive data sets. These platforms can comprehend open form information like social media, natural language, and email responses since AI solutions also perceive emotion and communication like a human.

Artificial Intelligence application in marketing:

1. Data analysis

This is the fundamental idea of AI. Data obtained from traditional measurements, consumer engagement, inbound communications, new business generation, and any other inputs from various communication





The challenges, potential and future of digital therapeutics

THE CHALLENGES, POTENTIAL AND FUTURE OF DIGITAL THERAPEUTICS

SUVARNA VADJE*, BHUSHAN PIMPLE, MOHINI KUCHEKAR

PES MODERN COLLEGE OF PHARMACY, NIGDI, PUNE.

Introduction

The healthcare industry now offers stakeholders more options than ever before as it increasingly digitizes. The improvement of treatment and health monitoring both inside and outside of healthcare settings can be attributed to the growing adoption of intelligent medical devices, software programmes, and cloud-based platforms. Nonetheless, innovation is still urgently needed in healthcare. It keeps relying on Digital health technology due to a lack of physicians, illness outbreaks, and the need to reduce supplier prices.

Digital therapeutics (DTx), defined by the Digital Therapeutics Alliance as "evidence-based therapeutic interventions driven by high-quality software programs to prevent, manage, or treat a medical disorder or disease. A wide range of physical, mental, and behavioral health disorders can be helped, treated, managed, or prevented with the use of digital therapies, which are specialized tech-based tool that use specialized software. They can be categorized as any recognized software-based treatment method. Healthcare providers typically work with internal or external developers to plan, build, and execute digital treatments. Smartphone apps are often used to deliver DTx solutions. This makes them more accessible by delivering treatment directly to patient's homes.

History

In 1995, Dr. Joseph Kvedar from Boston, USA, led a program to learn the development and application of technology for delivering care outside the traditional setup of a hospital or a doctor's office while suggesting the "one-to-many model of care." The idea was to expand the physicians' scope by overcoming time, place and personnel limitations that restrict healthcaredelivery while also taking better care of patients with fewer resources by providing access, convenience, and efficiency. This attempt by Dr. Kvedar could be attributed to being among the first made by researchers in the digital health/DTx domain.

- The use of digital products to produce better health outcomes has been documented in the literature since at least 2000. Dr. Tom Ferguson first used the phrase "E-patient" in 1999, but it wasn't until almost ten years later that it became widely known. Since 2012, the word "DTx" has been used formally. Patients who are "equipped, enabled, empowered, and engaged in their health and healthcare decisions" are referred to as "e-patients." Currently, there are an increasing number of e-patients. They are more interested in making decisions about their care and desire to do so. People anticipate their doctors to provide them with well-informed responses to their inquiries about medicine and health technologies. The necessity for digital health and related tools is unavoidable in such a conscious world.
- The Food and Drug Administration (FDA) approved the first prescription digital therapeutic five years ago (PDTx). PDTx are digital therapies that are recommended by a doctor and covered by



Artificial intelligence & machine learning in robotics

ARTIFICIAL INTELLIGENCE & MACHINE LEARNING IN ROBOTICS

PADMAJA KORE, KAJAL PAWADE.

PES MODERN COLLEGE OF PHARMACY, NIGDI, PUNE.

Introduction

Automation, robotics, artificial intelligence, machine learning, and automation are the theoretical and analytical pillars on which robotics and artificial intelligence studies are based. The use of robotics, artificial intelligence, and machine learning technologies can be used in this body of literature as both independent and dependent variables. Independent variables can be used to see how the use of these technologies affects a variety of outcomes, such as effects on labour, productivity, growth, and firm organisation. Dependent variables can be used to examine factors that encourage or discourage the adoption and use of these technologies. It is crucial that organisational researchers characterise any such constructs in their research carefully in order to distinguish these similar but different constructs from one another. An "automatically controlled, reprogrammable, multipurpose manipulator, programmable in three or more axes, which can be either fixed in place or mobile for use in industrial automation applications" is what the International Federation of Robots (IFR), an international industrial group focused on commercial robotics, defines as an industrial robot. Footnote4 While this description is a good place to start other robotics may have different ideas about things like whether a robot must be automatically controlled or can operate on its own, or whether it needs to be programmable. In a broader sense, a robot may be any machine that is able to do difficult actions or activities automatically. General artificial intelligence refers to computer software that has the capacity to reason and act independently; nothing comparable exists at the moment. Software that uses highly complex computational techniques to identify patterns in data and forecast the future is referred to as "narrow artificial intelligence." In this sense, the software "learns" from existing data and is referred to as "machine learning," but this is distinct from real learning.

In manufacturing and production processes, automation refers to the employment of largely automatic, probably computer-controlled systems and equipment that replace some or all of the jobs that were previously completed by human labour. As advancements like the steam engine and the cotton gin can be seen as automating formerly manual operations, automation is not a new idea. Researchers in this field are concerned about the ways and contexts in which increased usage of robotics and artificial intelligence technologies may result in increased automation as well as the possible effects that such increased automation may have on the workforce and organisational design.

Numerous industry analysts contend that the most important and undoubtedly one of the most fascinating areas of robotic research is the application of AI. An intelligent robot might act and carry out all kinds of jobs in a human-like fashion, even if intelligent computers may one day be able to "think" like a human.



Potential applications of human machine interface technology in different domains

POTENTIAL APPLICATIONS OF HUMAN MACHINE INTERFACE TECHNOLOGY IN DIFFERENT DOMAINS

PADMAJA KORE, UJWALA DESAI

PES MODERN COLLEGE OF PHARMACY, NIGDI, PUNE

Introduction

A Human-Machine Interface (HMI) is a user interface or dashboard that connects a person to a machine, system, or device. While the term can technically be applied to any screen that allows a user to interact with a device, HMI is most commonly used in the context of an industrial process.

Applications of Human-Machine Interface

1. HMI in healthcare & rehabilitation engineering

In the fields of neurology, neurosurgery, psychology, medical diagnostics, and rehabilitation engineering, HMI technology is currently having a considerable impact. The sensors-based HMI technology is crucial for saving lives, whether it is in essential, life-supporting systems or to monitor the respiratory parameters during dialysis for renal patients. The life support for trauma and transport (LSTATTM) is a stretcher-based self-contained life-supporting unit that provides emergency care during the transport of a patient in critical time to save life in road accidents and injuries that occur in remote areas where full hospital facilities are not available. The HMI-based mobile healthcare devices with quick and reliable findings are widely utilised for diagnostic purposes in the monitoring of diabetes, blood pressure, hypertension, or any other health-related parameter of an individual. Using HMI-based home measures, which accurately track isolated diastolic hypertension, pulse pressure, and systolic hypertension, the total cardiovascular prognosis can be determined.

2. Human prostheses and robotic surgery controls

By combining different tactile and 3D acceleration sensors with real-time communication systems based on EEG pattern identification and feature extraction, the new technical systems of brain control technology-based BCI systems are designed to control the movements of prosthetic hands. BCI now only successfully supports a few key bodily actions because of the limitations and difficulties in pattern identification and feature extraction in EEG data. Due to the lack of synchronised multi DOF control capability and the scarcity of independent controls and repeatability, using surface EMG signals to control a prosthetic hand with greater degrees of freedom is challenging. The implanted electrode approach yields superior outcomes for gaining better control with prosthetic hands. With the use of minimally invasive surgery techniques, this was initially adopted on animals and eventually on humans. The volunteer was able to intuitively and simultaneously control two degrees of freedom with the prosthetic hand using this way, which was not achievable with surface EMG controls.

4.3. Sensory substitution systems

The general functional principle of the sensory substitution system is to transmit the stimuli characteristic of one sensory medium into stimuli of another sensory medium such as touch to vision or any other form.





Artificial intelligence in human resource management

ARTIFICIAL INTELLIGENCE IN HUMAN RESOURCE MANAGEMENT

PADMAJA KORE, GAYATRI GADEKAR

PES MODERN COLLEGE OF PHARMACY, NIGDI, PUNE.

Introduction

Software, machines, and computers all fall under the umbrella of artificial intelligence. The term "robot" was originally used in the year 1920 during a science fiction play by the Czech author Karel Capek called RossumoviUniverzálnRoboti, which translates to Rossum's Universal Robots, popularly known as R.U.R. John McCarthy coined the phrase "artificial intelligence" in 1956 during his initial academic meeting on the topic. But this journey to gain a deeper understanding of this region had begun much earlier. First, we can discuss the shift in power; client-based services will become more automated, including help desks, chatbots, customer care, and assistance centres. Reconfiguring the connection between professionals and end users will increase availability and reduce time-consuming chores. When it comes to sourcing and purchasing responsibilities, AI will be able to swiftly compile all smart data and produce dashboards that are more effective. Employees must now factor in the help and methods of the machine in their regular work. While they might be replaced by AI in some tasks. Artificial intelligence is useful for a number of corporate processes where it can help to lessen the workload and stress on humans. Business changes quickly and requires quick responses. Organizations can inform their current performance and daily operations by deploying AI systems. Due to mounting commercial pressure, harsh managers recognized the value of artificial intelligence in the workplace. Nowadays, artificial intelligence is being integrated into an organization's whole structure. In the human resource department, for example, all human functions—such as candidate screening, hiring, aligning human resource activities, and performance management-are carried out using AI systems. Yet, there is currently a lack of a general framework for AI application in the human resource management study field, as well as the unique dimensions of human resource management, to examine its specific application. As a result, this article provides a conceptual AI application to the HRM model based on the six dimensions of HRM and the primary technical applications of AI in order to instruct businesses on how to use AI technology to support human resource management. On the basis of the examination of the Leap.ai and Baidu industrial instances, we talk about the hiring and training practices used in AI applications. The suggested AIHRM framework offers conceptual direction and practical application suggestions for the integration of human resource management with AI technology. There are also some suggested areas for future research.

Applications of AI in human resource management

HR departments are using tools like data analysis, artificial intelligence, and cloud computing to simplify resources. The use of artificial intelligence or digital technologies in HR like a chatbot, machine learning, and robot process automation is common practice in human resource management which support recruitment, screening, onboarding, interviewing, etc.





Artificial intelligence in life style

ARTIFICIAL INTELLIGENCE IN LIFE STYLE

PADMAJA KORE, ABHIJIT DESHMUKH

PES MODERN COLLEGE OF PHARMACY, NIGDI, PUNE

Introduction

Artificial intelligence (AI) has recently incorporated itself into our daily lives in ways that we might not even be aware of. It has spread so far that many people are still oblivious of its effects and how much we depend on it.

Many of us pick up our laptop or cell phone as soon as we wake up to begins our day. Our decisionmaking, planning, and information-seeking processes now all automatically include doing this. Once we've switched on our devices, we instantly plug into AI functionality such as:

- · face ID and image recognition
- emails
- apps
- social media
- · Google search
- · digital voice assistants like Apple's Siri and Amazon's Alexa
- online banking
- driving aids route mapping, traffic updates, weather conditions
- shopping
- leisure downtime such as Netflix and Amazon for films and programs

A crucial aspect in business is and will continue to be global communication and networking. Making use of data science and artificial intelligence is crucial, and its potential development trajectory is unbounded.

Application:

Greater consumer brand associations, according to the CBBE idea, increase the perceived value of brands. Increased perceived brand value strengthens consumer faith in the brand. As a measure of consumer-brand interaction, it has been operationalized as a multi-dimensional construct largely composed of brand association, perceived value, brand trust, and brand loyalty. Greater consumer brand trust is correlated with higher brand loyalty. Consider that consumer brand meaning and a favourable brand connection are both essential drivers of brand equity that may be achieved through social approbation. The respect earned as a result of brand ownership in a referent community, which is enhanced by a smartphone's design, favourably influences user brand association. Luxurious brands are therefore very sought-after by Personalization as a process interlinks customers and marketers and solidifies the relationship between them. Positive connections have a role in encouraging customer engagement (CE) behaviours. Consumer relationships that also involve emotional bonding move to a level of engagement. One of the main reasons for AI's appeal is said to be the high level of personalization it provides.





Artificial intelligence in social media

ARTIFICIAL INTELLIGENCE IN SOCIAL MEDIA

PADMAJA KORE, NIKITA PAWAR

PES MODERN COLLEGE OF PHARMACY, NIGDI, PUNE.

Introduction

Artificial intelligence helps social media platforms control the pool of information and make sense of it in order to understand new trends, user behaviour, and their interests, find and block abusive content, and for a variety of other purposes. Al also plays an important role in social media marketing by allowing brands to measure enterprise performance and identify users who can be converted into potential customers. Al has the potential to revolutionize how brands market on social media platforms such as Facebook, Instagram, and Twitter. It can automate many time-consuming social media management tasks and even perform large-scale social media monitoring. Al allows social media marketers to get closer to their target audience and learn about their preferences. This helps them target their ads in a better way as well as create content in a better way.

Nowadays, social networks directly remind us of well-known websites in this field, such as Facebook, Twitter, and Instagram. Social networks are an essential component of social media. We can share all of our daily activities with a group of people who live in a virtual world thanks to social networks. Furthermore, we must distinguish between a social network and social media. Because of their ability to connect people and share diverse information, media such as television, radio, and even the press are social networks. However, because they lack the ability to interact with viewers, these media are limited and static. As a result, we refer to them as static media.

We now use the terms social network and social media interchangeably without realizing the distinction. To put it simply, social media encompasses social networks and forums, blogs, and even question and answer platforms. In conclusion, social networks are only a subset of social media. Today, we can define social media as a mode of communication characterized by social interactions between users and the use of content as a sharing tool. This definition applies to social networks as well. Each individual can now create a personalized message with unique content in the form of text, photo, video, etc. A network is considered social if it allows users to share content in various forms with other network users. Furthermore, social networks allow users to add friends and form new relationships in order to build a diverse contact list. Finally, social media offers a plethora of tools that allow Internet users to express themselves, have fun, learn new things, form new communities, and share their thoughts.

Applications of Artificial Intelligence in social media-

A. Chatbots -

A chatbot is a piece of artificial intelligence software that can maintain a conversation or discussion with a user using natural language on various platforms such as email applications, websites, or mobile applications. Chatbots respond as highly advanced and highly promising expressions of human-machine interaction. Chatbots, on the other hand, are merely a basic evolution of a question-and-answer system



Artificial intelligence in agriculture

ARTIFICIAL INTELLIGENCE IN AGRICULTURE

PADMAJAKORE, PRATIKSHA HAJARE
PES MODERN COLLEGE OF PHARMACY, NIGDI, PUNE

Introduction

John McCarthy first suggested a study based on the premise that "every element of learning or any other characteristic of intelligence can, in theory, be so precisely described that a machine can be made" at the 1955 Dartmouth Conference, which is where the term "Artificial Intelligence" was first used to replicate it. Due to its ability to address issues that humans struggle to handle effectively, artificial intelligence (AI), one of the core areas of computer science, has today permeated a number of industries, including manufacturing, healthcare, education, and finance. Humans are still astounded by what Intelligence is capable of.

In 1997, IBM's Deep Blue defeated world chess champion Garry Kasparov, and in 2016, AlphaGo defeated world Go champion Lee Sedol. These victories serve as examples of how artificial intelligence (AI) can outperform the majority of human brainpower.

Agriculture, a crucial aspect of any nation, continues to be one of the biggest obstacles at the moment. Approximately 820 million individuals worldwide suffer from hunger today. Furthermore, 70 percent more food must be created because the world's population is projected to increase to 9.1 billion in 2050. In addition to the anticipated expenditures in agriculture, additional investment will be required because without it, by 2050, 370 million people would go hungry. In addition, it is anticipated that there will be an expanding gap between the water supply and demand, and by 2025, it is likely that over three billion people will face water stress.





Artificial intelligence in e-commerce

ARTIFICIAL INTELLIGENCE IN E-COMMERCE

PADMAJA KORE, SURABHI SHINDE

PES MODERN COLLEGE OF PHARMACY, NIGDI, PUNE.

Introduction

Artificial intelligence is usually associated with the artificial fabrication of human minds that are capable of learning, planning, perceiving, and processing natural language. It focuses on the theory and creation of computer systems that can perform tasks which need human intelligence, like speech recognition, visual perception, decision-making, and language translation. The Technology sector known as artificial intelligence mostly uses machines designed to function like humans. The father of artificial intelligence, John McCarthy, defined it as "the scientific and technical knowledge of developing smart computer programmes in particular". There is now no doubt that artificial intelligence is the way of the future and gradually it will begin to impact every aspect of human life. Online platforms that cover a wide range of Internet services, such as marketplace services, search engines, social networks, application stores, communication services, and payment systems, are the significant components in e-commerce.AI has been used in the financial and e-commerce sectors with the main goal of designing standard, reliable product quality control methods and the search for new ways to reach and serve customers, while also maintaining low cost. These goals include a better customer experience, effective supply chain management, improved operational efficiency, reduced mate size.'

The Application of Artificial Intelligence Technology in Electronic Commerce -

In the field of electronic commerce, artificial intelligence technology has gradually developed into a powerful tool to boost sales growth and maximize e-commerce operations. Artificial intelligence technology is becoming increasingly mature and is dramatically changing the way people work and live. The following are the main ways that artificial intelligence is now being used in the world of e-commerce:

Chatbots

To improve consumer satisfaction and offer better services to clients, the majority of financial and ecommerce websites use chatbots. Artificial intelligence and machine learning techniques were used in
the development of these chatbots. They have the capacity to act in human-like ways. These chatbots are
capable of learning, and based on the availability of past data, they can give customers the best
recommendations. Chatbots can assist customers in finding the right products, checking the availability
of products, comparing different products, and ultimately assisting customers with payment. The chatbot
can also help customers in getting in touch with the appropriate customer support representatives if they
have any complaints or inquiries. Customers can communicate with the robots via text, voice, and even
images.

Recommendation Engine



Antidrug antibodies

ANTIDRUG ANTIBODIES

TUSHAR JHA, PADMAJA KAMBLE, UJWALA DESAI

PES MODERN COLLEGE OF PHARMACY, NIGDI, PUNE.

Monoclonal antibodies are antibodies that are identical and are each a clone of a single parent cell. They are derived from one type of immune cell. The introduction of mAb has contributed a lot to various diagnostic applications such as Inflammatory Bowel Disease (IBD), Multiple Sclerosis(MS) and Rheumatoid Arthritis(RA). They were first produced by the fusion of myeloma cells and splenic cells from a mouse which was immunized against an antigen.

mAb were invented by George Kohler and Cesar Milsten. Later, in 1988 Greg Winter pioneered the technique to humanize monoclonal antibodies. Treatment with mAbis not designed in order to "cure", but to target and modulate specific immune pathways. Hence, discontinuation of mAb treatment may lead to the re-appearance of the disease.

APPLICATIONS:

Diagnostic Applications:

mAbs in Biochemical Analysis:

- Pregnancy
- Cancers
- Hormonal disorders
- Infectious diseases

mAbs in Diagnostic Imaging:

- Cardiovascular diseases
- Cancers
- Immunohistopathology of cancers
- Hematopoietic Malignancies
- Bacterial Infections

2. Therapeutic Applications:

1) Direct Therapeutic Agents:

- In destroying disease-causing organisms
- In the treatment of cancer
- In the immunosuppression of organ transplantation
- In the treatment of AIDS

2) Targeting Agents in Therapy:

- Immunotoxins
- Drug delivery
- Dissolution of blood clots
- Radio immunotherapy





Liquid roll-on formulation having foot deodorizing and antimicrobial activity

LIQUID ROLL-ON FORMULATION HAVING FOOT DEODORIZING AND ANTIMICROBIAL ACTIVITY

PRASHANT PATANKAR, VITTHAL CHOPADE, PRAVEEN CHAUDHARI

PES MODERN COLLEGE OF PHARMACY, NIGDL PUNE

Abstract: Sweating is a biological function that helps to synchronize body temperature. The most common areas of sweating include armpit, face, palm, and sole of feet. Like armpit odour, foot odour is found to be large issue. Foot odor is caused by gram positive microbial-metabolism. Flora on the surface of the foot's skin is capable of breaking down a lipid and protein filled fluid secreted on the skin by exocrine glands, particularly sebaceous and apocrine glands. The lipids and proteins present in this secreted fluid are broken down by microbial enzymes called lipases and proteases. The existence of one or more of Staphylococcus epidermis, Bacillus subtilis and Propionibacterium Acnes on foot surface may trigger the generation of isovaleric and propionic acids, which in turn can cause a distinctive odor of feet. The present study evaluated a combination of natural oils against the odour causing bacteria, namely, Bacillus subtilis and Staphylococcus epidermidis. İt is found that a mixture of lemon oil, neem oil and tulsi oil when formulated into a liquid roll-on formulation exhibited synergistic antibacterial activity. The liquid roll-on formulation was prepared using different polymers such as Carbopol, Xanthan gum, HPC & PVP/VA copolymer and tested for appearance, homogeneity, viscosity, pH, spreadability, color, physical stability, antibacterial activity, irritation test, and deodorizing performance. The liquid roll-on formulation found to have desired properties such as clarity, spreadability, quick absorption post application, and nonstickiness. The liquid roll-on formulation also demonstrated antibacterial efficiency against the bacteria which causes a strong foot odour.

Keywords: Foot odour; Lemon oil; Tulsi oil; Neem oil; Liquid Roll-on; Bacillus subtilis; Staphylococcus epidermidis.

1. Introduction

Foot odour is known to be triggered by the secretion of glands such as eccrine and sebaceous glands. The secretion contains various amino acids, including serine, alanine, leucine, isoleucine and valine. Amongst these amino acids, valine, leucine, and isoleucine are accountable for forming foot odour; serine and alanine are considered basic amino acids responsible for moistening sweat. The amino acids such as leucine, valine, and isoleucine are broken down by microorganisms present on the skin surface into lower fatty acids, which are volatile in nature. It is known that gram-positive bacteria metabolism causes a strong foot odour. Microbial enzymes such as proteases or lipases disrupt the secretion of protein and lipids into fatty acids and amino acids that get vaporized. These volatilized compounds are perceived as unpleasant odorants. Amoore and Kanda et al., found that isovaleric acid appears to be a crucial odorant. Further, Sawano and Ara et al. found that foot odour consists of isovaleric acid and various free fatty acids such as propionic, isobutyric, and butyric acids. Further, a mild foot odour was observed in sensory tests in human-being by utilizing cultures of S. epidermis, C. minutissiumum and S. hominis, amild foot





A case study report on anorectal fistula

Abstract Code: MCOP-14

A CASE STUDY REPORT ON ANORECTAL FISTULA

Padmaja Kore*, Nikhita Kumbhar¹, Srishti Jha²,

Anuradha More

Progressive Education society's Modern College
of Pharmacy, Yamunanagar, Nigdi, Pune-

411044

Abstract

Anal fistula is a frequent benign illness; however, the complex variety poses a challenge in clinical practice. This case was notable for its extended medical history and complicated clinical presentation. The disease's appearance is complex and unusual due to its long-term development. We made a precise diagnosis of anal fistula using medical imaging examinations, and subsequently performed a fistulectomy to correct it. During the post-operative period, the patient made a good recovery. The treatment of





Mednme: apersonalizede-health toolfor patients and health care providers

Abstract Code: MCOP-16

MEDNME: APERSONALIZEDE-HEALTH TOOLFOR PATIENTS AND HEALTHCAREPROVIDERS

Esha Patel*¹, Dr. Anjali Kumbhar²

PES's Modern College of Pharmacy, Sector 21,

Yamunanagar, Nigdi, Pune-44.

Abstract

Introduction: The innovations in e-Health applications for the management of personal health, introduce a new era for the people and healthcare providers, aiming to optimize and manage the drug therapy for disease, towards advanced personalized tools. Empowerment of patient is associated with strategies that allow the people to gain control over their own health and lives.

Objectives:It is a mobile application for the people, in order to upload and store medical records, has pill reminder, daily log book for health related notes and drug counselling in simple English language etc. This application also has Hindi version of it for 141 crores Indian citizens. This also addresses the needs of pharmacists during the dispensing of prescriptions to patients and also helps physicians and other healthcare providers for

--





Epidemiological study of anti- snake venom use in snake bite patients

Abstract Code: MCOP-19

EPIDEMIOLOGICAL STUDY OF ANTI-SNAKE VENOM USE IN SNAKE BITE PATIENTS

Rajani Mali*, Sujata Thokal¹

Progressive Education Society's, Modern

College of Pharmacy, Nigdi, Pune 411044.

Abstract

Introduction: Snake bites are the common cause of morbidity and mortality in tropical nations. It is a serious problem in many sectors &becomes an occupational disease. In India, there are approximately 236 species of snakes the most of which are non-poisonous and 13 known species that are toxic and responsible for most of the venomous bites lead to cause panic reaction and local injury.

Objective:

- To perform the epidemiological study for snake bite patients and to evaluate whether or not ASV was given to patients who had been treated in hospitals.
- 2. To study and compare the low and high dose of ASV given in the patients for thetreatment. Methodology: 156 Patients with history of venous snake bite with signs of envenomation were included in the study after taking proper informed consent. Data were collected on predesigned, pre-tested, and structured questionnaire form and master chart by

--





Type D personality and its association with myocardial abstract code: mcop-20 infarction patients

interviewing the study. Immediately, low dose (30 to 50 ml) of ASV was started and patients were kept under intensive observation with supportive care & titrated up to 500 ml.

Result: Among the 156 patients, there were 74 males and 82 females. 91 patients had vasculotoxic, 43 patients had neurotoxic and 20 patients had mixed type of envenomation. In study, Average dose of ASV given was 48.11 ml.

Conclusion: The epidemiological study shows the epidemics of the ASV use, those who came to the hospital earlier needed a low dose of ASV to save the lives of victims of poisonous snake bites with proper support management.

Keywords: Anti-Snake Venom (ASV), Snake bites,epidemiological study

Abstract Code: MCOP-20

TYPE D PERSONALITY AND ITS ASSOCIATION WITH MYOCARDIAL INFARCTION PATIENTS

Rajani Mali*, SatywanKumbhar¹, Swapnil Ghatule²

Progressive Education Society's Modern collage of pharmacy, Nigdi, Pune 411044

Abstract

Introduction: Type D (Distress) personality is a newly Identified risk factor for cardiac outcomes can also deteriorate the health outcomes of myocardial infarction patients. Type D personality is based on two global stable personality traits including negative affectivity (NA) and social inhibition (SI). Negative affectivity is the tendency to experience various negative emotions. Social inhibitions is the

tendency to inhibit the expression of emotions in social interaction.

Objective: Estimate prevalence and Relationship between type D personalities in myocardial Infarction patients.

Methodology: In this study we had selected patients of acute myocardial infarction and DS 14 questionnaires and a proforma were filled by the consenting patients. NA and SI score was calculated based on the responses recorded in the DS 14 questionnaire and patients were analysed for their psychological status. If the patient was having NA score>10 and SI score >10 then that person was considered as having Type D personality.

Result: Total 205 patients were followed among which 153 were male and 52 were females. Prevalence of type D personality was found to be 15.12 and the prevalence of negative affectivity was 50.73 and social inhibition was 17.56.

Conclusion: These findings focus a new approach on type D and suggest a role in explaining link between type D and poor prognosis in myocardial infarction patients. NA and SI are global personality traits that may have special association with hypertension and coronary diseases.

Keywords: DS 14 questionnaire, Type D (Distress) personality, negative affectivity (NA) and social inhibition (SI)

Abstract Code: MCOP-21

MATERIOVIGILANCE PROGRAM OF INDIA

Pranay Prakash Nimbalkar Vishwanath Karad World Peace University, Kothrud, Pune.



Toxic pesticides drift- a study of 20 cases

technologies for the treatment and sometimes digital biomarkers are also used. In UK, Germany, France this therapy is been utilized by some of the patients. Telemedicine is the delivery of the healthcare at the distance and the most important mediator between the clinical trials and new drug discovery. Rapid and widespread adoption of digitalization of healthcare through DTx& telemedicine are the boon for the golden era of the healthcare system worldwide. Many health apps on smartphones, standards for data storage, opt out option from information, technical security, data audits, and data sharing needs to be executed in absolute manner.

Keywords: Digital therapeutics, Telemedicine

Abstract Code: MCOP-28

PHARMACEUTICAL CARE

Pranav Shinde, Krushna Sakwan, SanikaLamkhade, Sanjana Shettigar, Sakshi Jadhav

Indira College of Pharmacy, Nanded.

Abstract

The pharmaceutical care is defined as "The responsible Provision of chug therapy for the purpose of achieving definite Therapeutic outcomes that improve the patient's quality of life. Pharmaceutical care is a practice in which the practitioner takes responsibility for a patient's drug-related needs, and is held accountable for this commitment. In the course of this practice, responsible drug therapy is provided for the purpose of achieving positive patient outcome. The types of pharmaceutical care includes SOAP Analysis, CORE pharmacotherapy, FARM Analysis, PRIME pharmacotherapy Plan, P-

Pharmaceutical based problem, patient not receiving a prescribed drug, Routine monitoring (Lab Data), R-risk, to patients-ADR.

Keywords: Pharmaceutical Care, Pharmacotherapy Plan

Abstract Code: MCOP-29

TOXIC PESTICIDES DRIFT- A STUDY OF 20 CASES

Rajani Mali*,SavataDhadge¹, SukshamtaBalure² Progressive Education Society's Modern collage

of pharmacy, Nigdi, Pune 411044

Abstract

Introduction: A pesticide is a substance used in agricultural production to control pests/disease. It can lead to accidental poisoning, poisoning by oral route, or while spraying in field. All patients developed toxic effects of pesticide spray while spraying plants that were almost as tall as themselves. Airborne movement of pesticide to unintended targets is called pesticide drift.

Objective: To study toxic effects of pesticides due to inappropriate handling.

Methodology: An observational study of 20 consecutive cases was admitted to Medicine wards in 5 months due to toxic effects of organophosphates while spraying. All cases were medico-legal; history was taken, about victim's education, pump used, protective measures taken, weather conditions, type of crops, approximate height of plants in relation to victim's height. All patients consented to be part of study.

Result: The age group of patients were 17-50 years.15% Patient were literate, none of the educated individual had agricultural knowledge. Average height of victims was 165cm. In 12





Phytochemical evaluation, pharmacological activities and toxicological profile of impatiens balsamina

cases, crops were about 6 to 8 inches above the patient's height. In 8 cases, they were at face level.95% patients had mild to moderate form of illness from which they recovered.Maximum days of hospitalization were 9 days, minimum 2 days and average is 1 day.3 patients had required ventilator support out of which 2 (10%) survived and 1 (5%) succumbed.

Conclusion: Drift of pesticides while spraying is common and can lead to serious consequences, even death. Precaution should be taken. Operative use of pesticides should be provided.

Keywords: Pesticide Drift, Organophosphates

Abstract Code: MCOP-30

DIGITAL THERAPEUTICS AND TELEMEDICINE

Anuradha More, Amrut Godbharle, Aishwarya Mahangade, Padmaja Kore

Progressive Education Society's Modern College of Pharmacy, Nigdi, Pune-411044

Abstract

Digital therapeutics refers to all technologies that interact with patients for health-related purposes. Digital Therapeutics provides evidence-based therapeutic interventions utilizing high quality software programs to prevent manage or treat medical disorders and diseases. They are used alone or in combination with drugs, devices, or other therapies to optimize patient care and health outcomes. Telemedicine uses electronic and telecommunication technologies to share medical information even when the patient and doctor are not in the same room. Telemedicine uses virtual mode for interaction which is very beneficial as it avoids cross-contamination of infectious diseases.

Keywords: Digital Therapeutics, Telemedicine, Telecommunication

Abstract Code: MCOP-31

PHYTOCHEMICAL EVALUATION, PHARMACOLOGICAL ACTIVITIES AND TOXICOLOGICAL PROFILE OF IMPATIENS BALSAMINA L

Pushkar Karande1*, Srishti Jha1, Bhushan

Pimple¹, Mohini Kuchekar¹, Suvarna Wadje¹.

P.E Society's Modern College of Pharmacy, Nigdi, Pune

Abstract

Impatiens balsamina (rose balsam) belonging to the family balsaminaceae is an annual herb which is native to south East Asia. It has been used as cathartic, emetic, diuretic and has been used in treatment of wounds, inflammation of skin and jaundice. Various studies on this plant reveal the presence of flavonoids, naphthoquinone, quinones, triterpenoid, saponins, alkaloids and leucoanthocyanins. The plant and its different parts like seed, stem, leaf and flowers possesses various pharmacological activities antifungal, antibacterial, antioxidant and antipruritic properties. This comprehensive review summarizes all the available information on Impatiens balsamina from various sources including PubMed, Elsevier, Springer link, Science direct, Scopus along with various literature reviews from 1958 to 2022 in order to provide updated information on Impatiens balsaminafor future investigational works.

Keywords: Impatiens balsamina (rose balsam)Phytochemical Evaluation, Pharmacological Activitiy





Phytochemical evaluation and pharmacological activities of neolamarckia cadamba

Abstract Code: MCOP-32

PHYTOCHEMICAL EVALUATION AND PHARMACOLOGICAL ACTIVITIES OF NEOLAMARCKIA CADAMBA

Manali Majgaonkar ¹, YogishGarhwani ¹*, Rutuja Mane ¹, Pavan Mare ¹, Mohini

Kuchekar¹, Mohini Upadhye²

¹P.E Society's Modern College of

Pharmacy, Nigdi, Pune

²P.E Society's Modern College of
Pharmacy (For Ladies), Moshi, Pune

Abstract

The Neolamarckiacadamba is one of the important medicinal plants belonging to the Rubiaceaefamily.N. Cadamba occurs naturally from Sri Lanka, India, Nepal and Bangladesh eastward through Malaysia to New Guinea. It is crucially significant as it has the largest number of phytochemicals and secondary metabolites (viz., N. cadambagenic acid, cadamine, quinovic acid, \(\beta\)-sitosterol, cadambine, etc.) having pharmacological and biological properties like antidiabetic, analgesic, antipyretic, inflammatory, antidiarrheal, diuretic laxative, etc. It can be used as an alternative to various synthetic chemical compounds in the prevention as well as the treatment of several incurable diseases. Moreover, the N. cadamba is one of the ornamental plants with religious comprehensive review significance. This summarizes all the available information on Neolamarckiacadamba from various sources including PubMed, Elsevier, Springer link, Science direct, Scopus along with various literature reviews till 2022 in order to provide updated information

Neolamarckiacadambafor future investigational works

Keywords: Neolamarckiacadamba,

Phytochemical Evaluation, Pharmacological Activity

Abstract Code: MCOP-33

HEALTH RELATED QUALITY OF LIFE

Gauri Pednekar*, Gayatri Patil, Dr Sanket Kadam, Dr Ramdas Shinde Dr.D.Y. Patil College of Pharmacy, Akurdi. Pune 411044

Abstract

A multi-dimensional concept called Healthrelated Quality of Life (HRQOL) is frequently used to analyse the health state affecting one's quality of life. We have selected Rheumatoid Arthritis being the 2nd most prevalent autoimmune disease and its diagnosis by the application of Artificial Intelligence.

Objective: This study created and evaluated a strategy using Artificial Intelligence for merging the measures into a summary score in order to address this issue. Health-related quality of life is an effective tool of general health as it collects data on people's physical and mental health statuses as well as the effects of health status on quality of life.

Methodology: This involves methods to diagnose Rheumatoid Arthritis. Self-perceived health status, physical and emotional functioning, and other variables are frequently used to measure HRQOL. The field will progressively use artificial intelligence. Payers, care providers, and life sciences organisations currently use a variety of AI technologies.







Medical health card

Methodology :Typicalformulaforinsulin oral filmsincludesthefollowinghowever not limitedto

- 1. 5 to 20 wt % permeationenhancers
- 2. 0.5 to 10 wt % insulinorinsulinanalogue
- 3. 10 to 30 wt % plasticizer

insulin

4. 40 to 90 wt % watersolubleandhydrophilicpolymer
Results: Thethin film is anotheraspect of theinventionadvantageouslyusedfortreatingalldia betesexampleType 1, type 2, congenitaldiabetesandgestationaldiabetes.

Conclusion: Since thedemandsideforpharmaceuticaltreatment has beenchangingandnowadaystheapproachesis morepatientcentredandqualitybasedsoeventually it wouldonly be necessarytoevidenceproperlytheadvantages of

Illustrate film weighingincludefrom 10 mg to 30 mg.

portablesafeandefficaciouswithtargeteddeliveryw

hileofferingconvenientPharmaceuticaldosage

film

Thefilmsmaybeappliedbuccalpalatalorsublingually. Theproducedthin film can be packagedexampleindividually a singlepouchessingleunitdoses.

Alternativelyinsulinnanoparticles can be preparedbythenanoprecipitationbased on theacidbaseneutralizationmethodandthenencapsulatedintothinfilmstherebyusing a simpleprocessintegration of nanoparticleand film formingprocesses and adopting a bottom to top Nanoparticlemanufacturing approach

Keywords: İnsulin Films, Type 1, type 2, congenital diabetesand gestationaldiabetes.

Abstract Code: MCOP-36

MEDICAL HEALTH CARD

Gaurav Memane, SumedhaSavane, Vaishnavee Deshmukh, Mr. Devendra Visokar; Dr. Anjali Kumbhar; Dr. Sunita Pawar

PES Modern College of Pharmacy, Nigdi, Pune.

Abstract

The aim of this proposed e-health card system is to improve efficiency, access and accountability of health care services. Medical health card is a card which consists of complete demographic details, past medical and medication history, social history and present medical condition treatment and reports of the patient which can be scanned by unique QR code and is accessible in normal emergency Approximate number of MD doctors in Maharashtra 10Lakhs 41k with atleast 50-60 OPD patients per day. Data isn't stored. Patients doesn't keep prescription properly and unaware of their own medical, medication and allergic history. This health card will be help to overcome all the noted problems and will helpful in accidental, emergency and chronic disease patient.Among the given sample size of 100; 40 people were not familiar with their clinical condition.Out of which 9.6% were unknown to their disease while 8.4% were unknown to their allergy. The most common unknown factor was their medical/medication history which scored the highest percentage that is about 16.4%. Apart from this scenario any medical emergency requires the basic information of patients like their Blood group. In this study 5.6% people found to be in this need of information. This card

174



Effects of subacute administration of 4- hydroxyisoleucineon cognitive, suicidal, and sexual behavior in social isolation stress-induced olfactory bulbectomized rats

standardized fenugreek seed extract (INDUS1520) for skin applications.

Methods: The INDUS1520 is characterized and standardized for total and select groups of flavonoid glycosides. The aqueous solution of INDUS1520 was evaluated using *in vitro* assessments at concentrations (sensitization: 12 samples ranging from 0.20 μg/ml – 400 μg/ml, cutaneous irritation: 16 mg +/-2 mg , and eye irritation: 1%, 3% and 5 %) and *in vivo* clinical safety at the concentrations of 1%, 3% and 5 % (primary patch test and human repeat insult patch test, HRIPT) as per the international guidelines and reported procedures.

Results: The total flavonoid content of INDUS1520 was 94.08% (i.e.940.8 mg quercetin equivalent (mg QE) per g (colorimetric method) and 38.55% (high-performance liquid chromatography method). The content of selected flavonoids from group 1 (vitexin+isovitexin+vitexin 2-O-rhamnoside) was 22.73 and Group-2 (vicenin 1+vicenin 2+vicenin 3+schaftoside+isoschaftoside+orientin+isovitexin) was 15.82%. INDUS1520 at tested

concentrations did not show skin sensitizing, cutaneous irritant and eye irritant properties during *in vitro* and human clinical safety testings (primary patch test and HRIPT).

Conclusion: The present study demonstrated the non-irritant and non-sensitizing nature of INDUS1520 on the skin and eyes and suggested robust safety for development toward potential skin care or dermatological applications.

Keywords: flavonoid glycosides, fenugreek seed extract, dermatological application

Abstract Code: MCOP-39

EFFECTS OF SUBACUTE
ADMINISTRATION OF 4HYDROXYISOLEUCINEON COGNITIVE,
SUICIDAL, AND SEXUAL BEHAVIOR IN
SOCIAL ISOLATION STRESS-INDUCED
OLFACTORY BULBECTOMIZED RATS

Padmaja Kore^{1,*}, Prasad A Thakurdesai²

¹Progressive Education Society's Modern

²Indus Biotech Limited, 1, Rahul Residency, Off SalunkeVihar Road,

College of Pharmacy, Nigdi, Pune, India.

Kondhwa, Pune-411048, India

Abstract

Objective:Evaluation of effects of subacute oral administration of (2S, 3R, 4S)-4-hydroxyisoleucine (4-HI) on cognitive, suicidal, and sexual behaviour in social-isolation stress-induced olfactory bulbectomized (Iso-OBX) in rats

Methods:Bilateral olfactory bulbectomy (OBX) was induced in 30 Sprague Dawley rats. After a recovery period of 14 days, the rats were randomized into five groups of 6 rats each and stressed with social isolation (individual housing). The rats were orally treated with either vehicle (OBXIso), a standard antidepressant, fluoxetine (30 mg/kg) or 4HI (10, 30, 100 mg/kg) once a day from day-14 onwards. A separate group of 6 rats with social isolation but without OBX (ShamIso) was also maintained. The sexual behaviour (latency and frequency of mounting and Intromission), cognitive/spatial memory-related (reference and working memory in a radial maze), and suicidal behaviour (aggression, irritability, and passive avoidance) parameters were measured on day-28, day-32,

176





Mass spectroscopy in bioanalytical method development

subjected to wet lab synthesis, followed by an in vitro biological evaluation. The structures of all the synthesized compounds were confirmed by spectral analysis and were subjected to The Aldoketoreductase inhibition assay enzyme assay. Chlopropamide was used as a standard for the assay, and it displayed 0.018 µM IC50 value. Compound 1f, 1g, 1i, 1j, and 1v exhibited 15.55, 15.85, 13.95, 14.48, and 13.45 µM IC50 values, respectively. The proposed 15 compounds of sulphonylurea with a coumarin ring system were synthesized in good yield using the developed schemes. All the reactions were monitored by the TLC one spot technique and the structures of the synthesized compounds were confirmed by IR, 1H NMR, 13C NMR, Mass spectra, and C H N analysis.

Keywords: Aldo-Keto Reductase (AKR) inhibitors, Type 2 diabetes mellitus, Coumarin Derivative

Abstract Code: PC-04

MASS SPECTROSCOPY IN BIOANALYTICAL METHOD DEVELOPMENT

Vasudha Bavadekar*, Dr.Angha Joshi
PES's Modern College of Pharmacy, Nigdi,
Pune, Maharashtra.
SCES's Indira College of Pharmacy,
Tathawade, Pune, Maharashtra.

Abstract

Modern bioanalytical chromatography-mass spectrometry has so many potential applications that any attempt to standardise them becomes arbitrary. It would be more accurate to state that chromatography-mass spectrometry finds use in every field of biology and medicine. Understanding the pharmacokinetics of any drug and/or its metabolites requires the development and validation of bioanalytical methods. Liquid chromatography-mass spectrometry MS/MS) is a method that combines mass spectrometry and liquid chromatography (or HPLC). For the qualitative and quantitative examination of drug compounds, drug products, and biological samples, laboratories frequently use (LC-MS/MS). This article discusses different extraction methods, such as liquid-liquid extraction, solid phase extraction, and protein precipitation, which are crucial for sample preparation and LC-MS/MS sample detection. Modern bioanalytical methods are multitargeted in terms of the analytes they target and standardised in terms of the matrices they use, the capacity of chromatography to detect traces of analytes in the presence of a large number of biomatrix macro components Current applications of metabolomics include clinical diagnosis and anti-doping control. Procedures for preparing biological samples for instrumental analysis are being developed and streamlined to increase adaptability.

Keywords: bioanalytical chromatography-mass spectrometry

Abstract Code: PC-05

TACRINE DERIVATIVES AS POTENTIAL
ACETYLCHOLINE ESTERASE
INHIBITORS: PRE-ADMET ANALYSIS
AND COMPUTATIONAL STUDY

Rupali Arvind Jinturkar*
Ph.D. Research Scholar,

Department of Pharmaceutical Chemistry, PES Modern College of Pharmacy, Nigdi, Pune



Tacrine derivatives as potential acetylcholine esterase inhibitors: pre-admet analysis and computational study

Savitribai Phule Pune University, Pune, Maharashtra, India.

Abstract

Objectives: To discover and develop some Tacrine analogues as potential Acetylcholine esterase (AChE) inhibitors in light of the fact that N-substitution on tacrine reduces its pre-existing side effects and improved inhibition. The goal of this work was to perform computational study of new Tacrine derivatives for Pre-ADMET and molecular docking in order to identify prospective lead molecules.

Materials and Methods: Each of the proposed derivatives was subjected to an in-silico for Pre-ADMET study and virtual screening by molecular docking. Molecules meeting all of the criteria and had a higher binding affinity with the Acetylcholine esterase enzyme were discoved. Research on the binding interaction of the most was effective drugs conducted AutoDockmolecular docking tool. Novel Series of N-substituted Tacrine was designed by considering all the data analyzed from literature survey. It was observed that m-4, m-1, m-6, m-7and m-12 displayed much less binding free energy (PDB ID: 7E3I) than the reference inhibitor and all derivatives demonstrated druglikeness properties with less toxicity by pre-ADMET study. This article described the designing of fifteen novel N-substituted tacrine derivatives. All were subjected to Pre-ADMET study and molecular docking. The results showed that all compounds exhibited promising AChE inhibitory activity. Also, from pre-ADMET study it can be concluded that all designed molecules showed Drug-likeliness. The

above findings serve as models for future research and derivatization of AChE inhibitors.

Keywords: Acetylcholine esterase (AChE) inhibitor,N-substituted Tacrine

Abstract Code: PC-06

GREEN SOLVENTS: AN ECO-FRIENDLY APPROACH IN ANALYTICAL CHEMISTRY

Sheetal Chaudhari*, Dr. V. V. Chopade
Department of Pharmaceutical Chemistry, PES's
Modern College of Pharmacy, Nigdi, Pune

Abstract Since the last three decades, chemical research has grown exponentially, along with the use of hazardous and toxic solvents, reagents, and reactants, causing long-term environmental harm. Environmental concerns are currently a popular subject for laboratory investigations. It is crucial that all analytical experiments be secure and considerate of the environment. There are several improper procedures used in small-scale experiments in the field of analytical chemistry, which could be detrimental to the analyst and the environment. An unregulated disposal of organic solvent wastes is one of these methods. There has been a modest trend towards using green chemistry concepts in research, development, and implementation as a result of new inventions and advancements in the field. Yet, due to recent advancements in materials and techniques that complement the green approach, the usage of green analytical chemistry has significantly increased during the past ten years.

Keywords: Green solvent, green analytical chemistry, Ecofriendly

180





Green solvents: an eco-friendly approach in analytical chemistry

Savitribai Phule Pune University, Pune, Maharashtra, India.

Abstract

Objectives: To discover and develop some Tacrine analogues as potential Acetylcholine esterase (AChE) inhibitors in light of the fact that N-substitution on tacrine reduces its pre-existing side effects and improved inhibition. The goal of this work was to perform computational study of new Tacrine derivatives for Pre-ADMET and molecular docking in order to identify prospective lead molecules.

Materials and Methods: Each of the proposed derivatives was subjected to an in-silico for Pre-ADMET study and virtual screening by molecular docking. Molecules meeting all of the criteria and had a higher binding affinity with the Acetylcholine esterase enzyme were discoved. Research on the binding interaction of the most effective drugs was conducted AutoDockmolecular docking tool. Novel Series of N-substituted Tacrine was designed by considering all the data analyzed from literature survey. It was observed that m-4, m-1, m-6, m-7and m-12 displayed much less binding free energy (PDB ID: 7E3I) than the reference inhibitor and all derivatives demonstrated druglikeness properties with less toxicity by pre-ADMET study. This article described the designing of fifteen novel N-substituted tacrine derivatives. All were subjected to Pre-ADMET study and molecular docking. The results showed that all compounds exhibited promising AChE inhibitory activity. Also, from pre-ADMET study it can be concluded that all designed molecules showed Drug-likeliness. The

above findings serve as models for future research and derivatization of AChE inhibitors.

Keywords: Acetylcholine esterase (AChE) inhibitor,N-substituted Tacrine

Abstract Code: PC-06

GREEN SOLVENTS: AN ECO-FRIENDLY APPROACH IN ANALYTICAL CHEMISTRY

Sheetal Chaudhari*, Dr. V. V. Chopade

Department of Pharmaceutical Chemistry, PES's Modern College of Pharmacy, Nigdi, Pune

Abstract


Since the last three decades, chemical research has grown exponentially, along with the use of hazardous and toxic solvents, reagents, and reactants, causing long-term environmental harm. Environmental concerns are currently a popular subject for laboratory investigations. It is crucial that all analytical experiments be secure and considerate of the environment. There are several improper procedures used in small-scale experiments in the field of analytical chemistry, which could be detrimental to the analyst and the environment. An unregulated disposal of organic solvent wastes is one of these methods. There has been a modest trend towards using green chemistry concepts in research, development, and implementation as a result of new inventions and advancements in the field. Yet, due to recent advancements in materials and techniques that complement the green approach, the usage of green analytical chemistry has significantly increased during the past ten years.

Keywords: Green solvent, green analytical chemistry, Ecofriendly






Development of terbinafine hydrochloride niosomal in situ gel for opthalmic drug delivery










158











Design and evaluation of an in-situ gel for ophthalmic drug delivery of Gatifloxacine

derivative displays relatively poor aqueous solubility and thus poor afficacy when at orally. The current research was undertaken for the intravaginal administration of send or all. It is considered by the constraint of the constraint I and then leaded into in situ gel. DSC and FT-IR studies indicated that the and drugs were compatible with each other. The XRD pattern revealed strong, tion peaks that indicated the materials were crystalline. The λ max of the drugs and at 305 nm and 370 nm, respectively. The optimized in situ gel will be evaluated a serio and time, pH, viscosity, texture profile analysis, drug content, homogeneity, not fairn and the drug release. The stability studies will be conducted according to ICH set. The Pre-clinical evaluation will be carried out by conducting in vitro bloodhesian in vitro cell viability study, cytotoxicity study, Phermacokinetics study, and in vivo licacy study to report the antifungal efficacy of combinatorial drug regimen.

A REVIEW: GLEOGELS USED IN OPHTHALMIC DRUG DELIVERY SYSTEM Archana Dangi Ratoriya Sage University Indore (M.P.)

of gels generally composed primarily of a liquid component and an added gelator and in formation of a stabilized three-dimensional matrix. They are considered due, eften biacompatible, have a long shelf life, are resistant to microbial mentation, and may be thermoreversible. Disapples are non-newtonian, and thus exhibit thing projecties which allow them to formulations are very promising for controlled a of aphthelinic formulations, both for the front and the back of the eye. Treatment of es in the posterior segment of the eye, such as macular degeneration, diabetic tespents, and plaucome pose difficulty due to berriers for diskway of drugs to the back of the excepting, and plaucome pose difficulty due to berriers for diskway of drugs to the back of the excepting are respectable of based obegels, may be a potential whiche for targeted delivery of all hydrathatic or hydrophilic drugs. Obegel applications are various, including chemistry, semecturicals, cosmetics, biotechnologies and food technology. In pharmacology, they are are dead of variotice delivery platforms for active ingredients via diverse routes such as audiented, and and parenteral. This review provides a global view of eleopels, such as nature, where characterizations and properties. An emphasis is placed on the most recent challenges are all the desires of eleoperties or comprising normal distincts. used in the design of eleggels as potential controlled delivery systems. A sention is provided to their newest therapeutic applications.

A-115

DEVELOPMENT AND CHARACTERIZATION OF NIOSOMAL GEL FOR THE TOPICAL OMINISTRATION OF LOSARTAN POTASSIUM

dikatta Vaishnovi, Tirunogori Mometho, Marri Ruthiko Retna Veni Sasain Naidu Vanita Pharmacy Maha Vidyalaya, Tarnaka, Secunderahad, Telangana State,

rtan postassium is an angiotensin II receptor antagonist, used in the treatment of tession, Losarten potassium is generally available in the form of oral formulation with a mic bioavailability of 25-33%. In order to increase its bioavailability, topical on of Losartan gotassium was attempted. The topical administration of this drug was done by femoulating a gel incorporated with nissones. After screening span 80 was whether a neminic surfactant. Drug excipient competibility study was done by FFIR "Retriscope, Ether injection method was used to prepare nissones though thin film hydration method was also tried. Six formulations were developed by taking different ratio of span 80 to characterist. The perpared missones were characterised for apparament, consistency, clarity, certical size, zeta potential and entrapment efficiency. These nissonnal preparations are NUMBERSTATED. crated in gel where Carbopol 934 was used as celling agent. These micsomal gel Abbuts were evaluated for pH, in vitro drug release studies using Franz diffusion cell. 6 size of FT formulation was found to be 1835.0 nm. F1, F2 and F3 nicsome ns entrapment efficiency was found to be 78%, 58% and 55% respectively. The pH Trust to be in the limits which indicated less chances of irritancy on skin. The sate terrial of the niscomal dispersion is also said within the limit range i.e., 3.7.m/l. The "nispersity holes was also found out to be within the limits i.e., seem than 0.7, the value to 0.54 which indicates uniform niscomal vesicles. The in vitro release study was carried out Optimized formulations F1, F2 and F3 and it was found that F1 formulation has high drug Campared to F2, F3. Thus, Losertan potassium can be tried for topical application to realiability and further studies are required to be performed for pharmacodynamic

and pharmacokinetics in animals

A-116

FORMULATION AND IN-VITRO EVALUATION OF MOUTH MELTING TELMISARTAN TABLETS USING NATURAL SUPERDISINTEGRANTS Sonthilnathan P, Sonthil S P, Sonthamarai R Periyar College of Pharmaceutical Sciences, Tiruchirapalli, Tamilhadu, India senthilb.pharm23@gmail.com

This tablet is made utilizing the direct compression method and a natural superfising such as powdered wax gourd seeds and pumpkin pulp, to benefit from substances that cause the medication to dissolve quickly in water through wicking, swelling, or any other mechanisms. There are a variety of accipients that can be added to desage forms to achieve this type of property, but the disintegrant is the essential adjuvant. Superdisintegrant are a class of never compounds that have been created nexealty. So create effective mouth-dissolving tablets and get around the drawbacks of traditional tablet dosage forms, a variety of superdisintegrant, including synthetic, semisynthetic, natural, and co-processed mixtures, have been used. The goals of this study are to highlight the various categories of superdisintegrants and their function in the release of drugs from tablets. The effectiveness of superdisantegrants and mor function in the release of drugs from tablers. The effectiveness of co-processed excipient blends, diverse synthetic superdisintegrants, natural superdisintegrants from various plant sources. Due to their wide availability, law cost, anxistomental friendliness, emoliant properties, ability to underge numerous chemical medifications, and potential for degradability and compatibility as a result of their natural origin, natural materials like gums, muclages, and powders have been widely used in the field of drug delivery. Because it contains superdisintegrants, it dissolves swiftly, causing the medicine to be absorbed quickly, leading to a quick commencement of effect. As a result of the drug's direct orial placement, its horizontal-bility is increased. direct oral absorption, its bioavailability is increased.

DESIGN AND EVALUATION OF AN IN-SITU GEL FOR OPHTHALMIC DELIVERY OF GATIFLOXACIN

Upandra C. Galgatta, Manali M. Majgaonkar, Gauri P. Shevade
PES's Modern College of Pharmacy, Nigdi, Pune-410344

In the market, conventional eye drops are available for the treatment of bacterial conjunctivities but due to initiations like elimination and less pre-conneal contact time it is necessary to develop a desage form which provide sustained drug release which can improve design frequency. The objective of the investigation was to design and evaluate an in-situ gel of aptitionacins as drug delivery system to the eye of obtained as ustained drug release. Plearance F 127 and carbopol 934 P are used as gelling agent. In situ gel was formulated by using combination of polymers having therms-sensitive and pH sensitive gelation rescribed mechanism is insulated tear flittly. 3.2 factorial design was used for optimization of batches. Cald method was used for preparation of in situ gel. The optimized batch F6 formed clear gel within 9.3 to ser 3.5 8.0 C. these deep new contraction of 94.1.5% within 2.5 informed the Kommunical Market Market Sensitive Communication of the Kommunication of the Communication within 9-10 see at 35.0 C, showed drug release of 94.16 % within 7 h followed by Kammyar-pappas model of drug rolease. The optimized batch was found to be isotonic and exhibited better zone of inhibition against Staphylococcus aureus and Pseudomonas aeruginosa as compared to marketed eye drop and drug solution. In situ gel proved to be suitable and safe for nistration of gatifloxacin (antibiotic) through ophthalmic routs. The ease of administration ass dosing frequency can help to increase patient compliance.

A-118

DEVELOPMENT AND EVALUATION OF ALLOPURINGL GEL THROUGH **IONTOPHORESIS TECHNIQUE** Nikhat Parbin, Venkatesh DP and Sateesha SB addy College of Pharmacy, Soldavanahalli, Achit nagar post, Bengaluru,

Acharya & BM Reddy College of Pharmacy, Soldevanahalli, Achit India-560107. vunkateshdp@acharya.ac.in

Our aim of research was to investigate transformed penetration of Alloqurinol by passive and inotophoretic administration. Drug was characterized by melbing point, FTIR, DSC & UV analysis, Alloqurinol get was prepared by using different polymers such as Carbogol 3934. PHMC KAM, Sedism CMC & Sodium Alginate at different concentrations and prepared formalisations were subjected to various evaluation parameters such as drug content, viscosity, apreadability coefficient, Ipl. in vitro drug release studies. Chicken skin was used for as view contents and the contents of the iontophaestic transdermal delivery. When compared to passive administration, cathodal iontophaesis (0.49 mA) significantly increases akin permeation. Iontophresic permeation reviewed that the standy state was increased when compared to passive permeation. The rate of permeation in the passive process was nearly constant at all times, whereas iontophresis


72" Indian Pharmaceutical Congress 2022

(2)





Gsk-3 beta inhibitor: an emerging anti-alzheimer agent with its insilico scaffold and virtual screening





Management of osteoarthritis and rheumatoid arthritis through diclofenac sodium along with herbal drugs

FORMULATION AND EVALUATION OF NANOPARTICLES CONTAINING BCS IV ANTICANCER DRUG FOR ORAL DELIVERY Divyo S. Wali and H. N. Shivako

dy's objective was to develop nanosized, nontoxic, and biocompatible based for oral drug delivery of a BCS IV anticancer agent. The nanoparticles were solvent evaporation method using homogenization and probe sonication der to understand the effect of combination of biocompatible polymers, the oner to approach retaining the total solid mass was kept constant. A P-gp efflux sed as both an emulsifier and as a matrix meterial component. The formulations to take advantage of efflux transporter inhibiter and cationic polymer, in arb as high emulsification effects, high drug encapsulation efficiency as well se of drug from the formulations. DLS indicated the formulated nanoparticles particle size ranging from 350 to 550nm with a poly dispersity index of less s wife the zeta potential above +ve 30mV indicated the stability of the de-The nanoparticle displayed higher entrapment efficiency that ranged from 80 to hs polarized release. The spherical shape of the nanoparticles was confirmed by a presence of drug characteristics peaks in FTIR ruled out the possible interaction e functional groups of the drug and the matrix material used. The studies indicated the matrix material used. The studies indicated the matrix material used. The studies indicated the matrix materials are studies indicated the materials are materials. bit the P-gp efflux and improve the bisavailability. The oral chemotherapy with oparticles could be an effective alternative to conventional invasive parenteral magement of breast cancer

A-364

AVAGEMENT OF OSTEDARTHRITIS AND RHEUMATOID ARTHRITIS THROUGH TOP DESIGNATION ALDING WITH HERBAL DRUGS
Tuchar M. Phalke, Devendra L. Visekar
Juden Colone of Pharmacy Nigdl Pune, Maharashtra, India-411044

on is local response of living mammalian tissues to injury characterized by five as - redress, swelling, heat, pain and functiolaesa. Inflammation is described as ession of changes which occurs in a living tissue when injured such that destroy its & vitality'. Diclofenac is an NSAID acts to lower infection by inhibiting ie-1 (COX-1) and cyclooxygenase-2 (COX-2) and oleo-gum resin consist of haride along with totracyclic and pentacyclic triterpene acids used for antiactivity. The volatile ail contains mono and sesquiterpenes which suppress ad has anti-rheumatic properties. The dictofenac containing herbal formulation ammatory activity with no side effects.

A-365

SOLUBILITY ENHANCEMENT OF KETOPROFEN DRUG BY PREPARING LIPIDS BASED FORMULATION

S. T. Landge and A. V. Chandes P. Wadhwani College of Pharmacy, Yavatmal(M.S) 445001 surajlandge@gmail.com

of this study was aimed at designing Ketoprofen capsule formulations with dailty of a peacocally water insoluble drug, with the intent of achieving a with significantly improved in vitro drug dissolution profile in comparison to duct Returen®. Several combination of surfactant, oil and co-solvent try to e having supra solubility, by tailoring their combination with the objective to e concept of increasing the solubility by virtue of application of an combination chain triglycerides and polysorbate 80 having high HLB value and ethyl acetate and stabilizer for the emulstion thus arriving at compositions C4. In vitro des on these capsules demonstrated that C4 was the most appropriate egards to its closeness in enhanced drug solubility when compared to rated stability study on the C4 composition in HDPE packaging further Iverse changes occur in the optimized formulation when eve oth as Disintegration time, drug content and in vitro dissolution.



A-366

FORMULATION, DEVELOPMENT AND EVALUATION OF ANTIDIARRHOEAL TABLETS OF RACECADOTRIL FOR PEDIATRIC USE Deepali Chaudhary and Nitin Dumore

Dadasaheb Balpande College of Diplome in Pharmacy, Besa, Nagpur, Maharashtra, India, 37, Nilesh Mahajan, Swati Wasnik , Dadasahab Balpande College of Pharmacy, Besa, Nappur, Maharashtra, India, 37.

Acute diarrhoea in children is a global health concern, with an estimated 2 billion episodes every year, an estimated 1.9 million children de from the alment each year, with the majority dying in poor countries, accounting for 18% of all fatalities in children under the age of tive. Racecadetril is an antisecretory medication that comes in tablet form and is used to treat arrhoea. It is when administered by the oral route, is well absorbed from the intestinal tract. This drug has a repetitive dose schedule, short biological half life (3h) and reduced bioavailability (30-40%). The goal of this work is to develop chewable tablets of racecadotril with an aim to reduce the first pass hepatic metabolism of the drug, to improve patient compliance, particularly in the psediatric class. Chewable racecadatril tablets were made by direct compression using a taste-masked racecadotril-cyclodextrin complex, and the tablets were tested for physicochemical properties. The result of the present study conclusively demonstrated that complexation of Racecadotril with cyclodextrin successfully masked its bitter taste. Optimized formulation F3 shows maximum fastest % cumulative drug release among all formulations at the end of 35 minutes. From the preliminary stability studies at 30 ± 2 °C and 65 ± 5 % relative humidity no substantial change observed in the quality of tables. during the storage period. Thus, it is concluded that chewable tablet of racecadotril with rapid tion using -cyclodextrin as a carrier can be possibly formulated in a more palatable patient friendly dosage forms.

A-367

FORMULATION AND DEVELOPMENT OF -FATTY ACID NUTRACEUTICAL BEADS Kajal J. Bhede, Tirupati M. Rasala, A. M. Ittad

Gurunanak College of Pharmacy, Nagpur, India, kajalbhede0306

Nutraceuticals have been in high demand as dietary supplements on the international market. A nutraceutical is a naturally nutrient-rich food that contains omega-3 fatty acid from various sources. Spinach seed, one of the oldest and most extensively used food supplements, has sources, apmaint series, one or the coases, and mass a scenariory and essential omega-3 fatty significant levels of alpha linolenic acid (ALA), fibre, proteins, and essential omega-3 fatty acids. The goal of this study was to create spinach seed oil beads containing omega fatty acids is a replacement supplement for marine sources. Spinach seed oil beads were formulated by onic gelation method. Batches were prepared for screening and optimized using Minitab 21.1.0. depending on the percentage of drug release and percentage of drug encapsulation afficiency. For the initial screening, Plackett Burman design was chosen and for optimization RSM was used. Following optimization and validation, the batches showed satisfactory results that met IP specifications. Results: Thirteen batches were developed and evaluated for % encapsulation efficiency and drug release. The prepared batches F3, F10, and F12 shown the best results. Conclusion: The presence of polyunsaturated fatty acids in spinach seed oil was determined by using the hexabromide test. Using the ionic gelation technique, nutritional benefits of the derived spinach seed oil's omega fatty acid were included in beads.

A-368

PREPARATION AND CHARACTERIZATION OF MESOPOROUS SLILICA NANOPARTICLES/NANOCARRIERS CONTAINING QUERCETIN FOR NOSE TO BRAIN DRUG DELIVERY

Sarita Ukey And Atul Hemki


S.K.B. COLLEGE OF PHARMACY, GADA, KAMPTEE, NAGPUR, INDIA-441104 saritaukey94@gmail.com

In the current research, nose-to-brain delivery via olfactory pathways have become a target of attention for drug delivery due to bypassing of the BBB. The antioxidant properties of Quercetin(QCT) was selected as the model drug to evaluate the feasibility of mesoporus silica nanoparticles (MSNs). We formulated spherical MSNs-QCT using a templating approach ting 350.9 nm particles with a high surface perosity and zeta potential mV). OCT were successfully leaded way solve the speciation techniques into MSNs. Drug leading were found to be uniform throughout the formulated MSNs-DCT with the minimum SD value (13.49 ± 0.0482). The related materials were characterized by SEM showed that MSNs-DCT having a spherical nature in 25.00 K X magnification. FTIR showed that week intermolecular interaction between QCT and MSNs molecules are attribute to the formation of MSNs-QCT. DSC and X-RPD demonstrated the formulation of MSNs-QCT by shifting and






Development and Characterization Of Niosomal In situ Gel Of Ritonavir





Formulation and evaluation of polyherbal hair oil for the management of scalp dandruff




Progressive Education Society's Modern College of Pharmacy, Nigdi, Pune 411044






Formulation and evaluation of micronutrient transdermal patch as a potential supplement







Qbd Driven method development and validation of Favipiravir and Siam by RP-HPLC



Progressive Education Society's Modern College of Pharmacy, Nigdi, Pune 411044





Herbal foot deodorizing spray with antimicrobial activity

C-184

SAFETY OF MASSAGE THERAPY Bedampet Deepika and Monapravya

Department of pharmaceutical sciences Joginpally B R pharmacy college Yenkapalli. Moinabad Hyderabad 500075, be tdeepika26@

After many years out of the lime light, massage therapy is now experiencing revival serious adverse effects were associated mostly with massage therapy techniques other than Swedish massage. Massage therapy has been notably affective in preventing prematurity enchancing growth of infants increase alternative, decrease depression and aggression, alleviating mota problems reducing pain and enchancing immune function, cover massage therapy reasearch from the last prevented for potential biochemical and physiological mechanism underlying massage therapy effects. The aim of this systemic review is to evaluate is potential for harm computerized literature searches were carried out in four data basases any type of massage therapy were retrieved adverse effect relating to massage oil or ice were excluded the majority of adverse effects were associated with exotic types of manul massage or massage delivered by laymen while massage therapist were rarely implicated the reported adverse events include cerebrovascula accidents displacement of a ureteral stent embolization of a kidney leguicers, nerve damage, posterior interosseous syndrome, pseudoneurism pulmonary embolism ruptured uterus strangulation of neck thyrotoxicosis and various pain syndrome serious adverse effect were associated mostly with massage techniques other than Swedish massage. Massage therapy is an ancient form of treatment that is now gaining popularity as part of the complementary and alternative medical therapy movement. A meta-analysis was conducted of studies that used random assignment to test the effectiveness of massage therapy mean affect sizes were calculated single application of massage therapy reduced state anxiety , blond pressure and heart rate but not negative mood immediately assissment of pain , and Blood pressure, and near rate out not registre micro ministratory assistant or pain and contribed level multiple applications reduced delayed assistant of pain reductions of trait anxiety and depression were massage therapy largest effect with a course of treatment providing benefits similar in magnitude to those of psychotherapy

C-185

HERBAL FOOT DEGOGRIZING SPRAY WITH ANTIMICROBIAL ACTIVITY nkar Prashant, Chopade Vitthal, Chaudhary Praveen and Dipali Theta PES's Modern College of Pharmacy, Nigdi. Pune, Maharashtra, India. patankarprashant01@gmail.com

In current, pandemic sanitizers are used to sanitize our hands to make them germ-free However, it is found that people either forget or neglect to sanitize their feet. This act may lead to corrying germs to home or passing from one person to another which may result into possibility of spreading infection. Additionally, sweaty feet and foot adour have been found to be common now days. The presence of foot microflora like Staphylococcus epidermis, Bacillus subtilis and Propionibacterium Acnes can lead to formation of isovaloric and propionic acids which are in turn responsible for the characteristic odor of feet. This paper is aimed to develop a natural antimicrobial foot spray which exhibit the high evaporating rate, high antimicrobial activity, and appropriate spray pattern. An antimicrobial formulation containing alcohol and natural activels having anti-microbial activity is developed which controls foot odour and infection or sanitize feet. The spray formulation of present research contains lemon oil, neem oil and tulsi oil that have antimicrobial activity as well as being oil, they help in long lasting skin moisturization. The foot spray containing a combination of lemon oil, neem oil and tulsi oil particularly in 1:1:0.5 shows highest zone of inhibition against both the bacteria, namely Bacillus subtifis and Staphylococcus epidermidis Foot spray deodorizes and prevents foot adour with regular use to ensure clean and healthy feet. The spray can be used anywhere with ease of application which covers the feet area susceptible for odour generation and germ deposit. The developed formulation exhibited the potential application as a rapidly dried antimicrobial soray for foot deodorant.

C-186

HERBAL CREAM FOR THE TREATMENT OF LEUCODERMA

Renuka Pothu, Y. Indira Muzib, Prashanti Chitrapu Institute of Pharmaceutical Technology, Sri Padmavati Mahila Vishwavidyalayam

The present invention is an herbal formulation and a method of its application which is effective for treating leucoderma or Vitiligo. The herbal formulation is prepared from extracts obtained from various plant parts of four different herbs namely Psoralea corylifolia, Embelia ribes, Curcuma lunga and Azadirachta indica, which are the active ingredients that is effective in treating leucoderma. The herbal formulation contains a mixture of three different phases such

www.ipcnagpur.com ---

as hydrophilic phase, lipophilic phase and essential oils. The active ingredient acts is as hydroprinic phase, recommended the affected parts
the proliferation of melanocytes and bring about repigmentation to the affected parts
short duration. It is a potent, cost effective formulation that does not produce any sig-Single application per day is sufficient for treatment. Hence it is easy to apply and a

C-187

PHYTOSOME: AN APPROACH TO DELIVER LAWSONIA INERMIS (HENNA) EXTRACT FOR ANTIFUNGAL ACTIVITY: FORMULATION AND DEVELOPMENT Zia Latif Patel

MCES's Allana College of Pharmacy

Formulation and Development of phytosomes of Lawsonia inermis(Henna) for A activity. Novel drug delivery system phytosomes were prepared by complexing per phyto-constituents with phospholigid mainly phosphatidylcholine which bind cons each other on a molecular level.N. Yigit et. al. reported that the Henna plant is Antifungal activity. The leaves of Lawsonia inermis were extracted using apparatus. The physicochemical properties of the prepared complex were analy ultraviolet-visible spectrometry (UV), infrared spectrometry (IR), and The chromatography (TLC). To overcome this limitation, Lawsonia inermis (Hennalphus complex was developed and subjected to pharmacautical investigation by particle size. analysis (differential scanning calorimetry), crystallographic (X-ray di morphology (scanning electron microscopy), spectroscopic methods (FT-IRI), salid dissolution (in vitro drug release) as well as stability study of the phytosome efficiently formulated into the phytosome with an average particle size of 149 ± 33 e potential of 11.02 ± 0.88 mV. The formation of the Henna phytosome complex was by DSCand FTIR analysis. The absorption of the Methanolic extractPhospholipid found to be greater than plain Methanolic extract at different time intervals do release study. The stability study and cell line study of henna phytos is romaining. In the current investigation, Lawsonia inermis (Hennalextract loaded F was successfully synthesised. It was discovered that the complex's dissolutio improved. It follows that Henna's phospholipid complex may be useful for a bioavailability for antifungal action.

C-188

NOVEL POD AGAINST DANDRUFF SQUAD

Shubham Munde, Niftin Ade, Norma Rebello, Vrushali Gokhale, Savita Tm St. John Institute of Pharmacy and Research, Palghar (E), Palghar-401404, Maharashtra, India, shubhamvmunde@gmail.com

The presence of Dandruff gives an indication of unhealthy state of the scalp a occurring condition accounted in around 50% of the population. Though not an in severe issue but yes does affects the professional outlook towards the infini intrinsic and extrinsic factors contributes to its pathogenesis, however Malass normal flora yeast is the major etiologic factor causing dandruff, that predi younger to old generation. It's a disorder constricted to the scalp resulti itching. Although several commercial effective anti-dandruff produc incorporating the actives, literature also reports their non-compliance and side consumers. The present study highlights the novel shampoo pods prepared with an active antifungal agent along with the goodness of traditional herbal corr Shikakai, Reetha and Aloe vera. The innovative product aims to prepare antid pods with accurate dosing which is not obtained in the commercial management pods with accurate dosing which is not dotained in the commercial measurements use of herbal ingredients to reduce the side effect of Kefoconazele. This work size bottle-less and figuid-free shampon by using an environment friendly package and a features to the customers. The product formula based on the preliminary studies of fair is optimized to ensure the requisite consumer elegance and efficacy towards do

C-189

FORMULATION AND CHARACTERIZATION OF PHOSPHOLIPID BASES DI DELIVERY SYSTEM OF COLOCASIA ESCULENTA EXTRACT Ashwini S.Ghagare, Prakash Itankar, Satyendra Prasad.
Rupali S. Prasad, Komal mule
Department of Pharmaceutical Sciences, Rashtrasant Tukadaji Maharaj Nagpur, Maharashtra, India 440033, phagareashwini 23@ymail.ca

in present study attempt was made for extraction of Colocasia esculenta is formulation and characterization of prepared Phytosomes. The study includes to Ethanul. Preliminary phytochemical screening of the extract showed the present

222

72[™] Indian Pharmaceutical Congr





Synthesis and conjugation of aromatase inhibitors for targeted drug in treatment cancer

inventive process of finding novel leads and aid in the process of drug B-131 development research. DEVELOPMENT OF NOVEL ACETYL CHOLINESTERASE INHIBITORS FROM BOTANICALS AS POTENTIAL TREATMENT FOR ALZHEIMER'S DISEASE B-134 Ritu Sapra, Sanjay Jain, Sumeet Prachand Faculty of Pharmacy, Medi-Caps University, AB Road, Indone, Madhya Pradesh 453331 ritu.mehndi@gmail.com DRUG DISCOVERY FOR MYCOBACTERIUM TUBERCULOSIS USING STRUCTU BASED COMPUTER- AIDED DRUG DESIGN: A REVIEW Pande Kalash , Gaikwad Sanjana, Dighada Narendra Nagpur College of Pharmacy, Wanadongri Nagpur 441110, Maharasi Alzheimer's disease (AD) is a neurodegenerative age-related brain disease that slowly destroys pandekalash4@gmail.com memory and thinking skills and, eventually, the ability to carry out the simplest tasks. The current therapeutic treatments include cholinesterase inhibitors (Donepazil, Rivastigmine and Galantamine) and N-Methyl-D-aspertate (NMIDA) antagonists (Memontine). However these Aim: The aim of present study was to review Drug Discovery for Mycobactorium Using Structure-Based Computer-Aided Drug Design. Computer-aided drug de treatments have been unable to halt AD progression. Therefore in this view, the present research was sought to perform structure-based pharmacophore modeling to identify potential comprises a broad range of theoretical and computational approaches that are ga drug discovery. Computer-aided drug design (CADD) has amerged as a pow candidate inhibitors from natural products i.e. Bacopa monriera, Ginkgo biloba, Acorus calamus, Epimedium kereanum, Rhododendron ponticum, Rhododendron lutaum, Corydalis solida, Glaucium corniculatum, and Buxus samperviren against hAChE. The generated models playing a crucial role in the development of new drug molecules. Structure-based and ligand-based drug design are two methods commonly used in computer-design(CADD). This review discuss about structure-based drug design for the drug of used as 3D queries in order to screen new scaffolds from a variety of chemical databases. The designed hybrids were screened for optimal ADME properties, BBB permeability followed Mycobacterium tuberculosis, provides an overview of the evolution of tuberc existing drug management and design of new anti-tuberculosis drugs deve by molecular decking. Final hit compounds were then subjected to molecular dynamics simulations to access binding with hAChE. Finally, four hit compounds that exhibited interactions at the active site of the enzyme were proposed as potential condidate molecules. contributions of computational techniques. Finding a compound that can target a cavity in a protain and interrupt its enzymatic activity is the crucial objective of drag discovery. Such a compound is then subjected to different tests, including clinical control of the compound of th for anti-hAChE .therapeutics tudy its effectiveness against the pathogen in the host. Results: Computer aided is useful for discovery of antibiotics against resistant Mycobacterium tuberculosis B-132 IN SILICO MOLECULAR DOCKING ANALYSIS OF POTENTIAL ANTI-ALZHEIMER B-135 PHYTOCHEMICALS PRESENT IN SARGASSUM SPECIES na Pande, Subhash Yende, Nidhi Sapkal, Abhay Ittadi MOLECULAR DEVELOPMENT, SYNTHESIS AND EVALUATION OF BENZIMID ANALOGUES AS ANTIMICROBIAL AGENT Gurunanak College of Pharmacy, Nagpur-440026. darshanapande07@gmail.co Kaustubh Desle, Ankita Lonker, Priyanka Sawant, Deepali Naha St. John Institute of Pharmacy and Research, Palghar, Maharashtra, India 4014): The Marine algae is the richest source of unique and structurally diverse compi Of these, Sargassum Species are reported to produce metabolites of structural classes which possesses several pharmacological activities. Acetylcholinesterase inhibitors are the one of The emergence of novel diseases and the growing resistance of outhous currently employed antibiotics necessitate the rapid development of a the most effective method for treating Alzheimer disease. In vivo and in vitro Anti-Alzheime activity of various compound and extracts of Sargassum species are proved earlier but the appropriate mechanism of action is not evidenced yet. Hence, the study is undertaken to at this time. Similarly invasive fungal infections are becoming a substantial cause. mortaity and morbidity, particularly for immunocompromised populations. In order potential target compounds with broad spectrum of antimicrobial activity, we evaluate the probable mechanism of Anti-Alzheimer activity of phytochemicals present Sargassum species using in sifico methods. Acetylchelinesterase (PDB ID: 4EY7) protein were synthesized and evaluated a new series of compounds bearing benzimidazole stal study we have designed three series of substituted benzimidazole derivatives. Ca used for this study. In the present work investigation, The in-silico Anti-AD potentials of docking was performed against target protein cytochrome P451 (CYP51) la selected 48 phytochemicals from Sargassum species via the inhibition of Acetylcholinesterase Molecular docking studies was performed using Chimera software integrated with Autodock demethylase of Candida albicans (PDB (D: 5V5Z) which was retrieved from RCS explored its binding interactions using PyRs. Based on best binding affinities, we s wise and for ligand-receptor interactions studies Discovery studio was used. ADMET Study was done by using swissADME and pkCSM. Based on the docking score, ligand-receptor ries of substituted (1H-Benzo(d)imidazol-1-yl) (phenyl) methanone derivatives (substituted N-I(1H-Benzo(d)imidazole-1-yl) mathyll-N-ethylanamine derivative interaction and ADMET studies, the optency of compound was judged. The result concluded that from the 46 phytochemicals the in silico investigation shows the active phytochemicals like n-hexadecanoic acid (-7.5 kcal/mol), 9-Detadecanoic acid methyl aster-(-7.4 kcal/mol), synthesized derivatives were characterized using IR, 1H-NMR, 13C-NMR and MI synthesized derivatives were evaluated for their antibacterial activity against grand gram-negative bacteria and also for antifungal activity. Based on the antibacter Mojabanchromanol (-11.3 kcallmol), Fuccidan (-7.1 kcallmol), Sargahydroquinoic acid (-11.0 kcallmol) Sargachromanol (-11.7 kcallmol), Sargachromanol A (-10.7 kcallmol), Liquiritigenin (data we analysed that the compounds D2, D3, C5, E2 and E3 were found to be in against Klobsiella pneumonia, with MIC value of 12.5 c/g/mL related to standard of 10.2 kcallmoll have good binding scores and interactions against Acetylcholinesterase Enzyme. Compound D4 and E3 also showed good efficacy against Salmonella typhi with N 12.5 µg/ml. Furthermore, all compounds shown to possess mild to moderate antifu In since ADMET Properties of Liquiritigenin, Sargachromanel A and n-Hexadecanoic acid was found in the acceptable range, and may be responsible for anti-Alzheimer activity. against Candida albicans and Aspergillus niger. B-133 COMPUTER AIDED DRUG DESIGN: AN OVERVIEW SYNTHESIS AND CONJUGATION OF AROMATASE INHIBITORS FOR TARGET Siddhant Randhe, Chaitanya Rarokar, Shreyash Borkar Nagpur College of Pharmacy, Wanadongri, Hingna ,Nagpur-441110. siddhantrandheprince@gmail.com that Cheende and Pravin C Discovery and development of a new drug is generally known as a very complex process which Efficacy of Tamoxifen is lowered due to its significant toxicity, including infus takes a lot of time and resources. So nowadays, Computer Aided Drug Design approaches are events, such as chilts, favor, headache, nausea, vemitting, dose limiting asphrotositits CNTs (Londed with Tamoxifee), efficacy of Tamoxifen is increased. CNTs are used as the Delivery of Tamoxifee, it acts as needle like work on fungal cell membrane & ess used very widely in order to increase the efficiency of the drug discovery and Various approaches of CADD are evaluated as promising techniques according to their need, in between all these structure-based drug design and ligand-based drug design approaches are known as very efficient and powerful techniques in drug discovery and development. These both methods the Cancerous cell membrane. UV-Visible Spectroscopy, NMR Assay studies Tamoxifen successfully loaded to the amide-functionalized Carbon nanotubes. R can be applied with molecular docking to virtual screening for lead identification and optimization. In the recent times computational tools are widely used in pharmaceutical industries and research areas to improve effectiveness and efficacy of drug discovery and that the efficacy and Target delivery of Tamexifen is increased which results in less of the drug along with normal cells being unaffected. The covalent linkage of Tame CATs is an approach that may be used to modulate the therapeutic action of the

Progressive Education Society's Modern College of Pharmacy, Nigdi, Pune 411044

72™ Indian Pharmaceutical Congres


ant pipeline. In this article we give an overview of computational approaches, which is

www.ipcnagpur.com






Formulation development and characterization of melatonin based higher spf herbal sunscreen formulation







Analysis of side effects observed due to cardiovascular drugs at a tertiary care hospital



Progressive Education Society's Modern College of Pharmacy, Nigdi, Pune 411044





Pharmacological studies on collagen induced arthritis in swiss albino mice

ed in PCOS rats that were treated with $-\beta$ -caryophyllene (p < 0.001) antioxidant capacity (p. 0.05), glutathione peroxidase, and superoxide dismutase significantly increased (p. 0.001). Conclusion: Treatment With $-\beta$ -caryophyllene folicular quality by increasing antioxidant activities and scavenging oxidant levels in D-44 CHENOPODIUM ALBUM AMELIORATES ACETIC ACID INDUCED ULCERATIVE COLITIS IN RATS. Sanya Lisboa, Ashish Kulkarni, Sheetal Kash Dr. D.Y Patil College of Pharmacy, Akurdi-411044, Maharashtra, India sanyalisboa@gmail.com politis (UC) is a chronic inflammatory disorder characterized by oxidative stress

at pro-inflammatory cytokines and colonic inflammation. Hydroalco abum (HYCA) is considered to possess potent antioxidant and anti-inflammato ss. The aim is to evaluate the possible mechanism of action of HYCA against acatic acid grative colitis in rats. UC was induced in Wistar rats by intrarectal administration of AL FYCA was administered (100, 200, 400 mg/kg, p.o.) for 7 days after colitis was on the 4th day. Clinical, morphological, and biochemical changes were assessed in interectal administration of AA caused a significant reduction in percentage body proposed stool consistancy score, macroscopic score, colon weight, weight to length day area, ulcer index, etc. it increased MDA, MPO levels, and depleted GSH levels, it also histological changes in colon as mucosal damage associated with infiltration of any calls in mucosa and submucosa. HYCA 400 mg/kg significantly restores loss of party weight, reduced stool consistency score, ameliorates macroscopic changes, and changes, colon weight to length ratio, ulcer index, reduced MPO, MDA level and SSH level when compared to Acetic acid induction control group. Results of the indicate the anti-infla natory and immunomodulatory potential of HYCA to heal or induced colitis in rats.

D-45 PHARMACOLOGICAL STUDIES ON COLLAGEN INDUCED ARTHRITIS IN SWISS ALBINO MICE wateja Sanjay Bhosale, Anuradha Majumdar agu of Pharmacy Nigdi, Puer, bhosale, swateja5093@gmail.com

it disease affecting over 1.3 million Americans and as much as 1% of the . The specific cause of RA is not known, and as a result there is no known the disease. Alim and Objective: To develop Revaluate the effect the Mitocurcumin takes a week) in Collagen induced arthritis model in mice. Material-Methods: Male also mice (20-25g). Freuend's adjuvant (complete (FCA) and incomplete (FAA), Bovine stagen, Mitocurcumin (test sample). DMSO. Induction of Collagen Induced Arthritis A FA was done ondays 0 (0.1 ml CFA emulsion at a site 0.5 cm away from the tail tester dose of 0.1 ml of collagen and IFA emulsion at a site 1.5 cm away from the ion site i.e., from tall base.), in mice of groups 2 and 4 (Disease control and Drug pactively) by intradermal injection. Mice were given 1 mg/ml Mitocurcumin in 1% ps 3 & 4 twice a week from the day of onset of initial symptoms of arthritis for 3 t of disease development was done by measuring clinical parameters, Parameters& cytokines using statistical analysis. Results: Global inflammatory s indicated by increased IL-6, nitrite levels & lipidperoxidationand significant fall in withs and GSH content in joint tissue of disease control mice. Significant reversal a and histopathological changes because of CFA immunization on intraperitoneel me observed; however, it is necessary to substantiate this effect using V designed clinical studies

D-46 ATIOXIDANT ACTIVITY OF CAULIFLOWER (BRASSICA OLERACEA L.)

& S.Patil Collage of Pharmacy, Chopda Dist:- Jalgeon, tushar36912@gmail.com

er of studies on the health benefits associated with fruits, vegetables, herbs detensive that they possess potent entioxidant, anti-inflammatory, enti-ted enti-carcinogenic activity. The potential antioxidant activity of water and s of cauliflower (Brassica oferacea L.) were investigated to evaluate their as a natural ingredient for foods or cosmetic application. measured by 2,2'-azino-bis(3- ethylbenzthiazoline-6-sulfonic acid)

[ABTS] radical scavenging, 1,1-diphenyl-2-gicryl-hydrazyl free radical (DPPH) scavenging, N,Ndimethyl-p-phenylenediamine dihydrochloride (DMPD) radical scavenging, superoxide anion (D2 -) radical scavenging, total antioxidant activity, reducing activity using Fe+3-Fe+2 transformation and CUPRAC assays, hydrogen peruxide (H2O2) scavenging, and ferrous metal chelating activity assays. The water extract of cauliflower (WEC) and ethanol extract of cauliflower (EEC), as antioxidents, neutralized the activity of radicals and inhibited the perexidetion reactions of linoleic acid emulsion. Total antioxident activity was measured personation rescues or mines, see minimum.

according to the ferric thiocynate method, or Tocopherol and trolox, a water-soluble analogue of tecopherol, were used as the reference antioxidant compounds. WEC and EEC showed 88.6% and 80.1% inhibition of lipid persolidation of finoleic acid emolsion, respectively, at the concentration of 30 μ g mi-1. On the other hand, at the same concentration, the standard antioxidants ct-tocopherol and trolox exhibited 68.1.4% and 81.3% inhibition of peroxidation of linoleic acid emulsion, respectively. In addition, WEC and EEC had effective DPPH , ABTS+, DMPD+, and superoxide anion radical scavenging, hydrogen peroxide scavenging, total reducing power, and metal chelating of ferrous ion activity. Also, those various antioxidant activities were compared to cr-tocopherol and trotox as references antioxidants.

EVALUATION OF FLAVONOID RICH EXTRACT OF TRIDAX PROCUMBENS LINN FOR ACUTE TOXICITY PROFILE AND ANTIUROLITHIATIC ACTIVITY Rupali M. Patil

MGSM, Smt. Saradchandrika Suresh Patil College of Pharmacy Chopda, India 425107. rupalikes7@gmail.com

Now-a-days interest of human in the use of traditional medicines has growing. To improve the acceptance, the variety of disage forms were formulated and developed. In the present work Tridax procumbens has been developed in the form of liquid dosage. The developed formulation evaluated for the process of the system of t was evaluated for antiurolithiatic action. The accelerated stability of syrup was evaluated during the period 6 months. The product was light brown semi-transparent syrup with swe taste and characteristic odor. The pH and density were found to be 5.39 ± 0.01 , 1.061 ± 0.13 gimi respectively for solected formulation (F2). There was no significant change observed in the evaluation parameters during the accelerated stability studies. The overall results concluded that the formulated syrup of Tridax showed to good antiprolithic property. This herbal syrup successfully reduced kidney stones by a non-toxic and convenient way.

D-48

EVALUATION OF CHEMOPREVENTIVE EFFECT OF AQUEOUS EXTRACT OF ABRUS PRECATORIOUS AGAINST DMBA INDUCED BREAST CANCER IN RATS Eswara Rao Puppala, Lohale Shravani, Venu Talla National Institute of Pharmaceutical Education & Research (NIPERI), Hyderabad, 500037.

lohalasharavani8@gmail.com

Aim & Objectives: This study was aimed at evaluating the chemoproventive potential of aqueous leaf extract of Abrus Precetorious (AP) on DMBA induced-breast cancer in rats. Materials and Methods: 42 female Sprague Dawley rats were divided in to seven groups and DMBA was administered through propharyngeal route to the rats to induce breast cancer. Het extraction protocol was employed in the preparation of aqueous extract of AP leaves. The histopathology of tumors, their size, multiplicity and morphological changes in mammary gland tumors were assessed to check its effect at callular level. The effect of AP extract on antioxidant status was evaluated by measuring oxidative stress markers like SOD, Catalase, GSH and MDA. Pharmacokinetic affect of AP on Doxorubicin was assessed by determining its plasma concentration using HPLC. Results: There was a significant (P < 0.001) weight difference between the control and treatment groups. We found difference in the median number of tumers and their volume between the control and treatment groups. Compared to DMBA treated group, in extract treated group less hybernoma, necrosis and inflammation was observed in histopthology. There was a significant (P < 0.001) difference in antioxidative activity of AP, since a restoration of the GSH pool and decreased amount of hydroperoxides were observed. We found increase in plasma concentration of dexorubicin in combination of Abrus Precatorious extract in ret plasma. Conclusion: This study has shown that the aqueous leaf extract of Abrus Precatorious has chemopreventive effect against DMBA-induced breast




72st Indian Pharmaceutical Congress 2022





Recent advances in studies on guillain barre syndrome.




Progressive Education Society's Modern College of Pharmacy, Nigdi, Pune 411044





Synthesis, molecular docking of atenolol impurity: insights from spectroscopic and pharmacokinetic approaches







Molecular docking for antiviral compounds against sars-cov-2: a computational study

optimization of AI and ML that has accelerated the discovery of novel drugs. metalloproteinases (MMPs) are large lineage protesses known as the metrincin superfamily of enzymes that are involved in mortifying all kind of extracellular matrix proteins. Under the retinoblastoma neoplastic conditions, the down regulation of MMP-2, MMP-9 via modulating

deregulated NF KB cascade to inhibit the progression of human retinoblastoma cell (HRC) have delineated the reduced proliferation, apoptosis, cell cycle, migration, and invasion of human retinoblastoma (RB) call line in vitro. In order to find new potential Matrix metalloproteinase inhibitors (MMPIs), by utilizing Open-source drug discovery tools Swiss Drug Design, UCSF Chimera & KNIME are deployed. Swiss Drug Design is employed for identification of similar analogs, UCSF Chimera is employed for the ligand-based pharmacophore generation of similar analogs of Nimbolide & KNIME with advanced API nodes to dock the molecule we used PDB ID [1HOV,1L6.J] (MMP2 & MMP9 (Gelstinasel) with a natural product of neem that have potential pharmacological evidences to downregulate mRNA expression of MMP-2, MMP-9 culminate to reduce metastasis and angiogenesis. The upgraded hore data pipeline from this study can be used for improved identification of new therapeutics against MMP controlled neoplasms, providing trailblazing insight on their binding mode.

B-155

NOVEL QUERCETIN-FOLIC ACID CONJUGATE-A PROMISING STRATEGY FOR CANCER TREATMENT

Ajay Kale, Asha Thomas, Vijaya Mandale, Ravindra Wavhale Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research , Pimpri, Pune Maharashtra-411018, India. ajaykale0999@gmail.com, 9970000243

The treatment of cancer has and continues to be a major challenge. As conventional chemotherapy drugs are associated with adverse effects, there exists the need for design of newer anti-cancer agents. Development of vitamin-phytochemical conjugates is a promising strategy for design of newer agents for treatment of cancer as this offers greater specificity reducing the undesired effects. In the present study novel ligands: berberine folic acid conjugate, quercetin-folic acid conjugates (QC-folic acid conjugate 1, QC-folic acid conjugate conjugate, quelcaser act acts of conjugate 1, CUR. folic acid conjugate 2, CUR-folic acid conjugate 2, CUR-folic acid conjugate 3) conjugates were designed. Molecular docking was carried out using Autodock tools on the human felate receptor alpha (PDB ID: 4LRH). Structure based drug likeness property, ADME/T and pharmacokinetic predictions were also carried out. The insilico studies showed that berberine- folic acid conjugate and QC- folic acid conjugate 1 displayed greater affinity (Lower binding energy -11, 2 and -12,0 Kcalimol respectively) compared to folio-acid standard (-10,8 Kcalimol). Based on these studies, QC- folio acid conjugate was then synthesized and characterized using appropriate chromatographic and spectroscopic tools. The over-expression of folio acid receptors in cancer cells helps in cellular internalization of this quercetin folic acid conjugate within the cancer cells by receptor mediated endocytosis. This will allow sustained and targeted release of quercetin in cancer tissues increasing specificity to cancer tissues. Further screening of this compound through cytotoxicity assay will help us to confirm its efficacy in treatment of cancer

B-156

MOLECULAR DOCKING FOR ANTIVIRAL COMPOUNDS AGAINST SARS-COV-2: A COMPUTATIONAL STUDY

shubham2799@gmail.com

COVID-19 has been the reason for the pandemic, which is induced by the SARS-CoV-2. Potential drugs are being used for its cure, but there's no specific drug for it. To get a specific Proteins urags are using used on a cute, and used in which molecular docking plays a vital role in computer-assisted drug designing. The aim of this study was to develop an appropriate anti-viral drug against the SARS-CoV-2 virus. In this research, we've tested the molecular navir (LV), Ritonavir, Zanamivir, Peramivir, Atazanavir, Daclatasvir, Raltegravir on the Receptor Binding Spike proteins of SARS-CoV-2. We further examined it in conjunction on the receiptor binding Spike proteins of Santo-Cov-L. We further examined in in conjunction with the docking results in response to the recently reported anti-AIDS drugs Lepinavir and ritonavir tablets, which have a peer effect on the treatment of novel coronavirus pneumonia and have toxic side effects. The results of the molecular docking indicate that Raitegravir, an antiviral HIV-drug (-7.68 kcalimol), had a higher binding affinity than the other medications tested and there is no evidence of Lapinavir or Ritonavir binding completely to major targets such as 2AJF. This docking result suggests that the anti-HIV drug could aid in COVID-19 drug discovery and lopinavir and ritonavir tablets may be ineffective for treating SARS CoV-2 infections. However, a further study that confirms antiviral activities by in vitro and in vivo

heads-up on compounds that may be effective. B-157

VIRTUAL SCREENING BY MOLECULAR DOCKING, AND PHARMACOK PARAMETERS OF COMPOUNDS CONTAINING 4-(1H-BENZIMIDAZOLE-Z-YLL AS A POTENTIAL ANTIMICROBIAL AGENT Trupti Kosarkar, Disha Dhabarde, and Jagdish Baheti Kamia Nebru College of Pharmacy, Butibori, Nagpur-441108. truptikosarkar@ge

Since antibiotic resistance has developed over time, a serious global epidemic has e order to properly treat bacterial antibiotic resistance, it is crucial to design a ne drug. The dihydrofolate reductase enzyme is obligatory for the biosynthesis of ani DNA. Peptide deformylase may be produced by bacteria during protein syntheinitiates with an N-formylmethionine residue. Molecular docking of design derivatives were studied on dihydrofolate reductase receptors and peptide defer ID:3SRW with resolution 1.70Å and PDB ID:1N5N with resolution 1.80Å) and co the reference drug ciprofloxacin. Designed compounds revealed superior bind ranges from -9.1 to -10.6 kcalimol and -8.2 to -9.2 kcalimol respectively, and o wed binding affinity -8.2kcal/mol and -8.3kcal/mol respectively, employing the Studio visualizer, PyRx, and Pymol software. Similarly, Swiss ADME was used to ex pharmacokinetics properties, BOILED Egg visuals, and oral bioavailability charact physicochemical parameters showed that none of the designed compounds ridate rule of five. Additionally, images of a boiled egg demonstrated a significant lie absorption by the human GI system and potential brain perm compounds have been further synthesized as novel antibacterial agents due to be bloavailability and excellent pharmacokinetic properties.

B-158

DESIGN, DOCKING STUDIES, SYNTHESIS, CHARACTERIZATION, IN: SILICO A IN- VITRO STUDY OF 2-0X0-QUINOLIN-2(1H)-1-YL-SUBSTITUTED / DERIVATIVES AS POTENTIAL ANTI-CANCER AGENTS Rohishma Rohidas Naik and Soniya V. Phadte

PESs Rajaram and Tarabai Bandekar College of Pharmacy, Formagudi, Ponda, 4034 India, rohishmanaik262@gmail.com

The present work deals with the design of a hybrid of quinolin-2-one with a substituted aromatic secondary amine derivatives for their possible anticancer silico studios of the thirty-two designed compounds revealed a docking score sar 152.872 to -100.275 with the PDB ID (4ASD) targeting the VEGFR (vascul growth factor receptor regulators. With active legend taken as soraferib and state doxorubicin. The standard drug doxorubicin had a dock score of -102.192, the BAX 1500 was -129.622, the compound N-(3-(2-)4-(2-aminoethyllpiperazin 1oxoquinolin1(2H)-yl|benzamide (4h1)has a dock score of -152.872.Ten de synthesized starting with reaction of salicyclic aldebyde and 4 chloroethyl 8 undergoing Knoevenagel condensation, followed by nucleophilic substit ed by another nucleophilic substitution reaction and lastly acylation re synthesized compounds were evaluated for IR, 1H, 13C NMR. The final del synthesized for their anticancer activity. The in-silico prediction of drug liken ADME characteristics were tabulated to establish that all the compounds prospective candidates for the treatment of hepatogenic carcinoma. Likewise, toxicity profile was computed estimating the acute oral toxicity of the taget classifying them in Class 4 and class 3 toxicity category The work carried out so the derivatives N-(3-(2-(4-(2-aminoethyl)piperazin-1- yl)acstyl)-2-oxoqui yilbenzamide(4h1) showed IC50 values $6.12\pm0.52~\mu\mathrm{g/ml}$ at 72hrs serve at Therapeutic agents against hepatogenic carcinoma, thus positing a starting pain more potent analogues.

B-159

DESIGN, SYNTHESIS, ANTIMICROBIAL EVALUATION OF NOVEL 2010 SUBSTITUTED ARYL-AZETIDINE BENZOTRIAZOLE DERIVATIVE Vijayshri Rokda

Department of Pharmacautical Science, Oriental University, Indore.


The novel 2-oxo-4-substituted aryl-azetidine benzotriazole derivatives 4a-4n was rowave technique. The synthesize characterized by IR, 1H NMR, 13C NMR and mass spectroscopic studies. All the

72" Indian Pharmaceutical Cong





In silico study of Triazole linked Quinazolione derivatives for anti-diabetic as Dipeptidyl peptidase inhibitory activity









INTERNATIONAL CONFERENCE ON DRUG DISCOVERY 2022

Reg id: 1689 Poster id CB67

In silico study of Triazole linked Quinazolione derivatives for anti-diabetic as Dipeptidyl peptidase inhibitory activity.

Gawande Sahil Shyam

Madake Harshada Harishchandra

Dr. Shailaija Jadhav

P.E.S Modern college of Pharmacy, yamunagar Nigdi,Pune (SPPU)

P.E.S Modern college of Pharmacy, yamunagar Nigdi, Pune (SPPU)

P.E.S Modern college of Pharmacy, yamunagar Nigdi, Pune (SPPU)

P.E.S Modern college of Pharmacy, yamunagar Nigdi, Pune (SPPU)

The objective of the study was to perform in silico molecular docking studies of proposed hits Triazole linked quinazolinone derivatives for the determination of their anti-diabetic activity. ADME study, The docking studies were performed to established the relationship between physicochemical and structural properties of the hits with their antidiabetic activity. In the docking study, the compounds were studied for their Dipeptidyl peptidase inhibitory (DPP-IV) activity GLP-1, and which may contribute, to their antidiabetic activity with the probable mode of action. In the docking study which show the minimum binding energy. In conclusion of docking study, the 3-dimensional structure of protein GLP-1 (5DMF) in complex with Sitagliptin was used in the present study. The molecules bound to the active site of GLP-1 residues like Thr347, Lbu384, Trp383, Phe404, Met343, Lbu347 of all the synthesized compounds as potent inhibitors since they have a better minimum binding energy and also interact with active site residue. We have perform In silico study on this 12 compounds (\$1A1-\$1A12). In the conclusion of docking study, the compounds might possess the Dipeptidyl peptidase inhibitory (DPP-IV) activity GLP-1, and this may contribute, to their antidiabetic activity with the probable mode of action. From the result of docking study, we have synthesized the compounds which show the minimum binding energy

 Andreia .P. Pereira, Structural Bioinformatics and High-Performance Computing Research Group, Evaluation of the Anti-Diabetic Activity of Some Common Herbs and Spices: Providing New Insights with Inverse Virtual Screening, Molecules 2019. 24. 4030.

2.Maria J. Meneses, Branca M. Silva, Mário Sousa, Department of Microscopy, Laboratory of Cell Biology, Unit for Multidisciplinary Research in Biomedicine, Antidiabetic Drugs: Mechanisms of Action and Potential Outcomes on Cellular Metabolism, Current Pharmaceutical Design, 2015, 21, 3606-3620.
3. Jian-Huy Hen Li, Via Chang, Presentation of Part Pharmaceutical Design, 2015, 21, 3606-3620.

3.Jian-Hua Hea, Li-Xia Chena, Progress in the discovery of naturally occurring anti-diabetic drugs and in the identification of their molecular targets, Fitoterapia 134 (2019) 270-289.


Gawande Sahil Shyam sahilgawande270@gmail.com








In silico study of quinazolinone-sulfonamide derivatives for Dipeptidyl peptidase-IV as anti- diabetic Activity





In sillico study of Novel Sulphonamide/Isothiocyanate Linked Quinazolinone Derivatives for DPP -IV inhibitory as antidiabetic activity



INTERNATIONAL CONFERENCE ON DRUG DISCOVERY 2022

Reg id: 1839 Poster id CR69

In sillico study of Novel Sulphonamide/Isothiocyanate Linked Quinazolinone Derivatives for DPP-IV inhibitory as antidiabetic activity

Shraddha gaikwad, Mrs.Pournima bhalekar, dr. Shailja jadhav, mr. Somdatta chawdhary 1) P.E.S modern college of pharmacy Nigdi, Pune (Savitribai phule university)

3) P.E.S modern college of pharmacy Nigdi, Pune (Savitribai phule university)

ABSTRACT

The objective of the study was to perform in silico molecular docking studies of proposed hits sulphonamides/isothiocyanate linked quinazolinone derivatives (3-{[([4-[2-(4-hydroxyphenyl) 4-oxo-3,4dihydroquinazolin3yl] benzene} sulfonyl) carbamothioyl] amino} phenyl) azinic acid into Dipeptidyl peptidase-IV (DPP-IV) inhibitors for the determination of their antidiabetic activity. There is clear evidence that inhibition of enzymes like DPP-IV can be used in the treatment of type 2 diabetes which further reduces the complications in the disease. Inhibition of the DPP-IV enzyme prolongs and enhances the activity of incretins that play an important role in insulin secretion and blood glucose control regulation. Molecular docking plays an important role in the rational design of drugs. We have performed in silico studies of sulphonamides/isothiocyanate linked quinazolinone derivatives for activity on DPP-IV enzyme. 15 Compounds (A1-A10, B1-B10, C1-C10, D1-D10, E1-E9) were studied for their binding affinity to (PDB ID 3OPM) 3D and 2D binding as potential Dipeptidyl peptidase-IV inhibitor. The compounds that obeyed Lipinski rule of five are subjected for pharmacokinetic parameters prediction and docking analysis. SwissDock ADME PreADMET software is used for the prediction of ADMET. Molecular docking showing binding of(3-{[([4-[2-(4hydroxyphenyl) 4-oxo-3,4dihydroquinazolin3yl] benzene} sulfonyl) carbonothioyl] amino} phenyl) azinic acid (C6) at DPP-IV inhibitor (PDB ID 30PM) 3D and 2D. The minimum binding energy indicated that the DPP-IV protein was successfully docked with compounds. The minimum binding energy indicated that the DPP-IV protein was successfully docked with compounds. The results showed that the binding affinity of C6 for the enzyme was -11.20 kcal/mol while that of standard was -6.79 kcal/mol. Other molecules also showed comparable binding affinities for the enzyme as compared to standard. We found the molecules bound to the active site of DPP-IV residues like Arg125, His740, Ser630, Glu206, Glu206, Phe354, Gly741, Trp629, Tyr547, Tyr666, and Phe357. This study suggested that the designed molecules had the potential to act as DPV-IV inhibitors. The pharmacokinetic and in silico studies conclude that the title compounds into DPP-IV inhibitors giving antidiabetic activity. Based on in silico study, we are in the process of synthesizing the title compound.

- Amuthalakshmi S, Anton Smith A. Insilico Design of a Ligand for DPP IV in Type II Diabetes. Adv. Biol. Res. 7 (6) (2013): 248 - 252
- Meduru H, Wang Y, Tsai J, and Chen Y. Finding a Potential Dipeptidyl Peptidase-4 (DPP-4) Inhibitor for Type-2 Diabetes Treatment Based on Molecular Docking, Pharmacophore Generation, and Molecular Dynamics Simulation, Int. J. Mol. Sci. 17(190) (2006): 2-12.

Shraddha Prakashrao gaikwad gaikwadshi addha 1999@gmuil.com







Targated delivery of 5-Fluorocil in breast cancer using hollow mesoporous alumina nanoparticles



INTERNATIONAL CONFERENCE ON DRUG DISCOVERY 2022

Reg id: 1692 Poster id FS51

Targated delivery of 5-Fluorocil in breast cancer using hollow mesoporous alumina nanoparticles

A) Ms. Ankita Patil

C) Dr. Pravin Chaudhary

PESs Modern college of Pharmacy Nigdi Pune Maharashtra PESs Modern college of Pharmacy Nigdi Pune Maharashtra PESs Modern college of Pharmacy Nigdi Pune Maharashtra

Mesoporous aluminas (MAs) with tunable structural properties including BET surface area, pore volume and pore size was successfully synthesized. The synthesis method was based on a sol-gel process by using surfactant cetrimonium bromide. The mesoporous alumina was characterized using thermogravimetry differential thermal analysis (TG-DTA) for decomposition and mass loss characteristics during calcination, X-ray diffraction (XRD) for bulk crystallinity, transmission electron microscopy (TEM) for nano scale morphology, scanning electron microscope (SEM) for local crystallinity and N 2 adsorption- desorption techniques for porous structural properties. The typical curve with a hysteresis loop which can be indication of cylindrical mesoporous channels present in mesoporous alumina can be observed. Based on molecular diameter was found out to be 3.54 Å, total surface area was 226.193 m2/g, and average pore radius was 6.26nm. It was observed that the particle size of MeAI was found to be 32.7nm. The entrapment efficiency and drug loading of the drug on mesoporous alumina was analyzed using a UV-VIS spectrophotometer. The entrapment efficiency and drug loading of 5-Flurouracil were found to be 36% and 42% respectively which was calculated using calibration curve and absorbance of supernatant solution. The dissolution study of drug loaded mesoporous alumina was conducted at pH 7.4 as dissolution medium which is found increased up to 5 hr. as compared to 30 minutes for pure drug. This confirms the sustain release of 5-fluorouracil through mesoporous alumina.


- 1. Kadi, Mohammad W.; Mohamed, Reda M.; Ismail, Adel A.; Bahnemann, Detlef W. (2020). Soft and hard templates assisted synthesis mesoporous CuO/g-C3N4 heterostructures for highly enhanced and accelerated Hg(II) photoreduction under visible light. Journal of Colloid and Interface Science, 223-233 (doi:10.1016/j.jcis.2020.07.001)
- Chauruka, S.R.; Hassanpour, A.; Brydson, R.; Roberts, K.J.; Ghadiri, M.; Stitt, H. (2015). Effect of mill type
 on the size reduction and phase transformation of gamma alumina. Chemical Engineering Science, 134, 774783. (doi:10.1016/j.cs.2015.06.004)
- Larry L Hench (1997). Sol-gel materials for bioceramic applications. 2(5), 610. (doi:10.1016/s1359-0286(97)80053-8)

Patil Ankita Pradeep ankitapatil1599@gmail.com





Influence of combination of phytoconstituents in ethanol withdrawal induced depression



INTERNATIONAL CONFERENCE ON DRUG DISCOVERY 2022

Reg id: 1173 Poster id PDD69

INFLUENCE OF COMBINATION OF PHYTOCONSTITUENTS IN ETHANOL WITHDRAWAL INDUCED DEPRESSION

- 1.Prashant Mali
- 2.Deepti Bandawane
- 1 Sinhgad College of Pharmacy Vadgaon Bk. Pune
- 2 PES'S Modern College of Pharmacy Nigadi Pune

The harmful and hazardous use of alcohol is a serious problem in the world. It results in serious health, social and economic harms, and is the third-leading risk factor for death and disability. Alcohol withdrawal from chronic alcohol consumption results in a variety of symptoms including hyperexcitability which can manifest as increased tremor, over activity of the autonomic nervous system and convulsions which can be potentially lethal. Ethanol exerts its biological action through multiple receptors, including ion channels like GABAA, NMDA, 5HT3, 5-HT2 receptors, certain peptides and neurosteroids. The primary goal of ayurvedic medicine is to help people live long, healthy and balanced lifewith lesser side effects and higher efficacy. The present study evaluated the effect of combination of phytoconstituents in ethanol withdrawal induced depression. Alcohol dependence was produced in rat for ethanol withdrawal signs; rat were individually housed in small cages and ethanol 2.4%, 4.8% and 7.2%, v/v was given to the rats in a liquid diet for 21 days and then was withdrawn from the diet and animals were observed at 0, 2, 4, 6, 8 h for withdrawal signs. Fluoxetine (20mg/kg) as a standard and Rutin (100 mg/kg) and Ellagic acid(100 mg/kg) was given for 7 subsequent days and behavioural parameters were observed. Oxidative stress parameters (MDA, NO) and antioxidant enzyme parameters (SOD, GSH, CAT) were performed. Histopathological study was done on rat brain. It was found that chronic treatment with Rutin and Ellagic acid in combination significantly reduced the signs of hyperexcitability (EWS) and decrease the duration of immobility than the control rats in tail suspension test and forced swim test. It can be concluded that combination of Rutin and Ellagic acid or similar active phytoconstituents may be used for treatment of ethanol withdrawal induced

Keywords: Alcohol withdrawal, dependence, antioxidant, hyperexcitability, depression.

1.Bhutada PS, Mundhada YR, Ghodki YR, Chaware P, Dixit PV, Jain KS, Umathe SN. Influence of sigma-l receptor modulators on ethanol-induced conditioned place preference in the extinction–reinstatement model. Behavioural Pharmacology. 2012 Feb 1;23(1):25-33.

 Long D., Long B., Koyfmanc A., The emergency medicine management of severe alcohol withdrawal, American Journal of Emergency Medicine, 2017;35:1005–1011.

3. Yusha'u Y, Muhammad UA, Nze M, Egwuma JM, Igomu OJ, Abdulkadir M. Modulatory role of rutin supplement on open space forced swim test murine model of depression. Nigerian Journal of Physiological Sciences. 2017 Dec 30;32(2):201-5.


Prashant D. Mali prashantdmali55@gmail.com







Pursuit of natural compound as a potential NMDA Antagonist: An In-silico insight



INTERNATIONAL CONFERENCE ON DRUG DISCOVERY 2022

Reg id: 1668 Poster id PDD70

Pursuit of natural compound as a potential NMDA Antagonist: An In-silico insight.

A) Ms. Asavari Ramesh Shinde.

A) PES Modern college of Pharmacy, Nigdi Pune.

B) PES Modern college of Pharmacy, Nigdi Pune C) PES Modern college of Pharmacy, Nigdi Pune

Alzheimer's disease is an unavoidable neurological disorder in which memory loss, cognitive decline, and eventual dementia are brought on by the death of brain cells. There is no recognized treatment for Alzheimer's illness. There is no way to stop or reverse the loss of brain cells in dementia. In the world, four medications from the cholinesterase inhibitor class-donepezil, tacrine, galantamine and rivastigmine approved for Alzheimer's disease treatment. Only one drug i.e., memantine is used as NMDA receptor antagonist for AD treatment. Consequently, the plan's objectives include measurements for current treatments as well as an improved focus on preventative and treatment research. In recent years, a number of pharmacologically active substances that were derived from plants, animals, and microbes have shown promise in the treatment of AD by focusing on various pathogenic processes. Natural products are promising source of novel bioactive compounds for therapeutic potential as NMDA receptor antagonists for Alzheimer's disease. In this research study we have screened natural compound database derived from zinc15. Firstly, natural compounds were screened for its BBB and ADMET properties. On the basis of that we got top 10 compounds for dynamics having desired stability with less side effects.


- 1) Sharma, G., Shukla, R., & Singh, T. R. (2021). Analysis of small molecules against the NMDA receptor: an insight from virtual screening and molecular dynamics simulation based findings. 1-19. https://doi.org/10.21203/rs.3.rs-568180/v1
- 2) Bhushan, I., Kour, M., Kour, G., Gupta, S., Sharma, S., & Yadav, A. (2018). Alzheimer's disease: Causes & treatment-A review. Annals of Biotechnology, 1(1), 1-8. http://meddocsonline.org/
- 3) Andrade, S., Ramalho, M. J., Loureiro, J. A., & Do Carmo Pereira, M. (2019). Natural compounds for Alzheimer's disease therapy: A systematic review of preclinical and clinical studies. International Journal of Molecular Sciences, 20(9). https://doi.org/10.3390/ijms20092313

shindeasavari31012000@gmail.com shindeasavari31012000@gmail.com





Virtual screening of phytochemical compounds as potential inhibitors against BACE 1 receptors



INTERNATIONAL CONFERENCE ON DRUG DISCOVERY 2022

Reg id: 1776 Poster id PDD92

Virtual screening of phytochemical compounds as potential inhibitors against BACE 1 receptors

- A) Sanket Rajendra Shirsath
- B) Saumdatta Y. Chaudhari
- C) Shailaia B, Jadhay
- A) PES's Modern College of Pharmacy, Nigdi, Pune.
- B) PES's Modern College of Pharmacy, Nigdi, Pune.
- C) PES's Modern College of Pharmacy, Nigdi, Pune

Alzheimer's is neurodegenerative illness brought on by the buildup of senile plaque in the brain, which disrupts the neural system and makes neuron less responsive to stimuli. There are currently few therapy options available for those with Alzheimer's disease (AD). Amyloid-(A) buildup in the brain is a crucial molecular development in the pathogenesis of AD. A peptide synthesis is decreased when amyloidogenic-secretase (BACE1) is suppressed. Therefore, the primary objective of our research is to identify novel, modest bioactive compounds that may enter the brain and inhibit BACE1. According to literature survey beta secretase 1 (BACE1) is the key player in the development of senile plaques and is therefore a target for Alzheimer's drugs. In this study, we have taken the 80,617 natural compounds from the Zinc 15 database. In further natural compounds were screen for its BBB and ADMET parameter, on the basis of that we further screened using the Autodock Vina. From those top 10 compounds were chosen for the Molecular Dynamics, which illustrates the necessary biological activity and less side effects.


- Cosconati, S., Marinelli, L., Di Leva, F. S., La Pietra, V., De Simone, A., Mancini, F., Andrisano, V., Novellino, E., Goodsell, D. S., & Olson, A. J. (2012). Protein flexibility in virtual screening: The BACE-1 case study. Journal of Chemical Information and Modeling, 52(10), 2697–2704. https://doi.org/10.1021/ci300390h
- Lee, S., Youn, K., Lim, G. T., Lee, J., & Jun, M. (2018). In silico docking and in vitro approaches towards BACE1 and cholinesterases inhibitory effect of citrus flavanones. Molecules, 23(7), 1–12. https://doi.org/10.3390/molecules23071509
- 3) Palakurti, R., & Vadrevu, R. (2017). Pharmacophore based 3D-QSAR modeling, virtual screening and docking for identification of potential inhibitors of β -secretase. Computational Biology and Chemistry, 68, 107–117. https://doi.org/10.1016/j.compbiolchem.2017.03.001

Shirsath Sanket Rajendra srshirsath28@gmail.com





Anti-arthritic activity in experimental animals by using Freund's Complete Adjuvant(FCA) model



INTERNATIONAL CONFERENCE ON DRUG DISCOVERY 2022

Reg id: 1735 Poster id PDD93

Anti-arthritic activity in experimental animals by using Freund's Complete Adjuvant(FCA) model.

A) PRATIKSHA KANTILAL HAJARE

- B) Dr.SONALI SUKHDEO NIPATE
- A) P.E.S. Modern college of Pharmacy Nigdi Pune-411044
- B) P.E.S. Modern college of Pharmacy Nigdi Pune-411044

Abstract

Arthritis is a condition in which joints are painful and stiff. If the joints are actually red, hot, swollen, and tender, this is often described as inflammatory arthritis. Due to their few side effects and the additive benefits of their constituent chemicals, traditional plant medicines continue to hold a prominent place in the modern pharmaceutical industry. Pinus roxburghii Sargent has many medicinal uses; like haemostatic, stimulant, analgesic & inflammatory, antioxidant, anthelmintic, digestive, liver tonic, diuretic, bronchitis, inflammations skin diseases. Pinus roxburghii sargent is known to be a rich source of terpenoids, flavonoids, tannins, and xanthones among other compounds. The aim of the study was to evaluate antiarthritis and activities of Pinus roxburghii sargent stem Bark in experimental animals using Freund's Complete Adjuvant(FCA) model. Present study showed that ethyl acetate fraction of Pinus roxburghii sargent at doses of (250 and 500 mg/kg) have shown promising effect in significant inhibition of pain perception parameters like dorsal Flexion, motility and Significant rise in Stair climbing score in comparison with disease control. Histological and radiological study reveals that experimental animals showed reduction in cellular infiltration, synovial hyperplasia and pannus formation in ankle joint, as well as the various imaging parameters like calcium deposition, bone erosion, connective tissue swelling around joints, spur formation and interspacing between the bones in comparison with disease control which suggest that test drug can block the disease progression in arthritic rats. Hence the Pinus roxburghii sargent stem bark contributed towards the antiarthritic activity.

1)Nipate SS., Hurali PB., Ghaisas MM. (2015). Evaluation of anti-inflammatory, anti-nociceptive and anti-arthritic activity of Indian ApisDorsata bee venom in experimental animals. Biochemical, histological and radiological assessment. Immunopharmacology and Immunotoxicology., 37(2), 171-184, 2)Kaushik D., Kumar A., Kaushik P., Rana A. (2012). Analgesic and anti-inflammatory activity of Pinus roxburghiiSarg. Adv Pharmacol Sci., 2012, Article ID 245431,6, 3)Khan I., Singh V., Chaudhary A. (2012). Hepatoprotective activity of Pinus roxburghiiSarg. wood oil against carbon tetrachloride and ethanol induced hepatotoxicity. Bangladesh J Pharmacol. 7(2), 94-9,

SONALI SUKHDEO NIPATE sonynipate@rediffmail.com





Anti-atherosclerotic activity of Origanum majorana L. in experimental animals



INTERNATIONAL CONFERENCE ON DRUG DISCOVERY 2022

Reg id: 1756 Poster id PDD94

Anti-atherosclerotic activity of Origanum majorana L. in experimental animals .

A) Ms.Dhanashri .V. Katkar

B) Dr.Sonali .S. Nipate

C) Dr.Bhushan .P. Pimpale

A) P.E.S. Modern College Of Pharmacy, Nigdi , Pune-44

B) P.E.S. Modern College Of Pharmacy, Nigdi , Pune-44

C) P.E.S. Modern College Of Pharmacy, Nigdi , Pune-44

Atherosclerosis is a chronic inflammatory disease that is marked by atheromas, patchy intimal plaques in arteries that cause thickening and hardening of arteries. It is reported that "Origanum majorana L." possess antiulcerogenic, antiproliferative, antioxidant, anticarcinogenic activities, and also it is an important remedy against thromboembolic disease. Present study designed for evaluation of the anti-atherosclerotic activity of hydro distilled volatile oil (OMO) of Origanum majorana L. in high-fat diet-induced atherosclerotic rats. From the in vitro studies, it was found that OMO possesses fibrinolytic, thrombolytic, and antiplatelet activity. As these activities can play an effective role in the anti-atherosclerotic activity. Atherosclerosis was induced using a high-fat diet model in experimental animals. Lipid and lipoprotein profile, atherogenic index, cardiac markers, histopathological examination of the aorta were determined in the end of study. OMO significantly showed that the level total cholesterol (TC), triglyceride (TG), low-density lipids(LDL), very low-density lipids(VLDL) levels were decreased while there is an increase in high-density lipids (HDL) level, SGPT, SGOT, ALP and significant changes in WBCs and platelet count, increasing clotting and decreasing platelet count and the inflammatory biomarkers i.e. CRP level in serum was negative as compared to the normal group and also showed fibrinolytic, thrombolytic, and antiplatelet aggregation activity. The result suggested that oregano oil having fibrinolytic, thrombolytic, and antiplatelet activity hence it contributed towards antiatherosclerosis activity in high-fat diet-induced atherosclerotic rats.

 Yagi E, Simandi B, Daood HG, Deak A, Sawinsky J. Recovery of pigments from Origanum majorana L. by extraction with supercritical carbon dioxide. J Agr Food Chem 2002; 50: 2297 2301.

 Yazdanparast R, Shahriyary L. Comparative effects of Artemisia dracunculus, Satureja hortensis and Origanum majorana on inhibition of blood platelet adhesion, aggregation and secretion. Vasc Pharmacol 2008; 48: 32-37.


3)Pandit, D., Chiplonkar, S., Khadilkar, A. Kinare. A Khadilkar, V., Divate, U., Evaluation of Risk of Atherosclerosis Indian Adults, Journal of the association of physicians of India, May 2013; Vol. 61.

Dr. SONALI SUKHDEO NIPATE sonynipate@rediffmail.com





Evaluating the Diabetic wound Healing Activity of Phytoconstituent Extracted from Ficus Racemosa LINN. Leaves Using Animal Model



INTERNATIONAL CONFERENCE ON DRUG DISCOVERY 2022

Reg id: 1764

Evaluating the Diabetic wound Healing Activity of Phytoconstituent Extracted from Ficus Racemosa LINN. Leaves Using Animal Model

A) Miss. Kajal Sunil pawade

B) Dr. Sonali. S. Nipte

A) P.E.S MODERN COLLEGE OF PHARMACY NIGDI PUNE-44

B) P.E.S MODERN COLLEGE OF PHARAMCY NIGDI PUNE-44

Skin serves as the body's first line of defense against various skin diseases and conditions, diabetic wounds are slow to heal and may last for a week, blood flow to the wound site is essential for wound healing. Because fewer oxygenated blood cells can reach the area and tissues recover more slowly as a result of constricted blood vessels, diabetes wound healing is difficult. Ficus racemosa has a wide range of medical benefits including anti-diabetic, anti-hyperglycemic, antioxidant, and hepatoprotective characteristics. It also has anti-inflammatory, antibacterial, gastroprotective, and antidiarrheal properties. F. Racemos fruit has wound-healing properties. In Ficus racemose leaf extract's flavonoid and tannin fraction significantly increased the proportion of the excision wound that was closed by increased in collagen production in an In-vivo & In-Vitro model used to evaluate the effect of the extract on diabetic wound healing. Thus, it can be inferred that the flavonoid fraction and tannin fraction of Ficus racemose extract have wound-healing properties and are useful for treating diabetic wounds.

1) Baby Joseph, S. Justine Raj. Phytopharmacological Properties of Ficus racemosa Linn- An overview Interntional Journal Of Pharmaceutical Science Review And Research. 2010;3(2),Article 025
2) Krishnamoorthy M Rao, R.V. Celestin baboo, Jayachandran. D. L, S.Jeganath, Md. Fareedullah, Md. Imtiaz Ahmed. Wound Healing Activity of Ficus racemosa Linn Fruit Extract. International journal of Pharmaceutical & Biological Archives 2011;2(4):1111-1113


Dr. Sonali S. Nipate sonynipte@rediffmail.com








GSK-3 Beta inhibitor: An emerging anti Alzheimer agent with its Insilco scaffold and virtual screening





In silico study of a natural compound as potential MAO-A inhibitor



INTERNATIONAL CONFERENCE ON DRUG DISCOVERY 2022

Reg id: 1741 Poster id PDD99

In silico study of a natural compound as potential MAO-A inhibitor

Author 1- Miss. Geeta A. Anawade Author 2- Mr. Somdatta Y. Chaudhari

Author 3- Dr. Shailaija B. Jadhav

Author 1- P.E.S.Modern College Of Pharmacy, Nigdi, Pune.

Author 2- P.E.S.Modern College Of Pharmacy, Nigdi, Pund

Author 3- P.E.S.Modern College Of Pharmacy, Nigdi, Pune

Alzheimer's disease (AD) is a progressive neurodegenerative disorder associated with aging that is the reason for dementia worldwide. AD has a severe impact on cognitive functions such as memory, resulting in a number of functional losses. The ongoing rise in AD incidence necessitates the rapid creation of effective therapeutic strategies. Deposit extensive study on this disease only a few drugs capable of delaying disease progression are currently available. It has been demonstrated that several pharmacologically active plant-based compounds can effectively treat AD by inhibiting a number of enzymes, including acetylcholinesterase (AChE), butyrylcholinesterase (BuChE), NMDA and monoamine oxidases (MAOs), which are discussed as potential targets. Monoamine oxidase has an essential role in the breakdown of neurotransmitter that leads to the creation of some neurotoxic chemicals, MAO enzymes are possible therapeutic targets for the treatment of such neurological disorders. MAO inhibition has a broad anti-Alzheimer effect due to the reduction of oxidative stress caused by MAO enzymes. There have been many MAO inhibitors introduced thus but there is still a need for a fresh, effective treatment alternative. Consequently, the goal of the current study was to find out potent natural compounds that could be used as a medication to treat AD without causing any side effects. To do this, 80,000 natural product libraries from the natural product database of ZINC15 were virtually screened using computational methods for knowing its ADMET properties and BBB parameters. The resulting compounds were used for docking studies using Autodock Vina. MD simulations of the top 10 compounds were performed to evaluate the dynamics and stability of these compounds in the presence of the MAO-A complex. From the study, we can say that natural compounds have greater potential for anti-Alzheimer.

 Şahin, S., & Dege, N. (2021). A newly synthesized small molecule: the evaluation against Alzheimer's Disease by in silico drug design and computational structure analysis methods. Journal of Molecular Structure, 1236. https://doi.org/10.1016/j.molstruc.2021.130337

2) Behl, T., Kaur, D., Sehgal, A., Singh, S., Sharma, N., Zengin, G., Andronie-Cioara, F. L., Toma, M. M., Bungau, S., & Bumbu, A. G. (2021). Role of monoamine oxidase activity in alzheimer's disease: An insight into the therapeutic potential of inhibitors. Molecules, 26(12), 1–21. https://doi.org/10.3390/molecules26123724

Sorokina, M., & Steinbeck, C. (2020). Review on natural products databases: Where to find data in 2020.
 Journal of Cheminformatics, 12(1), 1–51. https://doi.org/10.1186/s13321-020-00424-9

Geeta Anil Anawade geetaanavade111@gmail.com







Evalauation of antidiabetic and nephroprotective potential of cassia auriculata aerial parts in streptozotocin induced early diabetic nephropathy in rats

Reg id: 1748

EVALAUATION OF ANTIDIABETIC AND NEPHROPROTECTIVE POTENTIAL OF CASSIA AURICULATA AERIAL PARTS IN STREPTOZOTOCIN INDUCED EARLY DIABETIC NEPHROPATHY IN RATS

A) Gayatri Jaising Gadekar

B) Dr. D. D. Bandawane

C) Nilam Kiran Mhetre

A) P. E. S. Modern College of Pharmacy, Nigdi.

B) P. E. S. Modern College of Pharmacy, Nigdi.

C) P. E. S. Modern College of Pharmacy, Nigdi.

Diabetes mellitus is a group of metabolic diseases characterized by hyperglycemia resulting from defects in insulin secretion and/or action. Diabetic nephropathy is most common complication of diabetes. Streptozotocin is toxic to the insulin producing β cells of the islets of Langerhansin of pancreas, and thus widely employed to induce diabetes in experimental rats. Plant derived formulations and remedies provide provides effective treatment against various diseases. Cassia auriculata is one the herbs having traditional importance for the treatment of diabetes and its related complications. The hydroalcoholic, ethyl acetate and petroleum ether extracts of aerial parts of Cassia auriculata were studied for the nephroprotective, antihyperglycemic and antidiabetic activity. To evaluate the nephroprotective potential of Cassia auriculata histopathological study of kidney, serum total protein, urinary total protein, serum albumin and urinary albumin were estimated. The antihyperglycemic activity is evaluated by oral glucose tolerance test, fasting blood glucose, glycosylated hemoglobulin and serum insulin, glycogen content of liver and skeletal muscle, SGPT, SGOT and ALP parameters. The antioxidant potential is studied through DPPH radical scavenging activity, nitric oxide radical scavenging activity, reducing power assay, superoxide radical scavenging activity, Estimation of GSH, SOD, CAT, MDA peroxidation and histopathologic study of liver. The oral administration of hydroalcoholic extract showed significant reduction in SGPT, SGOT, ALP levels. The OGTD test result indicates that the extract decrease in the blood sugar level. The urinary total protein and albumin were increased while creatine clearance was decreased.

- Alberti, K., G., Zimmet, P., 2007. International Diabetes Federation: a consensus on Type 2 diabetes prevention. Diabetes 24, 451-463.
- American Optometric Association, 2009. Care of the Patient with Diabetes. Optimetric Clinical Practice Guideline.
- 3) Anadan, A., Eswaran, R., Doss, A., Sangeetha, G., Anand, S., P., 2011. Chemical compounds investigation of Cassia auriculata leaves- a potential folklore medicinal plant. Bulletin of Environment, Pharmacology and Life Sciences 1,20-23.


Dr. D. D. Bandawane deepti.bandawane@gmail.com







Protective effect of Hydroalcoholic extract of cassia auriculata leaves on High fructose Induced resistance in experimental animals



INTERNATIONAL CONFERENCE ON DRUG DISCOVERY 2022

Reg id: 1762 Poster id PDD103

Protective effect of Hydroalcoholic extract of cassia auriculata leaves on High fructose Induced resistance in experimental animals

- A) Pranali Anandrao Bhandare
- B) Dr. Deepti Dinesh Bandawane
- C) Pooja Nana Ingole
- A) PES Modern college of Pharmacy, Nigdi, Pune.
- B) PES Modern college of Pharmacy, Nigdi, Pune.
- C) PES Modern college of Pharmacy, Nigdi, Pune.

Insulin resistance refers to suboptimal response of body tissues, especially liver, skeletal muscle and fat to physiological amounts of insulin. Relative insulin resistance is integral to type DM. It is also defined as decreased sensitivity and responsiveness to insulin-mediated glucose disposal or inhibition of hepatic glucose production (HGP). Additionally, type 2 diabetes, metabolic syndrome, atherosclerosis, obesity, fatty liver, pregnancy, and stress are all common conditions associated with insulin resistance.

Plant derived formulations and remedies provide an effective means of treatment of various type's diseases. Cassia auriculata leaves significantly reduce hyperglycemia in test animals. Cassia auriculata is one such herb bearing traditional importance for the treatment of diabetes and its elated complications. Preliminary phytochemical analysis, qualitative phytochemical analysis, and quantitative phytochemical analysis are some of the techniques utilized to identify high fructose induced resistance. Test for alkaloids, flavonoids, tannins, saponins, and steroids in qualitative phytochemical analysis.

Cassia auriculata leaves extract was studies for its insulin resistant activity. For estimation of protective role of Cassia auriculata against IR serum glucose, lipid profile study, Blood glucose and glucose tolerance, serum enzyme like AST, ALT, ALP and FFD level and finally Histopathological study of liver was performed. The Hydro alcoholic extract administered to the animal showed significant decrease in high fructose induced increased glucose level, insulin level, and level of AST, ALP, LDL, and VLDL.


- G. Christopher PROUD, M. Richard DENTON; Molecular mechanisms for the control of translation by insulin. Biochem J 1 December 1997; 328 (2): 329–341.
- Hunter, S. J., & Garvey, W. T. (1998). Insulin action and insulin resistance: diseases involving defects in insulin receptors, signal transduction, and the glucose transport effector system 1. The American journal of medicine, 105(4), 331-345.
- Mayer-Davis, Elizabeth J., et al. "Intensity and amount of physical activity in relation to insulin sensitivity: the Insulin Resistance Atherosclerosis Study." Jama 279.9 (1998): 669-674.

Dr. D. D. Bandawane Deepti.Bandawane@gmail.com





Protective effect of hydroalcoholic extract of Punica granatum leaves on high fructose induced insulin resistance in experimental animals



INTERNATIONAL CONFERENCE ON DRUG DISCOVERY 2022

Reg id: 1747 Poster id PDD104

Protective effect of hydroalcoholic extract of Punica granatum leaves on high fructose induced insulin resistance in experimental animals

A) Nikita Gangaram Pawar
B)Dr. Deepti Dinesh Bandawane
C)Ashwini Chitrangad kotkar
A) P.E.S.Modern college of pharmacy, Nigdi
B)P.E.S.Modern college of pharmacy, Nigdi
C)P.E.S.Modern college of pharmacy, Nigdi

Insulin resistance (IR) is a state where body tissues have less sensitivity to insulin and as a result, downstream metabolic pathways that are regulated by insulin are impaired and blood glucose rises. Diet high in fructose induces IR in experimental rats and reduce insulin sensitivity associated with impaired action of hepatic insulin and glucose disposal from the body. Insulin resistance was induced in experimental animals by using high fructose diet. The fructose-enriched diet was composed of 21% protein, 60% carbohydrate (as fructose), and 5% fat (of total energy, % kcal), sodium 0.49%, and potassium 0.49%. Plant derived formulations and remedies provide an effective means of the treatment of various types diseases P. granatum Linn. (Punicaceae) is one such herb bearing traditional importance for the treatment of diabetes and its related complications. Punica granatum leaves extract was studied for its insulin resistant activity. For estimation of protective role of Punica granatum against IR serum glucose, serum insulin, lipid profile study, serum enzyme like AST. ALP, SGOT and SGPT level and finally histopathological study of liver section were performed. The hydroalcoholic extract administered orally to animal showed significant decrease in high fructose induced increased glucose level, insulin level, levels of SGOT, SGPT. AST. ALP, and LDL. VLDL.

1)Jaydeokar, Ashish V.; Bandawane, Deepti D.; Bibave, Kiran H.; Patil, Tushar V. (2014). Hepatoprotective potential of <i>Cassia auriculata</i> roots on ethanol and antitubercular drug-induced hepatotoxicity in experimental models. Pharmaceutical Biology, 52(3), 344–355.

experimental models. Pharmaceutical Biology, 52(3), 344–355.

2)Lansky, Ephraim P., and Robert A. Newman. "Punica granatum (pomegranate) and its potential for prevention and treatment of inflammation and cancer." Journal of ethnopharmacology 109.2 (2007): 177-206.


3) Haidari, Mehran, et al. "Pomegranate (Punica granatum) purified polyphenol extract inhibits influenza virus and has a synergistic effect with oseltamivir." Phytomedicine 16.12 (2009): 1127-1136.

Dr. Deepti D. Bandawane deepti.bandawane@gmail.com





Antihistaminic effects of azadirachta indica leaves in laboratory animals



INTERNATIONAL CONFERENCE ON DRUG DISCOVERY 2022

Reg id: 1751 Poster id PDD114

ANTIHISTAMINIC EFFECTS OF AZADIRACHTA INDICA LEAVES IN LABORATORY ANIMALS

- A) Ganesh Dattatray Pore
- B) Padmaja Kore
- C) Anuradha G More
- D) Akash Gaikwad
- E) Shivanjali Shinde
- F) Rutuja Sawkar
- G) Poonam Inamdar
- A) PES Modern college of Pharmacy, Nigdi, Pune
- B) PES Modern college of Pharmacy, Nigdi, Pune C) PES Modern college of Pharmacy, Nigdi, Pune
- D) PES Modern college of Pharmacy, Nigdi, Pune
- E) PES Modern college of Pharmacy, Nigdi, Pune
- F) PES Modern college of Pharmacy, Nigdi, Pune
- G) PES Modern college of Pharmacy, Nigdi, Pune

Azadirachta indica (Meliaceae) leaves have been traditionally used in the management of asthma and the current study was undertaken to scientifically validate the benefits of plant as an antihistaminic agent using the suitable animal model. The agents with antihistaminic properties are known to be good antiasthmatic agents; hence, in the current research work, the antihistaminic activity of an ethanolic extract of Azadirachta indica leaves (at a dose of 250 mg/kg, i.p.) was evaluated using haloperidol-induced catalepsy and clonidine-induced catalepsy in laboratory rats. The results showed that the ethanolic extract inhibits the catalepsy induced by the clonidine but no remarkable effect was observed on the catalepsy induced by haloperidol. This strongly suggests that, the inhibition is mediated through an antihistaminic action and there is no role of dopamine. Hence, in the present study, it is concluded that, the ethanolic extract has significant antihistaminic activity. The polar constituents in the ethanolic extract of leaves of Azadirachta indica may be responsible for the antihistaminic effects and therefore, the ethanolic leaves extract can be a better remedy as an antihistaminic agent.

KEY WORDS:

Asthma, Antihistaminic, Azadirachta indica, catalepsy bar, Haloperidol, Clonidine.

- 1. Puri H. S, Neem: the divine tree Azadirachta indica. Harwood Academic Publishers. 1999; 9-21.
- 2. Zong A., Cao H, Wang F. Anticancer

polysaccharides from natural resources: a review of recent research. Carbohydr. Polym. 2012; 90(4); 1395-


3. Efferth T., Koch E. Complex interactions between Phytochemicals. The Multi-Target Therapeutic concept of Phytotherapy. Curr. Drug Targets. 2011; 12(1); 122-132.

Dr. Padmaja Kore padmaja.kalshetti@gmail.com





Evaluation of In-Vitro Anthelmintic Potential of Various Extracts of Emblica Officinalis



INTERNATIONAL CONFERENCE ON DRUG DISCOVERY 2022

Reg id: 1822 Poster id PDD119

Evaluation of In-Vitro Anthelmintic Potential of Various Extracts of Emblica Officinalis

- A) Pradnya Khelbude
- B) Dr. Padmaja Kore
- C) Rashmi Tantri
- A) PES Modern college of pharmacy, nigdi, Pune
- B) PES Modern college of pharmacy, nigdi, Pune
- C)PES Modern college of pharmacy, nigdi, Pune

Title - Evaluation of In-Vitro Anthelmintic Potential of Various Extracts of Emblica Officinalis

Abstract -

The present study was aimed to evaluate the in-vitro anthelmintic potential of Emblica officinalis (Indian gooseberry) against Pheretima Posthuma (Indian earthworm). Methods: Different extracts of Emblica officinalis as methanolic, ethanolic and hydroalcoholic were prepared and used in different concentrations such as 10, 20 and 30 mg/ml with normal saline in the study. The worms were randomized in to 11 groups of six worms each of similar type. Piperazine citrate (10 mg/ml) was used as a reference standard. For each worm paralysis time and death time was observed. When there was no movement observed except for when the worm was shaken vigorously, paralysis (P) in min was noted and with confirmation of lack of movement even when the worm was shaken vigorously as well as when dipped in warm water (500 C), death time (D) in min was recorded. Results: In all the extracts, worms were paralyzed and death occurred in a dose dependent manner. The hydroalcoholic extract was proven as most potent amongst all the extracts. Conclusion: Emblica officinalis can be used as a potential herbal remedy for the treatment of helminths infection.

- Hotez PJ, Brindley PJ, Bethony JM, King CH, Pearce EJ, Jacobson J. Helminth infections: the great neglected tropical diseases. The Journal of clinical investigation, 2008:118(4):1311-21.
 Jourdan PM, Lamberton PH, Fenwick A, Addiss DG. Soil-transmitted helminth infections. The Lancet, 2018:391(10117):252-65.
- 3)Wang LJ, Cao Y, Shi HN. Helminth infections and intestinal inflammation. World journal of gastroenterology: WJG,2008:14(33):5125.
- 4)Shalaby HA. Anthelmintics resistance; how to overcome it? Iranian journal of parasitology,2013:8(1):18.
- 5)Ahmed AH, Ejo M, Feyera T, Regassa D, Mummed B, Huluka SA. In vitro anthelmintic activity of crude extracts of Artemisia herba-alba and Punica granatum against Haemonchus contortus. Journal of parasitology research, 2020, 2020.

Dr. Padmaja kore padmaja.kalshetti@gmail.com





Evaluation of in-vitro anthelmintic potential of various extracts of emblica officinalis



INTERNATIONAL CONFERENCE ON DRUG DISCOVERY 2022

Reg id: 1826 Poster id PDD121

EVALUATION OF IN-VITRO ANTHELMINTIC POTENTIAL OF VARIOUS EXTRACTS OF EMBLICA OFFICINALIS

Prajakta Dilip Tambe Dr.Padmaja Kore Modern college of pharmacy nigdi Modern college of pharmacy nigdi

The present study was aimed to evaluate the in-vitro anthelmintic potential of Emblica officinalis (Indian gooseberry) against Pheretima Posthuma (Indian earthworm). Methods: Different extracts of Emblica officinalis as methanolic, ethanolic and hydroalcoholic were prepared and used in different concentrations such as 10, 20 and 30 mg/ml with normal saline were used in the study. The worms were randomized in to 11 groups of six worms each (of similar type). Piperazine citrate (10 mg/ml) was used as a reference standard. For each worm paralysis time and death time was observed. When there was no movement observed except for when the worm was shaken vigorously, paralysis (P) in min was noted and with confirmation of lack of movement even when the worm was shaken vigorously as well as when dipped in warm water (500 C), death time (D) in min was recorded. Results: In all the extracts, worms were paralyzed and death occurred in a dose dependent manner. The hydroalcoholic extract was proven as most potent amongst all the extracts. Conclusion: Emblica officinalis can be used as a potential herbal remedy for the treatment of helminths infection.

REFERENCES

Adams DS, Griffin LA, Nachajko WR, et al, 1991. A synthetic DNA encoding a modified human urokinase resistant to inhibition by serum plasminogen activator inhibitor,
 J Biol Chem, 266, (13), 8476-8482.
 Nicolino FA, Nichols WW, Mehta JL, Saldeen TG, Schofield R, Ross M, Player DW, Pohl GB and Mattsson C, 1992. Sustained reflow in dogs with coronary thrombosis with K2P, anovel mutant of tissue-plasminogen activator, JACC, 20(1),228-235.
 Linen HR, Van Hoef B, De Cock F, Okada K, Ueshima S, Matsuo O and Collen D, 1991. On the mechanism of fibrinspecific plasminogen activation by staphylokinase, J Biol Chem, 266(18), 11826-11832.

Dr. Padmaja Kore padmaja.kalshetti@gmail.com







Effect of Standardized Extract of Commiphora Mukul Engl. (Burseraceae) on Bulbectomy Induced Sexual and Immune Dysfunction in Rats



INTERNATIONAL CONFERENCE ON DRUG DISCOVERY 2022

Reg id: 1801 Poster id PDD132

Effect of Standardized Extract of Commiphora Mukul Engl. (Burseraceae) on Bulbectomy Induced Sexual and Immune Dysfunction in Rats.

Surabhi Shinde, Padmaja Kalshetti, Prasad Thakurdesai PES's Modern College of Pharmacy, Yamuna nagar, Nigdi, Pune PES's Modern College of Pharmacy, Yamuna nagar, Nigdi, Pune PES's Modern College of Pharmacy, Yamuna nagar, Nigdi, Pune

The main objective of this study was to evaluate the standardized extract of Commiphora mukul Engl. (Burseraceae) in olfactory bulbectomy induced sexual and immune dysfunction in rats. Olfactory bulbectomy (OBX) was performed in male Sprague dawley rats (250-270gms). After recovery period of 14 days, 8 groups of animals were made (6 per group) as, Group-I rats served as SHAM control (Without surgery, burr holes drilled), Group-II rats served as OBX control group, Group-III, IV, V served as standard treatment groups i.e. imipramine, fluoxetine and desipramine (20mg/kg p.o., 30mg/kg p.o., 15mg/kg p.o.). All the treatments were continued for 14 days after recovery period. Sexual behaviour parameters were taken on 29th day and animals sacrificed at the end for brain dopamine estimation. All three standards as well as all three doses of hydro alcoholic extract of Commiphora mukul (HECM) does dependently normalized OBX induced sexual and immune abnormalities. There was a significant improvement in all the parameters of sexual behavior, altered differential leukocyte count, weight of spleen and thymus and brain DA level by the treatment with standards as well as two higher doses of HECM. Commiphora mukul at all the doses significantly improved sexual and immune dysfunction induced by OBX, which is comparable with standard drugs.

Keywords: stress, depression, olfactory bulbectomy, dopamine, sexual dysfunction

Licinio J. and Wong M.L., The Role of Inflammatory Mediators in the Biology of Major Depression: Central Nervous System Cytokines Modulate the Biological Substrate of Depressive Symptoms, Regulate Stress-Responsive Systems, and Contribute to Neurotoxicity and Neuroprotection, Molecular Psychiatry, 4, 1999, 317-327. Zajecka K, Strategies for the treatment of antidepressant related sexual dysfunction. Journal of Clinical Psychiatry, 62(13), 2001, 35-43.

Song C. and Leonard B. E., The effects of lithium chloride administration on some behavioral and immunological changes in bilaterally bulbectomized rat, Journal of Psychopharmacology, 8, 1994e, 440-447.


Padmaja Kalshetti padmaja.kalshetti@gmail.com







Molecular Docking, Dynamics and Synthesis of some N-heteroaryl Flavon Hybrid **Targeting Estrogen Receptor Alpha**(ER-α)



INTERNATIONAL CONFERENCE ON DRUG DISCOVERY 2022

Reg id: 1813 Poster id SMDD62

Molecular Docking, Dynamics and Synthesis of some Nheteroaryl Flavon Hybrid Targeting Estrogen Receptor Alpha $(ER-\alpha)$.

A) B. S. Fegade B) S. B. Jadhav C) S. Y. Chaudhari

 A) Gahlot Institute of Pharmacy, Koparkhairane, Navi Mumbai, Maharashtra 400709, INDIA and Modern College of Pharmacy, Sector 21, Yamuna Nagar, Nigdi, Pune, Maharashtra 411044, INDIA.

rn College of Pharmacy, Sector 21, Yamuna Nagar, Nigdi, Pune, Maharashtra 411044, INDIA. C) Modern College of Pharmacy, Sector 21, Yamuna Nagar, Nigdi, Pune, Maharashtra 411044, INDIA.

Background: Substitution of the N-heterocyclic ring on the flavon structure may potentiate its anticancer effect. Hormone related breast cancer is mostly caused by interactions with estrogen receptor alpha (ER-a), which functions as a transcription factor to control the transcription of numerous genes. Flavones are considered as a good substrate for the estrogen receptor.

Objective: A series of flavon derivatives with an N-heteroaryl ring at the 4' position of the B ring of flavon were

designed, prepared, and evaluated for breast cancer activity.

Method: Molecular docking was used to study the binding interactions of the PzFL, PzF, PiFL, PiF, and IFL compounds with ER-a. Molecular dynamics and simulation studies were carried out in order to determine the stability and convergence of protein ligand complexes. The compounds were produced by cyclizing chalcones, and chalcones were produced by Claisen-Schmidt condensation of substituted aldehydes and 2hydroxyacetophenone. Breast cancer activity was evaluated by the MTT assay on MCF-7 cell lines. Also, compounds were studied for their estrogen receptor binding potential on the same cell lines.

Results: Molecular docking of compounds showed the good docking score. Molecular dynamics of these compounds expressed stable RMSD, stable radius of gyration and low binding energy, suggested that ligand bound to protein is quite stable in complex. MTT assay on MCF-7 cell lines reported PzF and IFL were the most active compounds with lower IC50 values. ER-a binding assay of these compounds revealed the presence of binding interactions with receptor.

Conclusion: This study offers a viable reference point for the design of flavon-incorporated N-heterocyclic ring derivatives as breast cancer compounds.

Keywords: - Estrogen receptor alpha, Breast cancer, Flavon, MTT assay, Molecular dynamics

- Suganya J, Radha M, Naorem DL, Nishandhini M. In silico docking studies of selected flavonoidsnatural healing agents against breast cancer. Asian Pacific Journal of Cancer Prevention. 2014;15(19):8155-9.
- Chow E, Rendleman CA, Bowers KJ, Dror RO, Hughes DH, Gullingsrud J, Sacerdoti FD, Shaw DE. Desmond performance on a cluster of multicore processors. DE Shaw Research Technical Report DESRES/TR--2008-01. 2008 Jul 28.
- Shivakumar, D., Williams, J., Wu, Y., Damm, W., Shelley, J., & Sherman, W. Prediction of Absolute Solvation Free Energies using Molecular Dynamics Free Energy Perturbation and the OPLS Force Field. Journal of Chemical Theory and Computation, (2010). 6(5), 1509-1519.
- Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. Journal of immunological methods. 1983 Dec 16;65(1-2):55-63.
- Singla R, Gupta KB, Upadhyay S, Dhiman M, Jaitak V. Design, synthesis and biological evaluation of novel indole-benzimidazole hybrids targeting estrogen receptor alpha (ER-α). European journal of medicinal chemistry. 2018 Feb 25;146:206-19.

Bharti S. Fegade bhartigip@gmail.com





Synthesis, characterization and in-silico study of two key impurities of propranolol



INTERNATIONAL CONFERENCE ON DRUG DISCOVERY 2022

Reg id: 1755 Poster id SMDD190

Synthesis, characterization and in-silico study of two key impurities of propranolol.

A) Rutuja U. Gaikwad

B) Dr. Amit S. Tapkir

C) Sanket B. Bhatshankar

A) P. E. Society's, Modern College of Pharmacy, Nigdi, Pune 411044, Maharashtra.

B) P. E. Society's, Modern College of Pharmacy, Nigdi, Pune 411044, Maharashtra.

C) P. E. Society's, Modern College of Pharmacy, Nigdi, Pune 411044, Maharashtra.

Title: Synthesis, characterization and in-silico study of two key impurities of propranolol.

Abstract:

Impurity synthesis is upcoming market in next few years and which will play a vital role in pharma industry. The Present work has based on synthesis of propranolol impurity. Propranolol belongs to group of medicines called β blockers. propranolol blocks β1 and β2 receptors, but has weak activity on β3 subtype. Impurity plays major role in quality control of active pharmaceutical ingredient. Impurity may be more potent than related drug. In contest of impurity synthesis, to minimizes expenses in traditional synthesis we perform docking studies. The work represents the synthesis of some impurities, that act as a reference standard for impurity present in API. The docking studies were performed to established the high binding affinity of impurity as compare to their API. The ADMET study was carried out to know the pharmacokinetic properties, drug likeness relates to their API and establish toxicity. For Insilco study the target protein is potent G- protein coupled receptor kinase which is (5-UVC) imported from protein data bank from web. During synthesis we found two impurities of propranolol these are; 3- (napthalen- 1-yloxy) propane- 1,2-diol (imp 1) and 1,3-bis (napthalen-1-yloxy) propan-2-ol (imp 2). In docking study impurity imp2, show the equal and high binding affinity compare to their standard API Propranolol. In docking study interaction were visualized using Biovia Discovery Studio software in that imp2 showed hydrogen bond, hydrophobic interaction and electrostatic interaction but their API only showed hydrogen bond and hydrophobic interaction. In ADMET study imp2 was showed similar pharmacokinetic activity as to their API. In this study, the imp2 were successfully synthesized using the procedure presented in the scheme and were purified by recrystallization and column chromatography. The identification of compound was established by single spot TLC and spectral analysis involving IR, 1H NMR and Mass.

- Sanjay B. Bari, Bharati R. Kadam, Yogini S. Jaiswal, et al. Impurity profile: Significance in Active Pharmaceutical Ingredient. Eurasian J. Anal. Chem, 2007; 2(1): 32-53.
- Yy Anh Tran and Nguyen Hai Tai Tran et al., "Facile Synthesis of Propranolol and Novel Derivatives", Hindawi Journal of Chemistry, 2020.
- Poojashree. P et al., "A Review on Pharmaceutical Impurities and its Importance in Pharmacy" American Journal of Pharmtech Research, Vol.9, 2019.
- BIOVIA, Dassault Systèmes, Discovery Studio, v21.1.0.20298, San Diego: Dassault Systèmes, 2021.

Dr. Amit S. Tapkir amittapkir.8@gmail.com



Progressive Education Society's Modern College of Pharmacy, Nigdi, Pune 411044



Synthesis and Insilico study of six key impurities of Atenolol: β blocker



INTERNATIONAL CONFERENCE ON DRUG DISCOVERY 2022

Reg id: 1765 Poster id SMDD191

Synthesis and Insilico study of six key impurities of Atenolol: β blocker

A) Waghmare Pradnya Sangram

B) Dr. Amit S. Tapkir

C) sanket B. Bhatshankar

A)PES modern college of pharmacy, nigdi pune 411044, Maharasthtra

B)PES modern college of pharmacy, nigdi pune 411044, Maharasthtra

C)PES modern college of pharmacy, nigdi pune 411044, Maharasthtra

Title- Synthesis and Insilico study of six key impurities of Atenolol: β blocker

Abstract-

There is a vital role that the impurity standard play in the development of any drug. The goal of the present work has to be synthesis the impurity of the atenolol. To concise the work we performed docking study to find potential impurity. Atenolol is beta blocker medication preferably block \$1 receptor, primarily used to treat high blood pressure and heart associated chest pain. G-protein couple receptor kinase 2 (GRK2) inhibitor play an important role for the potential treatment of heart failure. For Insilico study GRK2 was consider as protein target (PDB id for GRK2-5UVC). To minimise expense in traditional synthesis we performed docking studies 6 types of impurity obtained Aimp1 {2-(4-hydroxyphenyl) acetamide}, {2-(4-(3-chloro-2-Aimp2 hydroxypropoxy)phenyl)acetamide}, Aimp3 {2-(4-(3-dihydroxypropoxy) phenyl)acetamide, Aimp4 {2-(4-(3-dihydroxypropoxy) phenyl)acetamide, Aimp5 {2,2' (((2-hydroxypropane-1,3-diyl)bis(oxy))bis(4,1-diyl)acetamide, Aimp5 {2,2' (((2-hydroxypropane-1,3-diyl)bis(0xy))bis(4,1-diyl)acetamide, Aimp5 {2,2' (((2-hydroxypropane-1,3-diyl)bis(0xy))bis(0xy)}acetamide, Aimp5 {2,2' (((2-hydroxypropane-1,3-diyl)bis(0xy))bis(0xy)}acetamide, Aimp5 {2,2' (((2-hydroxypropane-1,3-diyl)bis(0xy))bis(0xy)}acetamide, Aimp5 {2,2' (((2-hydroxypropane-1,3-diyl)bis(0xy))bis(0xy)}acetamide, Aimp5 {2,2' (((2-hydroxypropane-1,3-diyl)bis(0xy)}acetamide, Aimp5 {2,2' (((2-hydroxypropane-1,3-diyl)bis(0xy)}acetamide, Aimp5 {2,2' (((2-hydroxypropane-1,3-diyl)bis(0xy)}acetamide, Aimp5 {2,2' ((2-hydroxypropane-1,3-diyl)bis(0xy)}acetamide, Aimp5 {2,2' ((2-hydroxypropane-1,3-diyl)bis(0xy)}acetamide, Aimp5 {2,2' ((2-hydroxypropane-1,3-diyl)bis(0xy)}acetamide, Aimp5 {2, phenylnene))diacetamide, Aimp6 {2 2' ((((isopropylazanediyl)bis(2-hydroxypropane -3,1-diyl))bis (oxy)bis(4,1phenylene))diacetamide. Docking study results revels that, Aimp5 and 6 are more potent the standard drug atenolol. According to ADMET study necessary for understand safety and efficacy of drug. ADMET performed by webserver preadmet, swissadme. Aimp1, Aimp2, Aimp3, Aimp6 shows good ADMET property. For future prospect pharmaceutical industry reduce the level of impurity to their required threshold according to ICH guideline. We synthesized impurity which belong to emergency cardiovascular drug, so that they have high market value in pharmaceutical industry for concerning safety of potent drug. In our research work study, we have found impurity (Aimp5 and 6) have high binding affinity and required ADME properties which might be helpful as a drug rather than impurity from drug.

 Singh A, Goyal S, Jamal S, Subramani B, Das M, Admane N and Grover A: Computational identification of novel piperidine derivatives as potential HDM2 inhibitors designed by fragment-based QSAR, molecular docking and molecular dynamics simulations. Structural Chemistry 2016; 27(3): 993–1003. 5.

 Ajmani S, Jadhav K and Kulkarni SA: Group-based QSAR (G-QSAR): Mitigating interpretation challenges in QSAR. QSAR and Combinatorial Science 2009; 28(1): 36–51.
 Valday A and Lois S. Outstitution street and in the latest and the latest and the latest and the latest and the latest and the latest and the latest and the latest and the latest and the latest and the latest and the latest and the latest and

 Vaidya A and Jain S: Quantitative structure activity relationship: A novel approach of drug design and discovery. Journal of Pharmaceutical Sciences and Pharmacology, American Scientific Publishers 2014; 1: 219-32.

Dr. Amit S. Tapkir amittapkir #@gmail.com





Computational approach, synthesis and characterization of two key impurities of metoprolol



INTERNATIONAL CONFERENCE ON DRUG DISCOVERY 2022

Reg id: 1773 Poster id SMDD193

Computational approach, synthesis and characterization of two key impurities of metoprolol

A) Rashinkar Sneha Nandkumar

B) Dr. Amit S. Tapkir

C) Sanket B. Bhatshankar

A) PES Modern College Of Pharmacy Nigdi Pune 411044, Maharashtra

B) PES Modern College Of Pharmacy Nigdi Pune 411044, Maharashtra

C) PES Modern College Of Pharmacy Nigdi Pune 411044, Maharashtra

Title:

Computational approach, synthesis and characterization of two key impurities of metoprolol Abstract:

Impurity profile studies play significant roles in Active Pharmaceutical Ingredient development, which are closely related to the quality, safety and efficacy of drug product. The aim of present study has to synthesis and characterisation of impurities present in a drug Metoprolol. Metoprolol is selective beta-1 blocker. Beta blockers are also known as beta-adrenergic blocking agent, are medication that reduce blood pressure. Metoprolol commonly employed as the succinate and tartrate derivatives. Impurity has major impact on the quality of pharmaceutical substance. Sometimes impurities may be more potent than standard drug. For drug discovery process time, cost is too high, to reduce the expenses nowadays docking study is employed before the synthesis. The work represents the synthesis of some impurity that acts as a reference standard for impurities present in API. The goal of the work we were doing at the time was to create impurities from metoprolol. The ADMET study was carried out to know the pharmacokinetic properties. Drug likeliness relates to their API and establish toxicity. For insilico study the molecular docking study was used. Target protein used is G-protein coupled receptor kinase-2 (PDB ID:5UVC). During the synthesis two impurities of metoprolol were found, named as ethyl-2-(4-(2-hydroxy-3-(isopropylamino)propoxy)phenyl)acetate compound and hydroxy(isopropylamino)propoxy)phenyl) acetate compound D. In docking study, the compound C showed minimum binding energy than CD standard that is metoprolol. So, these can be the potent inhibitor of beta adrenoceptor. The compound C and CD standard showed the hydrogen bond, hydrophobic and electrostatic interaction but compound D showed only hydrogen bond and hydrophobic interaction. In this study, the compound C were successfully synthesized using the procedure presented in the scheme and were purified by recrystallization and column chromatography. Single spot TLC and spectrum analysis incorporating IR, 1H NMR, and Mass were used to identify the compound.

 Yy Anh Tran and Nguyen Hai Tai Tran et al., "Facile Synthesis of Propranolol and Novel Derivatives", Hindawi Journal of Chemistry, 2020

2) BIOVIA, Dassault Systèmes,

Discovery Studio,

v21.1.0.20298, San Diego: Dassault

Systèmes, 2021

3) Poojashree. P et al., "A Review on Pharmaceutical Impurities and its Importance in

Pharmacy" American Journal of Pharmtech Research, Vol.9, 2019

Dr. Amit S. Tapkir amittapkir.8@gmail.com





Potential effect of venom from various Venomous animals in cardiovascular disease



INTERNATIONAL CONFERENCE ON DRUG DISCOVERY 2022

Reg id: 1811 Poster id SMDD208

POTENTIAL EFFECT OF VENOM FROM VARIOUS VENOMOUS ANIMALS IN CARDIOVASCULAR DISEASE

A) Vinod Rajendra Gaikwad
B)Dr.Sonali S. Nipate
A)PES MODERN COLLEGE OF PHARMACY NIGDI PUNE
B)PES MODERN COLLEGE OF PHARMACY NIGDI PUNE

Hypertension account for 9.4 million deaths worldwide every year. Venom from animal kingdom is proven for many pharmacological and biological activities which can be used clinically. Chinese physicians use snake venom products routinely to treat stroke and view them as effective and relatively safe. In present study Daboia russelii (RV) and Mesobuthus tumulus (SV) venom studied for Anti-hypertensive activity by fructose and adrenaline induced hypertension model in rats. RV and SV consist of complex, aqueous mixture containing Arginine esterases, Bradykinin-potentiating peptides (BPP), Disintegrins, L-amino acid oxidases (LAAO), Phosphodiesterases (PDE), Phospholipase A2's (PLA2), PLA2-based presynaptic neurotoxins, Purines and pyrimidines, Russelobin and K+, Na+, Ca2+, Cl- channel toxins, Hypotensin peptide, lipolytic peptide, PGI2 and NO releasing peptide. It has been found that RV & SV possesses anti-hypertensive activity. In fructose and adrenaline induced hypertension, RV & SV able to decrease blood pressure, total cholesterol, triglyceride, VLDL & LDL. Increase HDL, blood clotting time which is supportive for hypertension treatment.

 Andersson O. K., Lingman M., Himmelmann A., Sivertsson R., Widgren B. R., Lingman, Himmelmann, Sivertsson, Widgren, 2004, Prediction of future hypertension by casual blood pressure or invasive hemodynamics? A 30-year follow-up study. Blood Press. 13 (6): 350-4.

2)Markland F. S. 1998. Snake venom fibrinogenolytic and fibrinolytic enzymes an updated inventory. Registry of Exogenous Hemostatic Factors of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 79: 668-74.


3)Stephen M. 2013. Biochemical and pharmacological properties of a new thrombin-like serine protease (Russclobin) from the venom of Russell's Viper (Daboia russelli russelli) and assessment of its therapeutic potential. Biochimica et Biophysica Acta 1830: 3476-3488.

Dr.Sonali S. Nipate sonynipate@rediffmail.com





A Validated Method Using HPTLC for Determination of Bilastine and Design New Drug Discovery of Antihistaminic Activity.



INTERNATIONAL CONFERENCE ON DRUG DISCOVERY 2022

Reg id: 1760 Poster id SMDD219

> A Validated Method Using HPTLC for Determination of Bilastine and Design New Drug Discovery of Antihistaminic Activity.

1.Ms. Chopade Dnyaneshwari Ravindra

2.Dr. Pallavi Patil

1.PES Modern college of pharmacy, nigdi, pune (SPPU)

2.PES Modern college of pharmacy, nigdi, pune.(SPPU)

Abstract

A sensitive, accurate and precise high-performance thin layer chromatographic method was developed for simultaneous estimation of Bilastin/BILAS in bulk and tablet dosage form. The successful separation was achieved ON CAMAG HPTLC. The stationary phase and n-Hexane: Methanol: Iso Propyl Alcohol (1:5:4 v/v/v) as mobile phase. Chromatographic analysis was carried out in the reflectance/absorbance mode at 277nm. The method was validated with respect to linearity, specificity, accuracy, precision, limit of detection and limit of quantitation and applied for analysis of drug in tablet dosage form. The Rf values were found to be 0.53 ± 0.02 for selected drug. The linear regression analysis data for the calibration plots showed a linear relationship in the concentration range 500-2500 ng/band with correlation coefficient 0.997. A validation study has been performed as per ICH guidelines. Inertsil C18 column (150 mm length x 2.1 mm, 3 µm particle size) and the mobile phase comprised of 0.1% formic acid and methanol (50:50 v/v) pumped at rate of 0.2 mL/min. The injection volume of drug was 10 µL and temperature of column was 40°C. The main objectives of this research were to in silico screen the bilastine as to develop antihistaminic activity. Docking studies on bilastine have been carried out using V Life MDS 4.3 software. The molecular docking analysis was carried out better understand the interactions between bilastine and receptors. Hydrophobic and hydrogen bond interactions lead to identification of active binding sites. Docking is an important tool in understanding the structural requirements for design of novel, potent and selective inhibitors and can be employed to design new drug discovery and can be used for antihistaminic activity.

- Jain SV, Bhadoriya KS, Bari SB, Sahu NK, Ghate M. Discovery of Potent Anticonvulsant Ligands as Dual NMDA and AMPA Receptors Antagonists by Molecular Modeling Studies. Med Chem Res 2012;21 (11):3465-84.
- VLife Molecular Design Suite 4.3, VLife Sciences Technologies Pvt. Ltd;www.Vlifesciences.com.
- 3. Hurtado FK, Ravanello A, Arend MZ, Wrasse M, Dalmora SL, Rolim CM.


Chopade Dnyaneshwari Ravindra dnyachopade61199@gmail.com







Evaluation of in-vitro anthelmintic potential of umbelliferone against pheretima posthuma



INTERNATIONAL CONFERENCE ON DRUG DISCOVERY 2022

Reg id: 1297 Poster id: SMDD260

EVALUATION OF IN-VITRO ANTHELMINTIC POTENTIAL OF UMBELLIFERONE AGAINST PHERETIMA POSTHUMA

A)Abhijit Balasaheb Deshmukh

B)Dr. Padmaja kore

C) Roshani Bhole

1)P E S Modern college of pharmacy, Nigdi, pune.

2)P E S Modern college of pharmacy, Nigdi, pune.

3) P E S Modern college of pharmacy, nigdi, pune.

Abstract:

Objective: The present study was aimed to evaluate the in-vitro anthelmintic potential of isolated phytoconstituent umbelliferone against Pheretima Posthuma (Indian earthworm). Methods: Three different concentrations (10, 20, 30 mg/ml in Dimethyl sulfoxide (DMSO) of umbelliferone were prepared, and six worms of similar type were placed in it. Observations were made for the time taken for paralysis and death of the individual worm. Meantime required for the paralysis (P) in min was noted when no movement of any sort could be observed, except when the worm was shaken vigorously; death time (D) in min was recorded after confirmation with lack of movement when shaken vigorously/ dipped in warm water (50 °C). Piperazine citrate (10 mg/ml) was used as a reference standard. Results: Umbelliferone demonstrated paralysis as well as the death of worms, especially at a higher concentration of 30 mg/ml in a shorter time as compared to reference drug Piperazine citrate. Conclusion: In the present study, Umbelliferone was tested for its anthelmintic activity against Pheretima posthuma. Various concentrations were used in the bioassay, which involved paralysis and death time of the worms. The phytoconstituent showed significant anthelmintic activity.

Key Words:

Pheretima Posthuma, Umbelliferone, Paralysis and Death time

1)Shalaby HA: Anthelmintics Resistance; How to Overcome it?. Iran Journal of Parasitology 2013; 8(1): 18-32.
2) Ahmed AH, Ejo M, Feyera T, Regassa D, Mummed B and SA Huluka: In-vitro anthelmintic activity of crude extracts of artemisia herba-alba and Punica granatum against Haemonchus contortus. J of Para Res 2020; 1-7: 2020.

3)Ren QC, Gao C, Xu Z, Feng LS, Liu ML, Wu X and Zhao F: Bis-coumarin derivatives and their biological activities. Current Topics in Medicinal Chemi 2018; 18(2): 101-13,

Dr Padmaja kore padmaja.kalshetti@gmail.com







ACADEMIC YEAR: 2021-2022


INDEX

| Sr. No. | Title of Books and chapters in edited volumes / Books Published / Conference proceedings | Page No. |
|---------|---|----------|
| | ВООК | |
| 1. | Therapeutic Benefits of medicinal herbs | 203 |
| 2. | Therapeutic Benefits of medicinal herbs | 203 |
| 3. | Advances in pharmaceutical and Biomedical sciences | 208 |
| 4. | Advances in pharmaceutical and Biomedical sciences | 208 |
| 5. | Advances in pharmaceutical and Biomedical sciences | 208 |
| 6. | Current approaches on COVID-19 | 213 |
| 7. | A practical book of pharmaceutical formulation | 217 |
| 8. | Cellular and molecular pharmacology | 222 |
| 9. | Advances in Pharmaceutical Sciences | 229 |
| 10. | Therapeutic application of potential herbs Vol-1 | 233 |
| 11. | Pharmaceutics - For first year Diploma in pharmacy | 236 |
| | BOOK CHAPTERS | |
| 12. | Chapter 4 A Review on Meta-Analysis of Randomized Controlled Trials on the Clinical Effectiveness and Safety of Remdesivir in Patients with Covid 19 Caused by SARS-COV-2 | 240 |
| 13. | Chapter 2 Review on Agrochemicals on Human Bodies" | 246 |
| 14. | Chapter 7 A Digital Image-Based Colorimetric Technique Use for Quantification of Green Active Pharmaceuticals Obtained from Natural Sources | 252 |
| 15. | Chapter 5 Study on the development and evaluation of novel Modified release prllet-based system for delivery of Desloratidine and Pesudoephedtrine Hydrochloride | 254 |






Therapeutic Benefits of medicinal herbs



203











Published By: Rubicon Publications

4/4A Bloomsbury Square, Bloomsbury Square, London, WC1A 2RP, England Email: rubiconpublications@gmail.com

Authors: Dr. Padmaja S. Kore and Dr. Anuradha G. More

The author/publisher has attempted to trace and acknowledge the materials reproduced in this publication and apologize if permission and acknowledgements to publish in this form have not been given. If any material has not been acknowledged please write and let us know so that we may rectify it.

© Rubicon Publications

Edition: 1st

Publication Year: 2022 ISBN: 978-1-913482-28-2

Book DOI: https://doi.org/10.33545/rp.book.33

Pages: 233
Price: £ 18





Contents

| S. No. | Chapters | Page No. |
|--------|--|----------|
| 1. | A Review on Phytochemistry and Pharmacological Profile of <i>Rheum palmatum</i> | 01-14 |
| | (Tejal M. Dodal) | |
| 2. | A Review on Phytochemistry and Pharmacological Profile of Astragalus genus | 15-44 |
| | (Surbhi Gupta, Pratiksha Kshirsagar and Radhika Baheti) | |
| 3. | A Review on Phytochemistry and Pharmacological Profile of Astragalus membranaceus | 45-58 |
| | (Shraddha S. Satkar) | |
| 4. | A Review on Phytochemistry and Pharmacological Profile of Fenugreek (Trigonella foenum-graecum L.) | 59-90 |
| | (Surbhi Gupta, Radhika Baheti and Pratiksha Kshirsagar) | |
| 5. | A Review on Phytochemistry and Pharmacological Profile of <i>Panax ginseng</i> | 91-120 |
| | (Pratiksha Kshirsagar, Radhika Baheti and Surbhi Gupta) | |
| 6. | A Review on Phytochemistry and Pharmacological Profile of <i>Centella asiatica</i> | 121-152 |
| | (Radhika Baheti, Surbhi Gupta and Pratiksha Kshirsagar) | |
| 7. | A Review on Phytochemistry and Pharmacological Profile of Neem (Azadirachta indica) | 153-178 |
| | (Pratiksha Kshirsagar, Surbhi Gupta and Radhika Baheti) | |





About the Authors

Dr. Padmaja Santosh Kore is working as Assistant Professor at the department of pharmacology, Progressive Education Society's Modern College of Pharmacy, Yamunanagar, Nigdi, Pune-44 since 2017 till date. Prior to this, she was associated with MAEER's

Maharashtra Institute of Pharmacy since 2011. She is having teaching experience of 12 years and she has guided 3 M-Pharm students for their project. She has published various review and research papers in peer reviewed, national and international research journals. She was awarded with best oral research paper award by ICSCCB-2015 organized at Pune. She has presented various oral research papers in some international conferences. She has reviewed 4 research papers and published several book chapters in national books and also there are 5 upcoming book chapters in international books. She is life member of APTI.

Dr. Anuradha Ghanshyam More is working as Assistant Professor at the department of Pharmaceutics, Progressive Education Society's Modern College of Pharmacy, Yamunanagar, Nigdi Puna 44 since 2017 till data. She is having tooking

Nigdi, Pune-44 since 2017 till date. She is having teaching experience of 14 years. She is approved research guide from Savitribai Phule Pune University, Pune, Maharashtra for M. Pharm in Pharmaceutics and she has guided 16 M. Pharm students for their research project. She has published various review and research papers in peer reviewed national and international research journals. She has presented oral research papers in some international conferences. She has authored two books on industrial pharmacy. She is actively involved in research. She is life member of APTI.


Published By Rubicon Publications 4/4A Bloomsbury Square, Bloomsbury Square, London, WC1A 2RP, England Email: rubiconpublications@gmail.com







Advances in pharmaceutical and Biomedical sciences







Advances in Pharmaceutical and Biomedical Sciences

Authors

Dr. Padmaja S. Kore

Dr. Anuradha G. More

Dr. Pravin D. Chaudhari

AkiNik Publications New Delhi





Published By: AkiNik Publications

AkiNik Publications 169, C-11, Sector - 3, Rohini, Delhi-110085, India Toll Free (India) — 18001234070

Authors: Dr. Padmaja S. Kore, Dr. Anuradha G. More and Dr. Pravin D. Chaudhari

The author/publisher has attempted to trace and acknowledge the materials reproduced in this publication and apologize if permission and acknowledgements to publish in this form have not been given. If any material has not been acknowledged please write and let us know so that we may rectify it.

© AkiNik Publications

Edition: 1st

Publication Year: 2022

Pages: 210

ISBN: 978-93-5570-011-7

Book DOI: https://doi.org/10.22271/ed.book.1451

Price: ₹ 945/-






Contents

| . No. | Chapters | Page No. |
|-------|--|----------|
| 1. | Plasma Therapy and COVID-19 (Vaishnavi Inde, Mugdha Banduke and Mansi Sewatkar) | 01-24 |
| 2. | Marine Derived Compounds against Covid-19 (Mugdha Vikas Banduke, Vaishnavi Inde and Mansi Sewatkar) | 25-42 |
| 3. | Molecules against Coronavirus (Harsh Mehta, Abhishek Nemaniwar and Trupti Dighe) | 43-66 |
| 4. | Ecology and Evolution of COVID-19 and its Latest Treatment Guidelines | 67-92 |
| 5. | (Mansi Sewatkar, Mugdha Banduke and Vaishnavi Inde) Pharma Industry in the Age of Artificial Intelligence and Machine Learning | 93-114 |
| 6. | (Trupti Dighe, Harsh Mehta and Abhishek Nemmaniwar) Role of Nutraceuticals in Combating Various Diseases (Surbhi Gupta, Pratiksha Kshirsagar and Radhika Baheti) | 115-138 |
| 7. | New approaches from nanomedicine and pulmonary drug delivery for the treatment of Tuberculosis (Radhika Baheti, Surbhi Gupta and Pratiksha Kshirsagar) | 139-154 |
| 8. | Recent Advancements in Dosage form Development and Modification in Pharmacological Actions of the active Pharmaceutical Ingredients (Abhishek Nemmaniwar, Trupti Dighe and Harsh Mehta) | 155-170 |
| 9. | Nano-delivery Systems for NSAIDs: Challenges and Breakthroughs | 171-190 |
| | (Surbhi Gupta, Pratiksha Kshirsagar and Radhika Baheti) | |
| 10. | Nano carriers as a Strategy for Oral Bioavailability Improvement of Poorly Water-Soluble Drugs (Pratiksha Kshirsagar Radhika Baheti and Surbhi Gunta) | 191-210 |





About the Author



She is having teaching experience of 12 years and she has guided 3 M-Pharm students for their project. She has published various review and research papers in peer reviewed national and international research journals. She was awarded with best oral research paper award by ICSCCB-2015 organized at Pune. She has presented oral research papers in some international conferences. She has reviewed 4 research papers and published several book chapters in national books and also there are 5 upcoming book chapters in international books. She is life member of APTI.

Dr. Anuradha Ghanshyam More is working as Assistant Professor at the department of Pharmaceutics, Progressive Education Society's Modern College of Pharmacy, Yamunanagar, Nigdi, Pune-44 since 2017 till date. She is having teaching experience of 14 years. She is approved research guide from

Savitribai Phule Pune University, Pune, Maharashtra for M. Pharm in Pharmaceutics and she has guided 16 M. Pharm students for their research project. She has published various review and research papers in peer reviewed national and international research journals. She has presented oral research papers in some international conferences. She has authored two books on industrial pharmacy. She is actively involved in research. She is life member of APTI.




Published by
AkiNik Publications,
169, C-11, Sector - 3, Rohini,
Delhi - 110085, India
Toll Free (India): 18001234070
Email: akinikbooks@gmail.com






Current approaches on COVID-19













| 4. Potential Skin Whitening Property of Aloe Vera (Prathamesh Jambhulkar) 5. Discussing known Information about COVID- 19 and Focusing on the Double Mutant Genetic Variation - Delta (Falak Patel) 6. Hair Growth - Focus on Herbal Therapeutic Medications and hair Vitalizing Spices (Payal Patel) 7. Mechanism of Action for Various Covid-19 Vaccines (Aishwarya Reddy) 8. Pathophysiology of Mucormycosis/Black Fungus & Associated Complications (Bhavik Gala) 9. Post - Covid Syndrome (Ishika Shukla) | | Contents | |
|--|--|--|----------|
| 2. Potential Therapeutic Activity of Camellia sinensis (Shreya Suhas Koche) 3. Drugs Employed in Covid-19 Treatment (Mahesh Ravindra Bhadane) 4. Potential Skin Whitening Property of Aloe Vera (Prathamesh Jambhulkar) 5. Discussing known Information about COVID- 19 and Focusing on the Double Mutant Genetic Variation - Delta (Falak Patel) 6. Hair Growth - Focus on Herbal Therapeutic Medications and hair Vitalizing Spices (Payal Patel) 7. Mechanism of Action for Various Covid-19 Vaccines (Aishwarya Reddy) 8. Pathophysiology of Mucormycosis/Black Fungus & Associated Complications (Bhavik Gala) 9. Post - Covid Syndrome (Ishika Shukla) 10. Potential Therapeutic Utilization of Turmeric in Different Pharmacological Categories | | S. No. Chapters | Page No. |
| 3. Drugs Employed in Covid-19 Treatment (Mahesh Ravindra Bhadane) 4. Potential Skin Whitening Property of Aloe Vera (Prathamesh Jambhulkar) 5. Discussing known Information about COVID- 19 and Focusing on the Double Mutant Genetic Variation - Delta (Falak Patel) 6. Hair Growth - Focus on Herbal Therapeutic Medications and hair Vitalizing Spices (Payal Patel) 7. Mechanism of Action for Various Covid-19 Vaccines (Aishwarya Reddy) 8. Pathophysiology of Mucormycosis/Black Fungus & Associated Complications (Bhavik Gala) 9. Post - Covid Syndrome (Ishika Shukla) 10. Potential Therapeutic Utilization of Turmeric in Different Pharmacological Categories | | 1. Potential Therapeutic Effect of Centella asiatica (Prajakta Wagh) | 01-16 |
| 4. Potential Skin Whitening Property of Aloe Vera (Prathamesh Jambhulkar) 5. Discussing known Information about COVID- 19 and Focusing on the Double Mutant Genetic Variation - Delta (Falak Patel) 6. Hair Growth - Focus on Herbal Therapeutic Medications and hair Vitalizing Spices (Payal Patel) 7. Mechanism of Action for Various Covid-19 Vaccines (Aishwarya Reddy) 8. Pathophysiology of Mucormycosis/Black Fungus & Associated Complications (Bhavik Gala) 9. Post - Covid Syndrome (Ishika Shukla) 10. Potential Therapeutic Utilization of Turmeric in Different Pharmacological Categories | | 2. Potential Therapeutic Activity of Camellia sinensis (Shreya Suhas Koche) | 17-34 |
| 4. Potential Skin Whitening Property of Aloe Vera (Prathamesh Jambhulkar) 5. Discussing known Information about COVID- 19 and Focusing on the Double Mutant Genetic Variation - Delta (Falak Patel) 6. Hair Growth - Focus on Herbal Therapeutic Medications and hair Vitalizing Spices (Payal Patel) 7. Mechanism of Action for Various Covid-19 Vaccines (Aishwarya Reddy) 8. Pathophysiology of Mucormycosis/Black Fungus & Associated Complications (Bhavik Gala) 9. Post - Covid Syndrome (Ishika Shukla) 10. Potential Therapeutic Utilization of Turmeric in Different Pharmacological Categories | | 3. Drugs Employed in Covid-19 Treatment (Mahesh Ravindra Bhadane) | 35-68 |
| Focusing on the Double Mutant Genetic Variation - Delta (Falak Patel) 6. Hair Growth - Focus on Herbal Therapeutic Medications and hair Vitalizing Spices (Payal Patel) 7. Mechanism of Action for Various Covid-19 Vaccines (Aishwarya Reddy) 8. Pathophysiology of Mucormycosis/Black Fungus & Associated Complications (Bhavik Gala) 9. Post - Covid Syndrome (Ishika Shukla) 10. Potential Therapeutic Utilization of Turmeric in Different Pharmacological Categories | | | 69-84 |
| Medications and hair Vitalizing Spices (Payal Patel) 7. Mechanism of Action for Various Covid-19 Vaccines (Aishwarya Reddy) 8. Pathophysiology of Mucormycosis/Black Fungus & Associated Complications (Bhavik Gala) 9. Post - Covid Syndrome (Ishika Shukla) 10. Potential Therapeutic Utilization of Turmeric in Different Pharmacological Categories | | Focusing on the Double Mutant Genetic Variation - Delta | 85-98 |
| 7. Mechanism of Action for Various Covid-19 vaccines (Aishwarya Reddy) 8. Pathophysiology of Mucormycosis/Black Fungus & Associated Complications (Bhavik Gala) 9. Post - Covid Syndrome (Ishika Shukla) 10. Potential Therapeutic Utilization of Turmeric in Different Pharmacological Categories | | Medications and hair Vitalizing Spices | 99-122 |
| Associated Complications (Bhavik Gala) 9. Post - Covid Syndrome (Ishika Shukla) 10. Potential Therapeutic Utilization of Turmeric in Different Pharmacological Categories | | | 123-138 |
| 9. Post - Covid Syndrome (Ishika Shukla) 10. Potential Therapeutic Utilization of Turmeric in Different Pharmacological Categories | | Associated Complications | 139-148 |
| 10. Potential Therapeutic Utilization of Turmeric in Different Pharmacological Categories | | 9. Post - Covid Syndrome | 149-162 |
| | | 10. Potential Therapeutic Utilization of Turmeric in Different Pharmacological Categories | 163-18 |





Published by: Weser Books

Weser Books, No. 79737 Äussere Weberstr. 57 02763 Zittau, Germany Email: weserbooks@gmail.com

Authors: Dr. Padmaja Santosh Kore and Dr. Smita Sadar

The author/publisher has attempted to trace and acknowledge the materials reproduced in this publication and apologize if permission and acknowledgements to publish in this form have not been given. If any material has not been acknowledged, please write and let us know so that we may rectify it.

© Weser Books

Edition: 1st

Publication Year: 2022

Pages: 181

ISBN: 978-3-96492-392-9


Book DOI: https://doi.org/10.33545/wb.book.212

Price: € 12






A practical book of pharmaceutical formulation













PHARMACEUTICAL FORMULATIONS (PRACTICAL)

ISBN 978-93-5451-690-0

First Edition

May 2022

Authors

The text of this publication, or any part thereof, should not be reproduced or transmitted in any form or stored in any computer storage system or device for distribution including photocopy, recording, taping or information retrieval system or reproduced on any disc, tape, perforated media or other information storage device etc., without the written permission of Authors with whom the rights are reserved. Breach of this condition is liable for legal action.

Every effort has been made to avoid errors or omissions in this publication. In spite of this, errors may have crept in. Any mistake, error or discrepancy so noted and shall be brought to our notice shall be taken care of in the next edition. It is notified that neither the publisher nor the authors or seller shall be responsible for any damage or loss of action to any one, of any kind, in any manner, therefrom. The reader must cross check all the facts and contents with original Government notification or publications.

Published By NIRALI PRAKASHAN

Abhyudaya Pragati, 1312, Shivaji Nagar, Off J.M. Road, Pune - 411005 Tel - (020) 25512336/37/39

Email: niralipune@pragationline.com

Polyplate

YOGIRAJ PRINTERS AND BINDERS

Survey No. 10/1A, Ghule Industrial Estate Nanded Gaon Road Nanded, Pune - 411041

DISTRIBUTION CENTRES

Nirali Prakashan (For orders outside Pune)

S. No. 28/27, Dhayari Narhe Road, Near Asian College Pune 411041, Maharashtra

Tel: (020) 24690204; Mobile: 9657703143 Email: bookorder@pragationline.com

Nirali Prakashan (For orders within Pune)

119, Budhwar Peth, Jogeshwari Mandir Lane Pune 411002, Maharashtra Tel: (020) 2445 2044; Mobile: 9657703145 Email: niralilocal@pragationline.com

MUMBAI

Rasdhara Co-op. Hsg. Society Ltd., 'D' Wing Ground Floor, 385 S.V.P. Road Girgaum, Mumbai 400004, Maharashtra

BENGALURU

Mobile: 7045821020, Tel: (022) 2385 6339 / 2386 9976 Email: niralimumbai@pragationline.com Dr. Sanjay J. Kahiran ndustan Abdai Ahad

DISTRIBUTION BRANCHES

DELHI Nirali Prakashan

Room No. 2 Ground Floor 4575/15 Omkar Tower, Agarwal Road Darya Ganj, New Delhi 110002 Mobile: 9555778814/9818561840 Email: delhi@niralibooks.com

KOLHAPUR

MINGS

JALGAON

Nirali Prakashan 438/2, Bhosale Plaza, Ground Floor Khasbag, Opp. Balgopal Talim Kolhapur 416 012 Maharashtra Mob: 9850046155 Email: kolhapur@niralibooks.com

Nirali Prakashan Maitri Ground Floor, Jaya

Apartments, No. 99, 6th Cross, 6th Main, Malleswaram, Bengaluru 560003 Karnataka; Mob : 9686821074 Email: bengaluru@niralibooks.com

Nirali Prakashan

34, V. V. Golani Market, Navi Peth, Jalgaon 425001, Maharashtra Tel: (0257) 222 0395 Mob: 94234 91860 Email: jalgaon@niralibooks.com

NAGPUR Nirali Prakashan

Above Maratha Mandir, Shop No. 3, First Floor, Rani Jhanshi Square, Sitabuldi Nagpur 440012 (MAH) Tel: (0712) 254 7129

Email: nagpur@niralibooks.com

SOLAPUR Nirali Prakashan

R-158/2, Avanti Nagar, Near Golden Gate, Pune Naka Chowk Solapur 413001, Maharashtra Mobile 9890918687 Email:solapur@niralibooks.com

marketing@pragationline.com | www.pragationline.com Also find us on f www.facebook.com/niraliboo





| Sr. | List of the Experiment | Page No. |
|-----|---|--------------------|
| No. | Preparation of Salicylic Acid Gel | Maquiactum a |
| 2. | Preparation of Cold Cream | ng amida 3 .d |
| 3. | | d. 6 hemole |
| 4. | Desparation And Evaluation of Arachis Oil Emulsion. | Macture o |
| 5. | Filling of Hard Gelatin Capsules and Evaluation | by Caldiam alu |
| 6. | Evaluation of Marketed Hard Gelatin Capsules | ou exentract. N |
| 7. | Filling and Sealing of Ampoules With Water For Injection | S to helt 20 |
| 8. | Preparation of Uncoated Paracetamol Tablets | reluzg-25 d |
| 9. | Evaluation of Prepared Uncoated Paracetamol Tablets | to nother 32 of |
| 10 | Evaluation of Marketed Paracetamol Tablets | b. Stracid grap |
| 11 | Chterland Enteric Coated Tablets | a. Salloydic acid |
| 12 | Preparation And Evaluation Of Calcium Carbonate (CaCO ₃) Suspension | Manual formulation |
| 13 | t Statishing Cream mean printainsy br | as man bl.46 .c |
| 14 | nd tooth powders. | s at an more 48 J |
| 1 | 5. Sodium Chloride Dextrose Infusion | 50 |
| | *** | |





ABOUT THE AUTHORS



Dr. Sushil Y. Raut, completed his B.Pharm from IPER, Wardha, Maharashtra and M. Pharm (Pharmaceutics) from NET Pharmacy College, Raichur, Karnataka. He has done his full time Ph.D. from Manipal Academy of Higher Education, Karnataka. He has over 12 years of teaching and 8 years of research experience. He has more than 32 research and review publications. His H-index is 11. He has given over 27 national as well as international research presentations. He filed three Indian patents in his credits. He is recipient of international research mobility fellowship to visit Taiwan and Dr. T.M.A. Pai fellowship. He was recipient of many prestigious awards. He guided over

15 postgraduate students. He has expertise in nanotechnology for targeted drug delivery, cosmetics, oral protein and peptide drug delivery. He is member of Maharashtra State Pharmacy Council and Association of Pharmaceutical Teachers of India.



Dr. Praveen D. Chaudhari is currently working as a Principal, Modern College of Pharmacy, Pune. te completed his Ph.D. in the year 2008 preceded by M. Pharm in Pharmaceutics in the year 1996. He has vast teaching and research experience of 24 years with 1.5 years of industrial experience. He guided 14 Ph.D. students and 65 M. Pharm students for their research work. His excellence in research is well recognized by 156 research and review publication, 02 granted and 04 applied patents. He has also published 06 books in the area of Pharmaceutics and Pharmaceutical Quality assurance. He had Fetch research grant of Rs. 34 lakhs from various funding agencies. His

excellence in the teaching and research field is well conferred by 10 national and state level awards, such as Best Principal Award 2017-18 Category – Professional colleges, by Savitribai Phule Pune University, Pune, IDMA Award 2016 For Best Research Paper in Pharmaceutics, Pharma HR Society's Principal of The Year Award 2015 etc. He served as a Dean, Faculty of Pharmaceutical Sciences, Savitribai Phule Pune University. He is currently serving as President, Association of Pharmaceutical Teachers (National), Chairman Board of studies: Pharmaceutics, Member Peer Team, NBA, and member for various statutory bodies at various university/National levels.



Dr. Sanjay J. Kshirsagar is working as Professor and Principal of MET Institute of Pharmacy, Nashik. He did Ph.D. from JNTU Hyderabad. He has more than 20 years of experience in academics and research. He has guided 50 students for M. Pharm and awarded as Best Research Guide by National Level Pharma Innova in 2013 and Pharma Excipients Poster Award from International AG, SCHWEIZ in 2019. Two students have been awarded with Ph.D. from SPPU under his guidance. He is acting as member of Board of Studies in Pharmaceutics of Savitribai Phule Pune University, Pune and Inspector of Pharmacy Council of India, India. He has published more than 160 research and review

articles in well reputed National/International Journals with cumulative impact factor 71. One patent is also on his name which is granted by Indian Patent Office. He is author of 07 books and 04 book-chapters. He has presented more than 20 papers in National and International conferences. He is well known personality in Pharmacy field.



Dr. Hindustan Abdul Ahad is currently working as Professor & Head Dept. of Industrial Pharmacy Director- PG studies Raghavendra Institute of Pharmaceutical Education and Research (RIPER) Ananthapuramu, A. P., INDIA. He is having 20 years of teaching experience. He guided 03 Ph.D. and 94 M. Pharm students and currently 10 PhD scholars are working under his guidance. He is having vast teaching and research experience evidenced by more than 300 research and review publications in various national and international journals. He delivered more than 50 invited sessions in versatile fileds of pharmaceutical sciences. He is also recipient of Best Educationist award-2015 by IIEM- NEW DELHI

niralipune@pragationline.com | www.pragationline.com

Also find us on f www.facebook.com/niralibooks



@nirali.prakashan










Cellular and molecular pharmacology







A Text Book Of

CELLULAR AND MOLECULAR PHARMACOLOGY

As Per PCI Regulations

For M. Pharm: Semester-I

Dr. Padmaja Santosh Kore

M.Pharm, Ph.D. (Pharmacology),
Assistant Professor, Department of Pharmacology,
Progressive Education Society's Modern College of Pharmacy,
Yanunanagar, Nigdi, Pune-411044.

Dr. Subhash Laxman Bodhankar

M.Sc, Ph.D. (Pharmacology),
Professor, Department of Pharmacology,
Bharati Vidyapeeth, Poona College of Pharmacy, Deemed to be University,
Paud Road, Erandwane, Pune-411038.

Price ₹ 300.00



N3763





CELLULAR AND MOLECULAR PHARMACOLOGY

ISBN 978-93-5451-579-8

First Edition

April 2022

The text of this publication, or any part thereof, should not be reproduced or transmitted in any form or stored in any computer storage system or device for distribution including photocopy, recording, taping or information retrieval system or reproduced on any disc, tape, perforated media or other information storage device etc., without the written permission of Authors with whom the rights are reserved. Breach of this condition is liable for legal action.

Every effort has been made to avoid errors or omissions in this publication. In spite of this, errors may have crept in. Any mistake, error or discrepancy so noted and shall be brought to our notice shall be taken care of in the next edition. It is notified that neither the publisher nor the authors or seller shall be responsible for any damage or loss of action to any one, of any kind, in any manner, therefrom. The reader must cross check all the facts and contents with original Government notification or Printed By : publications.

Published By NIRALI PRAKASHAN

Abhyudaya Pragati, 1312, Shivaji Nagar, Off J.M. Road, Pune - 411005 Tel - (020) 25512336/37/39 Email: niralipune@pragationline.com

Polyplate

YOGIRAJ PRINTERS AND BINDERS

Survey No. 10/1A, Ghule Industrial Estate Nanded Gaon Road Nanded, Pune - 411041

DISTRIBUTION CENTRES

Nirali Prakashan (For orders outside Pune)

S. No. 28/27, Dhayari Narhe Road, Near Asian College Pune 411041, Maharashtra Tel: (020) 24690204; Mobile: 9657703143 Email: bookorder@pragationline.com

Nirali Prakashan (For orders within Pune)

119, Budhwar Peth, Jogeshwari Mandir Lane Pune 411002, Maharashtra Tel: (020) 2445 2044; Mobile: 9657703145 Email: niralilocal@pragationline.com

MUMBAI Nirali Prakashan

Rasdhara Co-op. Hsg. Society Ltd., 'D' Wing Ground Floor, 385 S.V.P. Road Girgaum, Mumbai 400004, Maharashtra Mobile: 7045821020, Tel: (022) 2385 6339 / 2386 9976 Email: niralimumbai@pragationline.com

DISTRIBUTION BRANCHES

DELHI Nirali Prakashan

Room No. 2 Ground Floor 4575/15 Omkar Tower, Agarwal Road Darya Ganj, New Delhi 110002 Mobile: 9555778814/9818561840 Email: delhi@niralibooks.com

KOLHAPUR Nirali Prakashan

438/2, Bhosale Plaza, Ground Floor Khasbag, Opp. Balgopal Talim Kolhapur 416 012 Maharashtra Mob: 9850046155 Email: kolhapur@niralibooks.com

BENGALURU Nirali Prakashan

Maitri Ground Floor, Jaya Apartments, No. 99, 6th Cross, 6th Main, Malleswaram, Bengaluru 560003 Karnataka; Mob : 9686821074 Email: bengaluru@niralibooks.com

JALGAON Nirali Prakashan

34, V. V. Golani Market, Navi Peth, Jalgaon 425001, Maharashtra Tel: (0257) 222 0395 Mob: 94234 91860 Email: jalgaon@niralibooks.com

NAGPUR Nirali Prakashan

Above Maratha Mandir, Shop No. 3, First Floor, Rani Jhanshi Square, Sitabuldi Nagpur 440012 (MAH) Tel: (0712) 254 7129 Email: nagpur@niralibooks.com

SOLAPUR Nirali Prakashan

R-158/2, Avanti Nagar, Near Golden Gate, Pune Naka Chowk Solapur 413001, Maharashtra Mobile 9890918687 Email: solapur@niralibooks.com

marketing@pragationline.com | www.pragationline.com

Also find us on f www.facebook.com/niralibooks





| Unit - 1 : Cell Biology | 1.1 - 1.60 |
|---|--|
| Introduction | 1.1 an include a list handbook of |
| 1.1 Cell Organelle | 1.2 |
| 1.2 Structure and Functions of Cell Inclusions | plupari an bana zalayo (100 1.2 |
| 1.3 Genome | mail amount of many limits 1.5 |
| 1.3.1 Genome Investigations | apadipud 1.6 |
| 1.3.2 The Genome Organization | 1.6 |
| 1.3.3 Base Composition within the Genome | 1.7 |
| 1 2 4 Genome Organization Details | AND DESCRIPTION OF THE PARTY OF |
| 2.5 Eurotional Elements and Distribution of DNA within | Time Genome |
| 1.3.6 DNA Elements Required for Replication and Segre | gation of the Genome 1.8 |
| 1.3.7 Unique Sequences | 1.9 |
| 1.3.8 Repetitive Sequences | 1.10 |
| 1.3.9 Chromosomal Structure | IregA tona unintended E - 1.11 |
| 1.3.10 Composition and Structure of Chromatin | 24 AM 1.14 |
| 1.3.11 Chromatin Dynamics | na suprobet venA 1.15 |
| 1.3.12 Chromatin and Histone | 1.16 |
| 1.4 Gene Expression | 1.17 |
| 1.4.1 Transcription | 1.18 |
| 1.4.2 Translation | The state of the s |
| 1.4.3 Processing of the Protein as a Post Translational E | 1.20 |
| 1.5 siRNA (Silencing RNA) | called be paragall one 1.20 |
| 1.5.1 siRNA or Small Interfering RNA: Structure and Fu | (ICHO) |
| 1.5.2 Introduction to RNA management ou | a chimerphases attenting Dr |
| 1.5.3 Details of siRNA | 1.21 |
| 1.5.4 The Function of siRNA | 1.23 |
| 1.5.5 Applications of siRNA | 1.24 |
| 1.5.6 Challenges in the siRNA | 1.25 |
| 1.6 Micro RNA (miRNA) and Gene Regulation | 1.26 |
| 1.6.1 The Functions of miRNA | uninter multiplies (1.27 |
| 1.6.2 Applications of microRNA | ni basu sinamulupi 0201.27 |
| 1.6.3 Difference between siRNA vs miRNA | not anubecong latence at 1.30 |
| 1.6.4 miRNA in Research | nt brusileD to nobusties 1.30 |
| 1.7 Genet Mapping | 1.31 |
| 1.7.1 The Process of Creation of Genetic Map | 1.32 |
| 1.8 DNA Sequencing attenuated work to | 2nousologa one encom |
| 1.8.1 Gene Sequencing Technologies | 1.34 |
| 1.8.2 Applications of DNA Sequencing Technologies | |







| | 1.9 | Cell Cycle | | 1.35 | |
|----|---------|---|-----|--------|--|
| | | 1.9.1 Cell Division | | 1.35 | |
| | | 1.9.2 Phases of Cell Cycle | | 1.36 | |
| | | 1.9.3 Significance of Mitosis | | 1.39 | |
| | 1.10 | Meiosis | | 1.39 | |
| | | 1.10.1 Meiosis-I | | 1.40 | |
| | | 1.10.2 Meiosis-II | | 1.42 | |
| | | 1.10.3 Significance of Meiosis | | 1.43 | |
| | 1.11 | Cell Cycle Regulators | | 1.43 | |
| | | 1.11.1 Cyclins | | 1.43 | |
| | | 1.11.2 Cyclin-Dependent Kinases | | 1.44 | |
| | | 1.11.3 Maturation-Promoting Factor (MPF) | | 1.45 | |
| | | 1.11.4 The Anaphase-Promoting Complex/Cyclosome (APC/C) | | 1.47 | |
| | | 1.11.5 Checkpoints and Regulators | | 1.48 | |
| | 1.12 | Programmed Cell Death | | 1.49 | |
| | | 1.12.1 Events and Regulators | | 1.49 | |
| | | 1.12.2 Apoptosis | | 1.53 | |
| | | 1.12.3 Autophagy | | 1.55 | |
| | | 1.12.4 Necrosis and Autophagy | | 1.56 | |
| | | Exercise Exercise | | 1.56 | |
| Ur | nit - 2 | : Cell Signaling | 2.1 | - 2.36 | |
| | | Introduction Address of Genetic Variation 30A | | 2.1 | |
| | 2.1 | Classification of Cellular Signaling | | 2.3 | |
| | 2.2 | Signaling Receptors | | 2.5 | |
| | 2.3 | Classification of Receptor-Ligand Interaction | | 2.5 | |
| | 2.4 | Overview of Cell Signaling | | 2.7 | |
| | 2.5 | Forms of Signaling in Detail | | 2.8 | |
| | 7.7 | 2.5.1 Paracrine Signaling | | 2.8 | |
| | | 2.5.2 Autocrine Signaling | | 2.9 | |
| | | 2.5.3 Endocrine Signaling | | 2.10 | |
| | | 2.5.4 Signaling Through Cell-Cell Contact | | 2.10 | |
| | 2.6 | Types of Receptors | | 2.11 | |
| | | 2.6.1 Internal Receptors AMO seed box NO of wolf | | 2.11 | |
| | | 2.6.2 Cell-Surface Receptors | | 2.12 | |
| | 2.7 | Secondary Messengers | | 2.18 | |
| | | 2.7.1 Characteristic Features of Secondary Messenger System | | 2.18 | |
| | | 2.7.2 Types of Secondary Messengers | | 2.18 | |
| | 2.8 | Cellular Pathways | | 2.25 | |
| | | 2.8.1 Cycling AMP (cAMP) Signaling Pathway | | 2.25 | |
| | | 2.8.2 MAPK Pathway | | 2.26 | |
| | | 2.8.3 JAK-STAT Pathway | | 2.29 | |
| | • | Exercise | | 2.32 | |







| 3.10 | Various Applications of Recombinant DNA Technology | 3.50 |
|---------|---|------------|
| 3.11 | Gene Therapy | 3.51 |
| | 3.11.1 Gene Transfer Strategies | 3.51 |
| | 3.11.2 Production of Vaccines through rDNA Technology | 3.53 |
| | 3.11.3 Clinical Applications of Gene Therapy | 3.56 |
| 3 12 | Be weet Adverses in Good Thorsey | 3.59 |
| 0 | 2 12 1 Adona Associated Virus (AAV) - A Possible Solution | 3.59 |
| | 3.12.2 Regulated Production of Erythropoietin (EPO) | 3.60 |
| | Exercise | 3.61 |
| -14 - 4 | : Pharmacogenomics | 4.1 - 4.44 |
| 116 | Introduction | 4.1 |
| 4.1 | Gene Mapping and Cloning of Disease Gene | 4.2 |
| 4.1 | | 4.2 |
| | 4.1.1 Gene Mapping 4.1.2 Physical Mapping | 4.4 |
| | 4.1.2 Physical Mapping 4.1.3 Genome Sequencing | 4.4 |
| | 4.1.4 Cloning of a Disease Gene | 4.5 |
| 4.2 | Genetic Variation and its Role in Health/Pharmacology | 4.6 |
| 7.2 | 4.2.1 Mechanisms for Genetic Variation | 4.6 |
| | 4.2.2 Genetic Variation can occur in Three Ways | 4.6 |
| | 4.2.3 Causes of Genetic Variation | 4.6 |
| | 4.2.4 Sources of Genetic Variation | 4.6 |
| | 4.2.5 The Importance of Genetic Variation | 4.7 |
| | 4.2.6 Mechanism of Action of Genetic Variation | 1.8.2 4.7 |
| 4.3 | Genetic Polymorphism Affecting Drug Metabolism | 4.8 |
| 4.4 | Genetic Variation in Drug Transporters | 4.11 |
| 4.5 | Genetic Variations in G-protein Coupled Receptor | 4.12 |
| | 4.5.1 Structure and Functions of GPCRs | 4.14 |
| | 4.5.2 GPCR Coupling to G-proteins and Other Signaling Pathways | 4.14 |
| | 4.5.3 GPCR Binding Pockets | 4.14 |
| | 4.5.4 Spontaneous GPCR Signaling | 4.15 |
| | 4.5.5 Sequence Variations of GPCRs and Associated Diseases | 4.13 |
| | 4.5.6 V2 Vasopressin Receptors | 4.13 |
| 4.6 | Applications of Proteomics Sciences | 4.1 |
| | 4.6.1 Proteomics | 4.1 |
| | 4.6.2 Genomics | 4.20 |
| | 4.6.3 Metabolomics | 4.2 |
| | 4.6.4 Functionomics | 4.2 |
| | | 4.2 |
| 1.7 | 4.6.5 Nutrigenomics | 4.3 |
| 4.7 | Immunotherapeutics | 4.3 |
| | 4.7.1 Types of Immunotherapeutics | 4.3 |
| | 4.7.2 Humanization Antibody Therapy | |
| | 4.7.3 Immunotherapy in Clinical Practice (An Example of Cancer Chen | 4.3 |








| | 5.1 - 5.30 |
|--|------------|
| Unit - 5 : Cell Culture Techniques | 5.1 |
| 1 1 | 5.1 |
| 5.1 Basic Equipments used in Cell Culture Lab | 5.2 |
| 5.1.1 Cell Culture Hood | 5.2 |
| 5.1.2 Incubator | 5.2 |
| 5.1.3 Water Bath | 5.3 |
| 5.1.4 Centrifuge | 5.5 |
| 5 3 5 Pefrigerator or Freezer | 5.5 |
| 5.1.6 Cell Counter | 5.6 |
| 5.1.7 Inverted Microscope | 5.6 |
| 5.1.8 Cryoprservation | 5.7 |
| 5.1.9 Autoclave | 5.8 |
| and the Media | 5.9 |
| 0 11 C lb 10 | 5.12 |
| to dura for Cell Cultures; isolation | 5.17 |
| - was Allia Assess | 5.18 |
| Litatio Assay | 5.20 |
| I B Accord | 5.21 |
| Applications of Flow Cylometry | 5.22 |
| 5 9 1 Flow Cytometer | 5.23 |
| 5.8.2 Applications of Flow Cytometry | 5.24 |
| 5.9 Biosimilars | 5.25 |
| Electrical and analysis of the Control of the Contr | |
| Exercise Support Annual State Control and Contro | G.1 - G.16 |
| Glossary | |
| ELA 3.7.1 Principle and Associated Inc. 4.7.1 Avia | 1.1 - 1.1 |
| | |
| Index Online Asperdix The Index Index | L.1 - L.3 |
| ACAS Beachaophi of the Common | |
| Link References | |
| *** camolodali | |
| | |
| | |





Advances in Pharmaceutical Sciences







Edited Book

ADVANCES IN PHARMACEUTICAL SCIENCES

Editors

Dr. P. Saranraj

Department of Microbiology, Sacred Heart College (Autonomous), Tirupattur - 635 601, Tamil Nadu, India.

Dr. Narayan Dattatraya Totewad

Department of Microbiology, B. K. Birla College of Arts, Science and Commerce (Autonomous), Kalyan West, Kalyan – 421 304, Thane, Maharashtra, India.

Dr. Padmaja Santosh Kore

Department of Pharmacology, Progressive Education Society's Modern College of Pharmacy, Yamunanagar, Nigdi, Pune, Maharashtra, India

Published by



JPS Scientific Publications India

Progressive Education Society's Modern College of Pharmacy, Nigdi, Pune 411044



Copyright@2021 by JPS Scientific Publications. All Rights Reserved

Published by



JPS Scientific Publications, Tamil Nadu, India. E.mail: <u>jpsscientificpublications@gmail.com</u> Website: <u>www.jpsscientificpublications.com</u>

Published in India.

International Standard Book Number (ISBN): 978-81-951323-7-9

No part of this Edited book (E - book) may be reproduced in any form, by photostat, microfilm, xerography, or any other means, or incorporated into any information retrieval system, electronic or mechanical, without the written permission of the publisher. For permission to photocopy or use material electronically from this work, please contact the Book Publisher or Book Editor through the E.mail.

Trademark Notice: Any brand names and product names mentioned in this book are subjected to trademark, brand or patent protection and are trademarks or registered trademarks of their respective holders. The use of brand names, product names, common names, trade names, product description, etc. even without a particular marking in this work is in no way to be constructed to mean that such names may be regarded as unrestricted in respect of trademark and brand protection legislation and could thus be used by anyone.

JPS Scientific Publications also publishes its books in a variety of Electronic formats. Some content that appears in print may not be available in Electronic formats. For more information visit our publication website www.jpsscientificpublications.com



ii






Contents

| Chapter Number | Chapter Title and Authors | Page Number |
|-------------------|--|----------------|
| 1 | Phytate: A Boon to Pharmaceuticals - Suchita Bharambe and Swati Peshwe | 1 - 10 |
| 2 | Pharmacologic Drugs from Natural Sources - Remya Madan Gopal | 11 - 17 |
| 3 | Actinobacteria - A Treasure House of Unexplored Biomolecules - Reshma Ayswaria and Parimala Gnana Soundari Arockiam Jeyasundar | 18 - 37 |
| 4 | Pharmaceutical Components from Marine Flora and Fauna - J. Albino Wins and M. Murugan | 38 - 45 |
| 5 | Ethanobotanical Uses of Swertia chirayita -Abhishek Amit and Ashish Kumar Singh | 46 - 57 |
| 6 | Pharmacological Benefits of <i>Eleutherococcus senticosus</i> - B. Sindhuja, J. Rengaramanujam and J. Devakumar | 58 - 66 |
| 7 | Pharmacological Benefits of <i>Citrus maxima</i> (Burm.) Merr (Pomelo) Fruit Juice - <i>Fathima Nadeer and Jiby Abraham</i> | 67 - 76 |
| 8 | General Properties and Pharmacological Benefits of Syzygium jambos - Devakumar Joseph and Sudha Sivasubramanian | 77 - 83 |
| 9 | Pharmacological Activities of Some Terrestrial Plants and Marine Algae - T. Ramesh, A. Amuthavalli and T. Raajesh Kannan | 84 - 95 |
| 10 | Pharmacological Benefits of Cassia auriculata - A. S. Swarnalakshmi and Manikandan Venkatachalam | 96 - 106 |
| 11 | Exploration of Marine Derived Compounds for Drug Discovery - P. Subavathy and C. Shibana | 107 - 120 |





Therapeutic application of potential herbs Vol-1







Edited Book

THERAPEUTIC APPLICATIONS OF POTENTIAL HERBS

Editors

Dr. P. Saranraj

Department of Microbiology, Sacred Heart College (Autonomous), Tirupattur - 635 601, Tamil Nadu, India.

Dr. Padmaja Santosh Kore

Department of Pharmacology, Progressive Education Society's Modern College of Pharmacy, Yamunanagar, Nigdi, Pune, Maharashtra, India

Dr. Ahmed Omer Mead

Faculty of Medicine, Department of Histology and Embryology, Ondokuz Mayıs University, Samsun, Turkey

Published by



JPS Scientific Publications India






Contents

| Chapter Number | Chapter Title and Authors | Page Number |
|-------------------|--|----------------|
| 1 | Indian Medicinal Plant: Perpetual Keys in Medicinal Field - Tanmay Ghosh | 1 -12 |
| 2 | Therapeutic Properties of Solanum surattense Burm. F - S. Kiruthiga | 13 - 22 |
| 8 | Therapeutic Potential of <i>Mentha</i> sp. with Special Reference to Oral Candidiasis - <i>Pravin Deshmukh, Dnyandev Bhosale and Dhavalsinh Mohite-Patil</i> | 23 - 37 |
| 4 | Therapeutic Applications of Mint and Aloe vera - A. Mohanapriya and M. Ambiga | 38 - 51 |
| 5 | Medicinal Plants of Jharkhand and their Ethnobotanical Uses - Rechel Tirkey and Abhishek Amit | 52 - 60 |
| 6 | Medicinal Applications of Sesbania grandiflora (Agati) and Spinacia oleracea (Spinach) - V. Manikandan and A.S. Swarnalakshmi | 61 - 71 |
| 7 | A Comprehensive Review of Pharmacological Uses of a Few Medicinal Plants from India - <i>Shama Bhat</i> | 72 - 94 |
| 8 | Therapeutic Potential of Shivlingi (<i>Bryonial anciniosa</i>) – <i>Suchita Bharambe</i> | 95 - 100 |
| 9 | Plectranthus amboinicus - A Therapeutically Potential Herb for Ailments - M. S. Sindhu, G. V. Geethamala and M. Poonkothai | 101 - 116 |
| 10 | Burn Wound Management and Wound Healing with Herbals - Neha Ailani and Bela Nabar | 117 - 143 |
| 11 | Therapeutic Applications of Achillea millefolium - B. Sindhuja, J. Rengaramanujam and J. Devakumar | 144 - 149 |





Pharmaceutics - For first year Diploma in pharmacy







| BOOK WITH | I TEACHERS |
|--|--|
| Dr. Pravin Chaudhari M.Pharm.,Ph.D | Dr. Vijay Bhalla M.Pharm.,Ph.D |
| Principal Modern College of Pharmacy, Nigdi, Pune | Dean, Faculty of Pharmacy SGT University Gurugram, Haryana |
| | Dr. Rahul Singh M.Pharm.,Ph.D |
| | Chairman Neelsaroj Institute of Pharmacy, Chikkabanavara, Bangalore - 90 |
| Books Titles by the same Author in Book With Teachers India Private Limited First Year D Pharm | yc 1104 |
| Pharmaceutics Pharmaceutical Chemistry Pharmacognosy Human Anatomy and Physiology Social Pharmacy | Tollege of phase |
| Second Year D Pharm 1. Pharmacology 2. Community Pharmacy & Management 3. Biochemistry & Clinical Pathology 4. Pharmacotherapeutics 5. Hospital and Clinical Pharmacy 6. Pharmacy Law & Ethics | LIBRARY AND THE STREET |
| Salient Features | |
| ☐ Collection of "Core" Content. ☐ Lucid and easy language. ☐ To the point answers in crisp way. | Arm North Story |
| Remembering facts in the simplest way. Infusing confidence in the reader to appear in the reader to a | in the examinations |



Science and technology are constantly changing fields. New research and experience broaden the scope of informotion and knowledge. The author has tried his best in giving information

available to him while preparing the material for this book. Although, all efforts have been made to ensure optimum accuracy of the material, yet

it is quite possible some errors might have been left uncorrected. The publisher, the printer and the author will not be held responsible for any



All rights reserved. The text of this book, or any part thereof, should not be reproduced or transmitted in any form or stored computer storage system or device for distribution including photocopy, recording taping or information retrieval system or reproduced on any disc, tape, perforated media or other information storage device etc. without the written permission of Author, with whom the rights are reserved. Breach of this condition is liable for legal action.

Copyright @ Author and Publisher

Second Edition: 2022 First Edition: 2021

ISBN: 978-81-956362-0-4

Published by

Speakpharma Publication

B - 503 / 504, Vartek Vikas, B Wing, Andheri East, Mumbai, Maharashtra - 400069, India e-mail: speakpharma@gmail.com Contact: +91-9833211888

DISTRIBUTION CENTRES

MUMBAI

Speakpharma Publication 104 - 106, Mini Market Building, B P Road, Bhayandar East, Thane, Maharashtra - 401105 Contact: +91 - 9321037676 Speakpharma Publication B - 503/504, Vartex Vikas, B Wing, Opp. Andheri Railway Station, Andheri East, Mumbai - 400058 Contact: +91 - 9833211888

inadvertent errors or inaccuracies

BANGALORE

Speakpharma Publication, NIP Campus, Beside Pavithra School, Medharhalli, Chikkabanavara, Bangalore - 560090 Contact: +91 - 9833211555

DISTRIBUTION BRANCHES

DELHI

Speakpharma Publication, BWT Distribution Centre, New Delhi Contact: +91 - 8097948105

PUNE

Speakpharma Publication, BWT Distribution Centre, Pune, Maharashtra. Contact: +91 - 9820090466

KOLKATA

Speakpharma Publication, BWT Distribution Centre, Kolkata, West Bengal. Contact: +91 - 7400244113

UTTAR PRADESH

Speakpharma Publication, BWT Distribution Centre, Lucknow, Uttar Pradesh. Contact: +91 - 9833211888

PUNJAB

Speakpharma Publication, BWT Distribution Centre, Punjab Contact : +91 - 8097948104

GUJARAT

eakpharma Publication, BWT Distribution Centre, Gujarat Contact : +91 - 9820078466





PHARMACEUTICS


INDEX

| Ch. No. | NAME OF THE CHAPTER | PAGE No. |
|---------|-------------------------------------|----------|
| 1 | PHARMACY & PHARMACOPOEIA | 04 |
| 2 | PACKAGING MATERIALS | 16 |
| 3 | PHARMACEUTICAL AIDS & PRESERVATIVES | 21 |
| 4 | UNIT OPERATIONS | 26 |
| 5 | DOSAGE FORMS | 54 |
| 6 | PHARMACEUTICAL MANUFACTURING PLANTS | 110 |
| 7 | NOVEL DRUG DELIVERY SYSTEM | 117 |





Chapter 4 A Review on Meta-Analysis of Randomized Controlled Trials on the Clinical Effectiveness and Safety of Remdesivir in Patients with Covid 19 Caused by SARS-COV-2







ADVANCED REVIEW AND RESEARCH IN PHARMACEUTICAL SCIENCE

Volume - 3

Chief Editor

Dr. Chhavi Singla

Professor and Principal, Department of Pharmacy, School of Health Sciences, Sushant University Erstwhile Ansal University, Golf Course Road, Gurgaon, Haryana, India



AkiNik Publications New Delhi





Published By: AkiNik Publications

AkiNik Publications 169, C-11, Sector - 3, Rohini, Delhi-110085, India Toll Free (India) – 18001234070

Chief Editor: Dr. Chhavi Singla

The author/publisher has attempted to trace and acknowledge the materials reproduced in this publication and apologize if permission and acknowledgements to publish in this form have not been given. If any material has not been acknowledged please write and let us know so that we may rectify it

C AkiNik Publications

Publications Year: 2022

Pages: 109

ISBN: 978-93-5570-301-9

Book DOI: https://doi.org/10.22271/ed.book.1782

Price: ₹ 719/-







Contents

| 5. No | Chapters | Page No |
|-------|---|---------|
| 1. | Drug Biotransformation (Dr. R. Margret Chandira and Dr. P. Palanisamy) | 01-27 |
| 2. | Pellets-Technology (Dr. P. Palanisamy and Dr. R. Margret Chandira) | 29-48 |
| 3. | Phytosomes: A Novel Drug Delivery Formulation for Poly Herbal Medicines (M.V. Kumudhavalli, S. Sasiraj, N. Sharmila, R. Shivananthan and M. Kumar) | 49-66 |
| 4. | A Review on Meta-Analysis of Randomized Controlled Trials on the Clinical Effectiveness and Safety of Remdesivis in Patients with Covid 19 Caused by SARS-COV-2 (Mayur S. Tekade and Pallavi M. Patil) | |
| 5. | Emulgel: An Innovative Pharmaceutical Delivery System (Kajal Arvind Pradhan) | 77-86 |
| 6. | Artificial Intelligence in Alzheimer's Disease: A Next Ger Approach (Shikha Saxena, Ramanpreet Walia, Rohan Nagpal and Ankush Singha) | 87-109 |





| 7 | |
|---|--|
| | |
| | |
| | |
| | |
| Chapter - 4 A Review on Meta-Analysis of Randomized | |
| Controlled Trials on the Clinical Effectiveness | |
| and Safety of Remdesivir in Patients with Covid 19 Caused by SARS-COV-2 | |
| 25 044400 5, 51440 00 1 2 | |
| Authors | |
| Mayur S. Tekade Progressive Education Society's Modern College of Pharmacy, | |
| Yamunanagar, Nigdi, Pune, Maharashtra, India | |
| Progressive Education Society's Modern College of Pharmacy, | |
| Yamunanagar, Nigdi, Pune, Maharashtra, India | |
| | |
| | |
| | |
| | |
| | |
| | |
| <u> </u> | |

Page | 67





Chapter - 4

A Review on Meta-Analysis of Randomized Controlled Trials on the Clinical Effectiveness and Safety of Remdesivir in Patients with Covid 19 Caused by SARS-COV-2

Mayur S. Tekade and Pallavi M. Patil

Abstract


To offer updated information on the clinical efficacy of remdesivir in treating coronavirus illness, we conducted a systematic review and network meta-analysis of randomized controlled trials (RCTs) (COVID-19). Relevant articles published up to 18 November 2020 were searched in PubMed, Embase, Cochrane Library, ClinicalTrials.gov, and the WHO International Clinical Trials Registry Platform. With a total of 7324 patients, 52 RCTs were searched and four studies were included in the analysis. Remdesivir has no benefit in terms of mortality when compared to p=0.30, control group (OR=0.92 (95 percent CI 0.79 to 1.07), control group (OR=0.92 (95 percent CI 0.79 to 1.07), control group (OR=0.92 (95 percent CI 0. evidence of moderate grade) Rates that are much higher. Improvement in clinical outcomes (OR=1.52 (95 percent CI 1.24 to 1.87), p0.0001, poor quality) and a shorter time for clinical trials. p=0.0002, improvement (HR=1.28 (95 percent CI 1.12 to 1.46), HR=1.28 (95 percent CI 1.12 to 1.46), with remdesivir, a very low quality) was noticed versus. This is the control group. The chance of death was shown to be significantly reduced. (RR=0.75) of severe adverse events (95 percent CI 0.62 to 0.90), However, no difference was discovered (p=0.0003, low quality); however, no difference was detected (p=0.0003, low quality). In the possibility of respiratory illness. From a cost-benefit standpoint, we believe it should not be recommended for use, particularly in low and moderate-income areas. Countries with a lower middle income. Remdesivir may be useful in COVID-19 patients who are hospitalized in improving early clinical outcomes, lowering early death, and avoiding the use of high-flow supplemental oxygen and invasive mechanical ventilation. Remdesivir was well tolerated as well, with no major SAEs as compared to placebo, however, clinical investigations suggest that constant

Page | 69





Chapter 2 Review on Agrochemicals on Human Bodies"







Advances in Agriculture Sciences

Volume - 37

Chief Editor

Dr. R.K. Naresh

Professor, Department of Agronomy, College of Agriculture, Sardar Vallabhbhai Patel Univ. of Agri & Tech, Meerut, Uttar Pradesh, India



AkiNik Publications New Delhi







Published By: AkiNik Publications

AkiNik Publications 169, C-11, Sector - 3, Rohini, Delhi-110085, India Toll Free (India) – 18001234070 Phone No. – 9711224068, 9911215212 Email – akinikbooks@gmail.com

Chief Editor: Dr. R.K. Naresh

The author/publisher has attempted to trace and acknowledge the materials reproduced in this publication and apologize if permission and acknowledgements to publish in this form have not been given. If any material has not been acknowledged please write and let us know so that we may rectify it.

© AkiNik Publications

Publication Year: 2022

Pages: 86

ISBN:

Book DOI:

Price: ₹ 696/-








Contents

| Cha | apters | Page No |
|-----|---|---------|
| 1. | Physiological Mechanisms of Defoliation in Cotton (Chandrasekaran P, S. Ashok and S. Sampath) | 01-11 |
| 2. | Review on Agrochemicals on Human Bodies (Pallavi M. Patil, Samiksha Agarkar and Mayur S. Tekade) | 13-24 |
| 3. | Modern Approaches in Aflatoxin Free Groundnut Production (Prateem Bishnu, Parijat De, Abid Hayat, Deblina Roy, Soumyajyoti Das and Manab Kanti Mahato) | 25-43 |
| 4. | Maize Diseases and Their Effective Management in India (Dr. Kalpana Yadav and Dr. S. S. Sharma) | 45-58 |
| 5. | Festivals of Flowers: Promoting Floriculture, Eco-Tourism Socio-Economic Upliftment and Flower Conservation in NE India (Tadar Jamja, Ningombam Sushma Devi and Preeti Hatibarua) | 7. |
| 6. | Artificial Screening and Biochemical Studies for Identification of Powdery Mildew Resistant Sources in Sunflower (Helianthus annuus L.) (S. Divya, Dr. E. Jamuna, Dr. Srividya Srinivasan, Dr. M.A. Vennila and Dr. K. Geetha) | 77-86 |









Page | 13





Chapter - 2

Review on Agrochemicals on Human Bodies

Pallavi M. Patil, Samiksha Agarkar and Mayur S. Tekade

Abstract

Using gas chromatography-mass spectrometry, we created a rapid, reliable, and repeatable technique for identifying the urine metabolites of typical pesticides in a single analytical run (GCMS). Colorectal cancer is caused by a variety of environmental and hereditary causes, including pesticides (CRC). The goal of this research was to look at how organochlorine and organophosphorus insecticides might affect CRC patients. Organophosphorus pesticides are linked to illnesses such as cancer according to mounting research. In the province of Mazandaran in northern Iran, pesticides are abused on crops. Selected ion monitoring (SIM) gas chromatography-mass spectrometry was employed to build a method to assess free and total (free and bound) malondialdehyde (MDA) in fresh human plasma or rat liver microsomes. The biological samples and the dideuterated internal standard 3-hydroxy[1,3-2H2]-2-propenal were mixed before analysis (dMDA). Numerous pesticides have established negative effects, some of which could harm the thyroid. Comparatively speaking, very little research has looked into the connection between the risk of thyroid cancer and the presence of pesticide constituents.

Keywords: GC-MS, organophosphorus, ion-monitoring, thyroid, cancer

Introduction

We came up with the conclusion that agrochemicals may contribute to a wide range of cancers using all these cases. To minimise the severity of such pesticides, we examined the agrochemicals using a variety of methods, such as Gas Chromatography-Mass Spectrometry and ion monitoring (SIM). These methods were used to examine a few agricultural pesticides and insecticides in compliance with WHO criteria [1,2].

Case 1:


Gas Chromatography-Mass Spectrometry Analysis of Pyrethroid, Organophosphate, and Carbamate Metabolites in Human Urine (GCMS).

Page | 15





Chapter 7 A Digital Image-Based Colorimetric Technique Use for Quantification of Green Active Pharmaceuticals Obtained from Natural Sources











Chapter

A Digital Image-Based Colorimetric Technique Use for Quantification of Green Active Pharmaceuticals Obtained from Natural Sources

Vitthal V. Chopade and Jayashri V. Chopade

Abstract

Colorimetry is the determination of colors, as name indicates. This method can use for to find out the concentration of compound (solute) in a colored solution in terms of chemical analysis (solvent). We frequently need to quantify the quantity of a specific component in a combination or the concentration of a solution during scientific activity. The trick is to determine the color differences between various combinations and their absolute values. This is more instructive and scientifically valuable than relying on subjective judgments like the color of the solution. Colorimetry is the measurement of colors, as the name implies. It is the measurement of the concentration of a certain compound (solute) in a colored solution in terms of chemical analysis (solvent). We frequently need to quantify the quantity of a specific component in a combination or the concentration of a solution during scientific activity. The trick is to determine the color differences between various combinations and their absolute values. This is more instructive and scientifically valuable than relying on subjective judgments like the color of the solution. Colorimetry is used in a digital image-based (DIB) approach for determining active medicinal components. A computerized scanner with a controlled light intensity was connected to the detector. Different histograms were used to transform the photos. The colorimetric analysis of digital images provided for an easy-to-use and ecologically friendly method.

Keywords: colorimeter, digital image based (DIB) colorimetric analysis, quantification of color, UV-vis spectrophotometer, reflectance spectrophotometer, green active pharmaceuticals

1. Introduction

When a light of occurrence with intensity (Io) passes from a solution, a portion of the light is revealed (Ir), a portion is absorbed (Ia), and the rest is transmitted (It), Thus,

Ir + Ia + It = Io

IntechOpen



Chapter 5 Study on the development and evaluation of novel Modified release prllet-based system for delivery of Desloratidine and Pesudoephedtrine Hydrochloride

Trends in Pharmaceutical Research and Development Vol. 6





ISBN-13 (15) 978-93-90516-38-4 ISBN-13 (15) 978-93-90516-43-8

Editor: Dr. Wagih Mommtaz Ghannam, (Editor)

Professor, Department of General Surgery, Faculty of Medicine, Mansoura University, Egypt.

Publisher: Book Publisher International is an international publishing organization that publishes textbooks, atlases, monographs, e-books, reference books in scientific, technical, and medical areas.

Published : Dec 30,

2020

SKU: TPRD-V6Category: Medical Science Tags: Medical Science, Pharmaceutical





Chapter 5 Print ISBN: 978-93-90516-38-4, eBook ISBN: 978-93-90516-43-8

Study on the Development and Evaluation of a Novel Modified Release Pellet-based System for the Delivery of Desloratadine and Pseudoephedrine Hydrochloride

Sachin U. Kushare Atul A. Phatak and Praveen D. Chaudhari

DOI: 10.9734/bpi/tprd/v6

ABSTRACT

Modified-release multiple unit dosage form (MRMUD) of destoratadine and pseudoephedrine hydrochloride with different release profiles were prepared. The MRMUD system consisting the immediate-release pellets of destoratadine and sustained release pellets of pseudoephedrine employed to optimize the sustained release formulation where in polymer ratio (Ethyl cellulose) (X1) and % polymer coating (X2) were taken as independent variables. Optimization studies were carried out using the Design Expert Software, model dependent (curve fitting) method using the PCP Disso software. The *in vitro* drug release, model dependent (curve fitting) method using the PCP Disso software. The *in vitro* drug release followed Hixson-Crowell model and the drug release mechanism was found to be anomalous or non-fickian type. It was found that proper combination of ethyl cellulose and hydroxy propyl methyl pseudoephedrine hydrochloride for a period of 12 hrs. The statistical approach for formulation responses were in close agreement with the predicted values of the optimized formulations, formulation, the feasibility of the optimization procedure in developing sustained release formulation.

Keywords: MRMUD; designatedine; pseudoephedrine hydrochloride ethyl cellulose; HPMC; solution layering technique.

1. INTRODUCTION

The single-unit oral dosage forms (capsules or tablets) and multiple-unit dosage forms like pelletized dosage forms have closely similar drug release profiles but the pellets offer several added therapeutic advantages [1,2]. The pellets spread uniformly throughout the gastrointestinal tract. They are also found to empty gradually from the stornach with less intra and inter individual variations, thus giving better predictability for an administered dose. In contrast, the gastric emptying of a single unit dosage form is at random and with inherently large inter and intrasubject variations [3]. With the use of pellets, the risk of high local drug concentrations and toxicity associated with the intake of locally restricted tablets can also be avoided [4]. Premature drug release from enteric-coated tablets in the stornach potentially resulting in drug degradation or gastric mucosal irritation, can also be reduced with the coated pellets owing to their rapid transit time. Use of a mixed polymer coating was reported to show improved performance of enteric-coated pellets, in which the ratio of polymers in the mixture was the determining factor for drug release rate [5,6,7,8,9]. The risk of dose dumping from pellets is equally divided, and it is less likely that the pellets are disrupted [10]. Furthermore, modified-release profiles

Department of Pharmaceutics, P. E. Society's Modelin College of Pharmacy, Nigol, Pune-411 044, Maharashtre, India.

**Corresponding author: E-mail: atulapin@yahoo.com; College

College





ACADEMIC YEAR 2020-21


INDEX

| Sr. No. | Title of Books and chapters in edited volumes / Books Published / Conference proceedings | Page No. |
|---------|--|----------|
| | ВООК | |
| 1. | Instrumental Method of Analysis | 257 |
| 2. | Pharmacognosy and Phytochemistry-II | 262 |
| 3. | Lab manual of physical pharmaceutics I&II | 266 |
| 4. | Quality Assurance | 272 |
| 5. | Industrial Pharmacy -I | 274 |
| 6. | Pharmaceutical Validation (M.PHARM) SEM -II | 280 |
| 7. | A textbook of Pharmaceutical Manufacturing technology | 285 |
| 8. | Pharmaceutical Regulatory Science | 289 |
| | BOOK CHAPTERS | |
| 9. | Chapter 1 Origanum Majorana: The Fragrance of Health | 294 |
| 10. | Chapter 2 Piper nigrum (Black pepper): A Flavor for Health | 296 |
| 11. | Chapter 2 Therapeutic Activities of Nutmeg (Myristica fragrance) | 298 |
| 12. | Chapter 10 Nasal bioadhesive drug delivery system and their application | 301 |
| 13. | Chapter 5 Cellulosic material as bioinks for 3D printing applications | 303 |





Instrumental Method of Analysis









B.Pharma, Semester-VII

According to the syllabus based on 'Pharmacy Council of India'

Dr. S. Malathi

M.Pharm, Ph.D. Associate Professor PSG College of Pharmacy, Coimbatore

Dr. Pallavi Mangesh Patil

Ph.D. (Pharmaceutical Chemistry)
Assistant Professor
P.E. Society's Modern College of Pharmacy, Pune

Dr. Sunil Kumar

M.Pharm, MBA, Ph.D. Head of Department and Associate Professor BBDIT College of Pharmacy, Ghaziabad

Books are Available for Online Purchase at: tppl.org.in

Download old Question Papers from: www.questionpaper.org.in



THAKUR PUBLICATION PVT. LTD., LUCKNOW

* Ahmedabad * Bengaluru * Bhopal * Bhubaneswar * Chennai * Dehradun * Ernakulam * Hyderabad * Jaipur * Jalandhar * Kolkata * Nagpur * Patna * Pune * Rohtak *



Instrumental Methods of Analysis Edition 2020

Copyright © All Rights Reserved

This book is sole subject to the condition that it shall not, by way of trade or otherwise, be lent, resold, hired out, or otherwise circulated without the publisher's prior written consent, in any form of binding o cover, other than that in which it is published and without including a similar condition. This condition cover, other than that in which it is published and without limiting the rights under copyright reserved above, no part of this publication may be reproduced, stored in or transmitted in any form or by any means (electronic, mechanical, photocopying, recording or otherwise), without the prior written permission of both the copyright owner and the below mentioned publisher of this book.

Published by:

Thakur Publication Pvt. Ltd.

H.O.-645B/187, Abhishekpuram, Jankipuram Extension, Lucknow-226021

Mob.: 9415584997/98, 9235318591/94/95/96/97/22/17/24.

E-mail: thakurpublication@gmail.com Website: www.tppl.org.in

Our branch office in India:

- Thakur Publication Pvt. Ltd., 9-D, Gali No. 2, Rajendra Nagar, Shambhu Das Gate, Nauchandi, Meerut-250001. Mob. 9235318516, 9457820674.
- Thakur Publication Pvt. Ltd., Plot No. 109, Nava Naksha behind Jaiswal Restaurant, Near Choti Masjid, Nagpur-440017. Mob. 08840084584.
- Thakur Publication Pvt. Ltd., Colony No. 14, Ganesh Nagar Bhopkhel Post, CME Pune-411031. Mob. 09373086387, 9326863355, 9325036341, 9595076005/08.
- Thakur Publication Pvt. Ltd., House No. 46/1309, Kattikaran House, Feroz Gandhi Lane, Vaduthala (Post), Ernakulam, Kerala-682023, Mob. 9207296272, 9207296273, 9207296271.
- Thakur Publication, H.No. 765, Badwale Chamatkareshwar Mahadev Mandir, Godi ki Gali, Maniharon ka Rasta, Kishan Pol Bazar, Jaipur-302003. Mob. 9351193641.
- Maniharon ka Rasta, Kishan Pol Bazar, Japur-302005. Mol. 9331193041.

 Thakur Publication Pvt. Ltd., H.No. 12/14, Sukhram Nagar Society, Opp. Watar Tank, Lane No. 2, Rakhial Road, Gomtipur-Ahmedabad-380021. Mob. 9328829591, 9374374905, 9328622684.

 Thakur Publication, House No. 77-2 RT, Municipal Colony, Near Yashoda Hospital, Malakpet, Hyderabad-500036. Mob. 09396389594, 09391550531, 09346575384.
- Thakur Publication Pvt. Ltd., H.No. 110, Room No. 1, Ahinsa Vihar Colony Ayodhya Bypass Road Bhopal-462022. Mob. 9691717925, 9691717928.
- Thakur Publication Pvt. Ltd., Plot No. 3368/8777, Prachi Vihar, Post- GGP Colony, P.S. Mancheswar, Dist.- Khurda, Bhubaneswar-751025. Mob. 9337585809. Thakur Publication Pvt. Ltd., House No. 1076, Harbans Nagar, Jalandhar-144002. Mob. 9357816968, 8591828212, 8591850332.
- Thakur Publication Pvt. Ltd, House No. 8, Ambu Nagar, Main Road, Goverthanagiri, Avadi, Chennai-600054. Mob. 9543605656, 8144126950, 9543247241, 8124457101, 9543247130.
- Thakur Publication Pvt. Ltd, House No. 12/1, 1st Main Road, Chikkaudigudi, Bengaluru-560029. Mob. 9341835403, 9379798011, 9343859590, 8880441707.
- 13. Thakur Publishers, H.No.34, Ward No. 6, Behind Verma Petrol Pump, Bhiwani Chungi, Rohtak-124001. Mob. 7876991824, 7876991825, 9068601142, 9729004576.
- 14. Thakur Publication Pvt. Ltd, H.No.-1312, Purba Sinthee Road, Fakir Ghosh Lane, Dumdum, Kolkata-700030. Mob. 9337585809.
- 15. Thakur Publication Pvt. Ltd, H.No.-136/1, Shmith Nagar, Prem Nagar, Dehradun-248007, Mob. 7654998799, 9235318594,
- Thakur Publication Pvt. Ltd, Visthan Prince Palace opposite Rajapur, Manapur Masjid, Patna Bihar-800001, Mob. 8957411435/424, 9235318596/22.





| Contents |
|--|
| Chapter 1: UV Visible Spectroscopy |
| 1.1. UV-Visible Spectroscopy |
| 1.1.1. Introduction |
| 1.1.2. Theory |
| 1.1.3. Principle |
| 1.1.4. Electronic Transitions |
| 1.1.5. Chromophores 1.1.6. Auxochromes |
| 1.1.7. Spectral Shifts |
| 1.1.8. Solvent Effect on Absorption Spectra |
| 1.2. Beer & Lambert's Law - Derivation |
| 1.2.1. Introduction |
| 1.2.2. Deviations |
| 1.2.3. Limitations |
| 1.3. Woodward-Fieser Rule |
| 1.3.1. Introduction 1.3.2. Woodward-Fieser Rules for Calculating λ_{max} in Conjugated Dienes, Tr |
| |
| and Polyenes 1.3.3. Woodward-Fieser Rules for α,β-Unsaturated Carbonyl Compounds |
| 1.4. Instrumentation |
| 1.4.1. Introduction |
| 1.4.2. Sources of Radiation |
| 1.4.3. Wavelength Selectors |
| 1.4.4. Sample Cells or Cuvettes |
| 1.4.5. Detectors |
| 1.4.6. Recording System |
| 1.4.7. Power Supply |
| 1.4.8. Single Beam UV Spectrophotometer |
| 1.4.9. Double Beam UV Spectrophotometer 1.4.10. Comparison of Single Beam and Double Beam Spectrophotometers |
| 1.5. Applications |
| 1.5.1. Introduction |
| 1.5.2. Spectrophotometric Titrations |
| 1.5.3. Single Component Analysis Methods |
| 1.5.4. Multicomponent Analysis Methods |
| 1.6. Summary |
| 1.7. Exercise |
| Chapter 2: Fluorimetry |
| 2.1. Fluorimetry |
| 2.1.1. Introduction |
| 2.1.2. Molecular Luminescence |
| 2.1.3. Theory |
| 2.1.4. Concepts of Singlet, Doublet and Triplet Electronic States |
| 2.2. Factors Affecting Fluorescence |
| 2.2.1. Introduction |
| 2.2.2. Structural Factors |
| 2.2.3. Non-Structural Factors |
| 2.2.4. Quantitative Aspects of Fluorescence 2.2.5. Quenching |
| 2.2.5. Quenching |






| 2.3. Instrumentation 2.3.1. Introduction 2.3.2. Light Sources 2.3.3. Monochromators/Filters 2.3.4. Sample Cells/Cuvettes 2.3.5. Detectors 2.3.6. Polarisers 2.3.7. Single Beam Filter Fluorimeter 2.3.8. Double Beam Filter Fluorimeter 2.3.9. Summary 2.6. Exercise Chapter 3: IR Spectroscopy IR Spectroscopy IR Spectroscopy IR Spectroscopy Introduction 3.1.1. Introduction 3.2.2. Fundamental Modes of Vibrations in Polyatomic Molecules 3.2.3. Translational Energy 3.2.4. Rotational Frequencies 3.2.5. Vibrational Energy 3.2.6. Factors Affecting Vibrations 3.3.1. Introduction 3.3.2. Sources of Radiation 3.3.3. Monochromators (Wavelength Selectors) 3.3.4. Sample Cells and Sample Handling 3.3.5. Detectors 3.4. Applications 3.5. Summary 3.6. Exercise Chapter 4: Flame Photometry 3.1.1. Introduction 3.1.2. Theory 3.1.3. Principle 3.1.3. Origin of Spectra 3.1.4. Origin of Spectra 3.1.5. Introduction 3.1.2. Spectral Interferences 3.2.3. Instrumentation 3.3. Introduction 3.4. Signification of Spectra Interferences 3.5. Introduction 3.6. Exercise Chapter 4: Flame Photometry 3.1.1. Introduction 3.2. Spectral Interferences 3.2.1. Introduction 3.2. Introduction 3.2. Introduction Interferences 3.3. Instrumentation 3.4. Introduction 3.5. Introduction Interferences 3.6. Oxide Formation Interferences 3.7. Introduction 3.8. Intrumentation 3.9. Introduction 3.1. Introduction 3.1. Introduction 3.2. Atomisers | | |
|--|--|----------|
| 2.3.1. Introduction 2.3.2. Light Sources 2.3.3. Monochromators/Filters 2.3.4. Sample Cells/Cuvettes 2.3.5. Detectors 2.3.6. Polarisers 2.3.7. Single Beam Filter Fluorimeter 2.3.8. Double Beam Filter Fluorimeter 2.4. Applications 2.5. Summary 2.6. Exercise Chapter 3: IR Spectroscopy 3.1. Introduction 3.1.2. Principle 3.2.1. Introduction 3.2.2. Theory 3.2.3. Translational Energy 3.2.6. Factors Affecting Vibrations in Polyatomic Molecules 3.2.3. Translational Energy 3.2.6. Factors Affecting Vibrations 3.3. Instrumentation 3.3.1. Introduction 3.3.2. Sources of Radiation 3.3.3. Monochromators (Wavelength Selectors) 3.3.4. Sample Cells and Sample Handling 3.3.5. Detectors 3.4. Applications 3.5. Summary 3.6. Exercise Chapter 4: Flame Photometry 4.1.1. Introduction 4.1.2. Plame Photometry 4.1.3. Principle 4.1.4. Origin of Spectra 4.2. Interferences 4.2.1. Introduction 4.2.2. Spectral Interferences 4.2.3. Ionisation Interferences 4.2.4. Cation-Anion Interferences 4.2.5. Cacino-Cation Interferences 4.2.6. Oxide Formation Interferences 4.3. Instrumentation 4.3.1. Introduction 4.3.2. Atomisers | -9- | |
| 2.3.1. Light Sources 2.3.3. Monochromators/Filters 2.3.4. Sample Cells/Cuvettes 2.3.5. Detectors 2.3.6. Polarisers 2.3.7. Double Beam Filter Fluorimeter 2.3.8. Double Beam Filter Fluorimeter 2.4. Applications 2.5. Summary 2.6. Exercise Chapter 3: IR Spectroscopy 3.1. IR Spectroscopy 3.1. IR Spectroscopy 3.1. Introduction 3.1.2. Principle 3.2. Theory 3.2.1. Introduction 3.2.2. Fundamental Modes of Vibrations in Polyatomic Molecules 3.2.3. Translational Energy 3.2.4. Rotational Frequencies 3.2.5. Vibrational Energy 3.2.6. Factors Affecting Vibrations 3.3.1. Introduction 3.3.1. Introduction 3.3.3. Monochromators (Wavelength Selectors) 3.3.3. Sample Cells and Sample Handling 3.3.3. Detectors 3.3.4. Applications 3.5. Summary 3.6. Exercise Chapter 4: Flame Photometry 4.1.1. Introduction 4.1.2. Theory 4.1.1. Introduction 4.1.2. Theory 4.1.3. Principle 4.1.4. Origin of Spectra 4.2. Interferences 4.2.1. Introduction 4.2.2. Spectral Interferences 4.2.3. Ionisation Interferences 4.2.4. Cation-Anion Interferences 4.2.5. Cacion-Cation Interferences 4.2.6. Oxide Formation Interferences 4.2.7. Introduction 4.3.1. Introduction 4.3.1. Introduction 4.3.2. Atomisers | on | 71 |
| Applications Sources of Radiation Sources of Radiation Sources of Radiation Sources of Radiation Applications Summary Less order of Sources Chapter 3: IR Spectroscopy Introduction Translational Energy Substitutional Energy Energy Flame Photometry Introduction Substitutional Energy Later Substitution En | | 71 |
| Applications Sources of Radiation Sources of Radiation Sources of Radiation Sources of Radiation Applications Summary Less order of Sources Chapter 3: IR Spectroscopy Introduction Translational Energy Substitutional Energy Energy Flame Photometry Introduction Substitutional Energy Later Substitution En | | 71 |
| 2.3.6. Polarisers 2.3.7. Single Beam Filter Fluorimeter 2.3.8. Double Beam Filter Fluorimeter 2.4. Applications 2.5. Summary 2.6. Exercise Chapter 3: IR Spectroscopy 3.1.1. Introduction 3.1.2. Principle 3.2. Theory 3.2.1. Introduction 3.2.2. Fundamental Modes of Vibrations in Polyatomic Molecules 3.2.3. Translational Energy 3.2.4. Rotational Energy 3.2.5. Vibrational Energy 3.2.6. Factors Affecting Vibrations 3.3.1. Introduction 3.3.3. Instrumentation 3.3.1. Introduction 3.3.3. Monochromators (Wavelength Selectors) 3.3.4. Sample Cells and Sample Handling 3.3.5. Detectors 4.5. Summary 3.6. Exercise Chapter 4: Flame Photometry 4.1.1. Introduction 4.1.2. Theory 4.1.3. Principle 4.1.4. Origin of Spectra 4.1.1. Introduction 4.2.2. Spectral Interferences 4.2.1. Introduction 4.2.2. Spectral Interferences 4.2.3. Jonisation Interferences 4.2.4. Cation-Anion Interferences 4.2.5. Cation-Cation Interferences 4.2.6. Oxide Formation Interferences 4.2.7. Introduction 4.3.8. Intrumentation 4.3.9. Atomisers | rs/Filters | 72 |
| 2.3.6. Polarisers 2.3.7. Single Beam Filter Fluorimeter 2.3.8. Double Beam Filter Fluorimeter 2.4. Applications 2.5. Summary 2.6. Exercise Chapter 3: IR Spectroscopy 3.1.1. Introduction 3.1.2. Principle 3.2. Theory 3.2.1. Introduction 3.2.2. Fundamental Modes of Vibrations in Polyatomic Molecules 3.2.3. Translational Energy 3.2.4. Rotational Energy 3.2.5. Vibrational Energy 3.2.6. Factors Affecting Vibrations 3.3.1. Introduction 3.3.3. Instrumentation 3.3.1. Introduction 3.3.3. Monochromators (Wavelength Selectors) 3.3.4. Sample Cells and Sample Handling 3.3.5. Detectors 4.5. Summary 3.6. Exercise Chapter 4: Flame Photometry 4.1.1. Introduction 4.1.2. Theory 4.1.3. Principle 4.1.4. Origin of Spectra 4.1.1. Introduction 4.2.2. Spectral Interferences 4.2.1. Introduction 4.2.2. Spectral Interferences 4.2.3. Jonisation Interferences 4.2.4. Cation-Anion Interferences 4.2.5. Cation-Cation Interferences 4.2.6. Oxide Formation Interferences 4.2.7. Introduction 4.3.8. Intrumentation 4.3.9. Atomisers | luvettes | 72 |
| 2.3.7. Single Beam Filter Fluorimeter 2.3.8. Applications 2.5. Summary 2.6. Exercise Chapter 3: IR Spectroscopy 3.1. IR Spectroscopy 3.1.1. Introduction 3.1.2. Principle 3.2. Theory 3.2.1. Introduction 3.2.2. Fundamental Modes of Vibrations in Polyatomic Molecules 3.2.3. Translational Energy 3.2.4. Rotational Energy 3.2.5. Vibrational Energy 3.2.6. Factors Affecting Vibrations 3.3.1. Introduction 3.3.1. Introduction 3.3.3. Monochromators (Wavelength Selectors) 3.3.4. Sample Cells and Sample Handling 3.3.5. Detectors 4.3.5. Summary 3.6. Exercise Chapter 4: Flame Photometry 4.1.1. Introduction 4.1.2. Theory 4.1.3. Principle 4.1.4. Origin of Spectra 4.1.5. Introduction 4.2.1. Introduction 5. Spectral Interferences 4.2.1. Introduction 5. Spectral Interferences 4.2.1. Introduction 5. Spectral Interferences 6. Cation-Anion Interferences 6. Cation-Cation Interferences 6. Cation-Cation Interferences 6. Cation-Cation Interferences 7. Introduction Interferences 7. Introduction Interferences 7. Cation-Cation Interfer | | 73 |
| Chapter 3: IR Spectroscopy 3.1.1. IR Spectroscopy 3.1.2. Principle 3.2.2. Theory 3.2.3. Translational Energy 3.2.4. Rotational Energy 3.2.5. Vibrational Energy 3.2.6. Factors Affecting Vibrations 3.3. Instrumentation 3.3.1. Introduction 3.3.2. Sources of Radiation 3.3.3. Monochromators (Wavelength Selectors) 3.3.4. Applications 3.3.5. Detectors 3.4. Applications 3.5. Summary 3.6. Exercise Chapter 4: Flame Photometry 4.1.1. Introduction 4.1.2. Theory 4.1.3. Principle 4.1.4. Origin of Spectra 4.1.5. Interferences 4.2.1. Introduction 4.2.2. Spectral Interferences 4.2.3. Introduction 4.2.2. Spectral Interferences 4.2.3. Introduction 4.2.4. Cation-Anion Interferences 4.2.5. Cation-Cation Interferences 4.2.6. Oxide Formation Interferences 4.2.7. Introduction 4.3.8. Instrumentation 4.3.9. Introduction Interferences 4.2.1. Introduction Interferences 4.2.2. Cation-Cation Interferences 4.2.3. Introduction Interferences 4.2.4. Cation-Anion Interferences 4.2.5. Cation-Cation Interferences 4.2.6. Oxide Formation Interferences 4.3.1. Introduction 4.3.2. Atomisers | | 73 |
| Chapter 3: IR Spectroscopy 3.1.1. IR Spectroscopy 3.1.2. Principle 3.2.2. Theory 3.2.3. Translational Energy 3.2.4. Rotational Energy 3.2.5. Vibrational Energy 3.2.6. Factors Affecting Vibrations 3.3. Instrumentation 3.3.1. Introduction 3.3.2. Sources of Radiation 3.3.3. Monochromators (Wavelength Selectors) 3.3.4. Applications 3.3.5. Detectors 3.4. Applications 3.5. Summary 3.6. Exercise Chapter 4: Flame Photometry 4.1.1. Introduction 4.1.2. Theory 4.1.3. Principle 4.1.4. Origin of Spectra 4.1.5. Interferences 4.2.1. Introduction 4.2.2. Spectral Interferences 4.2.3. Introduction 4.2.2. Spectral Interferences 4.2.3. Introduction 4.2.4. Cation-Anion Interferences 4.2.5. Cation-Cation Interferences 4.2.6. Oxide Formation Interferences 4.2.7. Introduction 4.3.8. Instrumentation 4.3.9. Introduction Interferences 4.2.1. Introduction Interferences 4.2.2. Cation-Cation Interferences 4.2.3. Introduction Interferences 4.2.4. Cation-Anion Interferences 4.2.5. Cation-Cation Interferences 4.2.6. Oxide Formation Interferences 4.3.1. Introduction 4.3.2. Atomisers | lter Fluorimeter | 73 |
| Chapter 3: IR Spectroscopy 3.1.1. IR Spectroscopy 3.1.2. Principle 3.2.2. Theory 3.2.3. Translational Energy 3.2.4. Rotational Energy 3.2.5. Vibrational Energy 3.2.6. Factors Affecting Vibrations 3.3. Instrumentation 3.3.1. Introduction 3.3.2. Sources of Radiation 3.3.3. Monochromators (Wavelength Selectors) 3.3.4. Applications 3.3.5. Detectors 3.4. Applications 3.5. Summary 3.6. Exercise Chapter 4: Flame Photometry 4.1.1. Introduction 4.1.2. Theory 4.1.3. Principle 4.1.4. Origin of Spectra 4.1.5. Interferences 4.2.1. Introduction 4.2.2. Spectral Interferences 4.2.3. Introduction 4.2.2. Spectral Interferences 4.2.3. Introduction 4.2.4. Cation-Anion Interferences 4.2.5. Cation-Cation Interferences 4.2.6. Oxide Formation Interferences 4.2.7. Introduction 4.3.8. Instrumentation 4.3.9. Introduction Interferences 4.2.1. Introduction Interferences 4.2.2. Cation-Cation Interferences 4.2.3. Introduction Interferences 4.2.4. Cation-Anion Interferences 4.2.5. Cation-Cation Interferences 4.2.6. Oxide Formation Interferences 4.3.1. Introduction 4.3.2. Atomisers | Filter Fluorimeter | 74 |
| Chapter 3: IR Spectroscopy 3.1.1. Introduction 3.1.2. Principle 3.2.2. Theory 3.2.1. Introduction 3.2.2. Fundamental Modes of Vibrations in Polyatomic Molecules 3.2.3. Translational Energy 3.2.4. Rotational Frequencies 3.2.5. Vibrational Energy 3.2.6. Factors Affecting Vibrations 3.3. Instrumentation 3.3.1. Introduction 3.3.2. Sources of Radiation 3.3.3. Monochromators (Wavelength Selectors) 3.3.4. Sample Cells and Sample Handling 3.3.5. Detectors 3.5. Summary 3.6. Exercise Chapter 4: Flame Photometry 4.1. Introduction 4.1.2. Theory 4.1.1. Introduction 4.1.2. Theory 4.1.3. Origin of Spectra 4.2. Interferences 4.2.1. Introduction 4.2.2. Spectral Interferences 4.2.3. Ionisation Interferences 4.2.4. Cation-Anion Interferences 4.2.5. Cation-Cation Interferences 4.2.6. Oxide Formation Interferences 4.3.7. Introduction 4.3.8. Intrumentation 4.3.1. Introduction 4.3.1. Introduction 4.3.2. Intrumentation 4.3.3.1. Introduction 4.3.4. Intrumentation 4.3.5. Instrumentation 4.3.5. Intrumentation 4.3.6. Intrumentation 4.3.7. Atomisers | | 75 |
| Chapter 3: IR Spectroscopy 3.1.1. Introduction 3.1.2. Principle 3.2.1. Introduction 3.2.2. Fundamental Modes of Vibrations in Polyatomic Molecules 3.2.3. Translational Energy 3.2.4. Rotational Frequencies 3.2.5. Vibrational Energy 3.2.6. Factors Affecting Vibrations 3.3.1. Introduction 3.3.2. Sources of Radiation 3.3.3. Monochromators (Wavelength Selectors) 3.3.4. Sample Cells and Sample Handling 3.3.5. Detectors 3.4. Applications 3.5. Summary 3.6. Exercise Chapter 4: Flame Photometry 4.1.1. Introduction 4.1.2. Theory 4.1.3. Principle 4.1.4. Origin of Spectra 4.1.4. Origin of Spectra 4.1.5. Interferences 4.2.1. Introduction 4.2.2. Spectral Interferences 4.2.3. Ionisation Interferences 4.2.4. Cation-Anion Interferences 4.2.5. Cation-Cation Interferences 4.2.6. Oxide Formation Interferences 4.3.1. Introduction 4.3.1. Introduction 4.3.2. Atomisers | | 77 |
| 3.1.1. Introduction 3.1.2. Principle 3.2. Theory 3.2.1. Introduction 3.2.2. Fundamental Modes of Vibrations in Polyatomic Molecules 3.2.3. Translational Energy 3.2.4. Rotational Energy 3.2.5. Vibrational Energy 3.2.6. Factors Affecting Vibrations 3.3.1. Introduction 3.3.1. Introduction 3.3.2. Sources of Radiation 3.3.3. Monochromators (Wavelength Selectors) 3.3.4. Applications 3.3.5. Detectors 3.4. Applications 3.5. Summary 3.6. Exercise Chapter 4: Flame Photometry 4.1.1. Introduction 4.1.2. Theory 4.1.1.3. Principle 4.1.4. Origin of Spectra 4.2.1. Introduction 4.2.2. Introduction 4.2.3. Ionisation Interferences 4.2.4. Cation-Anion Interferences 4.2.5. Cation-Cation Interferences 4.2.6. Oxide Formation Interferences 4.3.1. Introduction 4.3.1. Introduction 4.3.2. Atomisers | | 78 |
| 3.1.1. Introduction 3.1.2. Principle 3.2. Theory 3.2.1. Introduction 3.2.2. Fundamental Modes of Vibrations in Polyatomic Molecules 3.2.3. Translational Energy 3.2.4. Rotational Energy 3.2.5. Vibrational Energy 3.2.6. Factors Affecting Vibrations 3.3.1. Introduction 3.3.1. Introduction 3.3.2. Sources of Radiation 3.3.3. Monochromators (Wavelength Selectors) 3.3.4. Applications 3.3.5. Detectors 3.4. Applications 3.5. Summary 3.6. Exercise Chapter 4: Flame Photometry 4.1.1. Introduction 4.1.2. Theory 4.1.1.3. Principle 4.1.4. Origin of Spectra 4.2.1. Introduction 4.2.2. Introduction 4.2.3. Ionisation Interferences 4.2.4. Cation-Anion Interferences 4.2.5. Cation-Cation Interferences 4.2.6. Oxide Formation Interferences 4.3.1. Introduction 4.3.1. Introduction 4.3.2. Atomisers | Chapter 2. ID Speetweener | |
| 3.1.1. Introduction 3.1.2. Principle 3.2. Theory 3.2.1. Introduction 3.2.2. Fundamental Modes of Vibrations in Polyatomic Molecules 3.2.3. Translational Energy 3.2.4. Rotational Energy 3.2.5. Vibrational Energy 3.2.6. Factors Affecting Vibrations 3.3.1. Introduction 3.3.1. Introduction 3.3.2. Sources of Radiation 3.3.3. Monochromators (Wavelength Selectors) 3.3.4. Applications 3.3.5. Detectors 3.4. Applications 3.5. Summary 3.6. Exercise Chapter 4: Flame Photometry 4.1.1. Introduction 4.1.2. Theory 4.1.1.3. Principle 4.1.4. Origin of Spectra 4.2.1. Introduction 4.2.2. Introduction 4.2.3. Ionisation Interferences 4.2.4. Cation-Anion Interferences 4.2.5. Cation-Cation Interferences 4.2.6. Oxide Formation Interferences 4.3.1. Introduction 4.3.1. Introduction 4.3.2. Atomisers | Chapter 3: 1K Spectroscopy | |
| Theory 3.2.1. Introduction 3.2.2. Fundamental Modes of Vibrations in Polyatomic Molecules 3.2.3. Translational Energy 3.2.4. Rotational Frequencies 3.2.5. Vibrational Energy 3.2.6. Factors Affecting Vibrations 3.3.1. Introduction 3.3.2. Sources of Radiation 3.3.3. Monochromators (Wavelength Selectors) 3.3.4. Sample Cells and Sample Handling 3.3.5. Detectors 3.4. Applications 3.5. Summary 3.6. Exercise Chapter 4: Flame Photometry 4.1. Introduction 4.1.2. Theory 4.1.3. Principle 4.1.4. Origin of Spectra 4.2.1. Interferences 4.2.1. Interferences 4.2.2. Spectral Interferences 4.2.3. Ionisation Interferences 4.2.4. Cation-Anion Interferences 4.2.5. Cation-Cation Interferences 4.2.6. Oxide Formation Interferences 4.3. Instrumentation 4.3.1. Introduction 4.3.2. Atomisers | N A STATE OF THE S | 80 |
| Theory 3.2.1. Introduction 3.2.2. Fundamental Modes of Vibrations in Polyatomic Molecules 3.2.3. Translational Energy 3.2.4. Rotational Frequencies 3.2.5. Vibrational Energy 3.2.6. Factors Affecting Vibrations 3.3.1. Introduction 3.3.2. Sources of Radiation 3.3.3. Monochromators (Wavelength Selectors) 3.3.4. Sample Cells and Sample Handling 3.3.5. Detectors 3.4. Applications 3.5. Summary 3.6. Exercise Chapter 4: Flame Photometry 4.1. Introduction 4.1.2. Theory 4.1.3. Principle 4.1.4. Origin of Spectra 4.2.1. Interferences 4.2.1. Interferences 4.2.2. Spectral Interferences 4.2.3. Ionisation Interferences 4.2.4. Cation-Anion Interferences 4.2.5. Cation-Cation Interferences 4.2.6. Oxide Formation Interferences 4.3. Instrumentation 4.3.1. Introduction 4.3.2. Atomisers | Cit. mic. al. liniest expineds | 80 |
| 3.2.2. Fundamental Modes of Vibrations in Polyatomic Molecules 3.2.3. Translational Energy 3.2.4. Rotational Frequencies 3.2.5. Vibrational Energy 3.2.6. Factors Affecting Vibrations 3.3.1. Introduction 3.3.2. Sources of Radiation 3.3.3. Monochromators (Wavelength Selectors) 3.3.4. Sample Cells and Sample Handling 3.3.5. Detectors 3.4. Applications 3.5. Summary 3.6. Exercise Chapter 4: Flame Photometry 4.1.1. Introduction 4.1.2. Theory 4.1.3. Principle 4.1.4. Origin of Spectra 4.2.1. Introduction 4.2.2. Interferences 4.2.3. Ionisation Interferences 4.2.4. Cation-Anion Interferences 4.2.5. Cation-Cation Interferences 4.2.6. Oxide Formation Interferences 4.3.1. Introduction 4.3.2. Atomisers | | 81 |
| 3.2.2. Fundamental Modes of Vibrations in Polyatomic Molecules 3.2.3. Translational Energy 3.2.4. Rotational Frequencies 3.2.5. Vibrational Energy 3.2.6. Factors Affecting Vibrations 3.3.1. Introduction 3.3.2. Sources of Radiation 3.3.3. Monochromators (Wavelength Selectors) 3.3.4. Sample Cells and Sample Handling 3.3.5. Detectors 3.4. Applications 3.5. Summary 3.6. Exercise Chapter 4: Flame Photometry 4.1.1. Introduction 4.1.2. Theory 4.1.3. Principle 4.1.4. Origin of Spectra 4.2.1. Introduction 4.2.2. Interferences 4.2.3. Ionisation Interferences 4.2.4. Cation-Anion Interferences 4.2.5. Cation-Cation Interferences 4.2.6. Oxide Formation Interferences 4.3.1. Introduction 4.3.2. Atomisers | | 83 83 |
| 3.2.3. Translational Energy 3.2.4. Rotational Frequencies 3.2.5. Vibrational Energy 3.2.6. Factors Affecting Vibrations 3.3.1. Introduction 3.3.2. Sources of Radiation 3.3.3. Monochromators (Wavelength Selectors) 3.3.4. Sample Cells and Sample Handling 3.3.5. Detectors 3.4. Applications 3.5. Summary 3.6. Exercise Chapter 4: Flame Photometry 4.1.1. Introduction 4.1.2. Theory 4.1.3. Principle 4.1.4. Origin of Spectra 4.2.1. Interferences 4.2.1. Introduction 4.2.2. Spectral Interferences 4.2.3. Ionisation Interferences 4.2.4. Cation-Anion Interferences 4.2.5. Cation-Cation Interferences 4.2.6. Oxide Formation Interferences 4.3.1. Introduction 4.3.1. Introduction 4.3.2. Atomisers | | 83 |
| 3.2.4. Rotational Frequencies 3.2.5. Vibrational Energy 3.2.6. Factors Affecting Vibrations 3.3.1. Introduction 3.3.2. Sources of Radiation 3.3.3. Monochromators (Wavelength Selectors) 3.3.4. Sample Cells and Sample Handling 3.3.5. Detectors 3.4. Applications 3.5. Summary 3.6. Exercise Chapter 4: Flame Photometry 4.1.1. Introduction 4.1.2. Theory 4.1.3. Principle 4.1.4. Origin of Spectra 4.2.1. Interferences 4.2.1. Introduction 4.2.2. Spectral Interferences 4.2.3. Ionisation Interferences 4.2.4. Cation-Anion Interferences 4.2.5. Cation-Cation Interferences 4.2.6. Oxide Formation Interferences 4.3.1. Introduction 4.3.2. Atomisers | nergy | |
| Jacob Salva Sample Cells and Sample Handling Jacob Sources of Radiation Jacob Sample Cells and Sample Handling Jacob Sources of Radiation Jacob Sample Cells and Sample Handling Jacob Sources of Radiation Jacob Sample Cells and Sample Handling Jacob Sources Chapter 4: Flame Photometry Lintroduction Jensies Sources Chapter 4: Flame Photometry Lintroduction Jensies Sources Chapter 4: Flame Photometry Lintroduction Jensies Sources Linterferences Jensies Sources Jensies Sour | uencies | 85 86 |
| 3.2.6. Factors Affecting Vibrations 3.3.1. Introduction 3.3.2. Sources of Radiation 3.3.3. Monochromators (Wavelength Selectors) 3.3.4. Sample Cells and Sample Handling 3.3.5. Detectors 3.4. Applications 3.5. Summary 5.6. Exercise Chapter 4: Flame Photometry 4.1.1. Introduction 4.1.2. Theory 4.1.3. Principle 4.1.4. Origin of Spectra 4.2.1. Interferences 4.2.1. Interferences 4.2.2. Spectral Interferences 4.2.3. Ionisation Interferences 4.2.4. Cation-Anion Interferences 4.2.5. Cation-Cation Interferences 4.2.6. Oxide Formation Interferences 4.3.1. Introduction 4.3.2. Atomisers | ray | 86 |
| 3.3.3. Monochromators (Wavelength Selectors) 3.3.4. Sample Cells and Sample Handling 3.3.5. Detectors 3.6. Applications 3.6. Exercise Chapter 4: Flame Photometry 4.1.1. Introduction 4.1.2. Theory 4.1.3. Principle 4.1.4. Origin of Spectra 4.2.1. Interferences 4.2.1. Interferences 4.2.2. Spectral Interferences 4.2.3. Ionisation Interferences 4.2.4. Cation-Anion Interferences 4.2.5. Cation-Cation Interferences 4.2.6. Oxide Formation Interferences 4.3. Instrumentation 4.3. Introduction 4.3. Atomisers | g Vibrations | 87 |
| 3.3.3. Monochromators (Wavelength Selectors) 3.3.4. Sample Cells and Sample Handling 3.3.5. Detectors 3.6. Applications 3.6. Exercise Chapter 4: Flame Photometry 4.1.1. Introduction 4.1.2. Theory 4.1.3. Principle 4.1.4. Origin of Spectra 4.2.1. Interferences 4.2.1. Interferences 4.2.2. Spectral Interferences 4.2.3. Ionisation Interferences 4.2.4. Cation-Anion Interferences 4.2.5. Cation-Cation Interferences 4.2.6. Oxide Formation Interferences 4.3. Instrumentation 4.3. Introduction 4.3. Atomisers | on | 90 |
| 3.3.3. Monochromators (Wavelength Selectors) 3.3.4. Sample Cells and Sample Handling 3.3.5. Detectors 3.6. Applications 3.6. Exercise Chapter 4: Flame Photometry 4.1.1. Introduction 4.1.2. Theory 4.1.3. Principle 4.1.4. Origin of Spectra 4.2.1. Interferences 4.2.1. Interferences 4.2.2. Spectral Interferences 4.2.3. Ionisation Interferences 4.2.4. Cation-Anion Interferences 4.2.5. Cation-Cation Interferences 4.2.6. Oxide Formation Interferences 4.3. Instrumentation 4.3. Introduction 4.3. Atomisers | " Registration of the second control of the | 90 |
| Chapter 4: Flame Photometry Introduction Introduction Interferences Interferences Introduction Interferences Introduction Interferences Interference | iation | 91 |
| Chapter 4: Flame Photometry Introduction Introduction Interferences Interferences Introduction Interferences Introduction Interferences Interference | rs (Wavelength Selectors) | 91 |
| Chapter 4: Flame Photometry Introduction Introduction Interferences Interferences Introduction Interferences Introduction Interferences Interference | nd Sample Handling | 93 |
| Chapter 4: Flame Photometry Introduction Introduction Interferences Interferences Introduction Interferences Introduction Interferences Interference | id bample Handing | 95 |
| Chapter 4: Flame Photometry 4.1. Flame Photometry 4.1.1. Introduction 4.1.2. Theory 4.1.3. Principle 4.1.4. Origin of Spectra 4.2.1. Interferences 4.2.1. Interferences 4.2.2. Spectral Interferences 4.2.3. Ionisation Interferences 4.2.4. Cation-Anion Interferences 4.2.5. Cation-Cation Interferences 4.2.6. Oxide Formation Interferences 4.3. Instrumentation 4.3. Introduction 4.3. Atomisers | | 96 |
| Chapter 4: Flame Photometry Introduction Introduction Introduction Compared to the principle Comp | | 98 |
| Chapter 4: Flame Photometry 4.1. Flame Photometry 4.1.1. Introduction 4.1.2. Theory 4.1.3. Principle 4.1.4. Origin of Spectra 4.2. Interferences 4.2.1. Introduction 4.2.2. Spectral Interferences 4.2.3. Ionisation Interferences 4.2.4. Cation-Anion Interferences 4.2.5. Cation-Cation Interferences 4.2.6. Oxide Formation Interferences 4.3. Instrumentation 4.3. Introduction 4.3. Atomisers | | 99 |
| 4.1. Flame Photometry 4.1.1. Introduction 4.1.2. Theory 4.1.3. Principle 4.1.4. Origin of Spectra 4.2.1. Introduction 4.2.2. Introduction 4.2.2. Spectral Interferences 4.2.3. Ionisation Interferences 4.2.4. Cation-Anion Interferences 4.2.5. Cation-Cation Interferences 4.2.6. Oxide Formation Interferences 4.3. Instrumentation 4.3.1. Introduction 4.3.2. Atomisers | | |
| 4.1.4. Origin of Spectra 4.2. Interferences 4.2.1. Introduction 4.2.2. Spectral Interferences 4.2.3. Ionisation Interferences 4.2.4. Cation-Anion Interferences 4.2.5. Cation-Cation Interferences 4.2.6. Oxide Formation Interferences 4.3. Instrumentation 4.3.1. Introduction 4.3.2. Atomisers | Chapter 4: Flame Photometry | |
| 4.1.4. Origin of Spectra 4.2. Interferences 4.2.1. Introduction 4.2.2. Spectral Interferences 4.2.3. Ionisation Interferences 4.2.4. Cation-Anion Interferences 4.2.5. Cation-Cation Interferences 4.2.6. Oxide Formation Interferences 4.3. Instrumentation 4.3.1. Introduction 4.3.2. Atomisers | etry and the state of the state | 10 |
| 4.1.4. Origin of Spectra 4.2. Interferences 4.2.1. Introduction 4.2.2. Spectral Interferences 4.2.3. Ionisation Interferences 4.2.4. Cation-Anion Interferences 4.2.5. Cation-Cation Interferences 4.2.6. Oxide Formation Interferences 4.3. Instrumentation 4.3.1. Introduction 4.3.2. Atomisers | | 10 |
| 4.1.4. Origin of Spectra 4.2. Interferences 4.2.1. Introduction 4.2.2. Spectral Interferences 4.2.3. Ionisation Interferences 4.2.4. Cation-Anion Interferences 4.2.5. Cation-Cation Interferences 4.2.6. Oxide Formation Interferences 4.3. Instrumentation 4.3.1. Introduction 4.3.2. Atomisers | | 10 |
| Interferences Introduction 4.2.1. Introduction 4.2.2. Spectral Interferences 4.2.3. Ionisation Interferences 4.2.4. Cation-Anion Interferences 4.2.5. Cation-Cation Interferences 4.2.6. Oxide Formation Interferences 4.3. Instrumentation 4.3.1. Introduction 4.3.2. Atomisers | | 103 |
| Interferences Introduction 4.2.1. Introduction 4.2.2. Spectral Interferences 4.2.3. Ionisation Interferences 4.2.4. Cation-Anion Interferences 4.2.5. Cation-Cation Interferences 4.2.6. Oxide Formation Interferences 4.3. Instrumentation 4.3.1. Introduction 4.3.2. Atomisers | ra | 104 |
| 4.2.2. Spectral Interferences 4.2.3. Ionisation Interferences 4.2.4. Cation-Anion Interferences 4.2.5. Cation-Cation Interferences 4.2.6. Oxide Formation Interferences 4.3. Instrumentation 4.3.1. Introduction 4.3.2. Atomisers | of many control | 10: |
| 4.2.3. Ionisation Interferences 4.2.4. Cation-Anion Interferences 4.2.5. Cation-Cation Interferences 4.2.6. Oxide Formation Interferences 4.3. Instrumentation 4.3.1. Introduction 4.3.2. Atomisers | A STATE OF THE STA | 10: |
| 4.2.4. Cation-Anion Interferences 4.2.5. Cation-Cation Interferences 4.2.6. Oxide Formation Interferences 4.3. Introduction 4.3.1. Introduction 4.3.2. Atomisers | | 100 |
| 4.2.5. Cation-Cation Interferences 4.2.6. Oxide Formation Interferences 4.3.1. Introduction 4.3.2. Atomisers | | 100 |
| 1.2.6. Oxide Formation Interferences 1.3. Instrumentation 1.3.1. Introduction 1.3.2. Atomisers | | 100 |
| 4.3.1. Introduction 4.3.2. Atomisers | nterferences | 10 |
| 1.3.1. Introduction 1.3.2. Atomisers | n Interferences | 10 |
| 4.3.2. Atomisers | | 10 |
| | | 107 |
| | | 108 |
| | | 109 |
| 3.4. Burners | | 109 |
| .3.5. Mirrors | | 112 |
| | | |






Pharmacognosy and Phytochemistry-II




























Lab manual of physical pharmaceutics I&II







| (21 | n PCE syllab | 9095 | S. Col | Page 1 |
|-----------------------|------------------------------------|------------------------------|----------------------------------|---------|
| | ens'i and il Phytochemistry | of Unit Operation | | |
| | | | LIBRA | ", Mgdi |
| | A Prac | tical N | lanual of | c |
| | | Physic | | |
| | Pha | rmaci | eutics | |
| | semistry I | and | II | |
| | Limistry II | unu | Figure Lot | |
| Stric | | | | тасу, |
| | tly As Per Syll | labus Prescri | bed for B. Phancil of India, Ne | |
| Seme | tly As Per Syll | labus Prescri | bed for B. Phai | |
| Seme | tly As Per Syll ster-III by Pha | labus Prescri | bed for B. Phai | |
| Seme | tly As Per Syll ster-III by Pha | labus Prescri | bed for B. Phai | |
| Seme | tly As Per Syll ster-III by Pha | labus Prescri armacy Coun | bed for B. Phai | |
| Seme | tly As Per Syll ster-III by Pha | labus Prescri armacy Coun | bed for B. Phan | |
| Seme Name of Session: | tly As Per Syllster-III by Pha | labus Prescri | bed for B. Phancil of India, New | w Delhi |
| Name of Session: | tly As Per Syllster-III by Pha | labus Prescri | bed for B. Phan | w Delhi |
| Seme Name of Session: | tly As Per Syllster-III by Pha | labus Prescri | bed for B. Phancil of India, New | w Delhi |





Phy

phy

fro

pr

te

W

St

u

p

Other Useful Titles

Human Anatomy and Physiology II
Pathophysiology
Lab Manual of Pharmaceutical Engineering
Lab Manual of Pharmaceutical Analysis
Pharmaceutical Validation
Lab Manual of Pharmacology
Lab Manual of Pharmacognosy and Phytochemistry I
Pharmacognosy and Phytochemistry I
Medicinal Chemistry II
Medicinal Chemistry I
Herbal Drug Technology
Drug Regulatory Affairs
Social and Preventive Medicine
Cell-Molecular Pharmacology
Experimental Pharmacology

For details visit, sites.google.com/site/detailsofbooks

The matter and format is copyrighted under copyright act by Author and Publisher. All rights of matter and its format are reserved by Publisher and Author. No part of the book can be reproduced, stored in or introduced into a retrieval system in any form or by any means (electronic, mechanical, photocopying, recording or any other) without the prior written permission of Publisher. The violation of copyright and any kind of plagiarism would be liable for legal action againt the person. All disputes will be settled in Ghaziabad Court. Publisher is not at all responsible for any kind of plagiarism.

ISBN 978-93-84875-54-1

Cost Rs. 189 only

Premiere Edition 2020

© Publisher and Authors

Acknowledement and Disclaimer: The author and publisher of this book has tried their best to ensure that the matter contained in the book is correct. However, the author and publisher make no warranty of any kind, expressed or implied, with regard to the statements contained in the book and shall not be liable in any event for any damages, arising out of the performance or use of these statements.

Published by Dr. Chanchal Mittal for UNNATI PUBLICATIONS, 9, SONA ENCLAVE, Modinagar, Ph. 09917436436, 09837007439. e-mail at unnati.publications@gmail.com.



| Ex. | Contents Description Page | 8 | DETERMINATION OF PARTITION COEFFICIENT OF BENZOIC ACID IN BETWEEN BENZENE AND WATER | 38 |
|-----|--|----|--|--------|
| lo. | PRACTICALS PHYSICAL PHARMACEUTICS I 1-54 | 9 | | 42 |
| 2 | DETERMINATION OF SOLUBILITY OF SOLID AT SOME 3 ROOM TEMPERATURE DETERMINATION OF PKa BY HALF SUBVENCES OF 8 NEUTRALIZATION/ HENDERSON HASSELBALCH EQUATION | 10 | CARBON TETRACHLORIDE DETERMINATION OF HLB NUMBER OF A SURFACTANT BY SAPONIFICATION METHOD DETERMINATION OF STABILITY CONSTANT & DONOR RECEPTOR RATIO OF PABA COMPLEX BY | 46 |
| 3 | DETERMINATION OF SURFACE TENSION OF 14 GIVEN LIQUID SAMPLE BY USING DROP COUNT | 95 | SOLUBILITY METHOD TO ASSAURANT METHOD TO ASSAU | 55-104 |
| 4 | DETERMINATION OF CRITICAL MICELLAR 19 CONCENTRATION OF GIVEN SURFACTANT | 1 | DETERMINATION OF PARTICLE SIZE AND SIZE DISTRIBUTION BY USING SIEVING METHOD | 57 |
| 5 | DETERMINATION OF FREUNDLICH AND 23 LANGMUIR ADSORPTION ISOTHERMS CONSTANTS BY USING ACTIVATED CHARCOAL | 2 | DETERMINATION OF PARTICLE SIZE AND SIZE DISTRIBUTION BY USING MICROSCOPIC METHOD | 60 |
| 6 | DETERMINATION OF PERCENT COMPOSITION OF 29 SODIUM CHLORIDE IN SOLUTION USING PHENOL WATER SYSTEM BY CST METHOD | 3 | DETERMINATION OF BULK DENSITY, TRUE DENSITY, AND POROSITY | 64 |
| 7 | THE pH TITRATION METHOD USED FOR 33 ESTIMATION OF STABILITY CONSTANT AND | 4 | DETERMINATION OF ANGLE OF REPOSE AND INFLUENCE OF LUBRICANT ON ANGLE OF REPOSE | 69 |
| | DONOR ACCEPTOR RATION FOR CUPRIC GLYCINE COMPLEX PROPRIES GLYCINE COMPLEX GLYCINE COMPLE | 5 | DETERMINATION OF VISCOSITY OF LIQUIDS BY USING OSTWALD'S VISCOMETER | 72 |






| 6 | EFFECT OF DIFFERENT SUSPENDING AGENT ON SEDIMENTATION VOLUME | 80 |
|-------------|--|-----|
| 7 ** \$2 | TO STUDY THE EFFECT OF DIFFERENT CONCENTRATION OF SINGLE SUSPENDING AGENT ON SEDIMENTATION VOLUME | 84 |
| 8 46 | VISCOSITY DETERMINATION OF SEMISOLIDS BY USING BROOKFIELD VISCOMETER (MULTIPLE POINT VISCOMETER) | 88 |
| 9 | DETERMINATION OF REACTION RATE CONSTANT FIRST ORDER | 91 |
| 10 | DETERMINATION OF REACTION RATE CONSTANT SECOND ORDER | 95 |
| 11 | SHELF LIFE DETERMINATION | 98 |
| 12 | ACCELERATED STABILITY STUDIES | 101 |
| | DETERMINATION OF A SIGN AND SIZE AND SIZE AND SIZE OF A SIZE AND S | 2 |
| | DETERMINATION OF BUEN BENSITY TRUETED DENSITY, AND POKOSITY EDISOLICE MUIDOS DENSITY, AND POKOSITY EDISOLICE MUIDOS | |
| | DETERMINATION OF ANGLE OF REPOSE AND INFLUENCE OF LOBRICANTON ANGLE OPHT REPOSE MATERIAL PORTAMITES | |
| | DETERMINATION OF VISCOSITY/OFLIGUIDS.BY USING OSTWALD'S VISCOMETER | |
| | | |
| | | |












Quality Assurance







About the Book

This textbook introduces details of Quality Assurance in a systematic way with exercises, Chapter 1 to 6 introduces QA, TQM, 1CH guidelines, QbD, 1SO 9000 and 14000, and NABL. Chapter 7 to 9 detail on organisation, personnel, premises, equipment and raw materials required in QC unit. Chapter 10 and 11 illustrate QC and GLP. Chapter 12 and 13 describe complaints and maintenance records. Chapter 14 and 15 detail on calibration and warehousing.

About the Author



Prof. (Dr.) R. Sundhararajan (M.Pharm, Ph.D) is presently working as Principal, Mohamed Sathak A.J.College of Pharmacy, Chennai. He is a very good academician with 25 years of teaching experience. He did his graduate from Annamalai University and Post Graduate from Birla Institute of Technology, Pilani, Rajasthan. He was awarded the Doctorate Degree in Pharmaceutical Sciences by The Tamil Nadu Dr. M.G.R. Medical University, Chennai. He has contributed many research and review articles in National and International journals. He has nearly 40 papers in both National and International Journals. He has attended 35 conferences and short term courses. He has guided more than 50 projects at both undergraduate and post graduate

level. He is life member in IPGA and IPA. He is an active examiner for various Universities like TNMGRMU, SRM University, SRMC University, Annamalai University, Prist University, Vel's University and Kerala University of Health Sciences. He is also Ph.D thesis evaluator, co-guide and doctoral committee member and external examiner for Ph.D exam at TNMGRMU, Annamalai University, Vel's University and Prist University.



Dr. M.V. Kumudhavalli completed her M.Pharm (Pharmaceutical Chemistry) and Ph.D (Pharmaceutical Chemistry) from VMRFDU, Salem Tamil Nadu in 2012. She started her carrier as lecturer from VMCP Salem Tamil Nadu from 1996. Presently she is working as Professor in Department of Pharmaceutical Analysis. She has total 23 years of teaching experience. She has a good track record of publishing research articles in various National and International journals repute (h.index 09). She has guided 42 M.Pharm students and presently supervising 6 Ph.D Scholars. She attended various National and International conferences. In addition she play a role as resource person in QIP organised by JSS college of Ooty, TN, sponsored by AICTE. She is the life member of IPA and other organisation. Her patent was

published in drug analysis.



Dr. Minal T. Harde (M. Pharm., PhD) is currently working as Assistant Professor at Modern College of Pharmacy, Nigdl, Pune, She has around 14 years of professional experience and has published more than 35 research papers in National and International Journal of repute, and presented 20 research papers in various conventions and conferences. She has published 4 books. She is approved PG guide of Savitribai Phule Pune University, Pune and has guided 14 PG students. She has received 3 research grants from various funding agencies like S.P.P.U and UGC. She was awarded as outstanding faculty of the year award in 2018. She is a life member of APTI.

As Per Pharmacy Council of India Syllabus B.Pharm 6th Semester

| Subjects | Author Name |
|---------------------------------------|---|
| Medicinal Chemistry- III | Prof. (Dr.) V.N. Indulatha, Dr. Rakesh Kumar, Dr. Neha Tiwari |
| Pharmacology- III | Mrs. Monika Saxena |
| Herbal Drug Technology | Dr. G. Arunachalam, Dr. V.E. Ida Christi, Dr. Prashant Kumar |
| Biopharmaceutics and Pharmacokinetics | Prof. (Dr.) N.B. Santha Sheela, Dr. N. Deattu, Mr. Sunil Kumar |
| Pharmaceutical Biotechnology | Dr. S. Jayaraman, Dr. Richa Ohri, Dr. Pankaj Verma |
| Quality Assurance | Prof. (Dr.) R. Sundhararajan, Dr. M.V. Kumudhavalli, Dr. Minal T. Harde |

MRP: ₹175

THAKUR PUBLICATION PVT. LTD.
LUCKNOW
www.tppl.org.in
Download Old OPs: www.questionpaper.org.in








Printed at: Savera Printing Press, Jankipuram, Lucknow, Mob. 9235318506/07






Industrial Pharmacy









Progressive Education Society's Modern College of Pharmacy, Nigdi, Pune 411044










TABLE OF CONTENTS

Unit - I

| Chap | ter - 1 Preformulation Studies | (1 - 1) to (1 - 52 |
|------|--|---------------------|
| 1.1 | Introduction | 1 - 1 |
| 1.2 | Physical Properties | 1 - 4 |
| 1.3 | Chemical Properties | 1 - 25 |
| 1.4 | BCS Classification of Drug and its Significance | e1 - 28 |
| 1.5 | Application of Preformulation | 1 - 30 |
| 1.6 | Stability Testing of Drugs | 1 - 43 |
| | Unit - II | |
| Chap | oter - 2 Tablets | (2 - 1) to (2 - 101 |
| 2.1 | Introduction | 2 - 1 |
| 2.2 | Excipients and Formulation Aspect of Tablets . | 2-6 |
| 2.3 | Granulation Methods and Compression of Tabl | lets2 - 16 |
| 2.4 | Equipments and Tablet Tooling | 2 - 28 |
| 2.5 | Processing Problems or Manufacturing Defects | s of Tablets 2 - 40 |
| 2.6 | Tablet Coating and its Types | 2 - 50 |
| 2.7 | Formulation Aspects of Tablet Coating and Coating Materials Used in Tablet Coating | 2 - 54 |
| 2.8 | Types of Equipment Employed in Tablet Coati | |
| 2.9 | Defects in Tablet Coating | 2 - 75 |
| 2.10 | QC and IPQC Tests for Tablets | |

(vii)

Unit - III

| Cha | oter - 4 Capsules (4 - 1) to (4 - 43) |
|------|---|
| 4.1 | Introduction and Types of Capsules |
| 4.2 | Introduction, Size and Production of HGC Shells 4 - 7 |
| 4.3 | Equipments Used in Filling and Finishing of HGC 4 - 10 |
| 4.4 | Special Techniques of Formulating Hard Gelatin Capsules 4 - 19 |
| 4.5 | Manufacturing Defects |
| 4.6 | Introduction to SGCs and its Advantages, Size and Applications of SGC |
| 4.7 | Nature of Capsule Shell and Capsule Content 4 - 27 |
| 4.8 | The Importance of Base Adsorption and Minim/Gram Factors |
| 4.9 | Production of Soft Gelatin Capsules |
| 4.10 | Packaging, Storage and Stability Testing of SGC 4 - 39 |
| 4.11 | Evaluation of Capsules |

TCA PHARMA

(vi)



| (viii) | | | | (ix) | |
|---|----------------------------------|-----|----------|---|-----------------------|
| Chapter - 5 Pellets .1 Introduction | (5 - 1) to (5 - 23) | 7.5 | | tions of Eye Lotions and s of Preparations | 7 - 1 |
| .1 Introduction | | 7.6 | | ers used in Ophthalmic Preparations, | |
| Pelletization Process and Equipme in the Manufacturing of Pellets | nt Used 5 - 7 | 7.7 | | ons of Ophthalmic Preparations | |
| Evaluation Parameters for Pellets . | 5 - 22 | | | Unit - V | Mer office |
| Unit - | IV | Cha | pter - 8 | Cosmetics | (8 - 1) to (8 - 35 |
| hapter - 6 Parenteral Product | s (6 - 1) to (6 - 96) | 8.1 | Introduc | ction and Classification of Cosmetics | 8-1 |
| .1 Introduction | 6-1 | 8.2 | Lipstick | s | 8-3 |
| 2.2 Preformulation Factors and Essent Additives, Importance of Isotonici | tial Requirements, Vehicles, | 8.3 | | oseams | |
| 3 Production Procedure, Production | Facilities and Controls, | 8.5 | Vanishi | ng Creams | 8 - 10 |
| Aseptic Processing | 6 - 23 | 8.6 | Toothpa | stes | 8 - 19 |
| .4 Formulation of Injections, Sterile LVP and Lyophilized Products | Powders, 6 - 58 | 8.7 | | es | |
| 5 Containers and Closure Selection, Ampoules, Vials and Infusion Flu | Filling and Sealing of ids6 - 69 | | | Pharmaceutical Aerosols | |
| 6.6 Quality Control Tests of Parenters | al Products 6 - 84 | 9.1 | Introduc | ction | 9 - |
| Chapter - 7 Ophthalmic Prepar | rations (7 - 1) to (7 - 29) | 9.2 | Compo | nents of Aerosol Package | 9-: |
| 7.1 Introduction | 7-1 | 9.3 | Types o | f Aerosol Systems | 9 - 18 |
| 7.2 Formulation Considerations | | 9.4 | Formula | ation and Manufacture of Pharmaceu | tical Aerosols 9 - 2: |
| | Methods of Preparations 7 - 6 | 9.5 | Evaluat | ion of Aerosols | 9 - 3 |
| 7.4 Formulations of Eye Ointments a | | 9.6 | | Control and Stability Studies for ceutical Aerosols | 9-3 |






| Ch | center 40 Beckening Materials Science |
|--|--|
| Cn | (10 - 1) to (10 - 51) |
| 10. | 1 Introduction |
| 10. | 2 Materials Used in the Packaging of Pharmaceutical Products |
| 10. | 3 Tamper-Resistant Packaging |
| 10.2 Materials Used in the Packaging Pharmaceutical Products 10.3 Tamper-Resistant Packaging 10.4 Factors Influencing Choice of Control Legal and Official Requirements 10.6 Stability Aspects of Packaging Materials 10.7 Quality Control Tests | 4 Factors Influencing Choice of Containers |
| 10. | .5 Legal and Official Requirements for Containers 10 - 37 |
| 10. | .6 Stability Aspects of Packaging Materials |
| 10. | .7 Quality Control Tests |
| So | olved University Question Papers (S - 1) to (S - 5) |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |






Pharmaceutical Validation (M.PHARM) SEM -II





















| | Contents | |
|-------------------|---|-----------|
| 1-1 | Introduction to Validation | Chapter 1 |
| n 8, 1.6 Factor | 1.1 Calibration 1,1.2 Validation 3,1.3 Validation Master P User Requirement Specification 7, 1.5 Qualification Acceptance Test (FAT)/ Site Acceptance Test (SAT) qualification 15 | |
| 17-5 | Qualification of Manufacturing Equipment | Chapter 2 |
| | 2.1 Introduction 17, 2.2 Dry Powder Mixer 17, 2.3 Fluidize 2.4 Tablet Compression 25, 2.5 Dry Heat Sterilizer (Hot Ai Autoclave (Steam Sterilizer) 29 | |
| 32-4 | Qualification of Analytical Instrument | Chapter 3 |
| | 3.1 Introduction 32, 3.2 UV-Visible Spectrophotometer Performance Liquid Chromatography (HPLC) 40 Chromatography-Mass Spectrophotometer (LC-MS) 43 | |
| 45-6 | Qualification of Manufacturing Equipment | Chapter 4 |
| , 4.3 Tap Densit | 4.1 Tablet Hardness Tester 45, 4.2 Friability tester 47, 4 Tester 52, 4.4 Dissolution Test Apparatus 57 | |
| 62-7 | Validation of Utility System | Chapter 5 |
| | 5.1 Introduction 62, 5.2 Validation life cycle 63, 5.3 Qualification 66, 5.4 Pure Steam 72, 5.5 Compressed Air and HVAC system 74 | |
| 78-9 | Process Validation | Chapter 6 |
| Types of Proces | 6.1 Definition 78, 6.2 Approach to process validation 7 process validation 85, 6.4 Documentation 85, 6.5 Ty Validation 86, 6.6 Process Validation of Dosage Form Filling (media filling) Validation 95 | |
| 98-10 | Analytical Method Validation | Chapter 7 |
| 98, 7.3 Parameter | 7.1 Introduction 98, 7.2 Strategy for Method Validation 98 for Analytical Method Validation 99 | |











A textbook of Pharmaceutical Manufacturing technology














CONTENTS Chapter 1 Pharmaceutical Industry Developments 1-30 1.1 Introduction 1, 1.2 Legal requirements and Licenses for API and formulation industry 1, 1.3 Plant Location-Factors influencing 8, 1.4 Plant layout 10, 1,5 Storage Space Requirements 14, 1.6 Sterile and Aseptic Area Layout 15, 1.7. Production Planning 21 Chapter 2 Aseptic Process Technology 31-85 2.1 Introduction 31, 2.2 Processing 31, 2.3. Manufacturing 33, 2.4 Manufacturing Flow Charts 34, 2.5. In process-quality control tests for sterile dosage forms 37, 2.6. Advanced sterile product manufacturing technology 50, 2,7. Process Automation in Pharmaceutical Industry 59, 2.8.1 Prefilled Syringe 65, 2.9. Lyophilization technology 77 Non-Sterile Manufacturing Process Technology 86-176 3.1 Non-Sterile Manufacturing Process Technology 86, 3.2. Advance nonsterile solid product manufacturing technology 100, 3.3. Coating technology 146, 3.3.1 Objectives/purposes of tablet coating 146, 3.3.2. Principles of coating 146 Chapter 4 Containers and Closures for Pharmaceuticals 177-243 4.1. Introduction 177, 4.2. The packaging material selected must have the following characteristics 177, 4.3. Categorically Differentiating Pharmaceutical Packaging 178, 4.4. The composition of packaging includes 178, 4.5. Factors affecting selection of Packaging Materials 178, 4.6. Types of containers and their performances 179, 4.7. FDA Regulations 225, 4.8, Quality control of packaging material 226, 4.9. Flexible packaging 229, 4.10. Product package compatibility 233, 4.11. Transit worthiness of package 235, 4.12. Stability aspects of packaging and evaluation of stability of packaging material 238













Pharmaceutical Regulatory Science













| | | -8 | | |
|--|--|--------|----------|--|
| | C | ont | tents | |
| | Module 1 | | 2.1.5. | FDA/Development (Non- |
| Chante | 1: Stages of drug discov | erv | | Clinical Activities) |
| 1.1. D | rug Discovery | 11 | 2.1.6. | |
| 75.56.57 | troduction | 11 | 2.2. | Summary Exercise |
| | istory of Drug Discovery | 11 | Victoria | Table Committee of the |
| 1.2. S | tages of Drug Discovery | 12 | Cha | pter 3: Innovator and Gener |
| | iscovery | 13 | 3.1 | Innovator and Generic Drugs |
| | roduct Characterisation | 13 | 3.1.1. | Introduction |
| | ormulation, Delivery, | 13 | 3.1.5. | Advantages of Generic Drugs |
| The state of the s | ackaging Development | | 3.1.6. | Disadvantages of Generic |
| | harmacokinetics and Drug | 13 | | Drugs |
| E | Disposition | | 3.1.7. | Concept of Generics |
| 1.2.5. P | reclinical Toxicology Testing | 13 | 3.1.8. | Generic Drug Approval Proces |
| | nd IND Application | | 3.1.9. | Generic Drug Produc |
| 1.2.6. B | tioanalytical Testing | 14 | 3.100 | Development |
| | | 14 | 3.2. | Summary |
| 1.3. 8 | ummary | 1.5 | 3.3. | Exercise |
| 1.4. I | Exercise | 15 | 2000 | FOR THE REPORT OF THE PARTY OF |
| | | | | Module 2 |
| | pter 2: Drug Developmen Process | it , | Ch | apter 4: Regulatory Appro Process |
| 2.1. 1 | Orug Development Process | 16 | 4.1. | Investigational New Dru |
| | ntroduction | 16 | | (IND) |
| 2.1.2 1 | Discovery and Development | 16 | 4.1.1. | Introduction |
| | Farget Discovery | 16 | 4.1.2 | Classification |
| 2.1.2.2.7 | Farget Validation | 17 | 4.1.5. | |
| 2.1.2.3. 1 | Lead Compound Identification | 17 | 4.1.6. | |
| 2.1.2.4.1 | Lead Optimisation | 17 | 4.1.7. | |
| 2.1.2.5. | The state of the s | 1 18: | 4.2. | New Drug Application |
| | (ngredients (APIs) | 1.00 | 4.2.1. | Introduction |
| | Pre-Clinical Studies | 18 | 4.2.2 | |
| | Absorption, Distribution | . 18 | 4.2.3. | |
| | Metabolism, and Excretion | | 4.2.4. | |
| | Proof of Principle / Proof o | 1 19 | 4.2.5. | |
| | Concept | - 10 | | NDAs |
| | In Vivo, In Vitro and Ex Viv | 0 19 | 4.2.6. | |
| | Assays | 10 | 4.2.7. | |
| | In Silico Assays | 19 | 4.2.8. | |
| 2.1.3.5. | Drug Delivery | | 4.3. | Appropriate Company |
| | Formulation Optimisation an | 20 | | Application (ANDA) |
| 211 | Improving Bioavailability Clinical Studies/Development | - 20 | 4.3.1. | |
| 2.1.4. | Biological Samples Collection | 20 | 4.3.2. | |
| | | of | 4.3.4. | A STATE OF THE PARTY OF THE PAR |
| | Storage and Shipment of Biological Samples | | 4.3.5 | |
| 2112 | | P. 20 | 4.3.6 | |
| | HIPAA, and Adverse Ever | | 4.3.7 | |
| 2.1.9.2. | Reporting) | - | 4.4. | Changes to an Approv |
| 6.1.4.6. | reporting) | | 4.4. | NDA/ANDA |
| | Pharmacodensmic (PI | 11:201 | | |
| | Pharmacodynamic (PI Biomarkers | 0) 20 | 4.4.1 | |







| 4.4.3. | Moderate Change | 50 | 5.6.1. | Organisational Structure 69 |
|------------|-------------------------------|---|--------|--|
| 1.4.4. | Minor Changes | 50 | 5.6.2. | Responsibilities 69 |
| | Assessing the Effect | | 5.6.3. | |
| | Manufacturing Changes | 25.00 | 5.7. | Drug Regulatory Agencies in 70 |
| 1.5. | Summary | 54 | 400.0 | Canada-Health Canada |
| 1.6. | Exercise | 54 | 5.7.1. | The state of the s |
| e.o. | Exercise | 34 | | Organisational Structure 71 |
| | | | 5.7.2. | Responsibilities 71 |
| Char | oter 5: Regulatory Author | nelties | 5.7.3. | Types of Applications 71 |
| Cital | | DESILIES | 5.8. | Summary 71 |
| | and Agencies | | 5.9. | Exercise 72 |
| 5.1. | Regulatory Authorities | and 56 | | Madul- 2 |
| | Agencies | | | Module 3 |
| 5.1.1. | Introduction | 56 | Chi | pter 6: Registration of Indian |
| 5.1.2. | Contraction Contraction | in 56 | | g Product in Overseas Market |
| | Different Countries | | 6.L | Indian Pharamaceutical 73 |
| 5.1.3. | Functions of Regulat | ory 57 | | Market |
| | Authority | | 611 | |
| 5.2. | Drug Regulatory Agencies | in 57 | 6.1.2 | Introduction 73 |
| 10 | India | 151E/07 | 0.1.2. | Government Initiatives to 73 |
| 5.2.1. | Introduction | 57 | | Promote the Pharmaceutical |
| | Organisation Structure | | 18.245 | Sector |
| rational s | | 01.36 | 6.1.3. | Rules Related to Export of 74 |
| | Regulatory Body in India | | | Drugs from India |
| 1.4.3, | Central Drug Standard | | 6.1.4. | Procedure for Export of 75 |
| | Control Organisation (CDSC | | | Pharmaceutical Products and |
| | Organisational Structure | 59 | | Medicines from India |
| | Types of Applications | 59 | 6.2. | Technical Documentation 76 |
| .2.4. | National Institute of Health: | and 59 | 6.3. | Drug Master Files (DMF) 76 |
| | Family Welfare (NIHFW) | | 6.3.1. | Types 77 |
| .2.4.1 | Organisational Structure | 60 | | |
| | Types of Applications | 60 | 6.3.2. | Content of Drug Master Files 78 |
| | Drug Technical Advis | | 240 | Submissions |
| - | Board (DTAB) | and the | 6.3.3. | |
| 251 | Organisational Structure | 60 | 1000 | Suggestions to Prepare DMF |
| | | 61 | 6.3.4. | |
| | Types of Applications | | | Master File |
| 1.6.0 | | ing 61 | 6.3.5. | Processing and Reviewing 80 |
| | Laboratory (CDTL) | | | Policies |
| | Organisational Structure | 61 | 6.3.6. | Holder Obligation 81 |
| | Types of Applications | 62 | 6.3.7. | Closure of a Drug Master File 82 |
| .3. | Drug Regulatory Agency | in 62 | 6.4. | Common Technical 82 |
| | USA - FDA | | 40.75 | Document (CTD) |
| .3.1. | Organisational Structure | 62 | 6.4.1. | A STATE OF THE PROPERTY OF THE |
| .3.2. | Responsibilities | 64 | 6.4.2. | |
| | Types of Applications | 64 | G.F.S. | |
| .4. | Drug Regulatory AgencY | 100000000000000000000000000000000000000 | 60 | Technical Document |
| | Australia -TGA | | 6.5. | Electronic Common 85 |
| 4.1 | Organisational Structure | 65 | | Technical Document (eCTD) |
| 4.2 | Responsibilities | 66 | 6.5.1. | |
| | | 1.50 | 6.5.2. | Organisation of e-CTD 86 |
| .4.3. | Types of Applications | 66 | 6.5.3. | e-CTD Ready Document 87 |
| .5. | Drug Regulatory Agencies | III 00 | 6.6. | ASEAN Common Technical 90 |
| | European Union- EMA | | | Document (ACTD) Research |
| .5.1. | Organisational Structure | 67 | 6.6.1. | Parts of ACTD 91 |
| 5.2. | Responsibilities | 68 | 6.6.2. | Scope of the Document 92 |
| .5.3. | Types of Applications | 68 | 6.7. | Summary 92 |
| 2.66 | Drug Regulatory AgencY | in 68 | 6.8. | Exercise 93 |
| .6. | Japan - MHLW | | March | 13 Table 100 100 100 100 100 100 100 100 100 10 |




| | | -16 | 0- | | |
|--------|--|-------|-----------|---|-----|
| | Module 4 | | 813.2 | Subjects | 12 |
| | | | | 100 A | 12 |
| | Chapter 7: Clinical Trails | | | Institutional Review | |
| 7.1. | Clinical Trials | 94 | 210000 | Board/Ethics Committee | |
| 7.1.1. | | 94 | 8.1.3.5. | Data and Safety Monitoring | 12 |
| 7.1.2. | | 94 | | Board (DSBM) | |
| 1 | Protocols | die . | 8.1.3.6. | Regulatory Authorities | 12 |
| 7.2 | Institutional Review Board | | | Medical Community and | 12 |
| | (IRB)/ Independent Ethical | | | Patients | |
| 281 | Committees (IEC) | 457 | 8.1.4. | Safety Monitoring in Different | 12 |
| 7.2.1. | The state of the s | 99 | | Phases of Clinical Trials | |
| 7.2.2. | | 99 | 8.2. | Summary | 12 |
| 7.2.3. | ALTERNATION OF THE PROPERTY OF | 99 | 8.3. | Exercise | 12 |
| 7.2.4. | | 101 | | | |
| 7.3. | Informed Consent Process | 102 | | Module 5 | |
| | and Procedures | | CO. | | |
| 7,3.1, | | 102 | 77.000.00 | pter 9: Regulatory Concep | |
| 7.3.2. | Verbal Consent Process | 103 | 9.1. | Regulatory concepts | 12 |
| 7.3.3. | | 103 | 9.1.1. | Introduction | 12 |
| 7.3.4. | | 104 | 9.1.2. | Basic Terminologies | 12 |
| 7.3.5. | | 104 | 9,1,3, | Laws and Act | 12 |
| 4.00 | Assessment | | 9.1.4. | Regulations and Guidelines | 12 |
| 7.3.6. | Required Signatures | 105 | 9.1.5. | Guidance | 12 |
| 7.3.7. | Subject Advocates | 106 | 9.2. | Orange Book | 12 |
| 7.3.8. | Reconsent and Significant New | 106 | 9.2.1. | History | 13 |
| | Findings | | 9.2.2. | Objective | 13 |
| 7.3.9. | English-Speaking Subjects | 106 | 9.2.3. | Content | 13 |
| 142701 | Unable to Read and Write | | 9.3. | Federal Register | 13 |
| 7.4. | GCP Obligations | 107 | 9.3.1. | Code of Federal Regulatory | 13 |
| 7.4.1. | Introduction | 107 | 305 | (CFR) | . 8 |
| 7.4.2. | Principal Investigator | 108 | 9.3.2. | Classification | 13 |
| 7.4.3. | Sponsors | 111 | 9.3.3. | Content | 13 |
| 7.4.4. | Monitor | 114 | 9.3.4. | Structure of Organisation | 13 |
| 7.4.5. | | 115 | 9.3.5. | Searching the CFR | 13 |
| 14000 | Clinical Trial | 444 | 9.3.6. | Search Examples | 13 |
| 7.4.6. | Purpose | 116 | 9.3.7. | Sample Code of Federal | 13 |
| 7.4.7. | TO SERVICE STREET, STR | 116 | - 00 | Regulations URLs | |
| 7.4.8. | Monitoring Plans | 118 | 9.4. | Purple Book | 13 |
| 7.4.9. | Monitoring Reports | 119 | 9.4.1. | Purpose | 13 |
| 7.5. | Summary | 120 | 9.4.2. | Content | 13 |
| 7.6. | Exercise | 120 | 9.4.3. | Biologics Price Competition and Innovation Act of 2009 | 13 |
| | hapter 8: Pharmacovigilenc | un. | | (BPCI Act) | |
| 8.1. | Safety Monitoring in Clinical | | 9.4.4. | Bio Similar Product | 13 |
| Della | Trials | 101 | 9.4.5. | Interchangeable Biological | |
| 8.1.L | | 121 | 4111 | Product | 9 |
| 8.1.2 | | 121 | 9.5. | Summary | 14 |
| 8.1.3. | | | 9.6. | Exercise | 14 |
| 0.1.3. | Monitoring In Salety | 161 | | Andreas American Section 1 | 18 |
| 8.1.3. | 1. Sponsor | 121 | | | |
| | STATE OF THE PARTY | | | | |
| | | | | | |
| | | | | | |
| | | | | | |





Chapter 1 Origanum Majorana: The Fragrance of Health





Science of Spices & Culinary Herbs, 2020, Vol. 3, 1-12



Origanum Majorana: The Fragrance of Health

Bhushan P. Pimple', Amrita M. Kulkarni and Ruchita B. Bhor

P. E. Society's Modern College of Pharmacy, Yamunanagar, Nigdi, Pune, India+110+4

Abstract: Origonum majorana Linn (Majorana hortensis) is an aromatic herb of Lamiaceae. The plant is native to Mediterranean and European parts, but can be cultivated easily in all tropical regions. The leaves and flowers are characterized by a pleasant aromatic odour that increases its scope for perfumery and food industries. Besides its culinary & perfumery importance, O. majorana has therapeatic relevance in the management of diabetes, hypertension, polycystic ovarian syndrome (PCOS), gastric ulcers, leukemia, breast adenocarcinoma, free radical scavenging, etc. The proposed chapter focuses on traditional uses, culinary and perfumery applications, recent advancements in phytochemistry and pharmacotherapeutics of Origonum majorana.

Keywords: Origanum majorana, Sweet majorana, Hyperglycemia, Hypertension, Adenocarcinoma.

INTRODUCTION

Traditional Claims [1 - 9]

- Decoction of fresh aerial parts of Origanum majorana was consumed to relieve flatulence in Colombia.
- Origanum majorana was used as a constituent in many herbal mixtures in Eastern Cuba for treating diabetes, catarrh, stomach pains and as a sedative.
- Majorana is still used as a traditional herb for cough, stomach aches and as a carminative in Jordan.
- Origanum spp. were used to produce sedation and for treating insomnia in Italy.
- Infusion of majorana leaves is a traditional application for hypertension in Morocco.
- In Cyprus, leaves of Origanum majorana in the form of infusion or inhalation were used to treat diabetes, hypertension, diarrhoea, migraine, stomach ache, cough, dysmenorrhea, asthma, bronchitis.

Prof. Atta-ur-Rahman, Prof. M. Iqbal Choudhary & Dr. Sammer Yausuf All rights reserved-© 2020 Bentham Science Publishers




^{*} Corresponding author Bhushan P. Pimple: Head, Department of Pharmacognosy, P.E. Society's Modern College of Pharmacy, Varrunaragat, Nigdi, Pare, Maharashtra, India 411 044; E-mail: bhusharqqimyle@cediffmail.com





Chapter 2 Piper nigrum (Black pepper): A Flavor for Health







Science of Spices & Cullwary Herbs, 2020, Vol. 2, 24-38.

CHAPTER 2

Piper nigrum (Black pepper): A Flavor for Health

Bhushan P. Pimple, Amrita M. Kulkarni and Ruchita B. Bhor

P. E. Society's Modern College of Pharmacy, Vamunanagar, Nigdi, Pune, India

Abstract: Piper Algram is an indigenous extensive wine of Piperaceae. It is predominantly cultivated in the humid and subcropical climate of Western Ghats of India, mainly in Kockan and Kerala. The berries of black pepper are developed on axillary catkins. The berries are warty and turn brownish-black on ripening and are strongly aromatic and pungent. The tolerable aroma of the black piper is exploited in cultinary preparations across the globe. Traditionally, it is used as a stimulant, antipyretic, analgesic, antiviral, and as a bioavailability enhancer. Consequently, the manifold use of black pepper has augmented its commercial and medicinal importance. Principle ingredients are alkaloids such as piperine, piperiongumine, and piperlongumina. Recent research proves its beneficial tule in the management of hyperlipidemia, obesity, cardiovuscular complications, diabetes, etc. The proposed chapter will apecifically highlight the phytochemical and pharmacological advancements in the research related to Poet wigram.

Keywords: Black pepper, Bioavailability enhancer, Piper nigrum.

INTRODUCTION (FIGS. 1+3)

Vernacular Names

Hindi: Pipar, piplamid

Marathi: Pimpli

Tamil: Kandan, lippilli, pppilli, thippili

Telugu: Pippallu Urdu: Pippal Gujarati: Pipli

*Corresponding author Bhushau P, Pinsple: Department of Pharmacognosy, P.E. Society's Modern College of Pharmacy, Yomensenger, Nigdi, Pure, Maharashera, India, Tel: +919970830030, E-mail bhashaappingle@rokffmail.com


Atta-ur-Rahman, M. Ighal Choudhary & Sammer Yousef All rights reserved-© 1620 Bentham Science Publishers







Chapter 2 Therapeutic Activities of Nutmeg (Myristica fragrance)







Contents

Contributors

Abbreviations

Preface

Part I: Natural Phytochemicals in Gastrointestinal Disorders

- Ethnopharmacology and Therapeutic Potential of Carica papaya
 - Gurpreet Singh, Pooja Chawla, Abdul Faruk, and Viney Chawla.
- 2. Therapeutic Activities of Nutmeg (Myristica fragrans)

Bhushan Prakash Pimple, Amrita Milind Kulkarni, and Ruchita Balu Bhor

- 3. Plant-Based Phytochemicals in the Prevention of Colorectal Cancer
 - Yana Puckett and Kyle Drinnon
- 4. Role of Medicinal Plants in the Treatment of Hemorrhoids

Yaw Duah Boakye, Daniel Obeng Mensah, Eugene Kusi Agyei, Richard Agyen, and Christian Agyare

Part II: Role of Spices and Herbs in the Management of Gastrointestinal Disorders

- 5. Health Benefits of Garlic (Allium sativum) in Gastrointestinal Disorders
 - Yaw Duah Boakye, Daniel Obeng Mensah, Eugene Kusi Agyei, Richard Agyen, Doreen Kwankyewaa Adjei, and Christian Agyare
- 6. Role of Onion (Allium cepa) in Gastrointestinal Disorders

Yaw Duah Boakye, Richard Agyen, Eugene Kusi Agyei, Daniel Obeng Mensah, Doreen Kwankyewaa Adjei, and Christian Agyare

- 7. Role of Lectins in Gastrointestinal Disorders
 - Hugh James Freeman
- Therapeutic Efficacy of Black Pepper in Gastrointestinal Disorders
 Mrinmoy Sarkar and Pooja Chawla
- Curative Properties of Chamomile in Gastrointestinal Disorders
 Mrinmoy Sarkar and Pooja Chawla
- 10. Pharmacology and Therapeutics of Dandelion in Gastrointestinal Disorders

Dilipkumar Pal and Supriyo Saha

Part III: Plant-Based Remedies in the Treatment of Gastrointestinal Diseases

11. Role of Alos vera in Irritable Bowel Disease

Dilipkumar Pal and Souvik Mukherjee





CHAPTER 2

ress

Therapeutic Activities of Nutmeg (Myristica fragrans)

BHUSHAN PRAKASH PIMPLE AMRITA MILIND KULKARNI, and RUCHITA BALU BHOR

ABSTRACT

Main phytochemicals in nutmeg (Myristica fragrans Houtt) are: myristicin, trimyristin, myristic acid, alpha-pinene, beta-pinene, etc. In the traditional system of medicine, nutmeg is preferably used to treat insomnia, depression, intestinal worms, and oligospermia. etc. Nutmeg extract has been scientifically proven to exhibit antimicrobial activity in GI flora thereby suppressing the levels of tumorigenic uremic toxins. Furthermore, methanol extract of nutmeg is effective in H. pylori-induced gastritis and DSS-induced colitis. This chapter focuses on the traditional claims and therapeutic benefits related to GI disorder of Myristica fragrans.

2.1 INTRODUCTION


Myristica fragrans Houtt (nutmeg) is widely distributed in western India (i.e., Kerala and Konkan) and is also cultivated in Srilanka and Indonesia. ¹⁶ The plant reaches up to 15 m of height. The seeds have hard testa lined with thin papery mace. ¹⁵ Kernel and mace of the seed are rich in essential oils (Fig. 2.1). Both the mace and kernel are normally used in culinary preparation owing to their aromatic principles. Table 2.1 presents traditional claims of nutmeg in different countries. Phytoconstituents in M. fragrans are listed in Table 2.2.

Author Copy





Chapter 10 Nasal bioadhesive drug delivery system and their application





10

Nasal Bioadhesive Drug Delivery Systems and Their Applications

Ravindra V. Badhel* and Sonali S. Nipatel

Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune,
Maharashtra, India

²P. E. Societies' Modern College of Pharmacy, Nigdi, Pune, Maharashtra, India

Abstract

The major challenges faced by the formulation scientists for the oral delivery of low dose and bio-macromolecular medicaments are their high first-pass hepatic clearance and low absorption, respectively. These challenges lead to the development of many alternative drug delivery routes in addition to most common Injection route. The examples of major alternative drug delivery systems are Transdermal (microneedle, iontophoresis, patches, and sprays). Intraocular, Sublingual, Rectal suppositories, Vaginal, Pulmonary (powders and aerosols) and Intranasal (drops, sprays, solutions, gels and powders).

Intranasal drug delivery is a well-known drug delivery route and has been extensively explored for the delivery of low dose drugs like drugs acting on Central Nervous System (CNS), hormones, nicotine substitutes, etc. Intranasal route has very large mucosal surface area facilitating rapid absorption of drugs. It bypasses the first-pass hepatic clearance of the drugs and the administration of the formulation is done through easily accessible non-invasive route (nasal cavity). Thus, it can facilitate local, systemic and CNS drug delivery and holds the advantages like fast action, low dose of drug required, high patient compliance and it is self-administrable.

In this chapter, the advancement in intranasal drug delivery formulations is discussed with focus on the role of mucoadhesive materials in them.

Keywords: Intranasal drug delivery, mucoadhesive materials, fast acting drug delivery systems, bio-adhesive, CNS delivery, Blood Brain Barrier (BBB)

*Corresponding author: ravindra.badhe@dypvp.edu.in; badheravi2@gmail.com

K.L. Mittal, I. S. Bakshi and J. K. Narang (eds.) Bioardhesives in Drug Delivery, (259–306) © 2020 Scrivener Publishing ELC


259

302





Chapter 5 Cellulosic material as bioinks for 3D printing applications







Cellulosic materials as bioinks for 3D printing applications



Ravindra V. Badhe , Sonali S. Mipate

Dr. D. Y. Patil Institute of Pharmacoutical Sciences and Research, Pingui-Chinchwad, Moharashtra india P. F. Societies' Modern College of Pharmacy Pune, Maharashtra India

1. Introduction

Regenerative medicine (RM) is a branch of biomedical engineering with research spanning from in wire techniques like organisid development, functional lissue development, organ-on-chip to in who therapeutic techniques like skin printing, mitificial puncreus, and hone fracture healing. It is based on three main pillars, biomaterial and 3D scaffold evel opment, biochemical signals, and stem cell/differentiated cell interaction with scaffold 11.21. Each pillar is very important to develop a successful regenerative therapy or technique. The biodegradable and biocompatible 3D scaffolds on generally developed from biopolymers. The important characteristics which need to be possessed by biopolymer for developing a 3D scaffold one, it should mimic extracellular matrix (ECM) by supporting (biocompatible) the seeded cells, biodegrading (in viscolis visco) in specific time without leaving harmful by products and should have sufficient mechanical strengths [3—9]. The most convenient way to construct 3D scaffolds using various biomaterials is ad-

The most convenient way to construct 3D scaffolds using various biomaterials is additive meanufacturing (AM). AM is also known as 3D printing, and it is the most upcoming technology having versatile applications involving designing and production of 3D structures developed for motor vehicles, consumer products, medical, and aero space. 3D printing technology is widely being used in motor vehicle and consumer product industries. The advantages of this technology, like affordability and freedom in designing of medical product, equipment, or tool, were noted by the resembners. This technology delivers the product of highest quality of safety, precision, and care; thus nowadays this technique is extensively studied for biomedical applications [10,11].

In medicine. AM is being explored for 3D printing of metallic, polymeric, ceramicbased prostheties, implants, and formulations. Whereas in RM, it is used together with a 3D bioprinter or bioplotter for top-down and bottom-up approach of tissue regeneration. For both approaches specialized bounks are used which are curefully developed using natural, composite (natural—natural, natural—synthetic or synthetic—synthetic crosslinked or non-cross-linked bleeds) or synthetic biopolymers. Bottom-up approach uses cell-laden bioinks to construct 3D architecture, whereas top-down approach uses biomaterials to construct 3D structure on which cells are seeded (Fig. 5.1).

The casting of 3D scaffolds for RM can be done using techniques such as laserassisted bioprinting, stereolithography, inkjet bioprinting, extrusion-based bioprinting.







ACADEMIC YEAR 2019-20

INDEX

| Sr. No. | Title of Books and chapters in edited volumes / Books Published / | Page No. | | | |
|-------------------------|---|----------|--|--|--|
| | Conference proceedings | | | | |
| CONFERENCES PROCEEDINGS | | | | | |
| 1. | Nutritive Values Dermacosmetic Properties and Medicinal Properties of Spiruling | 307 | | | |
| 2. | Translation of predictive in-vivo animal models to clinical | 310 | | | |
| 3. | Olfactory Bulbectomy: A renowned model for depression | 311 | | | |
| 4. | Biomarkers for neuropsychiatric disorder with respect to traditional animal house | 312 | | | |
| 5. | Topical applications of retinoid in dermatology | 313 | | | |
| 6. | Preparation and evaluation of sustained-release herbal matrix tablet | 314 | | | |
| 7. | Healthcare common procedure coding system (HCPCS) | 315 | | | |
| 8. | General procedure of medical coding | 317 | | | |
| 9. | An overview of clinical audit: a vital aspect to improve quality care | 318 | | | |
| 10. | Evaluation of antiurolithiatic activity of flavonoid rich fraction of sesbania grandiflora leaves in experimental animals | 319 | | | |
| 11. | An overview on basics of medical writing | 320 | | | |
| 12. | An overview of keratoconus and treatment | 321 | | | |
| 13. | To assess knowledge and practice of menstrual hygiene amongst the female students | 322 | | | |
| 14. | Evaluation of inhaler techniques use in asthma and copd patients at urban | 323 | | | |
| 15. | Development and evaluation of nanoliposomes and nanocochleates of docetaxel and paclitaxel | 324 | | | |
| 16. | How a long forgotten virus could help us solve antibiotic crisis? | 325 | | | |








| 17. | Diabetic foot ulcer and its management-a review | 326 |
|-----|---|-----|
| 18. | Overview current coding process | 327 |
| 19. | Dapsone induced hypersensitivity syndrome | 328 |
| 20. | Formulation, optimization and characterization of glibenclamide oral dispersible tablet by using solid dispersion technique | 329 |
| 21. | Coronavirus & covid 19 | 330 |
| 22. | Alopecia areata | 331 |
| 23. | Current scenario of medical coding | 332 |
| 24. | Current approaches in treatment of psoriasis | 333 |
| 25. | Necrobiosis lipoidica | 334 |
| 26. | Effect of moringa olifera non-alcoholic fatty liver diseases (nafld) | 335 |
| 27. | Phyto-nanoparticles for TDDS | 336 |
| 28. | An overview on anti-fraud software | 337 |
| 29. | Future & new trends in medical coding & billing | 338 |
| 30. | An overview of various software's used in medical coding | 339 |
| 31. | Trends in healthcare & automated coding | 340 |
| 32. | Proper patient counseling for type 1 diabetes mellitus in pediatric patients | 341 |
| 33. | Types of medical coding | 342 |
| 34. | Effect of alstoniascholaris (linn) on fructose induced insulin resistance | 343 |
| 35. | A brief note on cromhidrosis | 344 |






Nutritive Values Dermacosmetic Properties and Medicinal Properties of Spiruling













Int J Life Sci Phanna Res. (55N 2250 - D480; SP-69; "Current Trends in Phanmetology Research - Precivical Trials" 2020.

SP-19

NUTRITIVE VALUES, DERMACOSMETIC PROPERTIES AND MEDICINAL PROPERTIES OF SPIRULINA

SONALI S. NIPATE*, SHRADDHA S. MAKESHWAR

P.E.Society's, Modern College of Pharmacy, Nigdi, Pune-44.

ABSTRACT

Sporafine, blue green free-floating filamentous microalgae that grows in alkaline water bodies. From the past 400 years, Spirwline was consumed as food. Spiruline is a well-known source of valuable food supplements, such as proteins, vitamins, amino acids, minerals, fatty acids, etc. The antioxident, inflammatory, antidiabetic activities of Spiralina were demonstrated in a large number of preclinical studies. It boosts the immunity and increases resistance to various infections. Thus, these multi-beneficiary actions of spiralina make it an important natural product for the improvement of health of humans. In this review article an efforts are made to compile all the nutritive values, dermacosmetic properties and medicinal properties of Spiralina to serve as an easy source of literature.keywords: Anti-inflammatory,

Spirulins the blue green algae belong to the two genera namely Spirulina and Arthrospira, which coesists of Spaning the one green argue belong to the two general and a variable, it is filamentous, multicellular, 15 different species. Spirulina Platewrit is the most commonly available, it is filamentous, multicellular, blue-green microalgae. Spirulina is found to be magnificent source of macro and micro nutrients as per the chemical analysis. It is rich in proteins, vitamins, essential amino acids, essential fatty acids and dietary minerals. These loaded nutrients make spiralina an excellent beneficial for health, also a potential immunomodulant, anticanoer, antioxidant, antiviral and antibacterial. It has positive effects in malnutrition hyperlipidaemia, obesity, diabetes, heavy metal and chemical induced toxicity, inflammation, anaemia and damage caused due to radiation.³⁴

Morphology of Spirulina:

Spiruling and Arthrosphague non-heterocyst, unbranched filamentous, genera of order Nortocles and family Osillatoriaceae. On observation under microscope, presence of two filaments in a single unit and absence of cellular septation are major points that differentiate Spirulina from Athrospira Spirulina Plantesis a photoautotrophic, alkaliphilic cyanobacterium and filamentous which beforgs to Oscillatoriaceae and

Chemical composition of Spirulina: Spirulina is rich in carbohydrates, protein, lipids, vitamins, minerals, pigments, and enzymes; however, it has achieved a great value in food, pharmaceutical and cosmetic industries. Branched polysaccharide structurally similar to the glycogen forms the major polymeric component of S. Platensis Anionic structurily season to the grycogen forms the import puryment component of a remember Antonic polysaccharide that is higher in molecular weight are been isolated from spirulina which have antiviral and immunomodelation activities. If Spirulina content 50 to 70% proteins, which is higher than mest, eggs, dried milk, grains and soybeans. It contains all the essential amino acids like leucane, value and isoleucine. Major protein in spirulina are phycohiliproteins, phycocyanin C and allophycocyanin. These proteins have Phytocyanin is considered as the safe and natural food colorant used in chewing gums, confectionaries and dairy products.

13-15 The chromophore phycocyanobilin (PCB) present in spirulina is used as a supplemental dairy products.

13-15 The chromophore phycocyanobilin (PCB) present in spirulina is used as a supplemental dairy products. and is employed for various preventive and curative therapy in many diseases mediated by NADPH exidase hyperactivity like cardiovascular diseases, diabetes, metabolic syndrome, allergic reaction, rheumatoid arthritis, cancer, Parkinson's and Alzheimer's diseases.

Nutritive value of spiruline


Spirulina is one of the richest sources of proteins, it has five times greater protein content than meat. Spirulina comprises essential as well as non-essential amino acids, it contains highest amount of beta-

www.ilpr.com

Page 92



Translation of predictive in-vivo animal models to clinical trials





Olfactory Bulbectomy: A renowned model for depression

be stale by Phorne Rec. (SAV 2010 - 6480; SP-80; "Current Trends in Phornecology Research - Precinical Trials" 2020.

SP-25

OLFACTORY BULBECTOMY: A RENOWNED MODEL FOR DEPRESSION

GHODAKE SHWETAI AND KORE PADMAJA*

*P.E. Society's Modern College of Pharmacy, Yumunanagar, Nigdi, Punc-44, India

The offactory bulboctomized (OB) rat has been proposed primarily as an animal model for depression Certain behavioural changes were observed due to OBX such as increased in the hyperactivity when kept in an enclosed area also alterations in food enthused and conditioned taste eversion behaviour. kept in an enclosed area also alterations in food enthused and conditioned taste eversion behaviour. Likewise some of the alterations in the noradrenergic, serotonergic, cholinergic, GABAergic and glutamatergic neuroentamiter systems were also witnessed. The varieties of immune changes are also observed. An enhanced night-time secretion of corticosterone level is observed in OBX rats, which is normally suppressed or could be either decreased by devamethasone. However, many other behavioural, neurotransmitter and immune changes have been shown to be attenuated by chronic irrespective of acute antidepressant treatment. (TCA's) such as (anticiptyline), stypical mediators (example: mianserin), selective serotonin reuptake inhibitors (SSRI's) agent such as (paroxetine), reversible inhibitors of monoamine oxidase A (The well-knownmaclobamide), alsoputative antidepressant agents like 5-HT 1A agonists for example (zalospirone), non-competitive N-methyl-D-aspartate antagonists (MK-801) have demonstrated antidepressant-like activity during this model. The aim of this review is to revise the studies done using OBX model till date so as why is it the most renowned of all models for depression. renowned of all models for depression.

Keywords: Offactory bulbectomy, depression, neurotranomitters, immune system, behaviour

INTRODUCTION:

Depression is a chronic, recurring and usually life-directoning illness which affects up to 17% of the totalworld population. Medications suggested for depression those which are most effective such as tricyclic antidepressants (TCA's), selective revensible inhibitors of monoamine oxidase-A, and specific sententiaambiopressuris (ICA) 3, secente reversor institute of monomine oxidate-A, and specific scretominoradenaline (NA) respitate inhibitors are clinically employed for drug thesapy. However, these drugs can induce a variety of side-effects including carefule toxicity, hypopiesia, sexual dysfunction, body weight gain, and steep disorder. However, a significant population of depressed patients (20% to 30%) does not respond to these medications. This is partially due to our limited understanding of the precise neurobiological mechanisms associated with depression. Offsetory bulbectomy model is widely used for investigation of newer upcoming antidepressants

History of Otifactory bulbectomy as a model to study clinical depression:
Investigation of rats with bilateral lesions of observey bulbs was cast-off in evaluating the effect of anosmia on learning performance. After awhibst, clear impairment in possive avoidance learning after OB was reported. Additional studies revealed supplementary OBX induced behavioural alterations in sexual behaviour alterations in sexual behaviour alteration and the studies are could be used to distinguish importance anti-depressants and a year later the offsetory bulbectomized rats was accessible as a model for depression and the detection of newer arti-depressants for their efficacy. After its arrival as a predictive model for antidepressants, the study expanded in numerous directions. The brain related chemistry of animals was determined & slope of antidepressants grew up higher as compared to earlier ones. Presently, the OBX model is used as a predictive pharmacological model for as compared to earlier ones. Presently, the OBX model is used as a predictive pharmacological model for testing the efficacy of antidepressent drugs as well as a model for learning the cognitive debility and

Changes observed in olfactory bulbectomized rats or mice:

Behavioural changes:

Benarioural changes:
The typical and the most widely accepted behavioural pattern in the OBX model of depression is the significant increase in locomotor/exploratory activity-during the OFT. Mice stereotypically exhibit less exploratory behaviour during the first few minutes of pasting to a familiar open field arena. OBX race also

nova the com



Biomarkers for neuropsychiatric disorder with respect to traditional animal house

Int J Life Sci Pharma Res. ISSN 2250 - 0480; SP-09; "Current Trends in Pharmacology Research - Preclinical Trials" 2020.

BIOMARKERS FOR NEUROPSYCHIATRICDISORDERS WITH RESPECT TO TRANSLATIONAL ANIMAL MODELS

PADMAJA KORE*, VARSHA SATAVI

*P.E. Society's Modern College of Pharmacy, Yamunanagar, Nigdi, Pune-44, India

ARSTRACT

Unravelling neuropsychiatric disorders with the aid ofanimal models possess a substantial challenge due to the subjective and overlapping symptoms of the disease. The symptoms themselves are varied and have complex neurobiological mechanism behind them, of which we have radimentary understanding. Multifactorial etiology of such disorders contributes to unreliable diagnosis and inaccurate therapeutic regimen. Emergence of biomarkers will help in understanding the pathophysiology behind such debilitating disorders and aid in identify promising therapeutic targets. The drug targets hence found can be translated into therapeutic strategies. Statistical tools like genomics, proteomics and metabolomics along with the research domain criteria (RDoC) will lead to formation of robust animal models.

KEYWORD: Neuropsychiatric disorders, biomarkers, proteomics, genomics.

INTRODUCTION

Neuropsychiatry endeavor's to understand abnormal behaviour and behavioural disorders with the help of various neurobiological and psychological-social factors. Neuropsychiatryprovides a bridge between the disciplines of psychiatry, neurology and neuropsychology. Neuropsychiatric disorders are sometimes referred to as neurobehavioral disorders.

The complexity of neuropsychiatric disorders arises from the high level of etiologic heterogeneity and involvement of several multifactorial environmental and genetic factors 5.

Statusquo of the diagnostic tools and animal models for neuropsychiatric disorders

Current medical practice is standing on three pillars namely:-

- 1) The symptoms presented by the patient
- Diagnosis by the physician on the basis of the symptoms.
- 3) Prescribing an optimum therapeutic regimen.

From above, it can be concluded that the accurate diagnosis of any disorder plays a crucial role in providing the optimum therapeutic treatment. However in case of neuropsychiatric disorders; psychiatrists face an intricate amalgamation of emotional, behavioural and cognitive symptoms. Hence the diagnosis is often based on self-reported symptoms, behaviour of the patient and their mental history. In reality, these diagnostic evaluations are often incomplete, unstructured, open-ended, and prone to inaccuracy and may cause misdiagnosis of the patient "Translational animal models are essential for the bench-to-bedside journey of a potential drug molecule. Not only the animal models help assess the therapeutic efficacy of the drug molecule but also they help in understanding the underlying pathophysiology of the disease and then identify drug targets in accordance. As mentioned earlier, diagnosis of psychiatric disorders is largely based on the self-reported symptoms. However, self-reported symptoms like sadness, guilt, hallucination, etc. cannot be determined in animals. Some rational connections such as insomnin or abnormality in social behavior can be measured only to a certain estimate.

An ideal animal model should cover the etiology and pathophysiology of the disorder along with its symptoms and treatment in order to meet the following validation criteria.

- I. Construct validity.
- Face validity
- 3. Predictive validity.

Biomarkers: towards a new era

Biomarkers are objective, quantifiable characterists of biological processes used to indicate a pathological condition and/or pharmacological response to a therapeutic regimen.

Ideal characteristics of a biomarker in neuropsychiatric disorders

seem lifer com Page 120



Topical applications of retinoid in dermatology

Int 2 Life Sci Pharms Res. ISSN 2250 - 9480; 97-99; "Carrent Trends in Pharmacology Research - Precinical Trials" 2820.

SP-29

TOPICAL APPLICATIONS OF RETINOIDS IN DERMATOLOGY

PADMAJA KORE*, SHRADDHA MAKESHWAR¹
*P.E. Society's Modern College of Pharmacy, Yamanunagar, Nigdi, Pune-44, Juliu

ABSTRACT:

Recincids are derivatives of vitamin A, found in both natural and synthetic from Based on the molecular structure it is classified into three generation. Retinoids have been extensively studied worldwide. Retinoid is used to treat many skin conditions from acrae to photoaging. The use of retinoids is done topically and systemically. Retinoids are used in concer treatment and prevention. This article is a review of retinoid, its introduction, classification, and topical applications of retinoid in dermanology. Skin conditions such as acrae vulgaris, resacces, Psoriasis, Lichen planus, lehtlyosis, Darier's diseases, Skin aging and Skin pigmentation are been covered in the neview.

Key words: Retinoid, isotretinoin, tretinoin, alitretinoin.

INTRODUCTION:

Retinoid were introduced to dematology in 1980s. The pleiotropic effects of retinoids are been reported for its selective targeting. ^{1,2} The uses of rotinoid in the dematological field have been increased after its introduction due to the selective targeting of the certain skin structure, resulting in continuous broadening of the therapeutic range. The understanding of the retinoid function was cleared in late 1980s and early 1990s, after the identification of the retinoid binding protein. ^{1,4} After the introduction to retinoids, it is been extensively used in for systemic and topical treatments in various diseases. Retinoids are naturally found as well as available in synthetic forms showing specific biological effects. ²

Retinol (vitamin A) and retinoids:

Vit A has two fat soluble unoaturated isoprenoids, retinuidely de and retinoic acid which are necessary for growth and differentiation of epithelial tissues. Unlike retinoi, retinoids are derivatives of retinol and involved in the pathogenesis of certain skin diseases such as acre and psoriasis.

Classification of retinoids:

Retinoids is the derivative of vit A and classified into three generations depending upon the three substitution in its structural domain. The first-generation retinoids are noturally occurring non-aromatic retinoid which retained the cyclic structure of vit A; including retinoi, retinal, isotratinoin, tretinoin and altiretinoin. Second generation of retinoids has cyclic changes in the ring and are monoaromatic compound; it includes obetinate, motretinate and actiretin. (8) 1) Third generation of retinoids include adaptatene, tazarotene and becarrottene.

Dermatological application

Acne vulgaris

Acre vulgaris is the common skin problem. Retinoids are used in the treatment of the of acre vulgaris and related disorders as retinoids are comedolytic and anti-comedogenic. Retinoids are effective in both inflammatory and non-inflammatory acre treatment by normalizing keratinization and immunorsodulation. The retinoids also have preventive effects. However, after the clearance of the acre continuation retinoid prevent acre reoccurrence. Treatment, adaptatene and transfer are the retinoids that see topically used in the treatment of acre vulgaris; where adaptatene is more effective and stable than treatment.

Rosacea

Rosacea is another skin condition similar to the acne vulgaris, it is the condition that causes the redness and little bumps filled with pus. Topical application of retinoid helps in the treatment of resacea. According to the research adaptates has found to be effective in treating rosacea and reducing inflammatory

sewei Elpr.com




Page 134






Preparation and evaluation of sustained-release herbal matrix tablet








Healthcare common procedure coding system (HCPCS)













General procedure of medical coding







An overview of clinical audit: a vital aspect to improve quality care







Evaluation of antiurolithiatic activity of flavonoid rich fraction of sesbania grandiflora leaves in experimental animals





An overview on basics of medical writing

mirrolles and a company through the control of the

MCOP 08: EVALUATION OF ANTIUROLITHIATIC ACTIVITY OF FLAVONOID RICH FRACTION OF SESBANIA GRANDIFLORA LEAVES IN EXPERIMENTAL ANIMALS

Chaitali S. Waghmarel*, Sonali S. Nipatz

Modern College of Pharmacy, Yaoumanagae, Nigdi, Pune

Abstract:

Objective: The present study is to evaluate the antiurolithiatic effect of flavonoid rich fraction of Sesbania grandiflora leaves against calcium oxalate induced urolithiasis in experimental animals.

Methods: Urolithiasis was induced in rats by feeding them with ethylene glycol and ammonium chloride in drinking water. Antiurolithiatic activity of S. grandiflora was evaluated at two doses (200, 400 mg/kg) in experimental animals. Cystone (750mg/kg) was used as standard drug. The dose effect was estimated by biochemical changes in urine, serum and histological changes in kidney.

Result: Ethylene glycol-ammonium chloride feeding caused an increase in urinary volume, oxalate, phosphate and urea, uric acid levels along with decrease in magnesium. Treatment with S. grandiflora prevent the elevation of serum creatinine, uric acid, urea and blood urea mitrogen levels. Histological study revealed minimum damage and less number of calcium oxalate deposits in the kidney of S. grandiflora treated rats.

Conclusions: These results indicates that S. grandiflora reduced and prevented the growth of urinary stones. These finding supports the traditional use of S. grandiflora for urolithiasis. Keywords: Urolithiasis, Calcium Oxalate, Sesbania grandiflora, Ethylene glycol, Ammonium chloride

MCOP 09: AN OVERVIEW ON BASICS OF MEDICAL WRITING

Charmaine Richardson, Padmaja kore

Progressive educational society, modern college of pharmacy, Nigdi, Pune, India

Abstract:

Activity of producing scientific documentations by specialized writers who are typically not the ones who are scientists or doctors who performed or were involved in the research. In pharmacoutical world medical writing erupted as an essential field because industry recognized it requires special skills to produce well-structured documents that present information clearly and concisely. Required skills for medical writing are detailing, excellent writing and comprehension, interpersonal skills organizational skills and scientific skills. Clinical trial procedures are really complex, todious and lengthy till it leads to market approval and this demand for well written, stand compliant documents that medical and science professionals can easily and quickly read and understand.


Keywords: Scientific documentation, professionals, well-structured documents, complex writing and comprehension, interpersonal and organizational skills.

P.E.S. MODERN COLLEGE OF HIGHMAN, YAMEMANAGAR, NIGOL, PUNE - A4






An overview of keratoconus and treatment







To assess knowledge and practice of menstrual hygiene amongst the female students





Evaluation of inhaler techniques use in asthma and COPD patients at urban

SECTION AND CONTRACT CONSTRUCTIONS WITHOUT PRODUCTIONS

MCOP 12: IN SILICO DESIGN, SYNTHESIS AND EVALUATION OF IN-VITRO ANTI-TUBERCULOSIS ACTIVITY OF NEW 2-AMINO 6-METHYL PYRIDINE DERIVATIVES

Dayaneshwar Paithane*, Mukesh Mohite

Abstract:

The discovery of new anti-Tubercular agent is become necessary for effective TB treatment. Nowadays the strategy for new drug development is directed towards Computer Aided Drug Design (CADD) techniques such as Molecular Docking. In the present investigation docking study of different 2°, 5- dimethyl-4-phenyl [2,3'-bipyridin]-6'-amine derivatives on different targets was carried out with the reference of as standard pyrazinamide, streptomycin and ciprofloxacin drug. The docking experiments were performed by using Moule docking software. With the aim of developing new biologically active compound, a series of derivatives were 2',5-dimethyl-4-phenyl[2,3'-bipyridin]-6'-amine synthesized. The chemical structures of compounds were characterized by IR and NMR. The In-vitro anti-TB activity of synthesized compound was performed by using microplate Alamar Blue assay (MABA) and compound 1°C, 2°C & 4°C showed moderate to good antitubercular activity.

Key words: Molecular docking, Anti-tuberculosis drug, In-vitro study, Target identification, Drug discovery

MCOP 13: EVALUATION OF INHALER TECHNIQUES USE IN ASTHMA AND COPD PATIENTS AT URBAN COMMUNITY PHARMACY

Esha Patel¹, Narendra B. Parihar

Department of Pharmacology, PES Modern College of Pharmacy, Nigdi. Pune.

Abstract:

Method: It is cross sectional study based on survey where a proper questionnaire was designed for patients who visited to pharmacy to purchase prescription or refilling their inhaler are included. Samples of 95 patients were asked to solve the questionnaire from them 17 patients denied and also their socio-demographic details were captured during this study.

Result: Out of 78 patients enrolled in the study majority from 30-60 year of age group among them 42.31% were schooling, 32.05% where graduated and 25.64% were non schooling, 39.74% were diagnosed with COPD and 60.26% with asthma. The most common errors seen for MDI was in step 6 which was seen in 35 patients and step 7 which was seen in 43 patients. Same in DPI was in step 8 which was seen in 36 patients. The other findings are 32.05% patients do not gargle after use of inhales and about 47.43% patients were not comfortable to use inhalers in public and majority of patients clean the device very frequently after the use of inhales.

Conclusion: The results showed that there is a need of proper counselling and providing education to the patient about the use of inhaler device during each visit to achieve proper drug delivery and disease control.


Keywords: Metered dose inhaler (MDI), Dry powder inhaler (DPI)

P.E.S. MODERN COLLECT OF PRODUCE, YANGINARAGAE, MIGDL PUNE - 44





Development and evaluation of nanoliposomes and nanocochleates of docetaxel and paclitaxel.





How a long forgotten virus could help us solve antibiotic crisis?





Diabetic foot ulcer and its management-a review

WHEN THE COMPANY OF THE PROPERTY OF THE PARTY #### MCOP 25: RECENT ADVANCES IN ICHTHYOSIS AND ITS PATHOPHYSIOLOGY

Nikita Chaudhari, Kaloita Kulkarni, Robini R. Puiari

PES, Modern College of Plurmacy (For Ladies), Moslii, Pane

Abstract:

Ichthyosis refers to group of skin disorders also called as disorders of keratinization or comification (DOK), constitutes a heterogeneous group of skin diseases associated by the common clinical feature of abnormal barrier function, causing a default compensatory pathway of hyperproliferation, resulting into generalized or localized scaling of skin. Other clinical manifestations include generalized crythroderma, xerosis, palmoplantar and hypohydrosis keratoderma infections. Dependent on pathophysiology, mode of inheritance and clinical features, icthyosis was firstly classified at Ichthyosis Consensus Conference in 2009 into two forms: nonsyndromic forms having clinical features limited to the skin and syndromic forms including involvement of additional organ systems. This review mainly gives the details about the definition, types, etiology, epidemiology, prevalence rate, pathophysiology, immunology, clinical features, diagnosis and treatment of ichthyosis.

MCOP 26: DIABETIC FOOT ULCER AND ITS MANAGEMENT-A REVIEW

Prachi Gholve, D. D. Bundawane

Modern College of Pharmacy, Nagdi, Pune

Abstract

Diabetes mellitus (DM) is a serious and multifaceted disease affecting almost all the important organs in the body. DM is known to have many complications and Diabetic Foot Ulcer (DFU) is the most costly and devastating complication of DM. It affects 15% of diabetic patients during their lifetime. Multiple factors play a role in the development of DFU, The primary pathology is peripheral neuropathy and peripheral arterial disease (PAD) accompanied with deformities of foot anatomy due to motor neuropathy.

According to studies, blood sugar control, wound debridement, advanced dressings and offloading modalities should be a part of DFU management. Further, surgery to heal chronic ulcer and prevent recurrence should be considered as an essential component of management. DFU puts enormous financial burden on the patient and the health care services, even though it is preventable. Hence, proper patient education encourages them to regular foot care in order to prevent DFU. The aim of this review is to discuss the various risk factors for diabetic foot ulceration, pathogenesis, diagnosis, treatment and management of diabetic foot ulcers.


P.E.S. MODERN COLLEGE OF PRARMACY, YAMUNANAGAR, NIGER, PUNE + 61







Overview current coding process







Dapsone induced hypersensitivity syndrome




Progressive Education Society's Modern College of Pharmacy, Nigdi, Pune 411044






Formulation, optimization and characterization of glibenclamide oral dispersible tablet by using solid dispersion technique






Coronavirus & Covid 19






Alopecia Areata







Current scenario of medical coding



Progressive Education Society's Modern College of Pharmacy, Nigdi, Pune 411044





Current approaches in treatment of psoriasis




Progressive Education Society's Modern College of Pharmacy, Nigdi, Pune 411044






Necrobiosis lipoidica







Effect Of Moringa Olifera Non-Alcoholic Fatty Liver Diseases (NAFLD)







Phyto-Nanoparticles For TDDS

MCOP 51: PHYTO-NANOPARTICLES FOR TDDS Satkar S. S., More A. G. Modern College of Pharmacy, Nigdi; Pune, Maharashtra, India Abstract: Nanoparticles have the potential to effectively deliver drugs across the skin burrier. Phytopharmaceuticals are pharmaceuticals using traditional compounds derived from botanicals instead of chemicals. Because these natural ingredients are more easily and more readily metabolized by the body they produce fewer if any side effects and provide increased absorption in the bloodstream resulting in more thorough and effective treatments unlike pharmaceuticals produced from chemical compounds which are prone to adverse side effects. Topical or transdermal drug delivery is challenging because the skin acts as a natural and protective barrier. The aim of this review is to summarize various novel approaches, which have been developed for dermal and transdermal delivery of herbal drugs delivery to achieve better therapeutic response. Development and evaluation of colon targeted delivery of budesonide polymeric nanoparticles for colitis therapy Purpose: Targeted delivery of the drug at site of action in case of Inflammatory Bowel disease like colitis is the big challenge for formulators. The case where conventional drug delivery fails in severe stages of Inflammatory Bowel Disease, Nanoparticles is good dosage form to targeted inflammatory site. Method: Nanoparticles were prepared by using modified Nanoprecipitation method using probe sonication. Budesonide and Eudragit \$100 were weighed and dissolved in Ethanol as organic phase. Then this solution was added drop wise into the water containing Polexamer as aqueous phase under probe sonication for 10 - 15 min. The nanosuspension was subjected to rotavapor for removal of free ethanol. The mixture placed into oven for drying Nanoparticles. The formed nanoparticles were filled in capsules. Results: Nanoparticles formed were optimized and were evaluated for following parameters. Entrapment Efficiency 89.52%. In Vitro drug release for nanoparticles is 85.87% In Vitro drug release for capsules is 88.45%. Particle size was 318.8 nm. Stability study was carried out at 25°C +5°C for 1 month, 3 months and 6 months and formulation were stable. Conclusion: In current study we developed polymeric nanoparticles of Budesonide to target colon in the treatment of colitis which minimized drug release in the stomach and maximum drug release in colon for treatment of IBD, Ulcerative Colitis. Extensive clinical studies will further substantiate the merit of this novel formulation. Keywords: Budesonide; Eudragit S100; Colitis; Nanoparticles, Herbal drugs delivery, Phytonanoparticles. Transdermal delivery




An overview on anti-fraud software








Future & New Trends in Medical Coding & Billing





An overview of various software's used in medical coding







Trends in healthcare & automated coding








Proper Patient Counseling For Type 1 Diabetes Mellitus In Pediatric Patients







Types of medical coding





Effect of alstoniascholaris (linn) on fructose induced insulin resistance

MCOP 65: SYNTHESIS, MOLECULAR DOCKING, INSILICO ADME SCREENING AND INVIVO AND INVITRO SCREENING FOR ANALGESIC ACTIVITY OF 2-METHYLSULFANYL-1, 4-DIHYDROPYRIMIDINES Varsha L Sarode Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune Abstract: 2-Methylsulfanyl-1, 4-dihydropyrimidine derivatives (II) were synthesized in good yields by alkylation of 1,2,3,4-tetrahydropyrimidines (I) with methyl iodide in the presence of pyridine. Their structures were confirmed by IR and IH NMR, 13C NMR and Mass spectrometry. Molecular docking of a series of 2-methylsulfanyl-1, 4-dihydropyrimidine derivatives was done using cyclooxygonase-2 enzyme (PDB code 1PXX) to identify potential candidates with minimum dock score for analgesic activity. The docking of the title compound yielded dock scores ranging from -6.372 to -8.744. Insilico ADME and physicochemical properties screening was done using swiss ADME software. 3D Shape similarity study was done using ROCS (Rapid Overlay of Chemical Structures) software. Visualization of the result was done using VIDA software. Computeds are having 0.652 to 0.775 Tonimotto combine score which indicates 65.2 to 77.5 % shape and electrostatic similarities. All compounds were tested for analgesic activity by acetic acid induced writhing method. The compound IIh and III exhibited maximum analgesic activity. Compounds He Hf, Hg and Hk showed good activity. Remaining compounds showed moderate analgesic activity. Invitro cyclooxygenase COX-2 inhibition assay was done using COX 2 (human) Inhibitor screening assay kit. Title compounds exhibited inhibitory activity against COX-2 (IC50 = 0.66-0.87 µM). MCOP 66: EFFECT OF ALSTONIA SCHOLARIS (LINN) ON FRUCTOSE

MCOP 66: EFFECT OF ALSTONIA SCHOLARIS (LINN) ON FRUCTOSE INDUCED INSULIN RESISTANCE

> Varsha D. Satav*, Deepti D. Bandawane Modern College of Pharmacy, Nigdi, Pune

Abstract:

Fructose consumption has increased exponentially in the past decade due to excessive consumption of processed food and sugar sweetened beverages (SSB). The high levels of fructose are then metabolized via de novo lipogenesis (DNL) in the liver. The activation of DNL pathway increases serum levels of Triglycerides, Uric acid, Lactate and Diacylglycerol. This increased lipid production causes fatty infiltration in hepatocytes leading to hepatic steatosis. This altogether down regulates the insulin receptor substrate (IRS) cascade leading to insulin resistance. Insulin resistance can be induced in female Wistar rats by replacing water with 60% w/v fructose water for 21 days. The ethanolic extract of A. scholaris is rich in alkaloids. Ethanolic extract of A. scholaris bark has proven anti-diabetic activity due to increased glucose uptake thereby increasing the efficiency of insulin. A. scholaris has proven hepatoprotective activity. Ethanolic extract of A. scholaris may reverse Hepatic Insulin Resistance.

Keyword-Insulin resistance, De novo lipogenesis pathway, Fructose.

P.E.S. MODERN COLLEGE OF PHARMACY, YAMUNANAGAR, NGGE, PUNE - 48



Brief Note on Cromhidrosis

MCOP 67: PAINLESS HERBAL NANO-PATCH FOR POISONOUS SITUATION

Vighnesh Jadhay*, Pragati kod, Vanita Gade, Swati Deshmakh

Siddhant College of Pharmacy, Sudambre, Pune.

Abstract:

Background: Just creating a solution for the problem arising in the rural area for the poisonous bite of scorpion. Due to the lack of treatment and medication they are facing many problem and thereby using traditional method. This method is effective but taking more time for action and hence making a way to this problem by formulating herbal nanopatch for fast action. The main objective of this study was to prepare and evaluate herbal nanopatch containing nanoparticles of flavonoid, it can be used as Antivenomic and Anti-inflammatory activity with more effect and fast onset of action.

Method: Herbs are selected from Sudumbare village. The parts of plant such as leaves and seed dried at room temperature and grind to make a powder. This powder was extracted and Flavonoids was separated. Prepared nanoparticles from flavonoids by precipitation method and this nanoparticles used for prepare nanoparch by nanoprecipitation method.

Result: For greater activity drug particles converted to nanoparticles with varying proportions of flavonoid and PSA-PEG were prepared by nano-precipitation method. The Nanoparticles was evaluated by SEM analysis, microscopic analysis. The nanopartic containing a nanoparticles of flavonoids confirmed by shinoda test, TLC and maximum absorbance was found to be 284 nm.

Conclusion: This nanopatch content polyherb nanoparticles which can be used as antivenomic and anti-inflammatory activity with more effect and fast action.

MCOP 68: A BRIEF NOTE ON: - CROMHIDROSIS

Yogish D Garliwani, Padimaja S. Kore Modom College of Pharmacy, Nigo, Pune

Abstract:

Chromhidrosis is a rare condition characterized by the secretion of coloured sweat. It is caused by deposition of lipofuscin in the sweat glands. Cases of red, blue, green, yellow, pink & black sweat have been reported. Usually chromhidrosis affects the apocrine glands, mainly on the face and underarms. Limited number of treatment options exist including regular application of Capsaicin cream and prolonged relief may be provided by botulinium toxim treatment. It occurs mainly after the ingestion of certain dyes or drugs.

Keywords: Chromhidrosis, Colored sweat, Dyes, Drugs

AND THE PARTY OF T





ACADEMIC YEAR: 2018-2019

INDEX

| Sr. No. | Title of Books and chapters in edited volumes / Books Published / Conference proceedings | Page No. |
|---------|---|----------|
| | BOOKS | |
| 1. | Pharmaceutical Analysis | 348 |
| 2. | Computer Application in Pharmacy | 355 |
| 3. | Pharmaceutical Inorganic Chemistry | 362 |
| 4. | Biochemistry | 366 |
| 5. | Environmental Science | 371 |
| 6. | Pharmaceutical Analysis-I | 376 |
| | BOOK CHAPTERS | |
| 7. | Chapter 12 Anti-diarrohealscreeing (in vivo and in vitro methods | 386 |
| 8. | Chapter 9 Screening methods for drugs acting on renal system | 391 |
| | CONFERENCE PROCEEDINGS | |
| 9. | Formulation and development of guaifenesin extended release bi-layer tablets | 397 |
| 10. | Formulation and development of ritonavir dispersible tablets | 399 |
| 11. | Development and validation of stability indicating assay method for azelastine Hcl and ciclesonide by RP-HPLC | 400 |
| 12. | Development and validation of stability indicating assay method for azelastine Hcl and ciclesonide by RP-HPLC | 400 |
| 13. | Design, synthesis & biological evaluation of some anti-inflammatory agents | 401 |
| 14. | Design, synthesis & biological evaluation of some anti-inflammatory agents | 401 |





| 15. | Molecular docking, synthesis and biological evaluation of some 2-(5-h/chloro-((morpholino1-yl-methyl)-2-oxoindolin-3- ylidene)-n-substituted hydrazinecarbothioamides | 402 |
|-----|---|-----|
| 16. | Molecular docking studies of quinazolinone-sulfonamide hybrids for finding a potential dipeptidyl peptidase-4 (dpp-4) inhibitor for type-2 diabetes | 403 |
| 17. | Evaluation of protective activity of gentisic acid against 5-flurouracil induced toxicities in laboratory animals | 404 |
| 18. | In vitro antioxidant and anticholinesterase potential of owers of nyctanthesarbortristislinn.: a therapeutic lead for alzheimer's disease | 405 |
| 19. | <u>In vitro antioxidant and anticholinesterase potential of owers of nyctanthesarbortristislinn.</u> : a therapeutic lead for alzheimer's disease | 405 |
| 20. | Evaluation of the immunomodulatory activity of abelmoschus manihotlinn in various animal models | 406 |
| 21. | Development and evalution of spironolactone oral suspension | 407 |
| 22. | Development of self micro emulsifying drug delivery system and its in-vitro study for delivery of curcumin | 408 |
| 23. | Formulation and evaluation of acetazolamide nanosuspension for opthalmic delivery | 409 |
| 24. | Enhancement of solubility of glibenclamide by complexation with humic acid | 410 |
| 25. | Effect of surfactants and co-surfactants on phase behavior and physicochemical properties of self-nanoemulsifying drug delivery system loaded with plumbagin | 411 |
| 26. | Formulation development and evaluation of immediate release tablet of antiretroviral containing fixed dose combination drugs | 412 |
| 27. | Formulation development and evaluation of immediate release tablet of antiretroviral containing fixed dose combination drugs | 412 |
| 28. | Antibiotic loaded nanocomposite scaffolds for periodontal disease | 413 |
| 29. | Antibiotic loaded nanocomposite scaffolds for periodontal disease | 413 |








| 30. | Development of alphatocopherol loaded nanostructured lipid carrier (NLC) for topical drug delivery | 414 |
|-----|--|-----|
| 31. | Molecular modeling approach to develop dipeptidyl peptidase iv inhibitor as antidiabetic agent | 415 |
| 32. | Molecular docking study of albendazole onto vegfr-2 for anticancer therapy | 416 |
| 33. | Molecular docking study of albendazole onto vegfr-2 for anticancer therapy | 416 |
| 34. | Molecular docking study of albendazole onto vegfr-2 for anticancer therapy | 416 |
| 35. | Synthesis, evaluation and molecular docking of sulphonamide/ isothiocyanate linked quinazolinone derivatives as antidiabetic activity | 417 |
| 36. | LC-MS/MS characterization of alkaline stress degradation product : development and validation of stability indicating method of rivaroxaban by HPTLC | 418 |
| 37. | Development and validation of hptlc method for estimation of rosmarinic acid in plant extract and in polyherbal formulation | 419 |
| 38. | HPTLC method for qualitative and quantitative analysis of quercetin from epiphyllum oxypetalum | 420 |
| 39. | HPTLC method for qualitative and quantitative analysis of quercetin from epiphyllum oxypetalum | 420 |
| 40. | Stability indicating assay methods for candesartan cilexetil and hydrochlorothiazide in bulk and tablet dosage form by RP-HPLC | 421 |
| 41. | Anti-inflammatory potential of leaves flavonoid rich ethyl acetate fraction of methanolic extract of stereospermumsuaveolens dc in wistar rats | 422 |
| 42. | Protective effect of abutilon indicum linn. Leaves extract in high-fat diet (HFD) and streptozotocin-induced metabolic syndrome rats | 423 |
| 43. | Study of effect of sterculia foetidalinn.(sterculiaceae) seeds on insulin resistance in type ii diabetes mellitus in rats | 424 |






Pharmaceutical Analysis



348







349










TABLE OF CONTENTS

Unit - I

| Cha | pter - 1 Introduction to Pharmaceutical Analysis (1 - 1) to (1 - 34) |
|-----|--|
| 1.1 | Introduction |
| 1.2 | Techniques of Pharmaceutical Analysis |
| 1.3 | Methods of Expressing Concentration |
| 1.4 | Primary and Secondary Standards1 - 13 |
| 1.5 | Preparation and Standardization of Various Molar |
| | and Normal Solutions |
| Cha | pter - 2 Errors (2 - 1) to (2 - 13) |
| 2.1 | Sources and Types of Errors 2 - 1 |
| 2.2 | Methods of Minimizing Errors |
| 2.3 | Accuracy, Precision and Significant Figures 2 - 7 |
| Cha | oter - 3 Pharmacopoeias, Impurities and Limit Test (3 - 1) to (3 - 30) |
| 3.1 | Pharmacopoeia and History of Pharmacopoeia 3 - 1 |
| 3.2 | Impurity, Sources and Types of Impurities |
| 3.3 | Limit Test and Importance of Limit Test |
| | |

(vi)





| | Unit - II |
|---------------------------------|--|
| Cha | pter - 4 Acid - Base Titration (4 - 1) to (4 - 34 |
| 4.1 | Introduction |
| 4.2 | Theories of Acids and Bases |
| 4.3 | Titration Curves for Acids and Bases 4 - 1 |
| 4.4 | Acid - Base Indicators |
| 4.5 | Acid Base Titrations and Their Classification 4 - 2 |
| Cha | pter - 5 Non Aqueous Titration (5 - 1) to (5 - 1 |
| 5.1 | Introduction to Non-aqueous Titration 5 - |
| 5.2 | Solvents used in Non-aqueous Titration 5 - |
| | IInit III |
| | Unit - III |
| Cha | |
| Cha 6.1 | pter - 6 Precipitation Titration (6 - 1) to (6 - 2) |
| | Introduction to Precipitation Titration (6 - 1) to (6 - 2) |
| 6.1 | |
| 6.1 | Introduction to Precipitation Titration (6 - 1) to (6 - 2) Mohr's Method 6 - Volhard's Method 6 - |
| 6.1 6.2 6.3 6.4 | Introduction to Precipitation Titration (6 - 1) to (6 - 2) Mohr's Method 6 - Volhard's Method 6 - Fajan's Method 6 - 1 |
| 6.1 6.2 6.3 6.4 | Introduction to Precipitation Titration (6 - 1) to (6 - 2) Mohr's Method 6- Volhard's Method 6- Fajan's Method 6-1 apter - 7 Complexometric Titration (7 - 1) to (7 - 1) |
| 6.1 6.2 6.3 6.4 Cha | Introduction to Precipitation Titration (6 - 1) to (6 - 2) Mohr's Method 6- Volhard's Method 6- Fajan's Method 6-1 apter - 7 Complexometric Titration (7 - 1) to (7 - 1) |
| 6.1 6.2 6.3 6.4 Cha | Introduction to Precipitation Titration (6 - 1) to (6 - 2) Mohr's Method 6- Volhard's Method 6- Fajan's Method 6-1 Apter - 7 Complexometric Titration (7 - 1) to (7 - 1) Introduction 7 - |







| | (viii) Chelating Agents |
|------|--|
| .5 | Chelating Agents |
| 7.6 | Blank Titrations |
| 7.7 | Estimation of Magnesium Sulphate and Calcium Gluconate. 7 - 18 |
| Cha | pter - 8 Gravimetry (8 - 1) to (8 - 21) |
| 3.1 | Principles and Steps Involved in Gravimetric Analysis 8 - 1 |
| 8.2 | Types of Gravimetric Analysis 8 - 4 |
| 8.3 | Purity of Precipitate 8 - 9 |
| 8.4 | Estimation of BaSO ₄ 8 - 20 |
| Cha | pter - 9 Diazotisation Titration (9 - 1) to (9 - 7) |
| | Unit - IV |
| | |
| Ch | apter - 10 Redox Titrations (10 - 1) to (10 - 33) |
| 10. | Introduction |
| 10.2 | |
| 10. | 3 Principle: Redox Titrations |
| 10. | |
| | 5 Redox Indicators |
| 10. | Unit - V |
| 10. | |
| | |
| | napter - 11 Conductometric Titration (11 - 1) to (11 - 14) |
| | napter - 11 Conductometric Titration (11 - 1) to (11 - 14) .1 Introduction to Conductometry |
| CI | napter - 11 Conductometric Titration (11 - 1) to (11 - 14) 11 Introduction to Conductometry |






| Chapter - 12 Potentiometry (12 - 1) to (12 12.1 Introduction to Potentiometry and Electrochemical Cell | 11.3 Applications, Advantages and Disadvantages of Conductometric titrations | | |
|--|---|-------|--|
| and Disadvantages of Conductometric titrations | and Disadvantages of Conductometric titrations | 11 3 | |
| Chapter - 12 Potentiometry (12 - 1) to (12 12.1 Introduction to Potentiometry and Electrochemical Cell | Chapter - 12 Potentiometry (12 - 1) to (12 - 2) 12.1 Introduction to Potentiometry and Electrochemical Cell | | |
| 12.1 Introduction to Potentiometry and Electrochemical Cell | 12.1 Introduction to Potentiometry and Electrochemical Cell 12 - 12.2 Construction and Working of Reference Electrode (Standard Hydrogen, Silver Chloride Electrode, Calomel Electrode) 12 - 12 - 12 - 13 Indicator Electrodes (Metal and Glass Electrodes) 12 - 13 Methods to Determine Endpoints in Potentiometric Titrations 12 - 13 Applications of Potentiometry 12 - 2 Enapter - 13 Polarography (13 - 1) to (13 - 13 - 13 - 13 - 13 - 13 - 13 - 13 | | |
| 12.2 Construction and Working of Reference Electrode (Standard Hydrogen, Silver Chloride Electrode, Calomel Electrode) | (Standard Hydrogen, Silver Chloride Electrode, Calomel Electrode) | | (12 - 1) 10 (12 - 1) |
| (Standard Hydrogen, Silver Chloride Electrode, Calomel Electrode) | (Standard Hydrogen, Silver Chloride Electrode, Calomel Electrode) | | |
| Calomel Electrode) | Calomel Electrode) | 12.2 | |
| 12.3 Indicator Electrodes (Metal and Glass Electrodes) 12 12.4 Methods to Determine Endpoints in Potentiometric Titrations 12 12.5 Applications of Potentiometry 12 Chapter - 13 Polarography (13 - 1) to (13 - 3.1 Principle of Polarography and Iikovic Equation 13 | 2.3 Indicator Electrodes (Metal and Glass Electrodes) | | |
| 12.4 Methods to Determine Endpoints in Potentiometric Titrations | 2.4 Methods to Determine Endpoints in Potentiometric Titrations | 10.0 | Calomel Electrode) |
| Titrations | Titrations | | Proceedings (Wetai and Glass Electrodes)12 - |
| 12.5 Applications of Potentiometry | 2.5 Applications of Potentiometry | 12.4 | |
| Chapter - 13 Polarography (13 - 1) to (13 - 3.1 Principle of Polarography and Iikovic Equation | Chapter - 13 Polarography (13 - 1) to (13 - 13 - 13 - 13 - 13 - 13 - 13 - 13 | 12.5 | |
| 3.1 Principle of Polarography and Iikovic Equation | 3.1 Principle of Polarography and Iikovic Equation | | |
| 3.1 Principle of Polarography and Iikovic Equation | and Rotating Platinum Electrode | Cha | oter - 13 Polarography (13 - 1) to (13 - 1) |
| | and Rotating Platinum Electrode | 13.1 | Principle of Polarography and Iikovic Equation13 - |
| | Applications of Polarography | 13.2 | Construction and Working of DME |
| and Rotating Platinum Electrode | olved Sample Question D | | and Rotating Platinum Electrode |
| 3.3 Applications of Polarography | olved Sample Question Papers (S - 1) to (S - 7) | 13.3 | Applications of Polarography |
| olved Sample Question Papers (S - 1) to (S | | Solve | ed Sample Question Papers (S - 1) to (S - 7) |
| | | | |
| | | | |
| | | | |
| | | | and the Committee of th |
| | | | TCA PHARMA |
| TCA PHARMA | TCA PHARMA | | |





Computer Application in Pharmacy







COMPUTER **APPLICATIONS IN PHARMACY**

B.Pharm., Second Semester

According to the syllabus based on Pharmacy Council of India College of

Dr. R M. Akila

M.Pharm, Ph.D Associate Professor,

College of Pharmacy, Sri Ramakrishna Institute of Paramedical Sciences, Coimbatore

Dr. Pravin S. Uttekar

B.Pharm, M.Pharm, Ph.D (Pharmaceutical Sciences) Assistant Professor,

P.E. Society's Modern College of Pharmacy, Pune

Books are Available for Online Purchase at: tppl.org.in



THAKUR PUBLICATION PVT. LTD., LUCKNOW

* Meerut * Bhopal * Nagpur * Bhubaneswar * Jaipur * Jalandhar *

* Chennai * Bengaluru * Ahmedabad * Pune * Hyderabad * Rohtak * Kerala *



First Edition 2018

ISBN - 978-93-87483-20-0

Copyright © All Rights Reserved

This book is sole subject to the condition that it shall not, by way of trade or otherwise, be lent, resold, hired out, or otherwise circulated without the publisher's prior written consent, in any form of binding or cover, other than that in which it is published and without including a similar condition. This condition being imposed on the subsequent purchaser and without limiting the rights under copyright reserved above, no part of this publication may be reproduced, stored in or transmitted in any form or by any means (electronic, mechanical, photocopying, recording or otherwise), without the prior written permission of both the copyright owner and the below mentioned publisher of this book.

Published by:

Thakur Publication Pvt. Ltd.

FF-107, Adarsh Complex, Engineering College Crossing, Opp. Allahabad Bank, Lucknow-226021.

Mob.: 9415584997/98, 9235318591,94,95,96,97/22

Website: www.tppl.org.in E-mail: thakurpublication@gmail.com

Our branch office in India:

- Thakur Publication Pvt. Ltd., 9-D, Gali No. 2, Rajendra Nagar, Shambhu Das Gate, Nauchandi, Meerut-250001. Mob. 9235318516, 9457820674.
- Thakur Publication Pvt. Ltd., Plot No. 109, Nawa Nakash, Behind Jaiswal Restaurant, Near Choti Maszid, Nagpur-440017. Mob. 09595029116.
- Thakur Publication Pvt. Ltd., C.T.S. No-635, Flat No-T-7, Third Floor, Bhudhwar Peth, ABC Market, Pune-411002. Mob. 09373086387, 9326863355, 9325036341, 9595076005/08.
- Thakur Publication Pvt. Ltd., House No. 46/1309, Kattikaran House, Feroz Gandhi Lane, Vaduthala (Post), Ernakulam, Kerala-682023. Mob. 9207296272, 9207296273, 9207296271.
- Thakur Publication Pvt. Ltd., House No. 8, Ambu Nagar, Main Road, Goverthanagiri, Avadi, Chennai-600071. Mob. 9543605656, 8144126950, 9543247241, 8124457101, 9543247130.
- Thakur Publication, H.No. 765, Badwale Chamatkareshwar Mahadev Mandir, Godi ki Gali, Maniharon ka Rasta, Kishan Pol Bazar, Jaipur-302003. Mob. 9351193641.
- Thakur Publication, H.No. 12/14, Sukhram Nagar Society, Opp. Watar Tank, Lane No. 2, Rakhial Road, Gomtipur-Ahmedabad-380021. Mob. 9328829591, 9374374905, 9328622684.
- Thakur Publication, House No. 77-2 RT, Municipal Colony, Near Yashoda Hospital, Malakpet, Hyderabad-500036. Mob. 09396389594, 09391550531, 09346575384.
 Thakur Publishors H No. 172 Naina Giri J K. Bond Phonel 462023. Mob. 0601717025
- Thakur Publishers, H.No. 172, Naina Giri, J.K. Road Bhopal-462022. Mob. 9691717925, 9691717928, 7879146233.
- Thakur Publishers, Plot No. 3368/8777, Prachi Vihar, Post- GGP Colony, P.S. Mancheswar, Dist. Khurda, Bhubaneswar-751025. Mob. 9337585809.
 Thakur Publishers, House No. 1076, Harbans Nagar, Jalandhar-144002. Mob. 9357816968,
- 8591828212, 8591850332.
 12. Thakur Publishers, House No. 120, 2nd Main, 2nd Cross, Brindavan Nagar, D.R.C. Post, Bengaluru-560029. Mob. 9341835403, 9379798011, 9343859590, 8880441707.
- Thakur Publishers, H.No.34, Ward No. 6, Behind Verma Petrol Pump, Bhiwani Chungi, Rohtak-124001. Mob. 7876991824, 7876991825, 9068601142, 9729004576.





| | - 10 - |
|------------------|---|
| | Contents |
| | |
| 1.1. | Chapter 1: Number System |
| 1.1.1 | Trumber System |
| 1.1.2 | - introduction |
| 1.1.2 | |
| 1.1.2 | |
| 1.1.2 | 3. Octal Number System |
| 1.1.2 | 4. Hexadecimal Number System |
| 1.1.2 | 3. Relationship between Binamy O-t-1 |
| 1.2. | Conversion from One Number System to Another Introduction |
| 1.2.1. | |
| 1.2.2. | Dillary to Decimal Conversion |
| 1.2.3. | Decimal to Binary Conversion |
| 1.2.5. | Decimal to Octal Conversion Octal to Decimal Conversion |
| 1.2.6. | Octal to Bermal Conversion Octal to Binary Conversion |
| 1.2.7. | Binary to Octal Conversion |
| 1.2.8. | Decimal to Hexadecimal Conversion |
| 1.2.9. | Hexadecimal to Binary Conversion |
| 1.2.10 | Dinary to Hexadecimal Conversion |
| 1.3. | Arithmetic Operation |
| 1.3.1. | Introduction |
| 1.3.2. 1.3.3. | Billary Addition |
| 1.3.4. | Binary Subtraction |
| 1.3.5. | Binary Multiplication Binary Division |
| 1.4. | Signed Binary Numbers |
| 1.4.1. | Introduction |
| 1.4.2. | One's Complement |
| 1.4.3. | Two's Complement |
| 1.5. | Summary |
| 1.6. | Exercise |
| Cha | pter 2: Concept of Information Systems and Softwar |
| 2.1. | Information Systems (IS) |
| 2.1.1. | Introduction |
| 2.1.2. | Characteristics of Information Systems |
| 2.2. | Software |
| 2.2.1. | Introduction |
| 2.2.2. | Types of Software |
| 2.3.1. | Information Gathering Introduction |
| 2.3.2. | Information Gathering Tools |
| 2.4. | Requirement Tools |
| 2.4.1. | Introduction |
| 2.4.2. | System Requirements |
| 2.4.3. | User Requirements |
| 2.5. | Feasibility Analysis |
| 2.5.1. | Introduction |

358





| | | - 12 - | |
|-------|----------------|---|-----|
| | 3.2. | ALIVIL | |
| | 3.2. | - introduction | |
| | 3.2. | 2. Need and Significance of VMI | |
| | 3.2.: | 3. Difference between HTML and XML | |
| | 3.2.4 | 4. Syntax | |
| | 3.2.5 | XML Syntax Rules | |
| | 3.2.6 | 5. XML Editors | |
| | 3.3. | CSS (Cascading Style Sheets) | |
| | 3.3.1 | . Introduction | |
| | 3.3.2 | Benefits of Using Coo | |
| | 3.3.3 | Pagin Com. | |
| | 3.4. | Programming Languages | |
| | 3.4.1 | Introduction | |
| | 3.4.2. | Features of Programming Language | |
| | 3.4.3. | Classification of Programming Language | |
| | 3.4.4. | Classification of Programming Languages Efficient Programming Languages | |
| | 3.5. | Web Servers | |
| | 3.5.1. | Introduction Page 10 March 1997 | |
| | 3.5.2. | Elements of Web Servers | |
| | 3.5.3. | Operation and Characteristics | |
| | 3.5.4. | Operation and Characteristics of Web Server URLs | |
| | 3.5.5. | Server Products | |
| 6.450 | 3.6. | | |
| nd. | 3.7. | Exercise | |
| 1) | | - Actorise | |
| 1 | | | |
| | 4.1. | Chapter 4: Database | |
| | 4.1.1. | Database | |
| 112 | 4.1.2. | Introduction | |
| 1.151 | 4.1.2. | Characteristics of a Database | |
| | 4.1.3. | Objective of Database | |
| | 4.1.4. | Organisation of Database | |
| | 4.1.5. | MYSQL | |
| | 4.1.6.1. | MS Access 2007 | |
| | 4.1.6.1. | Starting Access and Creating Database | |
| | 4.1.6.2. | Access Window Components | |
| | 4.1.6.4. | Data Types | |
| | 4.1.6.4. | Advantages of Microsoft Access | |
| | | Disduvantages of Microsoft A | |
| | 4.1.7. 4.2. | | |
| | 4.2. | Summary | |
| | 4.3. | Exercise | 1 |
| | | Principal Project Management | 1 |
| | C | hapter 5: Application of Computers in Pharmacy-I | |
| | 5.1. | Application of Computers in Pharmacy-I | |
| | 5.1.1. | Introduction | 1 |
| | 5.1.2. | Drug Information Storage and Potrious | 10 |
| | 5.1.3. | That macokinetics | 10 |
| | 5.1.4. | Mathematical Model in Drug Decimal | 10 |
| | 5.1.5. | 110Spital and Clinical Phormacan | 10 |
| | 5.1.6. | Electronic Prescribing (ED) Control | 10 |
| | 5.1.7. | Electronic Discharge System | 10 |
| | | AND SHAFTEL HAIF CAN MOST LINE HARRING | 10 |
| | | | 411 |
| | | | |





| | - 13 - | |
|--------------------|--|------------|
| 5.1.8. | Barcode in Healthcare Industry | 107 |
| 5.1.8.1. | T 1 1 1 1 The till action | 108 |
| 5.1.8.2. | | 108 |
| 5.1.8.3. | Save Resources | 109 |
| 5.1.8.4. | Specimen Collection | 109 |
| 5.1.8.5. | Blood Transfusion Safety | 109 |
| 5.1.8.6. | Inventory Management | 109 |
| 5.1.9. | Automated Dispensing of Drugs | 109 |
| 5.1.10. | Mobile Technology and Adherence Monitoring | 111 112 |
| 5.2. | Summary | 114 |
| 5.3. | Exercise | 114 |
| C | hapter 6: Application of Computers in Pharmacy | -II |
| 6.1. | Application of Computers in Pharmacy – II | 115 |
| 6.1.1. | Introduction | 115 116 |
| 6.1.2. | Diagnostic System | |
| 6.1.2.1. | CAD Commercial CAD Products | 116 |
| 6.1.2.2. | | 117 |
| 6.1.2.3. | Components of CAD | 118 |
| 6.1.2.4. | Utility of CAD | 119 |
| 6.1.2.5. | Limitations of CAD System | |
| 6.1.2.6. | Applications of CAD | |
| 6.1.3. 6.1.3.1. | Lab-Diagnostic System Regulating Body | 120 |
| 6.1.3.1. | Oualifications | 121 |
| 6.1.3.3. | Surveillance of Clinical Laboratories | 121 |
| 6.1.3.4. | Professional Ethics | 121 |
| 6.1.3.5. | I aboutour | 122 |
| 6.1.4. | Patient Monitoring System | 122 |
| 6.1.5. | Pharma Information System | 124 |
| 6.2. | Summary Exercise | 129 |
| 6.3. | Exercise | 130 |
| | Chapter 7: Bioinformatics | 1 1150 |
| 7.1. | Bioinformatics | 13 |
| 7.1.1. | Introduction | 13 13 |
| 7.1.2. | Origin and History | 13 |
| 7.1.3. | Objectives | 13 |
| 7.1.4. | Concept | 13 |
| 7.1.5. | Scope | 13 |
| 7.1.6. | Applications | 13 |
| 7.1.7. 7.1.8. | Advantages | 13 |
| 7.1.6. | Summary | 13 |
| 7.3. | Exercise | 13 |
| | Chapter 8: Bioinformatics Databases | |
| 0.1 | Bioinformatics Databases | 13 |
| 8.1. 8.1.1. | | 13 |
| 8.1.1. | D. 1 . 1D . 1 | 13 |
| 8.1.2.1. | 로마를 위한 경험을 보면 있다면 보고 있다면 보고 있다면 보고 있다면 보고 있다면 보고 있다. 그리고 있는 그는 사람들은 사람들은 사람들은 사람들은 사람들은 사람들은 사람들은 사람들은 | 13 |
| 0.1.2.1. | | |






| 8.1.2.2. Features 8.1.2.3. Classification 8.1.2.4. Information Retrieval from Biological Databases 8.1.2.5. Pitfalls of Biological Databases 8.1.3. Impact of Bioinformatics in Vaccine Discovery 8.2. Summary 8.3. Exercise Chapter 9: Chromatographic Data Analysis 9.1. Introduction 9.1.2. Types of Chromatography Data System 9.1.3. Method Files 9.1.4. Instrument Control Files 9.1.5. Sequence File 9.1.6. Acquisition of Chromatographic Data 9.1.7. Management of Data 9.1.8. Interpretation of Chromatographic Data 9.1.9. System Suitability Test Calculations 9.1.10. Calibration 9.1.11. Reports and Collation of Results 9.1.12. Architecture of a Networked CDS | |
|--|----------|
| 8.1.2.4. Information Retrieval from Biological Databases 8.1.2.5. Pitfalls of Biological Databases 8.1.3. Impact of Bioinformatics in Vaccine Discovery 8.2. Summary 8.3. Exercise Chapter 9: Chromatographic Data Analysis 9.1. Chromatographic Data Analysis 9.1.1. Introduction 9.1.2. Types of Chromatography Data System 9.1.3. Method Files 9.1.4. Instrument Control Files 9.1.5. Sequence File 9.1.6. Acquisition of Chromatographic Data 9.1.7. Management of Data 9.1.8. Interpretation of Chromatographic Data 9.1.9. System Suitability Test Calculations 9.1.10. Calibration 9.1.11. Reports and Collation of Results 9.1.12. Architecture of a Networked CDS | |
| 8.1.2.5. Pitfalls of Biological Databases 8.1.3. Impact of Bioinformatics in Vaccine Discovery 8.2. Summary 8.3. Exercise Chapter 9: Chromatographic Data Analysis 9.1. Chromatographic Data Analysis 9.1.1. Introduction 9.1.2. Types of Chromatography Data System 9.1.3. Method Files 9.1.4. Instrument Control Files 9.1.5. Sequence File 9.1.6. Acquisition of Chromatographic Data 9.1.7. Management of Data 9.1.8. Interpretation of Chromatographic Data 9.1.9. System Suitability Test Calculations 9.1.10. Calibration 9.1.11. Reports and Collation of Results 9.1.12. Architecture of a Networked CDS | |
| 8.1.3. Impact of Bioinformatics in Vaccine Discovery 8.2. Summary 8.3. Exercise Chapter 9: Chromatographic Data Analysis 9.1. Chromatographic Data Analysis 9.1.1. Introduction 9.1.2. Types of Chromatography Data System 9.1.3. Method Files 9.1.4. Instrument Control Files 9.1.5. Sequence File 9.1.6. Acquisition of Chromatographic Data 9.1.7. Management of Data 9.1.8. Interpretation of Chromatographic Data 9.1.9. System Suitability Test Calculations 9.1.10. Calibration 9.1.11. Reports and Collation of Results 9.1.12. Architecture of a Networked CDS | |
| Chapter 9: Chromatographic Data Analysis 9.1. Chromatographic Data Analysis 9.1.1. Introduction 9.1.2. Types of Chromatography Data System 9.1.3. Method Files 9.1.4. Instrument Control Files 9.1.5. Sequence File 9.1.6. Acquisition of Chromatographic Data 9.1.7. Management of Data 9.1.8. Interpretation of Chromatographic Data 9.1.9. System Suitability Test Calculations 9.1.10. Calibration 9.1.11. Reports and Collation of Results 9.1.12. Architecture of a Networked CDS | |
| Chapter 9: Chromatographic Data Analysis 9.1. Chromatographic Data Analysis 9.1.1. Introduction 9.1.2. Types of Chromatography Data System 9.1.3. Method Files 9.1.4. Instrument Control Files 9.1.5. Sequence File 9.1.6. Acquisition of Chromatographic Data 9.1.7. Management of Data 9.1.8. Interpretation of Chromatographic Data 9.1.9. System Suitability Test Calculations 9.1.10. Calibration 9.1.11. Reports and Collation of Results 9.1.12. Architecture of a Networked CDS | |
| Chapter 9: Chromatographic Data Analysis 9.1. Chromatographic Data Analysis 9.1.1. Introduction 9.1.2. Types of Chromatography Data System 9.1.3. Method Files 9.1.4. Instrument Control Files 9.1.5. Sequence File 9.1.6. Acquisition of Chromatographic Data 9.1.7. Management of Data 9.1.8. Interpretation of Chromatographic Data 9.1.9. System Suitability Test Calculations 9.1.10. Calibration 9.1.11. Reports and Collation of Results 9.1.12. Architecture of a Networked CDS | |
| 9.1. Chromatographic Data Analysis 9.1.1. Introduction 9.1.2. Types of Chromatography Data System 9.1.3. Method Files 9.1.4. Instrument Control Files 9.1.5. Sequence File 9.1.6. Acquisition of Chromatographic Data 9.1.7. Management of Data 9.1.8. Interpretation of Chromatographic Data 9.1.9. System Suitability Test Calculations 9.1.10. Calibration 9.1.11. Reports and Collation of Results 9.1.12. Architecture of a Networked CDS | 0 |
| 9.1. Chromatographic Data Analysis 9.1.1. Introduction 9.1.2. Types of Chromatography Data System 9.1.3. Method Files 9.1.4. Instrument Control Files 9.1.5. Sequence File 9.1.6. Acquisition of Chromatographic Data 9.1.7. Management of Data 9.1.8. Interpretation of Chromatographic Data 9.1.9. System Suitability Test Calculations 9.1.10. Calibration 9.1.11. Reports and Collation of Results 9.1.12. Architecture of a Networked CDS | 0 |
| 9.1.1. Introduction 9.1.2. Types of Chromatography Data System 9.1.3. Method Files 9.1.4. Instrument Control Files 9.1.5. Sequence File 9.1.6. Acquisition of Chromatographic Data 9.1.7. Management of Data 9.1.8. Interpretation of Chromatographic Data 9.1.9. System Suitability Test Calculations 9.1.10. Calibration 9.1.11. Reports and Collation of Results 9.1.12. Architecture of a Networked CDS | 0 |
| 9.1.3. Method Files 9.1.4. Instrument Control Files 9.1.5. Sequence File 9.1.6. Acquisition of Chromatographic Data 9.1.7. Management of Data 9.1.8. Interpretation of Chromatographic Data 9.1.9. System Suitability Test Calculations 9.1.10. Calibration 9.1.11. Reports and Collation of Results 9.1.12. Architecture of a Networked CDS | 0 |
| 9.1.3. Method Files 9.1.4. Instrument Control Files 9.1.5. Sequence File 9.1.6. Acquisition of Chromatographic Data 9.1.7. Management of Data 9.1.8. Interpretation of Chromatographic Data 9.1.9. System Suitability Test Calculations 9.1.10. Calibration 9.1.11. Reports and Collation of Results 9.1.12. Architecture of a Networked CDS | |
| 9.1.5. Sequence File 9.1.6. Acquisition of Chromatographic Data 9.1.7. Management of Data 9.1.8. Interpretation of Chromatographic Data 9.1.9. System Suitability Test Calculations 9.1.10. Calibration 9.1.11. Reports and Collation of Results 9.1.12. Architecture of a Networked CDS | |
| 9.1.5. Sequence File 9.1.6. Acquisition of Chromatographic Data 9.1.7. Management of Data 9.1.8. Interpretation of Chromatographic Data 9.1.9. System Suitability Test Calculations 9.1.10. Calibration 9.1.11. Reports and Collation of Results 9.1.12. Architecture of a Networked CDS | |
| 9.1.6. Acquisition of Chromatographic Data 9.1.7. Management of Data 9.1.8. Interpretation of Chromatographic Data 9.1.9. System Suitability Test Calculations 9.1.10. Calibration 9.1.11. Reports and Collation of Results 9.1.12. Architecture of a Networked CDS | |
| 9.1.7. Management of Data 9.1.8. Interpretation of Chromatographic Data 9.1.9. System Suitability Test Calculations 9.1.10. Calibration 9.1.11. Reports and Collation of Results 9.1.12. Architecture of a Networked CDS | |
| 9.1.8. Interpretation of Chromatographic Data 9.1.9. System Suitability Test Calculations 9.1.10. Calibration 9.1.11. Reports and Collation of Results 9.1.12. Architecture of a Networked CDS | |
| 9.1.9. System Suitability Test Calculations 9.1.10. Calibration 9.1.11. Reports and Collation of Results 9.1.12. Architecture of a Networked CDS | 11-11-1 |
| 9.1.10. Calibration 9.1.11. Reports and Collation of Results 9.1.12. Architecture of a Networked CDS | 1, 11,15 |
| 9.1.11. Reports and Collation of Results9.1.12. Architecture of a Networked CDS | 1.8.1 |
| 9.1.12. Architecture of a Networked CDS | THE S |
| or a riceworked CDD | HARLE |
| 9.2. Summary | 100 |
| | |
| 9.3. Exercise | 1.4 |
| 10.1. Laboratory Information Management Systems (LIMS) 10.1.1. Introduction | 1 |
| 10.1.2. LIMS Hardware and Architectures | 1 |
| 10.1.3. Different Types of LIMS | 1 |
| 10.1.4. Implementation of LIMS | 1 |
| | 1 |
| Transport Transporter Systems (THVIS) | 1 |
| | 1 |
| - The state of the date ments in Tree mical Development | 1 |
| Todacts | 1 |
| 10.3. Summary 10.4. Exercise | 1 |
| 10.4. Exercise | 1 |
| | |
| | |
| | |
| | |
| | |
| | |
| AZI Ding lakutasang Storags and Services | |
| | |
| 表。1907年1月1日 2月1日 1月1日 1月1日 1月1日 1月1日 1月1日 1月1日 | |
| | |
| | |
| | |
| | |






Pharmaceutical Inorganic Chemistry























| TABLE OF CONTENTS | Unit - IV |
|---|---|
| Unit - I Chapter - 1 Impurities in Pharmaceutical Substances (1 - 1) to (1 - 21) 1.1: Pharmacopoeia and History of Pharmacopoeia | Chapter - 4 Miscellaneous Compounds (4 - 1) to (4 - 16 4.1: Expectorants 4 - 4.2: Emetics 4 - 4.3: Hematinics 4 - 4.4: Poison and Antidote 4 - 4.5: Astringents 4 - 1 |
| Unit - II | Collections Platforneoposis of Society State bewellow of the |
| Chapter - 2 Acids, Bases, Buffers, Electrolytes, Dental Products (2 - 1) to (2 - 41) 2.1 : Acids, Bases and Buffers | $ \begin{array}{cccccccccccccccccccccccccccccccccccc$ |
| Chapter - 3 Gastrointestinal Agents (3 - 1) to (3 - 26) 3.1: Acidifiers. 3 - 1 3.2: Antacids 3 - 4 3.3: Cathartics. 3 - 12 3.4: Antimicrobials 3 - 16 | 5.6: Storage Conditions, Precautions and Pharmaceutical Application of Radioactive Substances |






Biochemistry



Progressive Education Society's Modern College of Pharmacy, Nigdi, Pune 411044









| The mono synthesis of Letty scott (Poster Alexandria) | (vii) |
|---|--|
| TABLE OF CONTENTS | Unit - II |
| Unit - I | Chapter - 3 Carbohydrate Metabolism (3 - 1) to (3 - 34) Glycolysis - Pathway, Energetics and Significance |
| Chapter - 1 Biomolecules (1 - 1) to (1 - 76) 1.1 Carbohydrates 1 - 1 1.2 Lipids 1 - 17 1.3 Nucleic Acids 1 - 32 1.4 Amino Acids 1 - 44 1.5 Proteins 1 - 58 Multiple Choice Questions with Answers 1 - 74 Chapter - 2 Bioenergetics (2 - 1) to (2 - 7) 2.1 Concept of Free Energy, Endergonic and Exergonic Reaction, Relationship between Free Energy, Enthalpy and Entropy 2 - 1 2.2 Redox Potential 2 - 2 2.3 Energy Rich Compounds and its Classification 2 - 3 2.4 Biological Significance of ATP and Cyclic AMP 2 - 3 Multiple Choice Questions with Answers 2 - 5 | 3.2 Tricarboxylic Acid Cycle / Citric Acid Cycle (TCA) - Pathways, Energetics and Significance |





| Synthesis and Significance of Biological Substances 5HT, Melatonin, Depamine, Nor Adrenaline, Adrenaline 6-26 Catabolism of Heme, Hyperbilirubinemia and Jaundice 6-43 Multiple Choice Questions with Answers 6-47 Unit - IV hapter - 7 Nucleic Acid Metabolism and Genetic Information Transfer (7-1) to (7-45) Bio synthesis of Purine and Pyrimidine Nucleotides 7-1 7.1.1 Biosynthesis of Purine Nucleotides 7-5 Catabolism of Purine Nucleotides 7-5 Catabolism of Purine Nucleotides 7-5 Catabolism of Purine Nucleotides 7-5 |
|--|
| Introduction to Nucleic Acids 7-14 7.4.1 DNA 7-15 Replication of DNA 7-19 Transcription OR RNA Synthesis 7-26 Genetic Code 7-29 |
| Protein Synthesis and Inhibitors |
| 3.5 |






| | Unit - V |
|-----|--|
| 8X | Now Adminishing Adversaling |
| Cha | pter - 8 Enzymes (8 - 1) to (8 |
| 8.1 | Introduction |
| 8.2 | Definition, Properties Nomenclature and IUB Classification of Enzymes |
| 8.3 | Enzyme Kinetics (Michaelis Plot, Lineweaver Burk Plot) |
| 8.4 | Enzyme Inhibitors with Example |
| 8.5 | Regulation of Enzymes Enzyme Induction and Repression, allosteric Enzymes Regulation |
| 8.6 | Therapeutic and Diagnostic Applications of Enzymes and Isoenzymes |
| 8.7 | Coenzymes Structural and Biological Functions |
| | Multiple Choice Questions with Answers |
| Sol | ved University Question Papers (S - 1) to (|
| | |
| 61 | |
| | |
| | |
| | |






Environmental Science




















| NICE I | |
|--------|---|
| 10 | Unit - I |
| | oter - 1 The Multidisciplinary Nature of Environmental Studies (1 - 1) to (1 - 65) |
| .1 | Introduction |
| .2 | Natural Resources |
| .3 | Renewable and Non-renewable Resources |
| .4 | Natural Resources and Associated Problems 1 - 10 |
| .5 | Forest Resources |
| .6 | Water Resources |
| .7 | Mineral Resources |
| .8 | Food Resources |
| .9 | Energy Resources |
| | Land Resources |
| | Role of an Individual in Conservation of Natural Resources . 1 - 56 |
| /ulti | ple Choice Questions with Answers1 - 62 |
| | Unit - II |
| ha | pter - 2 Ecosystems (2 - 1) to (2 - 32) |
| 2.1 | Concept of an Ecosystem2 - 1 |
| 2.2 | Structure and Function of an Ecosystem2 - 7 |
| 2.3 | Introduction, Types, Characteristic Features, |
| | Structure and Function of Ecosystems 2 - 11 |






| | | Unit - | Ш | |
|----------|----------------|------------------|------------------|--------------------|
| | | Ollic | | PERSONAL PROPERTY. |
| Chapter | - 3 Enviro | nmental Poll | ution | (3 - 1) to (3 |
| 2.1 Air | Pollution | | | |
| 3.1 Air | er Pollution | iphiary Nat | | |
| 3.2 Wat | Pollution | day vietnos. | e Multiplication | 13 1 - 100 |
| 3.3 Soil | tiple Choice O | puestions with A | nswers | |
| 14161 | impre cirera s | | | |
| 200 | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| 164-145M | | | | |
| | | | | |
| | | | | |
| | | | systems | |
| | | | | |
| | | | | |
| 1.1 | | | | |
| | | | | |
| | | stown | of discount | |






Pharmaceutical Analysis-I









Progressive Education Society's Modern College of Pharmacy, Nigdi, Pune 411044





First Edition: 2019

ISBN - 978-93-87093-01-0

Copyright © All Rights Reserved

This book is sole subject to the condition that it shall not, by way of trade or otherwise, be lent, resold, hired out, or otherwise circulated without the publisher's prior written consent, in any form of binding or cover, other than that in which it is published and without including a similar condition. This condition being imposed on the subsequent purchaser and without limiting the rights under copyright reserved above, no part of this publication may be reproduced, stored in or transmitted in any form or by any means (electronic, mechanical, photocopying, recording or otherwise), without the prior written permission of both the copyright owner and the below mentioned publisher of this book.

Published by:

Thakur Publication Pvt. Ltd.

FF-107, Adarsh Complex, Engineering College Crossing, Opp. Allahabad Bank, Lucknow-226021.

Mob.: 9415584997/98, 9235318595/22

Website: www.tppl.org.in E-mail: thakurpublication@gmail.com

Our branch office in India:

- Thakur Publication Pvt. Ltd., 9-D. Gali No. 2, Rajendra Nagar, Shambhu Das Gate, Nauchandi, Meerut-250001. Mob. 9235318516, 9457820674.
- Thakur Publication Pvt. Ltd., 629, Model Town, Near Indora Chowk, Post- Jaripatka, Nagpur-440014. Mob. 09595029116.
- Thakur Publication Pvt. Ltd., C.T.S. No-635, Flat No-T-7, Third Floor, Bhudhwar Peth, ABC Market, Pune-411002. Mob. 09373086387, 9326863355, 9325036341, 9595076005/08.
- Thakur Publication Pvt. Ltd., House No. 46/1309, Kattikaran House, Feroz Gandhi Lane, Vaduthala (Post), Ernakulam, Kerala-682023. Mob. 9207296272, 9207296273, 9207296271.
- Thakur Publication, H.No. 765, Badwale Chamatkareshwar Mahadev Mandir, Godi ki Gali, Maniharon ka Rasta, Kishan Pol Bazar, Jaipur-302003. Mob. 9351193641.
- Thakur Publication, H.No. 12/14, Sukhram Nagar Society, Opp. Watar Tank, Lane No. 2, Rakhial Road, Gomtipur-Ahmedabad-380021. Mob. 9328829591, 9374374905, 9328622684
- Thakur Publication, House No. 77-2 RT, Municipal Colony, Near Yashoda Hospital, Malakpet, Hyderabad-500036. Mob. 09396389594, 09391550531, 09346575384.
- Thakur Publishers, H.No. 172, Naina Giri, J.K. Road Bhopal-462022. Mob. 9691717925, 9691717928, 7879146233.
- Thakur Publishers, Plot No. 3368/8777, Prachi Vihar, Post- GGP Colony, P.S. Mancheswar, Dist.- Khurda, Bhubaneswar-751025. Mob. 9337585809.
- Thakur Publishers, House No. 1076, Harbans Nagar, Jalandhar-144002. Mob. 9357816968, 8591828212, 8591850332.
- Thakur Publishers, House No. 8, Ambu Nagar, Main Road, Goverthanagiri, Avadi, Chennai-600071. Mob. 9543605656, 8144126950, 9543247241, 8124457101, 9543247130.
- Thakur Publishers, House No. 120, 2nd Main, 2nd Cross, Brindavan Nagar, D.R.C. Post, Bengaluru-560029. Mob. 9341835403, 9379798011, 9343859590, 8880441707.
- Thakur Publishers, H.No.34, Ward No. 6, Behind Verma Petrol Pump, Bhiwani Chungi, Rohtak-124001. Mob. 7876991824, 7876991825, 9068601142, 9729004576.

Progressive Education Society's iviodern College of Pharmacy, Nigdi, Pune 411044





| | Contents | |
|----------|--|-------|
| | Chapter 1: Pharmaceutical Analysis | olu |
| | and Errors | • |
| 1.1. | Pharmaceutical Analysis | |
| 1.1.1. | Introduction and Definition | |
| 1.1.2. | Scope Scope | |
| 1.1.3. | | |
| 1.1.3. | . Classical Methods | |
| 1.1.3.2 | | |
| 1.1.3.3 | 3. Quantitative Analysis | |
| 1.1.3.4 | . Instrumental Methods | |
| 1.1.3.5 | . Microbiological Methods | |
| 1.1.3.6 | . Biological Methods | |
| 1.1.4. | Methods of Expressing Concentration | |
| 1.1.4.1 | . Normality or Normal Concentration | |
| 1.1.4.2 | . Molarity or Molar Concentration | |
| 1.1.4.3 | . Molality or Molal Concentration | |
| 1.1.4.4 | Formality or Formal Concentration | |
| 1.1.4.5 | . Mole Fraction | |
| 1.1.4.6 | Wildle Wi | |
| 1.1.4.7 | Equivalent Weight | |
| 1.1.4.8 | | |
| 1.1.4.9. | | |
| 1.1.4.10 | J. Percentage Composition by Volume | |
| 1.1.4.1 | I. Percentage Strength | |
| 1.1.4.12 | 2. Parts per Million (ppm) | |
| | 3. Mole Percent | |
| 1.1.5. | of Volumetric Analysis | lu ly |
| 1.1.5.1. |) Standards | |
| 1.1.5.2. | 1 | |
| 1.1.6. | Preparation and Standardisation of Various Molar and Normal Solutions | 10 |
| 1.1.6.1. | Oxalic Acid | 2 |
| 1.1.6.2. | Sodium Hydroxide | . 2 |
| 1.1.6.3. | Hydrochloric Acid | 3 |
| 1.1.6.4. | Sodium Thiosulphate | 3 |
| 1.1.6.5. | Sulphuric Acid | 3 |
| 1.1.6.6. | Potassium Permanganate | 3 |
| 1.1.6.7. | Ceric Ammonium Sulphate | 3 |
| 1.2. | Errors Introduction | 3 |
| 1.2.2. | - Cadellon | 3 |
| 1.2.3. | Sources Types | 3 |
| - imida | Types | 39 |





| 1.2.4. | Methods of Minimising Errors | 40 |
|----------|--|----|
| 1.2.5. | Accuracy and Precision | 41 |
| 1.2.6. | Significant Figures | 43 |
| 1.2.6.1. | Identifying Significant Digits | 43 |
| 1.2.6.2. | Rounding-Off Digits | 44 |
| 1.2.6.3. | Rules for Retaining Significant Figures | 44 |
| 1.3. | Summary | 45 |
| 1.4. | Exercise | 46 |
| | Chapter 2: Pharmacopoeias and | |
| | 1 imit Tocto | |
| 2.1. | Pharmacopoeias | 48 |
| 2.1.1. | Introduction | 48 |
| 2.1.2. | Indian Pharmacopoeia (I.P.) | 48 |
| 2.1.3. | British Pharmacopoeia (B.P.) | 50 |
| 2.1.4. | United States Pharmaconogie (U.S.D.) | 52 |
| 2.2. | Visit Pasts | 54 |
| 2.2.1. | | 54 |
| 2.2.2. | | 54 |
| 2.2.3. | T A CC A Y TO TO | 60 |
| 2.2.4. | * 1 . m . d . CT 1 . 1 . 0 . D . 100.53 | 61 |
| 2.2.5. | Visit That for Salahata (I.D. 1996) | 62 |
| 2.2.6. | T : : T : SY - (I D 1000) | 64 |
| 2.2.7. | | 65 |
| 2.2.8. | 71 : T : 6 7 1/4 D 1000 | 67 |
| 2.2.9. | Visit Test for House Matala (I.B. 1006) | 68 |
| | S. Carrier and C. Car | 70 |
| 2,3. | Summary | 71 |
| 2.4. | Exercise should be a supported to (value) and the supported to (value) and | |
| | Chapter 3: Acid Base Titrations | |
| 3.1. | Acid-Base Titrations | 73 |
| 3.1.1. | Introduction | 73 |
| 3.1.2. | Theories | 73 |
| 3.1.2.1. | Arrhenius Theory | 74 |
| 3.1.2.2. | Bronsted-Lowry Theory | 74 |
| 3.1.2.3. | Lewis Theory of Acids and Bases | 77 |
| 3.1.3. | Classification | 79 |
| 3.1.4. | Assay by Acid-Base Titrations | 79 |
| 3.1.4.1. | Acidimetry Titrations | 80 |
| 3.1.4.2. | Alkalimetry Titrations | 80 |
| 3.1.5. | Neutralisation Curves | 81 |
| 3.1.5.1. | Neutralisation of Weak Acid and Strong Base | 81 |
| 3.1.5.2. | | 82 |
| | | 83 |
| 3.1.5.3. | | 84 |
| 3.1.5.4. | Neutransation of weak Acid and weak base | 04 |





| | - 10 - | |
|----------|--|------------|
| 3.1.6. | The Past Indicators | A |
| 3.1.6. | 1. Theories | 8 |
| 3.1.6. | 2. Litmus Theory | |
| 3.1.6. | 3. Ostwald's Theory | 8 |
| 3.1.6.4 | 4. Ouinonoid Theory | 8 |
| 3.1.6.5 | 5. Examples | 8 |
| 3.1.7. | Applications | 8 |
| 3.1.8. | Estimation (Assay) of Sodium Benzoate | 8 |
| 3.2. | Summary | 9 |
| 3.3. | Exercise | 9 |
| | Chapter 4: Pharmacopueme | |
| 4.1. | Chapter 4: Non-Aqueous Titrations Non-Aqueous Titrations | |
| 4.1.1. | Non-Aqueous Titrations Introduction | 94 |
| 4.1.2. | | 94 |
| 4.1.3. | Basic Concepts | 95 |
| 4.1.4. | Principle Theory | 95 |
| 4.1.5. | | 96 |
| 4.1.5.1. | Non-Aqueous Solvents | 96 |
| 4.1.5.2. | and Holl-Dissociating Solvents | 97 |
| 4.1.5.3. | - and character of a Solvent | 98 |
| 4.1.5.4. | The state of the s | 99 |
| 4.1.5.5. | | *** |
| | Solvents over Aqueous | 101 |
| 4.1.6. | Assay by Non-Aqueous Titrations | 101 |
| 4.1.6.1. | Acidimetry Titrations | 102 |
| 4.1.6.2. | Alkalimetry Titrations | 103 |
| 4.1.7. | Indicators | |
| 4.1.8. | Applications | 105 |
| 4.1.9. | Estimation (Assay) of Ephedrine HCl | 106 107 |
| 4.2. | Summary | 107 |
| 4.3. | Exercise | 108 |
| | Chapter 5: Precipitation and | |
| | Complexometric Titrations | |
| 5.1. | Precipitation Titrations | |
| 5.1.1. | Introduction | 110 |
| 5.1.2. | Precipitation | 110 |
| 5.1.3. | Principle Principle | 110 |
| 5.1.4. | Theory Theory | 112 |
| 5.1.5. | Conditions for Formation of a Precipitate | 113 |
| 5.1.6. | Factors Affecting the Solubility of Precipitate | 114 |
| 5.1.6.1. | Effect of Acids | 114 |
| 5.1.6.2. | Effect of Temperature | 114 |
| 5.1.6.3. | Effect of Solvent on Solubility of Salts | 115 |
| S PORT I | of Soliton on Solubility of Salts | 115 |





| .1.6.4. | Common Ion Effect | 115 |
|----------------------|---|-------|
| .1.6.5. | Effect of pH | 115 |
| .1.7. | Indicators used in Precipitation Titrations | 116 |
| 5.1.7.1. | Adsorption Indicators | 116 |
| .1.7.2. | Miscellaneous Indicators | 117 |
| 5.1.8. | Precipitation Titration Methods | 117 |
| 5.1.9. | Mohr's Method | 118 |
| 5.1.10. | Volhard's Method | 119 |
| 5.1.11. | Modified Volhard's Method (I.P. 1985) | 121 |
| 5.1.12. | Fajan's Method | 122 |
| 5.1.13. | Applications of Precipitation Titrations | 123 |
| 5.1.14. | Estimation (Assay) of Sodium Chloride | 123 |
| 5.2. | Complexometric Titrations | 124 |
| 5.2.1. | Introduction | 124 |
| 5.2.2. | Principle Principle | 124 |
| 5.2.3. | Theory | 125 |
| 5.2.4. | Classification | 127 |
| 5.2.4.1. | Direct Titration | 127 |
| 5.2.4.2. | Back Titration | 127 |
| 5.2.4.3. | Replacement Titration | 127 |
| 5.2.4.4. | Indirect Titration | 128 |
| 5.2.5. | Chelates (Chelate Compounds) | 128 |
| 5.2.5.1. | Stability Constants | 129 |
| 5.2.5.2. | Masking Reagents | 130 |
| 5.2.5.3. | Demasking Reagents | 132 |
| 5.2.5.4. | Metal-EDTA Titration Curves | 133 |
| 5.2.5.5. | Applications of EDTA | 133 |
| 5.2.6. | Methods of End Point Detection | 134 |
| 5.2.6.1. | Complexometric/Metal Ion Indicators | 134 |
| 5.2.6.2. | Instrumental Methods | 135 |
| 5.2.7. | Applications | 136 |
| 5.2.8. | Estimation (Assay) of Calcium Gluconate | 139 |
| 5.2.9. | Estimation (Assay) of Magnesium Sulphate | 140 |
| 5.3. | Summary | 140 |
| 5.4. | Exercise northogist tumb/ | 142 |
| Ch- | -to- 6. Crayimatry and Diazotica | tion |
| Cna | pter 6: Gravimetry and Diazotisa | LIOII |
| 61 | Gravimetry | 144 |
| 6.1. 6.1.1. | Introduction | 144 |
| 10011000000 | Principles and Theories | 145 |
| 6.1.2.1 | Law of Mass Action and Reversible Reactions | 145 |
| 6.1.2.1. | Principle of Solubility Product | 146 |
| | Timespie of Solubility Froudet | 0 |
| 6.1.2.2. 6.1.2.3. | Common Ion Effect | 147 |





| | -12- | |
|----------|--|---------|
| 6.1.4. | Steps Involved in Gravimetric Analysis | 148 |
| 6.1.4.1. | 1 1 1 2 2 4 5 7 4 5 4 5 4 5 5 5 6 5 6 5 6 5 6 5 6 5 6 5 | 149 |
| 6.1.4.2. | | 149 |
| 6.1.4.3. | Destar Property of Post | - 150 |
| 0.1.4.5. | Precipitation) | 23.11.2 |
| 6.1.4.4. | | 151 |
| 6.1.4.5. | | 152 |
| 6.1.4.6. | | 152 |
| 6.1.4.7 | | 153 |
| 6.1.4.8 | | 154 |
| 6.1.5. | Applications | 154 |
| 6.1.6. | Estimation (Assay) of Barium Sulphate | 155 |
| 6.2. | Diazotisation Titrations | 156 |
| 6.2.1. | Introduction | 156 |
| 6.2.2. | Basic Principle | 157 |
| 6.2.3. | Theory | 157 |
| 6.2.4. | Methods | 158 |
| 6.2.5. | Instrumentation | 158 |
| 6.2.6. | Steps Steps | 159 |
| 6.2.7. | End Point Detection | 159 |
| 6.2.8. | Applications | 160 |
| 6.3. | Summary | 161 |
| 6.4. | Exercise | 162 |
| 4 500 | Company of the Compan | |
| | Chapter 7: Redox Titrations | 164 |
| 7.1. | Redox Titrations | 164 |
| 7.1.1. | Introduction | 165 |
| 7.1.2. | Concepts of Oxidation and Reduction | |
| 7.1.3. | Oxidising and Reducing Agents | 168 |
| 7.1.4. | Theory | 169 |
| 7.1.5. | Principles | 170 |
| 7.1.5. | 1. Redox Equivalent Weights | 171 |
| 7.1.5. | | 172 |
| 7.1.5. | | 172 |
| 7.1.5. | | 173 |
| 7.1.5. | | 174 |
| 7.1.5. | | 175 |
| 7.1.5. | | 176 |
| 7.1.6. | | 177 |
| 7.1.7. | | 170 |
| 7.1.7. | | 170 |
| 7.1.7. | | 100 |
| 7.1.7. | | |
| 7.1.8. | Applications | 183 |
| 7.2. | Titrations Involving Different Compounds | 103 |





| | -13- | |
|----------|--|-----|
| | | 183 |
| 7.2.1. | Introduction | 183 |
| 7.2.2. | Cerimetry (Ceric Sulphate Titrations) | 184 |
| 7.2.3. | lodinieuy | 187 |
| 7.2.4. | Iodometry | 188 |
| 7.2.5. | Bromatometry | 189 |
| 7.2.6. | Dichrometry | 191 |
| 7.2.7. | Titration with Potassium Iodate | 193 |
| 7.3. | Summary | 194 |
| 7.4. | Exercise | 194 |
| | Chapter 8: Conductometry | |
| 1 | Electrochemical Methods of Analysis | 195 |
| 8.1. | Introduction | 195 |
| 8.1.1. | Electro-Analytical Methods | 196 |
| 8.1.2. | | 197 |
| 8.2. | Conductometry Introduction | 197 |
| 8.2.1. | | 197 |
| 8.2.2. | Principle | 198 |
| 8.2.3. | Theory Terms Related to Conductometry | 199 |
| 8.2.4. | Terms Related to Conductomers | 200 |
| 8.2.5. | Instrumentation | 201 |
| 8.2.5.1. | Conductivity Meter | 201 |
| 8.2.5.2. | Conductivity Cell | 203 |
| 8.2.6. | Conductometric Titrations | 203 |
| 8.2.6.1. | Acid-Base Titrations | 206 |
| 8.2.6.2. | Displacement (or Replacement) Titrations | 207 |
| 8.2.6.3. | Precipitation Titrations | 207 |
| 8.2.6.4. | Redox (Oxidation-Reduction) Titrations | 208 |
| 8.2.6.5. | Complexometric Titrations | 208 |
| 8.2.7. | Applications | 211 |
| 8.3. | Summary | 212 |
| 8.4. | Exercise | 212 |
| | Chapter 9: Potentiometry | |
| 9.1. | Potentiometry | 214 |
| 9.1.1. | Introduction | 214 |
| 9.1.2. | Principle | 214 |
| 9.1.3. | Theory | 215 |
| 9.1.4. | Instrumentation/Equipment | 216 |
| 9.1.5. | Electrochemical Cell | 216 |
| 9.1.6. | Construction & Working of Reference Electrodes | 218 |
| 9.1.6.1. | A STATE OF THE PARTY OF THE PAR | 218 |
| 0160 | | 221 |
| 9.1.6.2. | | 222 |
| 9.1.6.3. | Construction & Working of Indicator Electrodes | 223 |
| 9.1.7. | Construction & Working of indicator Electrodes | 17 |






| 9.1.7.1. | Metal Electrode |
|-----------|--|
| 9.1.7.2. | Glass Floaten de |
| 9.1.8. | Potentiametria Tital |
| 9.1.8.1. | Acid Page Titretions |
| 9.1.8.2. | Compleyometrie Titanti |
| 9.1.8.3. | Oxidation-Reduction Titrations |
| 9.1.8.4. | |
| 9.1.9. | Methods of End Point Detection |
| 9.1.10. | Applications |
| 9.2. | Summary |
| 9.3. | Exercise |
| | |
| 7.00 | Chapter 10: Polarography |
| 10.1. | Polarography |
| 10.1.1. | Introduction |
| 10.1.2. | Dringinla |
| 10.1.3. | Theory |
| 10.1.4. | Polarographic Currents |
| 10.1.4.1. | Charging/Residual/Condenser Current |
| 10.1.4.2. | Wildrafton Chemont |
| 10.1.4.3. | Ilkovic Equation - Diffusion/Reducing Current |
| 10.1.4.4. | Kinetic Current |
| 10.1.5. | Half-Wave Potential |
| 10.1.6. | Instrumentation |
| 10.1.7. | Construction and Working of Dropping Mercury Electrode |
| 10.1.8. | Construction and Working of Rotating Platinum Electrode |
| 10.1.9. | Applications Applications |
| 10.2. | Summary |
| 10.3. | Exercise |
| | |
| | |
| | |
| | Chapter 9: Potentiometry |
| | |
| | |
| | Principle of the second |





Chapter 12 Anti-diarrhoeal screening (in vivo and in vitro methods)







© Bhalani Publishers

First Edition: 2018

ISBN No. 978-93-83794-04-1

All rights reserved. No part of this publication may be reproduced, stored in a system, or transmitted in any form or by any means, electronic, mechanical, photocomercording or otherwise, without the prior permission.

The author/editor & the publisher have taken special care to ensure that the recommendations specified in the text are precise. However in view of the corresponding to the dose for a few of the drugs as recommendations are requested to chemical transfer of the drugs are

Although the author/editor and the publisher have taken special care to ensure the information in this book was correct at the time of it being included in the in view of new information being available constantly, they are not liable to otherwise.

PUBLISHED BY:



Rajesh Bhalani for BHALANI PUBLISHERS

1201, Avanti Building, Neelkanth Kingdom, Vidyavihar (W), Mumbai - 400086.

Mob: +91 9867214519

E-mail: bhalanipublishers@gmail.com

PRINTED & BOUND BY:

ASHISH ARTS - Mumbai.

⋈: bharat.ashisharts@gmail.com



Satish Kumar Jain for

CBS PUBLISHERS & DISTRIBUTORS PVT. LTD.

4819/XI Prahlad Street, 24 Ansari Road,

Daryaganj,

New Delhi - 110002, India.

Ph.: 011-23289259, 23266861/67 Fax: 233

□: delhi@cbspd.com/cbspubs@airtelm


Website: www.cbspd.com

Corporate Office: 204 FIE, Industrial Area

Patparganj, Delhi - 110092 Ph.: 49344934, Fax: 49344935 ⊠: publishing@cbspd.com







by

Archana R. Juvekar

M. Pharm, Ph.D (Tech)

Professor in Pharmacology & Physiology
Department of Pharmaceutical Sciences & Technology,
Institute of Chemical Technology,
(University under Section 3 of UGC Act 1956;
Maharashtra Government's "Elite Status and Center of Excellence"
Formerly UDCT/UICT, University of Mumbai)
Nathalal Parekh Marg, Matunga, Mumbai - 411 019.

S. R. Naik

M.Sc. (Biochemistry), Ph.D. (Pharmacology)

Emiretus Professor,

Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research Center, Pune - 411018.

Ex. General Manager (R&D, QCL and QA), Hindustan Antibiotics Ltd. Pune - 411018.

Ex Professor and Principal, Prin. K. M. Kundnani College of Pharmacy, Mumbai - 400 005.

Professor and Principal of Institute of Pharmacutical Sciences, Lonavala, Pune.







CBS PUBLISHERS & DISTRIBUTORS PVT. LTD.





10

CONTENTS

| Chap No. | Name | Page No. | | |
|----------|--|----------|--|--|
| 1 | General Introduction to Central Nervous System | 1 | | |
| 2 | Experimental Methods in CNS Pharmacology | | | |
| 3 | Experimental Methods in Autonomic Pharmacology • General Introduction (37) | 37 | | |
| | Cardiac Muscle (39) Smooth Muscle (57) Skeletal Muscle (66) | | | |
| 4 | Screening Methods for Hepatoprotective Activity | 70 | | |
| 5 | Methods for Screening Anti-Hyperglycemic Agents | 82 | | |
| 6 | Methods for Screening Anti-Hyperlipidemic Agents | 88 | | |
| 7 | Screening Methods for Anti-Inflammatory, Anti-Arthritic | | | |
| | and Analgesic Drugs | | | |
| 8 | Anti-allergic and Anti-asthmatic Drugs Screening Methods | 117 | | |
| 9 | Screening Methods for Drugs Acting on Renal System | 138 | | |
| 10 | Screening Methods for Antioxidant Potential | 147 | | |
| 11 | Toxicological Methods and Techniques | 165 | | |
| 12 | Miscellaneous | 176 | | |
| 13 | Biostatistical methods in Pre-clinical Research | 198 | | |
| | Annexure | 244 | | |
| | Institutional Animal Ethics committee / Board | 245 | | |





188 Advances In Biomedical Experimental Techniques In Pharmacological Assays

ANTI-DIARROHEAL SCREENING (in-vivo and in-vitro) METHODS

INTRODUCTION:

Diarrhoea is characterized by alteration in secretion, absorption of water and electrolytes and alteration in motility of gastrointestinal tract. The pathophysiology includes change in active ion transport by either decreased sodium absorption or increased chloride secretion; change in intestinal motility; increase in luminal osmolarity and increase in tissue hydrostatic pressure. These mechanisms have been related to four broad clinical diarrhoeal groups: secretory, osmotic, exudative, and altered intestinal transit (Dipiro et al., 2010).





Fig. 12.1: Human gastrointestinal tract (Dipiro et al., 2010).

Water and electrolytes are absorbed as well as secreted in the intestine. Jejunum allows freely permeable salt and water which are passively absorbed secondary to absorption of nutrients (glucose, amino acids, etc). In the ileum and colon, active Na⁺K⁺ATPase mediated salt absorption occurs, primarily in the mature cells lining villous tips. In addition, glucose facilitated Na⁺ absorption takes place in the ileum






Chapter 9 Screening methods for drugs acting on renal system











© Bhalani Publishers

First Edition: 2018

ISBN No. 978-93-83794-04-1

All rights reserved. No part of this publication may be reproduced, stored in a system, or transmitted in any form or by any means, electronic, mechanical, photocomecording or otherwise, without the prior permission.

The author/editor & the publisher have taken special care to ensure that the recommendations specified in the text are precise. However in view of the corresponding to the corresponding to the dose for a few of the drugs as recommendations for drugs, specially for those drugs which are in the market or those which are not used frequently in day-to-day practice.

Although the author/editor and the publisher have taken special care to ensure the information in this book was correct at the time of it being included in the inview of new information being available constantly, they are not liable to otherwise.

PUBLISHED BY:



Rajesh Bhalani for BHALANI PUBLISHERS 1201, Avanti Building, Neelkanth Kingdom,

Vidyavihar (W), Mumbai - 400086.

Mob: +91 9867214519

E-mail: bhalanipublishers@gmail.com

PRINTED & BOUND BY:

ASHISH ARTS - Mumbai.

⊠: bharat.ashisharts@gmail.com



Satish Kumar Jain for

CBS PUBLISHERS & DISTRIBUTORS PVT. LTD.

4819/XI Prahlad Street, 24 Ansari Road,

Daryaganj,

New Delhi - 110002, India.

Ph.: 011-23289259, 23266861/67 Fax: 233

Website: www.cbspd.com

Corporate Office: 204 FIE, Industrial Area

Patparganj, Delhi - 110092 Ph.: 49344934, Fax: 49344935

⊠: publishing@cbspd.com





E

CONTENTS

| Chap No. | Name | Page No. | | |
|----------|--|----------|--|--|
| 1 | General Introduction to Central Nervous System | 1 | | |
| 2 | Experimental Methods in CNS Pharmacology | | | |
| 3 | Experimental Methods in Autonomic Pharmacology General Introduction (37) | | | |
| | Cardiac Muscle (39) Smooth Muscle (57) Skeletal Muscle (66) | | | |
| 4 | Screening Methods for Hepatoprotective Activity | 70 | | |
| 5 | Methods for Screening Anti-Hyperglycemic Agents | 82 | | |
| 6 | Methods for Screening Anti-Hyperlipidemic Agents | 88 | | |
| 7 | Screening Methods for Anti-Inflammatory, Anti-Arthritic and Analgesic Drugs | 92 | | |
| 8 | Anti-allergic and Anti-asthmatic Drugs Screening Methods | 117 | | |
| 9 | Screening Methods for Drugs Acting on Renal System | 138 | | |
| 10 | Screening Methods for Antioxidant Potential | 147 | | |
| 11 | Toxicological Methods and Techniques | 165 | | |
| 12 | Miscellaneous | 176 | | |
| 13 | Biostatistical methods in Pre-clinical Research | 198 | | |
| | Annexure | 244 | | |
| | Institutional Animal Ethics committee / Board | 245 | | |






SCREENING METHODS FOR DRUGS ACTING ON RENAL SYSTEM

INTRODUCTION

Diuretics are the drugs that inhibit the reabsorption of water from the tubules and thereby increase the volume of the urine. As the diuretics increase the rate of urination, they provide means for forced diuresis. Different types of diuretics include thiazide diuretics, loop diuretics, potassium sparing diuretics, carbonic anhydrase inhibitors, osmotic agents, xanthenes, vasopressin type 2 receptors antagonists and arginine vasopressin V_2 receptor antagonists.

Three main steps of urine formation include glomerular filtration, tubular reabsorption and tubular secretion. As shown in Fig. 9.1, most of the diuretics act on tubule portion of the nephrone and thereby inhibits reabsorption of sodium and other electrolytes.







Chapter 9: Screening methods for drugs acting on renal system 139

Proximal tubule is the site responsible for tubular reabsorption and secretion. It is involved in reabsorption of filtered glucose, amino acids, filtered sodium bicarbonate and sodium chloride. It is the site of secretion of drugs like penicillin, thiazide diuretics and loop diuretics.

Loop of Henle is an important site for reabsorption of filtered sodium chloride through Na+, K+, 2Cl- Symporter and also contributes in formation of concentrated urine by transporting the sodium chloride to the surrounding interstitium.

Early portion of distal tubule is responsible for reabsorption of filtered sodium chloride through Na+, Cl- symporter. Collecting duct is responsible for adjustment of final composition and volume of urine through the actions of aldosterone and antidiuretic hormone. Aldosterone, a mineralocorticoid promotes reabsorption of sodium whereas antidiuretic hormone promotes reabsorption of water from the collecting duct.

Each class of diuretics acts on different site of tubular portion to achieve diuretic effect. Diuretics like thiazides act on early portion of distal tubule whereas loop diuretics act on thick ascending limb of loop of Henle. Potassium sparing diuretics act on collecting tubule and carbonic anhydrase inhibitors act on proximal tubule.


Table 9.1: Sites of action and mechanism of action of diuretics

| Class of Diuretics | Site of action | Examples | Mechanism of action Inhibit reabsorption of Na ⁺ and Cl ⁻ by inhibiting Na ⁺ , Cl ⁻ symporter in early portion of distal tubule | | |
|--------------------------------|----------------------|--|---|--|--|
| Thiazide diuretics | Distal tubule | Hydrochor- thiazide, Chlorthiazide Indapamide | | | |
| Loop diuretics | Loop of Henle | Furosemide Ethacrynic acid Bumetanide Torsemide | Inhibit reabsorption of Na ⁺ by inhibiting membrane bound Na ⁺ , K ⁺ , 2Cl ⁻ symporter | | |
| Potassium sparing diuretics | Collecting tubule | Amiloride Spironolactone | Amiloride inhibit reabsorption of Na+ by blocking the exchange of sodium for potassium in | | |





Formulation and development of guaifenesin extended release bi-layer tablets







Savitribal Phule Pune University Sponsored International Conference On "Multidisciplinary Healthcare Research: Challenges, Opportunities And Newer Directions"



Scientific Oral Presentation Code: 0-PHOI

Tide: FORMULATION AND DEVELOPMENT OF GUAIFENESIN EXTENDED RELEASE BI-LAYER TABLETS

Sweety, R. Singh', Dr. Praveen Chaudhari', Mr. Mahesh Bhadgale I. P.E.S Modern College of Pharmacy, Nigdi, Pune, India. 2. Callidus Research Labs, Pvt. Ltd.

Abstract:

Purpose: Extended release formulations has significant advantage over immediate release to the patients. Extended release dosage forms are administered to patients in much fewer daily doses and achieve more therapeutic effect in few daily doses. Thus main objective was to develop Guaifenesin. Extended Release Bi-layer tablets. Method: The formulation comprises of two portion: i) immediate release formulation of guaifenesin and ii) an extended release formulation of guaifenesin. The formulation comprised of MCC and SSG for immediate release whereas HPMC E10M and carbopol were used for extended release layer. The total weight ratio of HPMC E10M to Carbopol were experimented at 2:1, 3:1, 4:1, 6:1, 5:25:1, 5:5:1.Result:The formulated bi-layer tablets were evaluated for thickness, hardness, friability, weight variation, in-vitro drug release. The bi-layer tablet showed an initial burst effect to provide the initial loading dose and which then sustained itself for 12hrs. Formulation T6 was selected as best formulation of the drug release as the formulation matched with the marketed formulation (Mucinex). The stability studies, water by K.F. dissolution was carried which reflected that the formulation was enough feasible. The entire formulation was carried out by QBD approach, D0E software was applied so as to get better optimized formulation amongst all. Conclusion: Hence from D0E results, friability above 200N was more feasible for the formulation and T6 was considered best as its dissolution profile matched with the innovator product. Thus 5.5:1(110mg; 20mg) of HMC E10M: Carbopol respectively was considered as optimized.



Scientific Oral Presentation Code: 0-PH02

Tide: FORMULATION AND DEVELOPMENT OF RITONAVIR DISPERSIBLE TABLETS

Mokshada M. Vable¹, Dr. Praveen Chaudhari¹, Mr. Mahesh Bhadgale²
1. P.E.S Modern College of Pharmacy, Nigdi, Pune, India.
2. Callidus Research Labs, Pvt. Ltd.

Abstract:

Purpose. Must of the medications are available in adult strengths hence adjustment for paediatric or geriatric dosage becomes difficult. This concern could be avoided by formulating tablet dosage forms like Dispersible tablets which are to be disintegrated in liquid before administration; giving a homogenous dispersion. Methods: In the present work attempt has been made to prepare Dispersible Tablets of Ritonavir using three approaches (i.) Direct compression, (ii.) Melt Granulation and (iii.) Ion Exchange Resin Complexation method using resins; Duolite and Amberlite. The API: Resin ratios experimented were 1:3, 1:2, 1:1,5, 1:1,1:0.75, 1:0.5. Furthermore, the optimized formulation was achieved by application of QBD approach and DOE software. Result: The formulated tablets were evaluated for various parameters which reflected that employing method (iii.) provided satisfactory results for in vitro drug release, disintegration time, other physical and chemical parameters in comparison with other two approaches, also the taste masking of highly bitter API was achieved. Based on trial batches, batch T9 showed desired results and its release profile was comparable with marketed formulation (Norvir® Powder for suspension). From DOE study, Duolite was observed to be beneficial candidate than Amberlite. Conclusion: Thus, results highlight that the dispersible tablets of Ritonavir could be successfully formulated by using ion exchange resin complexation method with API: Duolite in ratio 1:0.5 with 3% of disintegrant and 0.4% of lubricant delivering desired results like disintegration time within 1 minute and libre than 85% of drug release within 15 minutes.

Progressive Education Society's, Modern College of Pharmacy, Nigdi, Pune

Dates: 4 & 5 January 2019



Formulation and development of ritonavir dispersible tablets

Savitribai Phule Pune University Sponsored International Conference On "Multidisciplinary Healthcare Research: Challenges, Opportunities And Newer Directions"



Scientific Oral Presentation Code: 0-PHOI

Tide: FORMULATION AND DEVELOPMENT OF GUAIFENESIN EXTENDED RELEASE BI-LAYER TABLETS

Sweety. R. Singh, Dr. Praveen Chaudhari, Mr.Mahesh Bhadgale²
I. P.E.S Modern College of Pharmacy, Nigdi, Pune, India.
2. Callidus Research Labs, Pvt.Ltd.

Abstract:

Purpose: Extended release formulations has significant advantage over immediate release to the patients. Extended release dosage forms are administered to patients in much fewer daily doses and achieve more therapeutic effect in few daily doses. Thus main objective was to develop Guaifenesin. Extended Release Bi-layer tablets. Method: The formulation comprises of two portion: i) immediate release formulation of guaifenesin and ii) an extended release formulation of guaifenesin. The formulation comprised of MCC and SSG for immediate release whereas HPMC E10M and carbopol were used for extended release layer. The total weight ratio of HPMC E10M to Carbopol were experimented at 2:1, 3:1, 4:1, 6:1, 5.25:1, 5.5:1.Result:The formulated bi-layer tablets were evaluated for thickness, hardness, friability, weight variation, in-vitro drug release. The bi-layer tablet showed an initial burst effect to provide the initial loading dose and which then sustained itself for 12hrs. Formulation T6 was selected as best formulation of the drug release as the formulation matched with the marketed formulation (Mucinex). The stability studies, water by K.F. dissolution was carried which reflected that the formulation was enough feasible. The entire formulation was carried out by QBD approach, DOE software was applied so as to get better optimized formulation amongst all. Conclusion: Hence from DOE results, friability above 200N was more feasible for the formulation and T6 was considered best as its dissolution profile matched with the innovator product. Thus 5.5:1(110mg; 20mg) of HMC E10M: Carbopol respectively was considered as optimized.



Scientific Oral Presentation Code: 0-PH02

Tide: FORMULATION AND DEVELOPMENT OF RITONAVIR DISPERSIBLE TABLETS

Mokshada M. Vable, Dr. Praveen Chaudhari, Mr. Mahesh Bhadgale I. P.E.S Modern College of Pharmacy, Nigdi, Pune, India. 2. Callidus Research Labs, Pvt. Ltd.

Abstract:

Purpuse. Most of the medications are available in adult strengths hence adjustment for paediatric or geriatric dosage becomes difficult. This concern could be avoided by formulating tablet dosage forms like Dispersible tablets which are to be disintegrated in liquid before administration; giving a homogenous dispersion. Methods: In the present work attempt has been made to prepare Dispersible Tablets of Ritonavir using three approaches (i.) Direct compression, (ii.) Melt Granulation and (iii.) Ion Exchange Resin Complexation method using resins; Duolite and Amberlite. The API: Resin ratios experimented were 1:3, 1:2, 1:1.5, 1:1,1:0.75, 1:0.5. Furthermore, the optimized formulation was achieved by application of QBD approach and DOE software. Result: The formulated tablets were evaluated for various parameters which reflected that employing method (iii.) provided satisfactory results for in vitro drug release, disintegration time, other physical and chemical parameters in comparison with other two approaches, also the taste masking of highly bitter API was achieved. Based on trial batches, batch T9 showed desired results and its release profile was comparable with marketed formulation (Norvir® Powder for suspension). From DOE study, Duolite was observed to be beneficial candidate than Amberlite. Conclusion: Thus, results highlight that the dispersible tablets of Ritonavir could be successfully formulated by using ion exchange resin complexation method with API: Duolite in ratio 1:0.5 with 3% of disintegrant and 0.4% of lubricant delivering desired results like disintegration time within 1 minute and integration and integration of drug release within 15 minutes.


Progressive Education Society's, Modern College of Pharmacy, Nigdi, Pune

Dates: 4 & 5 January 2019





Development and validation of stability indicating assay method for azelastine HCL and ciclesonide by RP-HPLC







Design, synthesis & biological evaluation of some anti-inflammatory agents

Savitribai Phule Pune University Sponsored International Conference On "Multidisciplinary Healthcare Research: Challenges, Opportunities And Newer Directions"



Scientific Oral Presentation Code: 0-PCH03

Title: DESIGN, SYNTHESIS & BIOLOGICAL EVALUATION OF SOME ANTI-INFLAMMATORY AGENTS

Somdatta Y Chaudhari, Shailia B. Jadhay , Akash Panchal, Rukhsar Shaikh

1. Department of Pharmaceutical chemistry, Progressive Education Society's Modern College of Pharmacy, Yamunangar, Nigdi, Pune

E-mail: somu.chaudhari@gmail.com

Abstract

Purpose: Several literature reports had highlighted the significance of coumarin nucleus as a source of potential candidates for anti-inflammatory drug development. Various natural coumarins demonstrated potent anti-inflammatory activity through various mechanisms. Keeping in view the importance of naturally occurring coumarins, we have extensively explored these by synthesizing various derivatives as anti-inflammatory agents.

Method: A series of Coumarin NO-donating-2-pyrazoline derivatives were designed on the basis of PASS server, molecular docking, ADMET properties and then synthesized in good yield and short time using simple and efficient method. This method involved one pot reaction of salicylaldehyde, Ct-ketoester, substituted aldehyde and hydrazine hydrate in the presence of catalytic amount of Ferric Chloride hexahydrate [FeCl36H2O, 5moll%]. This reaction yields intermediate which on bromination by using Bromoacetyl bromide which gives bromoacetyl derivative of coumarin which is reacted with Silver nitrate to yield target compound (AAI-AA2S). The synthesized compounds were characterized using IR, NMR and Mass spectroscopy. The synthesized compounds were evaluated for Anti-inflammatory activity on carrageenan induced rat paw edema and compared with Celecoxib as Standard drug.

Result: The Coumarinyl pyrazoline derivatives AA8 and AA25 showed good activity at injected dose (55mg/kg) as compared to other synthesized compounds in the series but they were safer than standard in regards to gastric and cardiac toxicity. Introduction of nitrate ester group on pyrazoline lead to minimize gastric ulceration and cardiovascular toxicity induced by parent coumarin pyrazoline.

Conclusion: 1. Designed new method for one pot synthesis of coumaninyl pyrazolines which is impossible by convetional routes. 2. Synthesized compound have better NSAID activity without no cardiac and gastric side effects, so these derivatives may be



Scientific Oral Presentation Code: 0-PCH04

Title: QSAR DRIVEN GREEN CHEMISTRY SYNTHESIS, PHARMACOLOGICAL EVALUATION & DOCKING STUDIES OF NOVEL 1,2,3,4-TETRAHYDROPYRIMIDINE-2-THIOL DERIVATIVES AS POTENTIAL ANTICANCER, ANTIMICROBIAL AND ANTIFUNGAL AGENTS

S. L. Khan, G.S. Sonwane, Dr. S. P. Jain, Dr. M. A. Kale Rajarshi Shahu College of Pharmacy, Buldana E-mail: sharique.4u4@gmail.com

Abstract:

Purpose: QSAR studies were carried out on a series of 27 1,2,3,4-tetrahydropyrimidine-2-thiol derivatives to investigate structural requirements to inhibit the cancer. Methods: The statistically significant and optimum 2D-QSAR model having correlation coefficient r2 = 0.89 and cross-validated squared correlation coefficient q2 = 0.79 with external predictive ability of pred_r2 = 0.73 was developed by step-wise variable multiple linear regression (SW-MLR) method. Molecular field analysis was used to construct the best 3D-QSAR model using step-wise variable k-nearest neighbor (SW-kNI) method, showing good correlative and predictive abilities in terms of q2 = 0.77 and pred_r2 = 0.93. Results: These models (2D and 3D-QSAR) were found to yield reliable clues for further optimization and synthesis of 1,2,3,4-tetrahydropyrimidine-2-thiol derivatives. The microwave assisted synthesis were applied for the synthesis of derivatives and confirmed by IR and Melting point. Drug receptor interaction studies showed very good binding affinity of derivatives with breast cancer receptor (Progesterone) with several strong hydrogen bonds and hydrophobic interactions between many important amino acid residues. Also antimicrobial and antifungal activities were performed and compounds found to have better activity than various standard drugs. Conclusions: from presented work, it's concluded that this scalfold has promising pharmacological activities and there is further very much scope to design more novel derivatives.


Progressive Education Society's, Modern College of Pharmacy, Nigdi, Pune

Dates: 4 & 5 January 2019






Molecular docking, synthesis and biological evaluation of some 2-(5- h/chloro-((morpholino1-yl-methyl)-2-oxoindolin-3- ylidene)-n-substituted hydrazinecarbothioamides







Molecular docking studies of quinazolinone-sulfonamide hybrids for finding a potential dipeptidyl peptidase-4 (dpp-4) inhibitor for type-2 diabetes





Evaluation of protective activity of gentisic acid against 5-flurouracil induced toxicities in laboratory animals

Savitribai Phule Pune University Sponsored International Conference On "Multidisciplinary Healthcare Research: Challenges, Opportunities And Newer Directions"



Scientific Oral Presentation Code: O-COLOI

Tide: EVALUATION OF PROTECTIVE ACTIVITY OF GENTISIC ACID AGAINST 5-FLUROURACIL INDUCED TOXICITIES IN LABORATORY ANIMALS

Pujari Rohini R.*, Bandawane D. D.

Progressive Education Society's Modern College of Pharmacy Yamunanagar, Nigdi, Pune

Abstract

Purpose: Cancer is a leading cause of morbidity and mortality worldwide. Chemotherapy is the widely treatment modality but is associated with several multiple organ toxicities. The crucial fleed arises for a drug that can improve immune system of patient and ameliorate chemotherapy toxicity without having any negative impact on efficacy of chemotherapeutic agent. Natural products have been used worldwide thousands of years to treat various forms of diseases including cancer. Phenolic acids have shown the potential as effective agents for cancer prevention and immunomodulation. However, none of these phytoconstituents have been studied for their ability to protect toxicity of chemotherapeutic agents in animal models or clinical studies. 2,5-Dibydroxybenzoic acid or gentisic acid is an active metabolite of salicylic acid degradation. It is documented to possess a broad spectrum of biological activity such as anti-inflammatory, antirheumatic, antibiotic, anticarcinogenic, antimutagenic, antiatherogenic, skeletal muscle relaxant and antioxidant properties. The focus of the proposed study was preclinical evaluation of naturally occurring phenolic acid gentisic acid for its protective role against the toxicities induced by the most commonly used anticancer agent 5-Flurouracil. Methods: In light of this initial acute oral toxicity studies on laboratory animals was carried out and the results showed that the drug is found to be safe upto 2000 mg/kg. Results: Based on these results the four doses (3 mg/kg, 30 mg/kg, 100 mg/kg and 300mg/kg) of gentisic acid were evaluated for protective activity against 5-Flurouracil (35 mg/kg) induced multiple organ toxicities. The results revealed that 5-Flurouracil treatment caused severe toxicity to different organs like brain, kidney, liver and lungs by the virtue of alterations in biomarkers of these organs and cellular damage observed in histopathological studies. Conclusion: These alterations in the level of biomarkers and cellular damage to the organs were significantly and dose



Scientific Oral Presentation Code: O-COLO2

Title: IN VITRO ANTIOXIDANT AND ANTICHOLINESTERASE POTENTIAL OF FLOWERS OF NYCTANTHES ARBORTRISTIS-LINN.: A THERAPEUTIC LEAD FOR ALZHEIMER'S DISEASE

Arvind Naik 124, Deepti Bandawane', Pravin Chaudhari'

- 1. Progressive Education Society's Modern College of Pharmacy, Yamunangar, Nigdi, Pune
- 2. LSHGCT Gahlot Institute of pharmacy, Koparkhairane, Navi Mumbai

Abstract:

Purpose: Alzheimer's disease (AD) is a primary degenerative disease of the central nervous system. Increased level of the enzyme acetylcholinesterase (AChE) plays a key role in hydrolysis of the neurotransmitter Acetylcholine which worsens the condition of cognitive dysfunction. The chemical inhibition of AChE is a potent strategy for addressing signal related neuropathology and natural products are potential sources of compounds with such properties. Among the pathologic hypotheses of Alzheimer's disease, cholinergic deficit and oxidative stress have been implicated as two major hallmarks. Hence, inhibition of cholinesterase and oxidation are the two important strategies in the development of a drug for AD.

Method: Ethanolic extract of flowers of Nyctanthes arbortristis is used in this research to investigate its anticholinesterase and antioxidant potentials. Anticholinesterase activity was measured by modified Ellman method. Antioxidant potentials were evaluated by the DPPH method and nitric oxide scavenging activity.

Result: The IC50 values of the extract for DPPH and nitric oxide scavenging were 278.96 g/ml and 323.68 g/ml, respectively. The tested sample reflects potential antioxidative and anticholinesterase inhibitory effect which may warrant its effectiveness in the treatment of AD.

Conclusion: The ethanolic extract of flowers of Nyctanthes arbortristis showed promising antioxidant activity and anticholinesterase activity. According to the results stated above, it can be concluded that ethanolic extract of flowers of Nyctanthes arbortristis can be used as an accessible source of natural applies dants and anticholinesterase agents with ensuing health benefits to treat Alzheimer's disease.

Progressive Education Society's, Modern College of Pharmacy, Nigdi, Pune

Dates: 4 & 5 January 2019





In vitro antioxidant and anticholinesterase potential of owers of nyctanthesarbortristislinn.: a therapeutic lead for alzheimer's disease

Savitribai Phule Pune University Sponsored International Conference On "Multidisciplinary Healthcare Research: Challenges, Opportunities And Newer Directions"



Scientific Oral Presentation Code: O-COLOI

Tide: EVALUATION OF PROTECTIVE ACTIVITY OF GENTISIC ACID AGAINST S-FLUROURACIL INDUCED TOXICITIES IN LABORATORY ANIMALS

Pujari Rohini R.", Bandawane D. D.

Progressive Education Society's Modern College of Pharmacy Yamunanagar, Nigdi, Pune

Abstract

Purpose: Cancer is a leading cause of morbidity and mortality worldwide. Chemotherapy is the widely treatment modality but is associated with several multiple organ toxicities. The crucial fleed arises for a drug that can improve immune system of patient and ameliorate chemotherapy toxicity without having any negative impact on efficacy of chemotherapeutic agent. Natural products have been used worldwide thousands of years to treat various forms of diseases including cancer. Phenolic acids have shown the potential as effective agents for cancer prevention and immunomodulation. However, none of these phytoconstituents have been studied for their ability to protect toxicity of chemotherapeutic agents in animal models or clinical studies. 2,5-Dihydroxybenzoic acid or gentisic acid is an active metabolite of salicylic acid degradation. It is documented to possess a broad spectrum of biological activity such as anti-inflammatory, antirheumatic, antibiotic, anticarcinogenic, antimutagenic, antiatherogenic, skeletal muscle relaxant and antioxidant properties. The focus of the proposed study was preclinical evaluation of naturally occurring phenolic acid gentisic acid for its protective role against the toxicities induced by the most commonly used anticancer agent S-Flurouracil. Methods: In light of this initial acute oral toxicity studies on laboratory amimals was carried out and the results showed that the drug is found to be safe upto 2000 mg/kg. Results: Based on these results the four doses (3 mg/kg, 30 mg/kg, 100 mg/kg and 300mg/kg) of gentisic acid were evaluated for protective acityly against 5-Flurouracil (35 mg/kg) induced multiple organ toxicity against 5-Flurouracil (35 mg/kg) induced multiple organ toxicity against 5-Flurouracil treatment caused severe toxicity to different organs like brain, lodney, liver and lungs by the virtue of alterations in biomarkers of these organs and cellular damage observed in histopathological studies. Conclusion: These alterations in the level of biomarkers and cellular damag



Scientific Oral Presentation Code: 0-COLO2

Tide: IN VITRO ANTIOXIDANT AND ANTICHOLINESTERASE POTENTIAL OF FLOWERS OF NYCTANTHES ARBORTRISTIS LINN: A THERAPEUTIC LEAD FOR ALZHEIMER'S DISEASE

Arvind Naik 12*, Deepti Bandawane', Pravin Chaudhari

- 1. Progressive Education Society's Modern College of Pharmacy, Yamunangar, Nigdi, Pune
- 2. LSHGCT Gahlot Institute of pharmacy, Koparkhairane, Navi Mumbai

Abstract

Purpose: Alzheimer's disease (AD) is a primary degenerative disease of the central nervous system. Increased level of the enzyme acetylcholinesterase (AChE) plays a key role in hydrolysis of the neurotransmitter Acetylcholine which worsens the condition of cognitive dysfunction. The chemical inhibition of AChE is a potent strategy for addressing signal related neuropathology and natural products are potential sources of compounds with such properties. Among the pathologic hypotheses of Alzheimer's disease, cholinergic deficit and oxidative stress have been implicated as two major hallmarks. Hence, inhibition of cholinesterase and oxidation are the two important strategies in the development of a drug for AD.

Method: Ethanolic extract of flowers of Nyctanthes arbortristis is used in this research to investigate its anticholinesterase and antioxidant potentials. Anticholinesterase activity was measured by modified Ellman method. Antioxidant potentials were evaluated by the DPPH method and nitric oxide scavenging activity.

Result: The IC50 values of the extract for DPPH and nitric oxide scavenging were 278.96 g/ml and 323.68 g/ml, respectively. The tested sample reflects potential antioxidative and anticholinesterase inhibitory effect which may warrant its effectiveness in the treatment of AD.


Conclusion: The ethanolic extract of flowers of Nyctanthes arbortristis showed promising antioxidant activity and anticholinesterase activity. According to the results stated above, it can be concluded that ethanolic extract of flowers of Nyctanthes arbortristis can be used as an accessible source of natural anti-ecidants and anticholinesterase agents with ensuing health benefits to treat Alzheimer's disease.

Progressive Education Society's, Modern College of Pharmacy, Nigdi, Pune

Dates: 4 & 5 January 2019



Evaluation of the immunomodulatory activity of abelmoschus manihotlinn in various animal models







Development and evalution of spironolactone oral suspension

Savitribai Phule Pune University Sponsored International Conference On "Multidisciplinary Healthcare Research: Challenges, Opportunities And Newer Directions"



Scientific Poster Presentation Code: P-PH13

Title: FORMULATION, DESIGN AND DEVELOPMENT OF SELF-MICROEMULSIFYING DRUG DELIVERY SYSTEM OF NITRENDIPIN

Neha C. Patil *, Anilkumar J. Shinde, Harinath N. More
Dept. of Pharmaceutical Quality Assurance, Bharati Vidyapeeth college of Pharmacy, Near Chitranagari,
Kolhapur (M.S), India
E-mail: nehap0435@gmail.com

Abstract

Purpose: The objective of the present work was to formulate a self-micro emulsifying drug delivery system (SMEDDS) for Nitrendipine, which is widely used in the treatment of hypertension.

Method: Nitrendipine SMEDDS were formulated using a mixture of Ethyl oleate as oil, cremaphore RH40 as surfactant and PEG 400 as co-surfactant. The developed SMEDDS were evaluated for droplet size, zeta potential, self-micro emulsification time and drug content determination and in vitro diffusion profiles.

Result: The cumulative percentage release of optimized batch was observed 98.33%. The optimized batch of mean droplet size, polydispersity index, zeta potential and drug content were showed 67nm, 0.247, -38.2 and 99.85 ±0.024 respectively. The stability studies of solid SMEDDS, reveals that there was no significant decrease in drug release and drug content, hence the all the prepared formulation was found to be stable. The comparative in vitro release study of optimized batch and marketed formulation showed that the formulation of solid SMEDDS of nitrendipine showed more than 90% drug release in 60 min, whereas marketed preparation shows <80% drug release.

Conclusion: The study illustrated the self-micro emulsifying drug delivery system of Nitrendipine, owing to nanosized, has potential to enhance its absorption and solubility, dissolution, and consequently oral bioavailability.



Scientific Poster Presentation Code: P-PH14

Title: DEVELOPMENT AND EVALUTION OF SPIRONOLACTONE ORAL SUSPENSION

Komal P. Gaikwad, Dr. P. D. Chaudhari , Mahesh. M. Bhadgale
Department of Pharmaceutics , Modern College of Pharmacy, Nigdi, Pune, Maharashtra, India

Abstract:


Spironolactone Oral Suspension offers an excellent opportunity for manufacturers to separate themselves from their products efficacy, and protect against impersonator products. The immediate release suspension is proposed with the aim of reaching a high serum concentration in a short period of time. In this formulation Xanthan gum is used as suspending agent and glycerine is used as a dispersing agent suspension showed very good release within half—hourmore than 85% the in—ritro dissolution was performed in the USP dissolution apparatus in the 10000ml 0.1N HCI at the speed of 50 rpm for 1hr and from their release behaviour of the drug and similarity factor best formulation selected .formulation FI was selected as best formulation of the drug release as the formulation matched with reference product (Carospir). The entire formulation was carried out by QBD approach , DOE software was applied so as to get better optimized formulation amongst all. Hence from DOE results ,similarity factor above 50% was more feasible for the formulation and 3.6mg. 100mg of xanthan gum; Glycerin was considered optimized. Hence spironolactone oral suspension had all the qualities of immediate release formulation, from this research work it is evident that the formulated spironolactone oral suspension had optimum therapeutic effect as compared to the marketed formulation (Carospir).

Sill College Co.






Development of self-micro emulsifying drug delivery system and its in-vitro study for delivery of curcumin





Formulation and evaluation of acetazolamide nanosuspension for opthalmic delivery







Enhancement of solubility of glibenclamide by complexation with humic acid



Progressive Education Society's Modern College of Pharmacy, Nigdi, Pune 411044






Effect of surfactants and co-surfactants on phase behavior and physicochemical properties of self-nanoemulsifying drug delivery system loaded with plumbagin








Formulation development and evaluation of immediate release tablet of antiretroviral containing fixed dose combination drugs








Antibiotic loaded nanocomposite scaffolds for periodontal disease







Development of alphatocopherol loaded nanostructured lipid carrier (NLC) for topical drug delivery










Molecular modeling approach to develop dipeptidyl peptidase iv inhibitor as antidiabetic agent




Progressive Education Society's Modern College of Pharmacy, Nigdi, Pune 411044





Molecular docking study of albendazole onto vegfr-2 for anticancer therapy




Progressive Education Society's Modern College of Pharmacy, Nigdi, Pune 411044





Synthesis, evaluation and molecular docking of sulphonamide/ isothiocyanate linked quinazolinone derivatives as antidiabetic activity








Lc-ms/ms characterization of alkaline stress degradation product : development and validation of stability indicating method of rivaroxaban by hptlc







Development and validation of hptlc method for estimation of rosmarinic acid in plant extract and in polyherbal formulation




Progressive Education Society's Modern College of Pharmacy, Nigdi, Pune 411044






Hptlc method for qualitative and quantitative analysis of quercetin from epiphyllum oxypetalum








Stability indicating assay methods for candesartan cilexetil and hydrochlorothiazide in bulk and tablet dosage form by rp-hplc








Anti-inflammatory potential of leaves flavonoid rich ethyl acetate fraction of methanolic extract of stereospermum suaveolens DC in wistar rats







Protective effect of abutilon indicum linn. Leaves extract in high-fat diet (hfd) and streptozotocin-induced metabolic syndrome rats







Study of effect of sterculia foetidalinn (sterculiaceae) seeds on insulin resistance in type ii diabetes mellitus in rats





List of chapter/book along with the links redirecting to the source website

| Sr. No. | Name of the teacher | Title of the book/chapter s published | Title of the Paper | Title of the proceedings of the conference | Name of the conference | National / Internati onal | Year of publica tion | ISBN number of the proceeding | Affiliating Institute at the time of publication | Name of the publisher | Links |
|------------|---------------------------|--|-----------------------|---|------------------------------|------------------------------------|----------------------|--|---|-----------------------------|--|
| | | | | | ACADEN | MIC YEAR | 2022-23 | | | | |
| | | | | | | BOOKS | | | | | |
| 1 | Vittal V. Chopade | Quality control & standardizatio n of herbals | NA | NA | NA | National | 2022 | 978-93- 5585-029-4 | PES Modern College of Pharmacy, Nigdi, Pune- 411 044, | Technical Publication | https://technicalpub lications.in/product s/9789355850294-1 |
| 2 | Vittal V. Chopade | Pharmaceutic Organic Chemistry -II | NA | NA | NA | National | 2022 | 978-91- 5585-113-0 | PES Modern College of Pharmacy, Nigdi, Pune- 411 044, | Technical Publication | https://www.flipkar t.com/pharmaceutic al-organic- chemistry-ii-b- pharmacy-pci- syllabus- textbook/p/itmdd0a a1deaa1e2 |
| 3 | Kuchekar M.C. | Dietary supplements & nutraceuticals | NA | NA | NA | National | 2022 | 978-93- 5585-053-9 | PES Modern College of Pharmacy, Nigdi, Pune- 411 044, | Technical Publication | https://technicalpub lications.in/product s/9789355850539- 1# |
| 4 | Padmaja S. Kore | Principles of Drug Discovery | NA | NA | NA | National | 2022 | 978-93- 92867-15-6 | PES Modern College of Pharmacy, Nigdi, Pune- 411 044, | Career Pub. | https://www.amazo n.in/Principles- Drug-Discovery-as- PCI/dp/B0C9M62B HV/ref=sr_1_2?cri d=34XXCTIJM31 G3&keywords=Pri |





| | | | | | | | | | | | nciples+of+Drug+ Discovery&qid=16 90870027&sprefix =principles+of+dru g+discovery%2Cap s%2C208&sr=8-2 |
|---|--|---|----|----|----|-------------------|------|-----------------------|---|---------------------------------|--|
| 5 | Pallavi M. Patil, Vitthal V. Chopade | Pharmaceutic al Organic Chemistry - III | NA | NA | NA | National | 2023 | 978-93- 5585-247-2 | PES Modern College of Pharmacy, Nigdi, Pune- 411 044, | Technical Publication | https://technicalpub lications.in/product s/9789355852472- 1# |
| 6 | Pallavi M. Patil, Vitthal V. Chopade | Pharmaceutic al Organic Chemistry - III | NA | NA | NA | National | 2023 | 978-93- 5585-247-2 | PES Modern College of Pharmacy, Nigdi, Pune- 411 044, | Technical Publication | https://technicalpub lications.in/product s/9789355852472- 1# |
| 7 | Upendra C. Galgatte | Regulatory Affairs | NA | NA | NA | National | 2023 | 978-81- 961210-3-7 | PES Modern College of Pharmacy, Nigdi, Pune- 411 044, | Kripa Drishti Publication | https://books.kdpub lications.in/index.p hp/kdp/catalog/vie w/221/217/1952 |
| 8 | Padmaja S.Kore, Anuradha More | The Microbial World: Exploring the Diversity of Bacteria | NA | NA | NA | Internati onal | 2023 | 978-1- 80433-971-8 | PES Modern College of Pharmacy, Nigdi, Pune- 411 044, | Rubicon Publication s | https://www.rubico npublications.com/ books/1686734453- the-microbial- world-exploring- the-diversity-of- bacteria |

Progressive Education Society's Modern College of Pharmacy, Nigdi, Pune 411044







| 9 | Padmaja S. Kore, Anuradha G. More | The Microbial World: Exploring the Diversity of Bacteria | NA | NA | NA | Internati onal | 2023 | 978-1- 80433-971-8 | PES Modern College of Pharmacy, Nigdi, Pune- 411 044, | Rubicon Publication s | https://www.rubico npublications.com/ books/1686734453- the-microbial- world-exploring- the-diversity-of- bacteria |
|----|--|---|----|----|----|-------------------|------|-----------------------|---|--------------------------------------|--|
| 10 | Nikita K. Kale | A Textbook of Organic Chemistry | NA | NA | NA | Internati onal | 2023 | 978-93- 5757-313-9 | PES Modern College of Pharmacy, Nigdi, Pune- 411 044, | Scientific Internation al pub. | https://www.flipkar t.com/textbook- organic- chemistry/p/itm1ac a1e43d0583?pid=9 789357573139 |
| 11 | Rupali Jinturkar, Sheetal chaudhari | Elements of Pharmacother apeutics | NA | NA | NA | National | 2023 | 97815- 43347-25-8 | PES Modern College of Pharmacy, Nigdi, Pune- 411 044, | PV publication | https://drive.google .com/file/d/111yD2 7sIQA- NAYgfNw1eHp y VirzySvh/view?usp =sharing |
| 12 | Rupali Jinturkar, Sheetal chaudhari | Elements of Pharmacother apeutics | NA | NA | NA | National | 2023 | 97815- 43347-25-8 | PES Modern College of Pharmacy, Nigdi, Pune- 411 044, | PV publication | https://drive.google .com/file/d/111yD2 7sIQA- NAYgfNw1eHp y VirzySvh/view?usp =sharing |







| | | | | | ВОО | К СНАРТІ | ERS | | | | |
|----|-------------------------------|--|---|----|-----|----------|------|-----------------------|---|--|---|
| | Kalyani Shrinivas Kakad | Recent Advances in Pharmaceutic al Sciences Volume-7 | Chapter 4 Quantitativ e analysis of ursolic acid in the leaves of species of genus tecoma and tabebuia of bignoniace ae family by high- performanc e thin-layer chromatogr aphic method | NA | NA | National | 2022 | 978-81- 952065-9-9 | PES Modern College of Pharmacy, Nigdi, Pune- 411 044, | Innovare Academic Science Pvt Ltd | https://www.akinik. com/products/1695/ recent-advances-in- pharmaceutical- sciences |
| 14 | Kalyani Shrinivas Kakad | Recent advances in pharmaceutic al sciences volume - 8 | Chapter 2 Recent Advances in Microfluidi cs for Drug Screening and Its Application s | NA | NA | National | 2022 | 978-93- 5570-434-4 | PES Modern College of Pharmacy, Nigdi, Pune- 411 044, | AkiNik Publication , New Delhi. | https://www.akinik. com/products/1925/ recent-advances-in- pharmaceutical- sciences |
| 15 | Ujwala S. Desai | Recent Advances in Pharmaceutic al Sciences volume-9 | Chapter 9 Review article: ophthalmic niosomal in situ gel | NA | NA | National | 2022 | 978-81- 952065-5-1 | PES Modern College of Pharmacy, Nigdi, Pune- 411 044, | Innovare Academic Science Pvt Ltd | https://innovareaca demics.in/img/book s/Recent Advances in Pharmaceutical Sciences Volume 9.pdf |







| 16 | Padmaja S. Kore | The Microbial World: Exploring the Diversity of Bacteria | Chapter-8 Prevotella histicola | NA | NA | Internati onal | 2023 | 978-1- 80433-971-8 | PES Modern College of Pharmacy, Nigdi, Pune- 411 044, | Rubicon Publication s | https://www.rubico npublications.com/ books/1686734453- the-microbial- world-exploring- the-diversity-of- bacteria |
|----|--------------------|---|--------------------------------------|----|----|-------------------|------|-----------------------|---|-----------------------------|--|
| 17 | Padmaja S. Kore | The Microbial World: Exploring the Diversity of Bacteria | Chapter-9 Prevotella denticola | NA | NA | Internati onal | 2023 | 978-1- 80433-971-8 | PES Modern College of Pharmacy, Nigdi, Pune- 411 044, | Rubicon Publication s | https://www.rubico npublications.com/ books/1686734453- the-microbial- world-exploring- the-diversity-of- bacteria |
| 18 | Padmaja S. Kore | The Microbial World: Exploring the Diversity of Bacteria | Chapter-10 Prevotella micans | NA | NA | Internati onal | 2023 | 978-1- 80433-971-8 | PES Modern College of Pharmacy, Nigdi, Pune- 411 044, | Rubicon Publication s | https://www.rubico npublications.com/ books/1686734453- the-microbial- world-exploring- the-diversity-of- bacteria |
| 19 | Padmaja S. Kore | The Microbial World: Exploring the Diversity of Bacteria | Chapter-11 Prevotella bryantii | NA | NA | Internati onal | 2023 | 978-1- 80433-971-8 | PES Modern College of Pharmacy, Nigdi, Pune- 411 044, | Rubicon Publication s | https://www.rubico npublications.com/ books/1686734453- the-microbial- world-exploring- the-diversity-of- bacteria |







| 20 | Padmaja S. Kore | The Microbial World: Exploring the Diversity of Bacteria | Chapter-12 Prevotella fusca | NA | NA | Internati onal | 2023 | 978-1- 80433-971-8 | PES Modern College of Pharmacy, Nigdi, Pune- 411 044, | Rubicon Publication s | https://www.rubico npublications.com/ books/1686734453- the-microbial- world-exploring- the-diversity-of- bacteria |
|----|---------------------|---|--|----|----|-------------------|------|-----------------------|---|-----------------------------|--|
| 21 | Padmaja S. Kore | The Microbial World: Exploring the Diversity of Bacteria | Chapter-13 Prevotella albensis | NA | NA | Internati onal | 2023 | 978-1- 80433-971-8 | PES Modern College of Pharmacy, Nigdi, Pune- 411 044, | Rubicon Publication s | https://www.rubico npublications.com/ books/1686734453- the-microbial- world-exploring- the-diversity-of- bacteria |
| 22 | Padmaja S. Kore | The Microbial World: Exploring the Diversity of Bacteria | Chapter-14 Prevotella saccharolyt ica | NA | NA | Internati onal | 2023 | 978-1- 80433-971-8 | PES Modern College of Pharmacy, Nigdi, Pune- 411 044, | Rubicon Publication s | https://www.rubico npublications.com/ books/1686734453- the-microbial- world-exploring- the-diversity-of- bacteria |
| 23 | Anuradha G. More | The Microbial World: Exploring the Diversity of Bacteria | Chapter-15 Prevotella brevis | NA | NA | Internati onal | 2023 | 978-1- 80433-971-8 | PES Modern College of Pharmacy, Nigdi, Pune- 411 044, | Rubicon Publication s | https://www.rubico npublications.com/ books/1686734453- the-microbial- world-exploring- the-diversity-of- bacteria |
| 24 | Anuradha G. More | The Microbial World: Exploring the Diversity of Bacteria | Chapter-16 Prevotella bivia | NA | NA | Internati onal | 2023 | 978-1- 80433-971-8 | PES Modern College of Pharmacy, Nigdi, Pune- 411 044, | Rubicon Publication s | https://www.rubico npublications.com/ books/1686734453- the-microbial- world-exploring- the-diversity-of- |







| | | | | | | | | | | | bacteria |
|----|---------------------|---|--|----|----|-------------------|------|-----------------------|---|-----------------------------|--|
| 25 | Anuradha G. More | The Microbial World: Exploring the Diversity of Bacteria | Chapter-17 Prevotella timonensis: Pathogenici ty and Immune Response | NA | NA | Internati onal | 2023 | 978-1- 80433-971-8 | PES Modern College of Pharmacy, Nigdi, Pune- 411 044, | Rubicon Publication s | https://www.rubico npublications.com/ books/1686734453- the-microbial- world-exploring- the-diversity-of- bacteria |
| 26 | Anuradha G. More | The Microbial World: Exploring the Diversity of Bacteria | Chapter-18 Prevotella loescheii | NA | NA | Internati onal | 2023 | 978-1- 80433-971-8 | PES Modern College of Pharmacy, Nigdi, Pune- 411 044, | Rubicon Publication s | https://www.rubico npublications.com/ books/1686734453- the-microbial- world-exploring- the-diversity-of- bacteria |
| 27 | Anuradha G. More | The Microbial World: Exploring the Diversity of Bacteria | Chapter-19 Prevotella pallens | NA | NA | Internati onal | 2023 | 978-1- 80433-971-8 | PES Modern College of Pharmacy, Nigdi, Pune- 411 044, | Rubicon Publication s | https://www.rubico npublications.com/ books/1686734453- the-microbial- world-exploring- the-diversity-of- bacteria |
| 28 | Anuradha G. More | The Microbial World: Exploring the Diversity of Bacteria | Chapter-20 Prevotella buccalis | NA | NA | Internati onal | 2023 | 978-1- 80433-971-8 | PES Modern College of Pharmacy, Nigdi, Pune- 411 044, | Rubicon Publication s | https://www.rubico npublications.com/ books/1686734453- the-microbial- world-exploring- the-diversity-of- bacteria |
| 29 | Anuradha G. More | The Microbial World: Exploring the Diversity of Bacteria | Chapter-21 Prevotella amnii | NA | NA | Internati onal | 2023 | 978-1- 80433-971-8 | PES Modern College of Pharmacy, Nigdi, Pune- 411 044, | Rubicon Publication s | https://www.rubico npublications.com/ books/1686734453- the-microbial- world-exploring- the-diversity-of- |







| | | | | | | | | | | | <u>bacteria</u> |
|---|--|---|----|----|-------|----------|---------|-----------------------|---|-----------------------|--|
| | | | | | ACADE | MIC YEAR | 2021-22 | | | | |
| | | | | | | BOOKS | | | | | |
| 1 | Padmaja S.Kore Anuradha G. More | Therapeutic Benefits of medicinal herbs | NA | NA | NA | National | 2022 | 978-1- 91348-228-2 | PES Modern College of Pharmacy, Nigdi, Pune- 411 044, | Rubicon Pub. | https://www.rubico npublications.com/ books/1647345754- therapeutic- benefits-of- medicinal-herbs |
| 2 | Padmaja S.Kore Anuradha More | Therapeutic Benefits of medicinal herbs | NA | NA | NA | National | 2022 | 978-1- 91348-228-2 | PES Modern College of Pharmacy, Nigdi, Pune- 411 044, | Rubicon Pub. | https://www.rubico npublications.com/ books/1647345754- therapeutic- benefits-of- medicinal-herbs |
| 3 | Padmaja S.Kore Anuradha More & P.D.Chau dhari | Advances in pharmaceutic al and Biomedical sciences | NA | NA | NA | National | 2022 | 978-9- 35570-011-7 | PES Modern College of Pharmacy, Nigdi, Pune- 411 044, | Akinik Publication | https://www.akinik. com/products/1451/ advances-in- pharmaceutical- and-biomedical- sciences |
| 4 | Padmaja S.Kore Anuradha More & P.D.Chau dhari | Advances in pharmaceutic al and Biomedical sciences | NA | NA | NA | National | 2022 | 978-9- 35570-011-7 | PES Modern College of Pharmacy, Nigdi, Pune- 411 044, | Akinik Publication | https://www.akinik. com/products/1451/ advances-in- pharmaceutical- and-biomedical- sciences |
| 5 | Padmaja S.Kore Anuradha | Advances in pharmaceutic al and | NA | NA | NA | National | 2022 | 978-9- 35570-011-7 | PES Modern College of Pharmacy, | Akinik Publication | https://www.akinik. com/products/1451/ advances-in- |







| | More & P.D.Chau dhari | Biomedical sciences | | | | | | | Nigdi, Pune- 411 044, | | pharmaceutical- and-biomedical- sciences |
|----|-----------------------------|---|----|----|----|----------|------|--------------------------|---|----------------------|--|
| 6 | Padmaja S.Kore | Current approaches on COVID- 19 | NA | NA | NA | National | 2022 | 978-3- 96492-392-9 | PES Modern College of Pharmacy, Nigdi, Pune- 411 044, | Weser books | https://amzn.eu/d/2 D2Cv0x |
| 7 | P.D.Chau dhari | A practical book of pharmaceutic al formulation | NA | NA | NA | National | 2022 | 978- 9354516-90- 4 | PES Modern College of Pharmacy, Nigdi, Pune- 411 044, | Nirali Prakashan | https://www.amazo n.in/-/hi/Dr-Sushil- Y- Raut/dp/B0B25338 LB |
| 8 | Padmaja Kore | Cellular and molecular pharmacolog y | NA | NA | NA | National | 2022 | 978-93- 5451-579-8 | PES Modern College of Pharmacy, Nigdi, Pune- 411 044, | Nirali Prakashan | https://www.amazo n.in/Bodhankar- CELLULAR- MOLECULAR- PHARMACOLOG Y- Semester/dp/B09X F7V36D |
| 9 | Padmaja Kore | Advances in Pharmaceutic al Sciences | NA | NA | NA | National | 2022 | 978-81- 951323-7-9 | PES Modern College of Pharmacy, Nigdi, Pune- 411 044, | JPS Sci. Pub. | https://www.amazo n.in/Advances- Pharmaceutical- Sciences-P- Saranraj- ebook/dp/B09Q24 D6Z7 |
| 10 | Padmaja Kore | Therapeutic application of potential herbs Vol-1 | NA | NA | NA | National | 2022 | 978-81- 951323-2-4 | PES Modern College of Pharmacy, Nigdi, Pune- 411 044, | JPS Sci.Pub. | https://www.amazo n.com/Therapeutic- Applications- Potential-Herbs- Saranraj- ebook/dp/B09TBZ ZK1T |
| 11 | P.D. Chaudhar | Pharmaceutic s - For first | NA | NA | NA | National | 2022 | 978-81- 956362-0-4 | PES Modern College of | Speakphar ma Pub. | https://www.amazo n.in/-/hi/Dr-Rahul- |







| | • | D: 1 | <u> </u> | | | 1 | | 1 | DI | - | 0: 1/1/01056262 |
|----|----------------------|---|---|----|-----|-------------------|------|--|---|--------------------------------|---|
| | i | year Diploma | | | | | | | Pharmacy, | | Singh/dp/81956362 |
| | | in pharmacy | | | | | | | Nigdi, Pune- | | <u>09</u> |
| | | | | | | | | | 411 044, | | |
| | | | | | ВОО | K CHAPTI | ERS | | | | |
| 12 | Pallavi M. Patil | Advanced Review and Research in Pharmaceutic al Science Vol. 3 | Chapter 4 A Review on Meta- Analysis of Randomize controlled Trials on the Clinical Effectivene ss and Safety of Remdesivir in Patients with Covid 19 Caused by SARS- COV-2 | NA | NA | National | 2022 | 978-93- 5570-301-9 | PES Modern College of Pharmacy, Nigdi, Pune- 411 044, | AkiNik Publication | https://www.akinik. com/products/1684/ advanced-review- and-research-in- pharmaceutical- science |
| 13 | Pallavi M. Patil | Advances in Agriculture Sciences Vol 37 | Chapter 2 Review on Agrochemi cals on Human Bodies" | NA | NA | National | 2022 | 978-93- 5570-299-9 | PES Modern College of Pharmacy, Nigdi, Pune- 411 044, | AkiNik Publication | https://www.resear chgate.net/publicati on/364352723_Adv ances in Agricultu re Sciences |
| 14 | Vittal V. Chopade | Colorimetry | Chapter 7 A Digital Image- Based Colorimetri c Technique Use for Quantificat ion of | NA | NA | Internati onal | 2022 | 978-1- 83962-941-9 , EBOOK (PDF) ISBN 978-183962- 940-2 | PES Modern College of Pharmacy, Nigdi, Pune- 411 044, | Open intech London UK | https://www.intech open.com/chapters/ 79532 |







| 15 | Atul Anand Phatak | Trends in Pharmaceutic al Research and Development Vol 6 | Green Active Pharmaceut icals Obtained from Natural Sources Chapter 5 Study on the developme nt and evaluation of novel Modified release prllet-based system for delivery of Desloratidi ne and Pesudoeph edtrine Hydrochlor | NA | NA | National | 2022 | 978-93- 90516-38-4 e book ISBN 978-93- 90516-43-8 | PES Modern College of Pharmacy, Nigdi, Pune- 411 044, | Book Publisher Internation al | https://www.bookpi .org/media- promotion/discussi on-on-study-on- the-development- and-evaluation-of- a-novel-modified- release-pellet- based-system-for- the-delivery-of- desloratadine-and- pseudoephedrine- |
|----|-------------------------|---|--|----|--------|----------|---------|---|---|--|--|
| | | | ide | | | | | | | | <u>hydrochloride/</u> |
| | | | | | ACADEN | MIC YEAR | 2020-21 | | | | |
| | | | | | | BOOKS | | | | | |
| 1 | Pallavi M. Patil | Instrumental Method Of Analysis | NA | NA | NA | National | 2020 | 978-93- 90031-65-8 | PES Modern College of Pharmacy, Nigdi, Pune- 411 044, | Thakur Pub. | https://www.amazo n.in/INSTRUMEN TAL-METHODS- ANALYSIS-Dr- Malathi- ebook/dp/B08D6R P95M |







| 2 | Mohini C. Kuchekar | Pharmacogno sy and Phytochemist ry-II | NA | NA | NA | National | 2020 | 978-93- 90041-96-1 | PES Modern College of Pharmacy, Nigdi, Pune- 411 044, | Technical Pub | https://www.amazo n.in/Pharmacognos y-Phytochemistry- Prof-Wadekar- Kuchekar/dp/81766 02914 |
|---|--------------------------|---|----|----|----|----------|-------------|-----------------------|---|-----------------------|--|
| 3 | Atul A. Phatak | Lab manual of physical pharmaceutic s I&II | NA | NA | NA | National | 2020 | 978- 9384875541 | PES Modern College of Pharmacy, Nigdi, Pune- 411 044, | Unnati pub | https://drive.google .com/file/d/1T0Mm gT1ui_my1jbzg6rI ytmFTwpxS- Uy/view |
| 4 | Minal T. Harde | Quality Assurance | NA | NA | NA | National | 2020 | 978-93- 89627-90-9 | PES Modern College of Pharmacy, Nigdi, Pune- 411 044, | Thakur Publication | https://infomedbooks.com/single/106 |
| 5 | P.D.Chau dhari | Industrial Pharmacy -I | NA | NA | NA | National | 2020- 21 | 978-93- 89750-19-5 | PES Modern College of Pharmacy, Nigdi, Pune- 411 044, | Technical Pub | https://technicalpub lications.in/collecti ons/pharmacy/prod ucts/978938975019 5-1 |
| 6 | Shital V. Patil | Pharmaceutic al Validation (M.PHARM) SEM -II | NA | NA | NA | National | 2021 | 97815- 43344-84-4 | PES Modern College of Pharmacy, Nigdi, Pune- 411 044, | PV. Publication | https://pvbooks.in/p roduct/pharmaceuti cal-validation-m- pharm-sem-ii/ |







| 7 | Shital V. Patil | A textbook of Pharmaceutic al Manufacturin g technology | NA | NA | NA | National | 2021 | 97815- 43345-22-3 | PES Modern College of Pharmacy, Nigdi, Pune- 411 044, | PV. Publication | https://www.amazo n.in/PHARMACE UTICAL- MANUFACTURI NG- TECHNOLOGY- M-PHARM- SYLLABI/dp/B09 DBK59KZ |
|----|----------------------|---|---|----|-----|-------------------|------|-----------------------|---|-----------------------|---|
| 8 | Chopade V.V | Pharmaceutic al Regulatory Science | NA | NA | NA | National | 2021 | 978-93- 90972-02-9 | PES Modern College of Pharmacy, Nigdi, Pune- 411 044, | Thakur publication | https://www.amazo n.in/Pharmaceutical -Regulatory- Science-Rajinder- Vitthal/dp/9390972 027 |
| | | | | | ВОО | K CHAPTI | ERS | | | | |
| 9 | Bhushan P. Pimple | Herbs Spices and Medicinal Plants for Human Gastro- intestinal Disorders Health Benefits and Safety | Chapter 1 Origanum Majorana: The Fragrance of Health | NA | NA | Internati onal | 2020 | 978- 9811468353 | PES Modern College of Pharmacy, Nigdi, Pune- 411 044, | Bentham Sciences | https://www.amazo n.com/Science- Spices-Culinary- Herbs-Pre- clinical/dp/9811468 354 |
| 10 | Bhushan P. Pimple | Science of Spices and Culinary Herbs - Latest Laboratory, Pre-clinical, | Chapter 2 Piper nigrum (Black pepper): A Flavor for | NA | NA | Internati onal | 2020 | 978- 9811468353 | PES Modern College of Pharmacy, Nigdi, Pune- 411 044, | Bentham Sciences | https://www.amazo n.com/Science- Spices-Culinary- Herbs-Pre- clinical/dp/9811468 354 |







| | | and Clinical | Health | | | | | | | | |
|----|----------------------|---|--|----|----|-------------------|------|-----------------------|---|------------------------------------|--|
| | | Studies | пеанн | | | | | | | | |
| | | Volume-3 | | | | | | | | | |
| 11 | Bhushan P. Pimple | Herbs Spices and Medicinal Plants for Human Gastro- intestinal Disorders Health Benefits and Safety | Chapter 2 Therapeuti c Activities of Nutmeg (Myristica fragrance) | NA | NA | Internati onal | 2020 | 978- 1774637142 | PES Modern College of Pharmacy, Nigdi, Pune- 411 044, | CRC Press Taylor & Fransis | https://www.applea cademicpress.com/ herbs-spices-and- medicinal-plants- for-human- gastrointestinal- disorders-health- benefits-and- safety/9781774637 |
| 12 | Sonali S Nipate | Bioadhesive in drug delivery | Chapter 10 Nasal bioadhesiv e drug delivery system and their application | NA | NA | Internati onal | 2020 | 978-1-119- 64019-6 | PES Modern College of Pharmacy, Nigdi, Pune- 411 044, | WILEY, Scrivener Publication | https://www.wiley. com/en- gb/Bioadhesives+in +Drug+Delivery-p- 9781119640196 |
| 13 | Sonali S Nipate | Advanced 3D printed systems and nanosystems for drug delivery and tissue engineering | Chapter 5 Cellulosic material as bioinks for 3D printing application s | NA | NA | Internati onal | 2020 | 978-0-12- 818471-4 | PES Modern College of Pharmacy, Nigdi, Pune- 411 044, | Elsevier | https://books.googl e.co.in/books/about /Advanced_3D_Pri nted_Systems_and Nanosyst.html?id= 1n7VDwAAQBAJ &printsec=frontcov er&source=kp_read _button&hl=en≠ wbks=1&newbks_r edir=0&gboemv=1 &redir_esc=y#v=o nepage&q&f=false |





| | ACADEMIC YEAR 2018-19 | | | | | | | | | | | |
|---|-----------------------|---|----|----|----|----------|--------|-----------------------|---|-------------------|---|--|
| | | | | | | BOOKS | | | | | | |
| 1 | V.V.Cho pade | Pharmaceutic al Analysis | NA | NA | NA | National | Sep-18 | 978-93-332- 1873-3 | PES Modern College of Pharmacy, Nigdi, Pune- 411 044 | Technical Pub. | https://www.tppl.or g.in/2020/bpharm- 1st-semester- books/3043- pharmaceutical- analysis-i.html | |
| 2 | P.S.Uttek ar | Computer Application in Pharmacy | NA | NA | NA | National | 2018 | 978-93- 87483-20-0 | PES Modern College of Pharmacy, Nigdi, Pune- 411 044, | Thakur Pub. | https://www.tppl.or g.in/2020/bpharm- 2nd-semester- books/3232- computer- applications-in- pharmacy-book- for-bpharm-2- semester- 9789387483200.ht ml | |
| 3 | V.V.Cho pade | Pharmaceutic al Inorganic Chemistry | NA | NA | NA | National | Aug-18 | 978-93-332- 1862-7 | PES Modern College of Pharmacy, Nigdi, Pune- 411 044 | Technical Pub | https://technicalpub lications.in/product s/9789333218627-2 | |
| 4 | M.T.Har de | Biochemistry | NA | NA | NA | National | Mar-19 | 978-93-332- 0017-2 | PES Modern College of Pharmacy, Nigdi, Pune- 411 044, | Technical Pub. | https://technicalpub lications.in/product s/9789333200172-1 | |
| 5 | Chopade V.V. | Environmenta 1 Science | NA | NA | NA | National | Mar-19 | 978-93-332- 0019-6 | PES Modern College of Pharmacy, Nigdi, Pune- | Technical Pub | https://www.amazo n.in/Environmental -Sciences-Gautam- S-Palshikar- | |

Progressive Education Society's Modern College of Pharmacy, Nigdi, Pune 411044





| | | | | | | | | | 411 044, | | <u>ebook/dp/B0814JF</u> <u>8QH</u> |
|---|-------------------|--|--|----|----|----------|------|-----------------------|---|--|---|
| 6 | Chopade V.V. | Pharmaceutic al Analysis-I | NA | NA | NA | National | 2019 | 978-93- 87093-01-0 | PES Modern College of Pharmacy, Nigdi, Pune- 411 044, | Thakur Pub. | https://www.amazo n.in/B- PHARMACY- PHARMACEUTIC AL-ANALYSIS- SEM-I- SYLLABUS/dp/93 33218734 |
| | BOOK CHAPTERS | | | | | | | | | | |
| 7 | D.D.Ban dawane | Advances in Biomedical Experimental Techniques in Pharmacologi cal Assays | Chapter 12 Antidiarroheal screeing (in vivo and in vitro methods | NA | NA | National | 2018 | 978-93- 83794-04-1 | PES Modern College of Pharmacy, Nigdi, Pune- 411 044, | Bhalani Publisher and CBS Publisher | https://www.amazo n.in/Advances- Biomedical- Experimental- Techniques- Pharmacological/dp /B07KXRY5Q7 |
| 8 | D.D.Ban dawane | Advances in Biomedical Experimental Techniques in Pharmacologi cal Assays | Chapter 9 Screening methods for drugs acting on renal system | NA | NA | National | 2018 | 978-93- 83794-04-1 | PES Modern College of Pharmacy, Nigdi, Pune- 411 044 | Bhalani Publisher and CBS Publisher | https://www.amazo n.in/Advances- Biomedical- Experimental- Techniques- Pharmacological/dp /B07KXRY5Q7 |